

SUPPLEMENT II
TO
THE JAPANESE
PHARMACOPOEIA
SEVENTEENTH EDITION

Official from June 28, 2019

English Version

THE MINISTRY OF HEALTH, LABOUR AND WELFARE

Notice: This *English Version* of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic.

The Ministry of Health, Labour and Welfare Ministerial Notification No. 49

Pursuant to Paragraph 1, Article 41 of Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Act No. 145, 1960), this notification stated that a part of the Japanese Pharmacopoeia was revised as follows*.

NEMOTO Takumi

The Minister of Health, Labour and Welfare

June 28, 2019

A part of the Japanese Pharmacopoeia (Ministerial Notification No. 64, 2016) was revised as follows*.

(The text referred to by the term “as follows” are omitted here. All of the revised Japanese Pharmacopoeia in accordance with this notification (hereinafter referred to as “new Pharmacopoeia” in Supplement 2) are made available for public exhibition at the Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare, at each Regional Bureau of Health and Welfare, and at each Prefectural Office in Japan).

Supplementary Provisions
(Effective Date)

Article 1 This Notification is applied from June 28, 2019.

(Transitional measures)

Article 2 In the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in new Pharmacopoeia] and drugs which have been approved as of June 28, 2019 as prescribed under Paragraph 1, Article 14 of Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of June 27, 2019 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the same law (hereinafter referred to as “drugs exempted from approval”)], the Standards established in the previous Pharmacopoeia (limited to part of the Standards for the drugs concerned) may be accepted to conform to the Standards established in the new Pharmacopoeia before and on December 31, 2020. In the case of drugs which are listed in the new Pharmacopoeia (excluding those listed in the previous Pharmacopoeia) and drugs which have been approved as of June 28, 2019 as prescribed under the Paragraph 1, Article 14 of the same law (including those exempted from approval), they may be accepted as those being not listed in the new Pharmacopoeia before and on December 31, 2020.

(Partial revision of Products Delivery Rules of National Institute of Infectious Diseases)

Article 3 Omitted.

*The term “as follows” here indicates the content of Supplement II to the Japanese Pharmacopoeia Seventeenth Edition from General Notice to Ultraviolet-visible Reference Spectra (pp. 2877 – 2991).

CONTENTS

Preface	i
Supplement II to The Japanese Pharmacopoeia, Seventeenth Edition	2877–2991
General Notices	2877
General Rules for Preparations	2879
General Tests, Processes and Apparatus ...	2881
2.01 Liquid Chromatography	2881
2.26 Raman Spectroscopy.....	2882
2.46 Residual Solvents	2884
2.51 Conductivity Measurement	2891
2.66 Elemental Impurities—Procedures ...	2893
6.16 Rheological Measurements for Semi- solid Preparations	2896
6.17 Insoluble Particulate Matter Test for Therapeutic Protein Injections	2900
9.01 Reference Standards	2901
9.21 Standard Solutions for Volumetric Analysis	2901
9.22 Standard Solutions	2901
9.41 Reagents, Test Solutions.....	2901
9.42 Solid Supports/Column Packings for Chromatography.....	2908
Official Monographs	2909
Crude Drugs and Related Drugs	2973
Infrared Reference Spectra	2985–2987
Ultraviolet-visible Reference Spectra	2989–2991
General Information	
G1 Physics and Chemistry	
Control of Elemental Impurities in Drug Products.....	2993
G3 Biotechnological/Biological Products	
Host Cell Protein Assay	2997
Total Protein Assay.....	3000
G4 Microorganisms	
Media Fill Test (Process Simulation)	3000
Microbiological Environmental Moni- toring Methods of Processing Areas for Sterile Pharmaceutical Products ...	3000
Parametric Release of Terminally Steri- lized Pharmaceutical Products	3000
G5 Crude Drugs	
Purity Tests on Crude Drugs using Genetic Information	3000
On the Scientific Names of Crude Drugs listed in the JP	3005
G8 Water	
Quality Control of Water for Pharma- ceutical Use	3006
G10 Others	
Basic Concepts for Quality Assurance of Drug Substances and Drug Prod- ucts.....	3006
Concept on Impurities in Chemically synthesized Drug Substances and Drug Products.....	3008
Glossary for Quality by Design (QbD), Quality Risk Management (QRM) and Pharmaceutical Quality System (PQS).....	3010
International Harmonization Imple- mented in the Japanese Pharmaco- poeia Seventeenth Edition	3014
Index	3019
Index in Latin Name	3039
Index in Japanese	3041

PREFACE

The 17th Edition of the Japanese Pharmacopoeia (JP) was promulgated by Ministerial Notification No.64 of the Ministry of Health, Labour and Welfare (MHLW) on March 7, 2016.

In July 2016, the Committee on JP established the basic principles for the preparation of the JP 18th Edition, setting out the roles and characteristics of the JP, the definite measures for the revision, and the date of the revision.

It was agreed that the JP should provide an official standard, being required to assure the quality of medicines in Japan in response to the progress of science and technology and medical demands at the time. It should define the standards for specifications, as well as the methods of testing to assure overall quality of all drugs in principle, and it should have a role in clarifying the criteria for quality assurance of drugs that are recognized to be essential for public health and medical treatment.

The JP has been prepared with the aid of the knowledge and experience of many professionals in the pharmaceutical field. Therefore, the JP should have the characteristics of an official standard, which might be widely used by all parties concerned, and it should play an appropriate role of providing information and understanding about the quality of drugs to the public. Moreover, as a pharmaceutical quality standard, it should contribute promoting and maintaining of advancedness as well as international consistency and harmonization of technical requirements in the international community.

At the Committee, the five basic principles of JP, which we refer to as the “five pillars”, were established as follows: 1) Including all drugs which are important from the viewpoint of health care and medical treatment; 2) Making qualitative improvement by introducing the latest science and technology; 3) Further promoting internationalization in response to globalization of drug market; 4) Making prompt partial revision as necessary and facilitating smooth administrative operation; and 5) Ensuring transparency regarding the revision, and disseminating the JP to the public. It was agreed that the Committee on JP should make efforts, on the basis of these principles, to ensure that the JP is used more effectively in the fields of health care and medical treatment by taking appropriate measurements, including getting the understanding and cooperation of other parties concerned.

It was also agreed that JP articles should cover drugs, which are important from the viewpoint of health care and medical treatment, clinical performance or merits and frequency of use, as soon as possible after they reach the market.

The target date for the publication of JP 18th Edition (the Japanese edition) was set as April 2021.

JP drafts are discussed in the following committees that were established in the Pharmaceuticals and Medical Devices Agency: Expert Committee; Sub-expert Committee; Sub-committee on Manufacturing Process-related Matters; Committee on Chemicals; Committee on Antibiotics; Committee on Biologicals; Committee on Crude Drugs; Committee on Pharmaceutical Excipients; Committee on Physico-Chemical Methods; Committee on Drug Formulation; Committee on Physical Methods; Committee on Biological Methods; Committee on Nomenclature for Pharmaceuticals; Committee on International Harmonization; and Committee on Reference Standards. Furthermore, working groups are established under the Expert Committee, Committee on Pharmaceutical Excipients, Committee on Physico-Chemical Methods and Committee on Drug Formulation.

The committees initiated deliberations on several revisions.

Draft revisions covering subjects in General Notices, General Rules for Preparations, General Tests, Monographs, Ultraviolet-visible Reference Spectra and Infrared Reference Spectra for which discussions were finished between April 2017 and November 2018, were prepared for a supplement to the JP 17.

Numbers of discussions in the committees to prepare the supplement drafts were as follows: Expert Committee (11, including a working group); Sub-committee on Manufacturing Process-related Matters (6), Committee on Chemicals (18), Committee on Antibiotics (3); Committee on Biologicals (7); Committee on Crude Drugs (15); Committee on Pharmaceutical Excipients (10); Committee on Physico-Chemical Methods (11, including a working group); Committee on Drug Formulation (19, including working groups); Committee on Physical Methods (7); Committee on Biological Methods (6); Committee on Nomenclature for Pharmaceuticals (5); Committee on International Harmonization (4).

It should be noted that in the preparation of the drafts for the supplement, generous cooperation was

given by the Pharmaceutical Technology Committee of the Kansai Pharmaceutical Industries Association, the Pharmacopeia and CMC Committee of the Pharmaceutical Manufacturers' Association of Tokyo, the Tokyo Crude Drugs Association, the International Pharmaceutical Excipients Council Japan, the Home Medicine Association of Japan, the Japan Kampo Medicines Manufacturers Association, the Japan Flavor and Fragrance Materials Association, the Japan Medical Plants Federation, the Japan Pharmaceutical Manufacturers Association, the Federation of Pharmaceutical Manufacturers' Association of Japan, the Parenteral Drug Association Japan Chapter, the Japan Reagent Association, the Japan Oilseeds Processors Association, the Japan Analytical Instruments Manufacturers' Association, and the Asian Society of Innovative Packaging Technology.

The draft revisions were examined by the Committee on JP in January 2019, followed by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC) in March 2019, and then submitted to the Minister of Health, Labour and Welfare. In the Committee on JP, Mitsuru Hashida took the role of chairman from January 2011 to June 2019.

In consequence of this revision, the JP 17th Edition carries 2008 articles, owing to the addition of 34 articles and the deletion of 3 articles.

The principles of description and the salient points of the revision in this volume are as follows:

1. The Supplement II to JP 17th Edition comprises the following items, in order: Notification of MHLW; Contents; Preface; General Notices, General Rules for Preparations; General Tests, Processes and Apparatus; Official Monographs; then followed by Infrared Reference Spectra and Ultraviolet-visible Reference Spectra; General Information; and as an appendix a Cumulative Index containing references to the main volume, the Supplement I and the Supplement II.

2. The articles in Official Monographs, Infrared Reference Spectra and Ultraviolet-visible Reference Spectra are respectively placed in alphabetical order in principle.

3. The following items in each monograph are put in the order shown below, except that unnecessary items are omitted depending on the nature of the drug:

- (1) English title
- (2) Commonly used name(s)
- (3) Latin title (only for crude drugs)
- (4) Title in Japanese

- (5) Structural formula or empirical formula
- (6) Molecular formula and molecular mass
- (7) Chemical name
- (8) Chemical Abstracts Service (CAS) Registry Number
- (9) Origin
- (10) Limits of the content of the ingredient(s) and/or the unit of potency
- (11) Labeling requirements
- (12) Method of preparation
- (13) Manufacture
- (14) Description
- (15) Identification tests
- (16) Specific physical and/or chemical values
- (17) Purity tests
- (18) Potential adulteration
- (19) Loss on drying or Ignition, or Water
- (20) Residue on ignition, Total ash or Acid-insoluble ash
- (21) Tests being required for pharmaceutical preparations
- (22) Other special tests
- (23) Assay
- (24) Containers and storage
- (25) Shelf life
- (26) Others

4. In each monograph, the following physical and chemical values representing the properties and quality of the drug are given in the order indicated below, except that unnecessary items are omitted depending on the nature of drug:

- (1) Alcohol number
- (2) Absorbance
- (3) Congealing point
- (4) Refractive index
- (5) Osmolar ratio
- (6) Optical rotation
- (7) Constituent amino acids
- (8) Viscosity
- (9) pH
- (10) Content ratio of the active ingredients
- (11) Specific gravity
- (12) Boiling point
- (13) Melting point
- (14) Acid value
- (15) Saponification value
- (16) Ester value
- (17) Hydroxyl value
- (18) Iodine value

5. Identification tests comprise the following items, which are generally put in the order given

below:

- (1) Coloration reactions
- (2) Precipitation reactions
- (3) Decomposition reactions
- (4) Derivatives
- (5) Infrared and/or ultraviolet-visible absorption spectrometry
- (6) Nuclear magnetic resonance spectrometry
- (7) Chromatography
- (8) Special reactions
- (9) Cations
- (10) Anions

6. Purity tests comprise the following items, which are generally put in the order given below, except that unnecessary items are omitted depending on the nature of drug:

- (1) Color
- (2) Odor
- (3) Clarity and/or color of solution
- (4) Acidity or alkalinity
- (5) Acidity
- (6) Alkalinity
- (7) Chloride
- (8) Sulfate
- (9) Sulfite
- (10) Nitrate
- (11) Nitrite
- (12) Carbonate
- (13) Bromide
- (14) Iodide
- (15) Soluble halide
- (16) Thiocyanate
- (17) Selenium
- (18) Cationic salts
- (19) Ammonium
- (20) Heavy metals
- (21) Iron
- (22) Manganese
- (23) Chromium
- (24) Bismuth
- (25) Tin
- (26) Aluminum
- (27) Zinc
- (28) Cadmium
- (29) Mercury
- (30) Copper
- (31) Lead
- (32) Silver
- (33) Alkaline earth metals
- (34) Arsenic
- (35) Free phosphoric acid
- (36) Foreign matters

- (37) Related substances
- (38) Isomer
- (39) Optical isomer
- (40) Polymer
- (41) Residual solvent
- (42) Other impurities
- (43) Residue on evaporation
- (44) Readily carbonizable substances

7. The following paragraphs of General Notices were revised:

- (1) Paragraph 5: “Shelf life” in the monographs on preparations were removed from the standards for conformity, because that the stability of a pharmaceutical preparation differs depending on the formulation, type of the container and packaging and the control of the storage temperature, etc.
- (2) Paragraph 13: As the cases for drug approval with the quality control using the real time-release testing (RTRT) have been accumulated, the rules of RTRT for drug release were added when RTRT is adopted as an alternative method.
- (3) Paragraph 46: “Expiration Date” in Official Monograph was changed to “Shelf life” in the Supplement I to JP 17th Edition. In this revision, the rule for expression of expiration date was removed.

8. The following paragraphs were newly added to the General Rules for Preparations:

- (1) The following item was newly added to the [3] Monographs for Preparations basing on the discussion about needs of this item following release of the guideline for developing liposomal formulations:
3-1-4. Liposome Injections

9. The General Rules for Preparations was revised as follows in general:

- (1) [3] Monographs for Preparations: “3-1. Injections”: the definition of “Liposome Injections” introduced in this revision was newly added, and “6.17 Insoluble Particulate Matter Test for Therapeutic Protein Injections” added to General Tests in this revision was referred and prescribed.

10. The following items were newly added to General Tests, Processes and Apparatus:

- (1) 2.26 Raman Spectroscopy
- (2) 2.66 Elemental Impurities – Procedures

- (3) 6.16 Rheological Measurements for Semi-solid Preparations
- (4) 6.17 Insoluble Particulate Matter Test for Therapeutic Protein Injections

11. The following items in General Tests, Processes and Apparatus were revised:

- (1) 2.01 Liquid Chromatography
- (2) 2.46 Residual Solvents
- (3) 2.51 Conductivity Measurement

12. The following Reference Standards were newly added:

Bromfenac Sodium RS
 L-Carnosine RS
 Doripenem RS
 Gatifloxacin RS
 Hydroxyethylcellulose RS for Identification
 Lanoconazole RS
 Microcrystalline Cellulose RS for Identification
 Residual Solvents Class 2C RS
 Sitagliptin Phosphate RS
 Sitagliptin Phosphate RS for System Suitability

13. The following Reference Standards were removed from “9.01 (2) The reference standards which are prepared by National Institute of Infectious Diseases.” and added to “9.01 (1) The reference standards which are prepared by those who have been registered to prepare them by the Minister of Health, Labour and Welfare, according to the Ministerial ordinance established by the Minister separately”:

Ampicillin RS
 Azithromycin RS
 Cefazolin RS
 Cefmetazole RS
 Fradiomycin Sulfate RS
 Meropenem RS

14. The following substances were newly added to the Official Monographs:

Bromfenac Sodium Hydrate
 Bromfenac Sodium Ophthalmic Solution
 Cefalotin Sodium for Injection
 Cefixime Fine Granules
 Clarithromycin for Syrup
 Diclofenac Sodium Suppositories
 Doripenem Hydrate
 Doripenem for Injection
 Ethylcellulose
 Felodipine
 Felodipine Tablets
 Gatifloxacin Hydrate

Gatifloxacin Ophthalmic Solution
 Gentamicin Sulfate Injection
 Gentamicin Sulfate Ointment
 Hydroxyethylcellulose
 Irinotecan Hydrochloride Hydrate
 Lanoconazole
 Lanoconazole Cream
 Lanoconazole Cutaneous Solution
 Lanoconazole Ointment
 Minocycline Hydrochloride Granules
 Nortriptyline Hydrochloride Tablets
 Polaprezinc
 Polaprezinc Granules
 Ritodrine Hydrochloride Injection
 Sitagliptin Phosphate Hydrate
 Sitagliptin Phosphate Tablets
 Sodium Valproate Extended-release Tablets A
 Sodium Valproate Extended-release Tablets B
 Telmisartan and Hydrochlorothiazide Tablets
 Valsartan and Hydrochlorothiazide Tablets
 Verapamil Hydrochloride Injection
 Goshuyuto Extract

15. The following monographs were revised:

Amphotericin B Tablets
 Beclometasone Dipropionate
 Betamethasone Dipropionate
 Anhydrous Dibasic Calcium Phosphate
 Microcrystalline Cellulose
 Chloramphenicol
 Chlorpromazine Hydrochloride
 Cholesterol
 Cloperastine Hydrochloride
 Dehydrocholic Acid
 Purified Dehydrocholic Acid
 Epirubicin Hydrochloride
 Estriol
 Etizolam
 Haloperidol
 Hydrocortisone
 Hydrocortisone Acetate
 Hydrocortisone and Diphenhydramine Ointment
 Hydroxypropylcellulose
 Hypromellose
 Imipramine Hydrochloride
 Imipramine Hydrochloride Tablets
 Isomalt Hydrate
 Mestranol
 Methylcellulose
 Methylprednisolone
 Pioglitazone Hydrochloride and Glimperide Tablets
 Saccharin

Saccharin Sodium Hydrate
 Light Anhydrous Silicic Acid
 Sodium Fusidate
 Teicoplanin
 Testosterone Enanthate
 Tipepidine Hibenazate Tablets
 Triamcinolone Acetonide
 Ursodeoxycholic Acid
 Amomum Seed
 Artemisia Capillaris Flower
 Belladonna Root
 Bitter Tincture
 Bofutsushosan Extract
 Boiogito Extract
 Calumba
 Powdered Calumba
 Cassia Seed
 Chrysanthemum Flower
 Eucalyptus Oil
 Gastrodia Tuber
 Glycyrrhiza Extract
 Crude Glycyrrhiza Extract
 Hochuekkito Extract
 Japanese Angelica Root
 Powdered Japanese Angelica Root
 Juzentaihoto Extract
 Kakkontokasenkyushin'i Extract
 Kamikihito Extract
 Kamishoyosan Extract
 Lithospermum Root
 Lycium Bark
 Nux Vomica
 Oriental Bezoar
 Otsujito Extract
 Platycodon Root
 Powdered Platycodon Root
 Platycodon Fluidextract
 Polygala Root
 Powdered Polygala Root
 Safflower
 Saposhnikovia Root and Rhizome
 Scopolia Rhizome
 Sinomenium Stem and Rhizome
 Swertia Herb
 Powdered Swertia Herb
 Swertia and Sodium Bicarbonate Powder
 Toad Cake
 Tokishakuyakusan Extract
 Yokukansan Extract

16. The following monographs were deleted:
 Adsorbed Habu-venom Toxoid
 Freeze-dried Tetanus Antitoxin, Equine

Compound Vitamin B Powder

17. The following articles were newly added to Ultraviolet-visible Reference Spectra:

Bromfenac Sodium Hydrate
 Doripenem Hydrate
 Felodipine
 Gatifloxacin Hydrate
 Irinotecan Hydrochloride Hydrate
 Lanoconazole
 Sitagliptin Phosphate Hydrate

18. The following articles were newly added to Infrared Reference Spectra:

Bromfenac Sodium Hydrate
 Doripenem Hydrate
 Ethylcellulose
 Felodipine
 Gatifloxacin Hydrate
 Irinotecan Hydrochloride Hydrate
 Lanoconazole
 Polaprezinc
 Sitagliptin Phosphate Hydrate

Those who were engaged in the preparation of the Supplement II to JP 17 are as follows

ABE Yasuhiro
 AITA Youhei
 AKAO Kenichi
 ARATO Teruyo
 ARIMOTO Keiko
 ARUGA Naoki
 ASAMA Hiroshi
 ASHIZAWA Kazuhide
 ASO Shinichiro
 ASO Yukio
 DEMIZU Yosuke
 EMURA Makoto
 FUCHINO Hiroyuki
 FUJII Makiko
 FUKAZAWA Hidesuke
 FUKUDA Shinji
 FUKUHARA Kiyoshi
 FURUICHI Harumi
 FURUKAWA Hiromitsu
 GODA Yukihiko
 GOTO Takashi
 GOTO Tamami
 HAISHIMA Yuji
 HAKAMATA Hideki
 HAKAMATSUKA Takashi
 HANADA Kentaro
 HANAJIRI Ruri

HARAZONO Akira
HASHIDA Mitsuru*
HASHII Noritaka
HATANO Rika
HAYASHI Ai
HAYASHI Akira
HAYASHI Yoshinori
HIGANO Taro
HIGUCHI Yasuhiko
HIYAMA Yukio
HORI Masatoshi
HYUGA Masashi
ICHINOSE Koji
IIMORI Jumpei
IKARASHI Yoshiaki
IKEDO Shingo
IMAMOTO Tsuyoshi
ISHIDA Masato
ISHII Akiko
ITAI Shigeru
ITO Michiho
ITO Ryoichi
ITO Yuji
IZUTANI Yusuke
IZUTSU Kenichi
KAMMOTO Toshihiro
KATAYAMA Hirohito
KATO Kumiko
KATORI Noriko
KAWAHARA Nobuo
KAWAI Tamotsu
KAWAMATA Tomomi
KAWANISHI Toru
KAWARASAKI Yoshihiko
KAWASAKI Nana**
KIJIMA Keiji
KIKUCHI Yutaka
KIKUCHI Yuuichi
KISHIMOTO Yasuhiro
KITAJIMA Akihito
KITAKA Atsushi
KIUCHI Fumiyuki
KOBAYASHI Takashi
KOCHI Rika
KOHAMA Ai
KOIDE Tatsuo
KOJIMA Takashi
KOKUBO Hiroyasu
KOMATSU Katsuko
KONDA Toshifumi
KONDO Seizo
KUBOSAKI Atsutaka
KUBOTA Kiyoshi
KUMASAKA Kenichi
KURIHARA Masaaki
KUSUNOKI Hideki
MAKIURA Toshinobu
MARUYAMA Takuro
MASADA Sayaka
MATSUMOTO Kazuhiro
MATSUMOTO Makoto
MATSUMURA Hajime
MIKAMI Eiichi
MISAWA Takashi
MITSUHASHI Takao
MIYATA Naoki
MIYAZAKI Tamaki
MIZUNO Takeshi
MORI Mitsuo
MORIBE Kunikazu
MORIMOTO Seiki
MORIMOTO Takashi
MORISAKI Takahito
MORIYASU Takako
MUROI Masashi
NAKA Nobuyuki
NAKAGAWA Hidehiko
NAKAGAWA Shinsaku
NAKAGAWA Yukari
NAKAKO Mayumi
NAKANO Tatsuya
NANAURA Mitsuo
NASU Masao
NISHIKAWA Noriaki
NOGUCHI Shuji
OBA Sumiaki
OBARA Sakaé
OGAWA Toru
OGURA Yasumitsu
OGURI Kazuki
OHGAMI Yasutaka
OKUBO Tsuneo
OKUDA Akihiro
OKUDA Haruhiro
OMURA Koichi
ONO Makoto
ONODA Hiroshi
OSUMI Yuko
OTSUKA Masami
OUCHI Tadashi
SAITO Hideyuki
SAKAI Eiji
SAKAMOTO Tomoaki
SANTA Tomofumi
SASAKI Hiroshi
SASAKI Kunio

SASAKI Satoshi
SASAKI Yuko
SATO Koji
SATO Kyoko
SATO Norihisa
SEGAWA Masashi
SEKIGAWA Fujio
SEKIGUCHI Michiko
SHIBATA Hiroko
SHIBAYAMA Keigo
SHIBAZAKI Keiko
SHIDA Shizuka
SHIMADA Yasuo
SHIMAZAWA Rumiko
SHIMIZU Masaro
SHIMOKAWA Sayuri
SHINOHARA Katsuaki
SHIRATORI Makoto
SHIROTA Osamu
SHODA Takuji
SUDO Hirotaka
SUDO Keiichi
SUGIMOTO Naoki
SUZUKI Mikio
SUZUKI Noriyuki
SUZUKI Ryoji
SUZUKI Shigeo
SUZUKI Tomoyuki
TADA Minoru
TADAKI Shinichi
TAKANO Akihito
TAKAO Masaki
TAKEDA Osami
TAKEDA Tomoko
TAKEUCHI Hirohumi
TAKEUCHI Hisashi
TANABE Toyoshige
TANAKA Masakazu
TANAKA Tomohide
TANAKA Satoshi
TANIMOTO Tsuyoshi
TERABAYASHI Susumu
TERADA Katsuhide
TERAOKA Reiko
TOKUMOTO Hiroko
TOKUNAGA Hiroshi
TOKUOKA Shogo
TOMIOKA Kiyoshi
TOYODA Taichi
TSUDA Shigeki
UCHIYAMA Nahoko
UETAKE Atsuhiro
WATANABE Takumi

YAMADA Rumiko
YAMAGUCHI Tetsuji
YAMAJI Hiroki
YAMAMOTO Keiji
YAMASHITA Chikamasa
YASUHARA Masato
YOMOTA Chikako
YONEDA Sachiyo
YONEMOCHI Etsuo
YOSHIDA Hiroyuki
YOSHIDA Naoya

*: Chairman, the Committee on JP

** : Acting Chairman, the Committee on JP

**Supplement II to
The Japanese
Pharmacopoeia
Seventeenth Edition**

GENERAL NOTICES

Change the paragraphs 5, 13 and 46 as follows:

5. The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. However, the headings of “Description” and in addition “Containers and storage” and “Shelf life” in the monographs on preparations are given for information, and should not be taken as indicating standards for conformity. Nevertheless, Containers under “Containers and storage” in the monograph on preparations containing crude drugs as main active ingredients are the standards for conformity.

13. When an assurance that a product is of the JP Drug quality is obtained consistently from data derived from the manufacturing process validation studies, and from the records of appropriate manufacturing process control and of the test results of the quality control, the performance of some test items in the monograph at release on a product may be omitted as occasion demands. Moreover, the quality evaluation of final products (drug substances and drug products) based on in-process data including in-process testing results and monitoring data on process parameters can replace specifications and test methods in the monograph or performing the test methods, if appropriate.

46. For the JP Drugs, the contents or potency in terms of units of the active ingredient(s) in the monographs have to be shown on the immediate container or wrapping of them.

GENERAL RULES FOR PREPARATIONS

[3] Monographs for Preparations

Change the following paragraphs:

3. Preparations for Injection

3-1. Injections

(1) Injections are sterile preparations to be administered directly into the body through skin, muscle or blood vessel, usually in form of a solution, a suspension or an emulsion of active substance(s), or of a solid that contains active substance(s) to be dissolved or suspended before use.

Parenteral Infusions, Implants/Pellets, Prolonged-Release Injections and Liposome Injections are included in this category.

(14) Unless otherwise specified, Injections and vehicles attached to preparations meet the requirements of Insoluble Particulate Matter Test for Injections <6.07> or Insoluble Particulate Matter Test for Therapeutic Protein Injections <6.17>.

Add the following next to 3-1-3. Prolonged Release Injections:

3-1-4. Liposome Injections

(1) Liposome Injections are injections to be used for intravenous administration, which are intended for improvement of in vivo stability, delivery to a target region and control of release, of active substance(s).

(2) Liposome Injections are usually prepared by using amphipathic lipid, etc. to make aqueous injections or freeze-dried injections in which closed microvesicles composed of a lipid bilayer membrane are dispersed.

(3) Liposome Injections have an appropriate function of controlled release.

(4) Liposome Injections have an appropriate particle size.

GENERAL TESTS, PROCESSES AND APPARATUS

Change the introduction to read:

General Tests, Processes and Apparatus includes common methods for tests, useful test methods for quality recognition of drugs and other articles related to them. Unless otherwise specified, acid-neutralizing capacity determination of gastrointestinal medicines, aerodynamic particle size measurement for inhalations, alcohol number determination, amino acid analysis of proteins, ammonium determination, arsenic determination, atomic absorption spectrophotometry, boiling point determination, chloride determination, conductivity measurement, congealing point determination, determination of bulk and tapped densities, digestion test, disintegration test, dissolution test, distilling range determination, elemental impurities procedures, endpoint determination in titrimetry, flame coloration, fluorometry, foreign insoluble matter test for injections, foreign insoluble matter test for ophthalmic liquids and solutions, gas chromatography, glycosylation analysis of glycoprotein, heavy metal determination, inductively coupled plasma-atomic emission spectrometry and inductively coupled plasma-mass spectrometry, infrared spectrophotometry, insoluble particulate matter test for injections, insoluble particulate matter test for ophthalmic liquids and solutions, insoluble particulate matter test for therapeutic protein injections, iron determination, laser diffraction measurement of particle size, liquid chromatography, loss on drying determination, loss on ignition determination, mass spectrometry, melting point determination, methanol determination, methods for color matching, methods of adhesion testing, microbial assay for antibiotics, mineral oil determination, nitrogen determination, nuclear magnetic resonance spectroscopy, optical rotation determination, osmolarity determination, oxygen flask combustion method, particle size determination, particle size distribution test for preparations, pH determination, powder particle density determination, qualitative test, raman spectroscopy, refractive index determination, release test for preparations for cutaneous application, residual solvents, residue on ignition determination, rheological measurements for semi-solid preparations, specific gravity and density determination, specific surface area determination, sulfate determination, test for bacterial endotoxins, test for glass containers for injections, test for metal particles in ophthalmic ointments, test for microbial limit, test for microbial limit for crude drugs, test for plastic containers, test for pyrogen, test for readily carbonizable substances, test for rubber closure for aqueous infusions, test for sterility, test for total organic carbon, test of extractable volume for injection, thermal analysis, thin-layer chromatography, turbidity measurement, ultraviolet-visible spectrophotometry, uniformity of

delivered dose for inhalations, uniformity of dosage units (test for content uniformity, mass variation test), viscosity determination, vitamin A assay, water determination, and X-ray powder diffraction are performed as directed in the corresponding articles under the General Tests, Processes and Apparatus. The tests for melting point of fats, congealing point of fatty acids, specific gravity, acid value, saponification value, ester value, hydroxyl value, unsaponifiable matter and iodine value of fats and fatty oils are performed as directed in the corresponding items under Fats and Fatty Oils Test, and sampling, preparation of sample for analysis, microscopic examination, purity test, loss on drying, total ash, acid-insoluble ash, extract content, essential oil content of crude drugs and assay of marker compounds for the assay of crude drugs and extracts of Kampo Formulations utilizing nuclear magnetic resonance (NMR) spectroscopy are performed as directed in the corresponding items under the Crude Drugs Test.

The number of each test method is a category number given individually. The number in brackets (< >) appeared in monograph indicates the number corresponding to the general test method.

2.01 Liquid Chromatography

Change the Section 7. Point to consider on changing the operating conditions as follows:

7. Point to consider on changing the operating conditions

Among the operating conditions specified in the individual monograph, inside diameter and length of the column, particle size of the packing material (pore size in the case of monolithic columns), column temperature, composition ratio of the mobile phase, composition of buffer solutions in the mobile phase, pH of the mobile phase, concentration of ion-pair forming agents in the mobile phase, ionic strength of the mobile phase, flow rate of the mobile phase, number and timing of mobile phase composition changes in gradient program, flow rate of mobile phase in gradient program, composition and flow rate of derivatizing reagents, and reaction time and chamber temperature in chemical reaction may be modified within the ranges in which the liquid chromatographic system used conforms to the requirements of system suitability.

Add the following:

2.26 Raman Spectroscopy

Raman spectroscopy is a vibrational spectroscopic technique, which evaluates a sample to be examined qualitatively or quantitatively by analyzing a spectrum obtained by dispersing very weak scattered light, having different wavelengths from irradiation light, generated when the sample is irradiated with the light. Raman scattering is observed when the polarizability of molecules changes with the vibration of chemical bonds of molecules in a sample.

Raman spectroscopy generally uses monochromatic laser light as excitation light. When the laser light is irradiated to the sample to be examined, the molecules in the sample is excited and the light with the same wavelength of the irradiation light, known as Rayleigh scattering, is scattered. The scattered light detected in the shorter wavelength side than the Rayleigh scattering is referred to as anti-Stokes scattering. The scattered light detected in the longer wavelength side than the Rayleigh scattering is referred to as Stokes scattering. Generally Stokes scattering with strong Raman scattering intensity is used for analysis. Raman spectra are usually indicated by Raman shift on the horizontal axis and Raman scattering intensity on the vertical axis.

Raman spectroscopy is capable of measuring samples (solid, semi-solid, liquid, gas, etc.) rapidly and non-destructively without pre-treatment. Application of Raman spectroscopy in the pharmaceutical field includes qualitative or quantitative evaluation of the active pharmaceutical ingredients and additives in drug substances or drug products. Raman spectroscopy can also be used for the evaluation of the physical conditions of substances, such as crystal form and crystallinity. Raman micro-spectroscopy can also be used for the evaluation of the distributions of active pharmaceutical ingredients and additives in the drug products. Furthermore, using an optical fiber probe enables it to measure the spectra of samples at a location remote from the equipment body without sampling, so that it can be used to perform pharmaceutical manufacturing process control online (or in-line).

1. Apparatus

Raman spectrometers are composed of a light source unit, a sample unit, a spectrometry unit, a detector unit, a signal processing unit, a data processing unit and a display-record-output unit. Raman spectrometers are classified into dispersive Raman spectrometers and Fourier transform Raman spectrometers according to their spectroscopic systems.

1.1. Light source

The laser which stably emits monochromatic light as excitation light to samples is used for the light source. The lasers include gas lasers such as a He-Ne laser and solid state lasers, and select a laser with wavelengths and output power according to the purpose. Pay attention to safety standards relating to a laser, when this test is performed.

1.2. Sample unit

The sample unit is composed of an optical system for col-

lecting Raman scattering light generated by irradiation of excitation light and a sample cell. Combination of these take the form of a sample chamber, while there are apparatuses with no sample chamber, such as optical fiber probes and portable Raman spectrometers that can be carried. Representative sample chambers are macroscopic sample chambers and microscopic sample chambers. The components of these optical systems are different, respectively.

1.3. Monochromator and detector

Many dispersive Raman spectrometers use an optical filter to eliminate excitation light and use a single monochromator combined with a multichannel detector, since the configuration is simple and high sensitivity can be obtained. Detectors include multiple elements detectors and single element detectors, and general dispersive Raman spectrometers use a multiple elements detector such as a CCD detector.

Fourier transform (FT) Raman spectrometers obtain spectra by Fourier transformation of interference waveforms using an interferometer. FT-Raman spectrometers are mainly used for near infrared Raman measurement.

2. Methods Used for Measurement

The Raman spectroscopy is applicable to solid samples having a complicated shape in addition to gas/solution samples inside a glass sample cell being transparent in the visible region, using mainly light in the visible region as excitation light. In the view of the size of a measurement region and Raman scattering efficiency, an optimum optical system is selected according to the sample. The excitation wavelength, the measurement mode of the apparatus, etc. are selected and set.

2.1. Macroscopic measurement

Since the macroscopic sample chamber has a high degree of freedom in the scattering configuration, samples can be measured irrespective of solid, liquid, gas, size and shape. It is also applicable to Raman measurement under low temperature, high temperature and high pressure which require the setting of a large sample cell. Usually, in the macroscopic sample chamber three configurations: forward scattering (transmission), 90° scattering and back scattering configurations, can be usable and an appropriate scattering configuration can be selected depending on a sample.

2.2. Microscopic measurement

The microscopic sample chamber is based on an optical microscope and applicable to local analysis. In the optical system of the microscopic sample chamber a microscope objective lens works simultaneously as an excitation light converging lens and a Raman scattering light condensing lens.

Mapping measurement repeats local measurements by moving a sample or laser light position to generate a Raman image showing the two or three dimensional distribution of Raman scattering intensity. Raman images are made by using various spectral information such as a ratio of the intensity of two bands.

2.3. Probe measurement

The optical fiber probe is the collective term of the apparatus of which sample section is separated from a Raman spectrometer body by using an optical fiber and is applica-

ble to *in situ* measurement and on-line (or in-line) measurement.

2.4. Measurement by portable apparatus

The portable Raman spectrometer is possible to carry and perform analysis using Raman spectroscopy outside of laboratory. Main application of this apparatus is judgement on acceptance of pharmaceutical materials. It is used for rather simple measurement.

2.5. Points to note in measurement

Note the following points for solid, liquid and suspended samples.

(i) Measurement of solid sample: There is a possibility that the filling status, the difference in the particle diameter and the roughness of the surface of the sample could affect the scattering intensity. When measuring a crystalline sample, be careful about the effect of crystal shape. There is also a possibility that the light transparency of the sample affect the spectrum intensity. When a sample is physically and chemically inhomogeneous, it might be recommended to enlarge the spot size of laser irradiation, measure plural samples, measure the plural points of the same sample or crush the sample to homogenize.

(ii) Measurement of liquid sample: It is possible to subtract the spectrum of the solvent if there is no interaction between the solvent and the sample. When there are insoluble matters in solution, remove the matters using a filter before measurement not to obtain the Raman scattering of the matters. When a sample shows high reactivity by laser irradiation in solution, measure the sample by stirring carefully not to irradiate the same place.

(iii) Measurement of suspended sample: A suspended sample may settle, so be careful about the positioning of laser irradiation. For samples that are prone to settle, devising measurement such as optimizing the irradiation time and stirring might be helpful. When the Raman scattering of a suspended sample is weak, it is also possible to subtract the spectrum of the solvent likewise the case of measurement of a liquid sample.

3. Factors that affect spectrum

When Raman spectroscopy is applied, note the following items as factors affecting spectra.

3.1. Temperature of sample

Sample heating by laser irradiation can cause a variety of effects, such as physical form change (melting and burning) and polymorph transform. Since the chance of sample heating is increased when the spot size of laser irradiation at the sample is squeezed, be careful not to damage sample when microscopic measurement is carried out. To prevent the sample overheating, a variety of methods can be employed such as suppressing laser output, irradiating a laser without focusing and cooling a sample.

3.2. Sample characteristics

Since Raman signals are very weak, the fluorescence of a sample itself and minute impurities may interfere with Raman scattering light. Fluorescence can be reduced by choosing an excitation light source with a longer wavelength, however it should be noted that it generally decreases the

intensity of the Raman scattering. Photobleaching resulted by laser irradiation before measurement, appropriate irradiation time and accumulation count may mitigate the fluorescence.

When measuring a colored sample, select the wavelength of an excitation laser depending on the absorption characteristics of the sample. When measuring a sample in a container such as, a cell for measurement, a bag or a bottle, take careful note of the spectral characteristics derived from the container in addition to the sample.

4. Control of apparatus performance

Estimate the accuracy of the wave number of Raman shift after adjusting a Raman spectrometer. Measure Raman spectra using an excitation laser utilized for actual measurement and an appropriate standard substance. Polystyrene is an example.

In the cases of 2.1., 2.2. and 2.3., make correction using at least three wave numbers among the below peak wave numbers (cm^{-1}) obtained from the spectrum of polystyrene. The number in parentheses indicates the permissible range.

620.9 (± 1.5)

1001.4 (± 1.5)

1031.8 (± 1.5)

1602.3 (± 1.5)

3054.3 (± 3.0) (Note: 3054.3 cm^{-1} cannot be measured depending on an excitation wavelength.)

In the case of 2.4., make correction in the same manner using at least three wave numbers among the below peak wave numbers (cm^{-1}).

620.9 (± 2.5)

1001.4 (± 2.0)

1031.8 (± 2.0)

1602.3 (± 3.0)

Other substance such as cyclohexane can be used as a standard substance, if it is validated.

5. Qualitative and quantitative analysis

5.1. Qualitative analysis

As Raman spectroscopy observe the vibrational energy of a molecule and can obtain a characteristic spectrum depending on the structure of a substance to be analyzed, qualitative analysis based on chemical structural information can be performed.

When the Raman spectra of a sample and the Reference Standard of a substance to be identified are compared and both spectra exhibit similar scattering intensities at the same Raman shifts, the identity of those can be confirmed.

When a sample treatment method for a solid sample is indicated in the monograph in the case of nonconformity of the scattering spectrum with that of the Reference Standard, treat the sample and the Reference Standard under the condition as directed in the monograph, then repeat the measurement.

When the characteristic scattering wave numbers of a substance to be identified are specified in the monograph, the clear appearance of the scattering of a sample at all the specified scattering wave numbers can confirm the identity of the sample with the substance to be identified.

Raman spectroscopy is also applicable to the process control of drug substances or drug products by using a score obtained from a Raman spectrum by a chemometric methodology such as principal component analysis, and characteristic peak wave numbers of the substance to be examined, as indices. Chemometrics usually means mathematical technique and statistic technique for quantization and informatization of chemical data.

5.2. Quantitative analysis

The concentrations of components of a sample to be analyzed can be calculated by calibration curves plotting the relationship between scattering intensity at a specified wave number and concentration. In the case where the composition of components of a sample is complicated, the concentrations of components in the sample can also be calculated by developing a calibration model about a spectrum measured using an existing standard sample by a chemometric methodology and applying the model to the spectrum of the sample to be examined. Chemometric methodologies for obtaining a calibration model include multiple regression analysis method and PLS (Partial least squares) regression analysis method.

The variation of peak intensity at around the reference values of wave numbers using a standard sample, polystyrene etc. used in 4., is preferable to be within $\pm 10\%$ compared to that obtained in the last measurement.

2.46 Residual Solvents

Change as follows:

The chapter of residual solvents describes the control, identification and quantification of organic solvents remaining in drug substances, excipients and drug products.

I. Control of residual solvents

1. Introduction

Residual solvents in pharmaceuticals (except for crude drugs and their preparations) are defined here as organic volatile chemicals that are used or produced in the manufacture of drug substances or excipients, or in the preparation of drug products. The solvents are not completely removed by practical manufacturing techniques. Appropriate selection of the solvent for the synthesis of drug substance may enhance the yield, or determine characteristics such as crystal form, purity, and solubility. Therefore, the solvent may sometimes be a critical parameter in the synthetic process. The test method described in this chapter does not address solvents deliberately used as excipients nor does it address solvates. However, the content of solvents in such products should be evaluated and justified.

Since there is no therapeutic benefit from residual solvents, all residual solvents should be reduced to the extent possible to meet product specifications, good manufacturing practices, or other quality-based requirements. Drug products should contain no higher levels of residual solvents than can be supported by safety data. Some solvents that

are known to cause unacceptable toxicities (Class 1, Table 2.46-1) should be avoided in the production of drug substances, excipients, or drug products unless their use can be strongly justified in a risk-benefit assessment. Some solvents associated with less severe toxicity (Class 2, Table 2.46-2) should be limited in order to protect patients from potential adverse effects. Ideally, less toxic solvents (Class 3, Table 2.46-3) should be used where practical.

Testing should be performed for residual solvents when production or purification processes are known to result in the presence of such solvents. It is only necessary to test for solvents that are used or produced in the manufacture or purification of drug substances, excipients, or drug products. Although manufacturers may choose to test the drug product, a cumulative method may be used to calculate the residual solvent levels in the drug product from the levels in the ingredients used to produce the drug product. If the calculation results in a level equal to or below that recommended in this chapter, no testing of the drug product for residual solvents needs to be considered. If, however, the calculated level is above the recommended level, the drug product should be tested to ascertain whether the formulation process has reduced the relevant solvent level to within the acceptable amount. Drug product should also be tested if a solvent is used during its manufacture.

The limit applies to all dosage forms and routes of administration. Higher levels of residual solvents may be acceptable in certain cases such as short term (30 days or less) or topical application. Justification for these levels should be made on a case by case basis.

2. General principles

2.1. Classification of residual solvents by risk assessment

The term "PDE" (Permitted Daily Exposure) is defined in this chapter as a pharmaceutically acceptable daily intake of residual solvents. Residual solvents assessed in this chapter were evaluated for their possible risk to human health and placed into one of three classes as follows:

(i) Class 1 solvents: Solvents to be avoided in manufacture of pharmaceuticals

Known human carcinogens, strongly suspected human carcinogens, and environmental hazards. Class 1 solvents are listed in Table 2.46-1.

(ii) Class 2 solvents: Solvents to be limited in pharmaceuticals

Non-genotoxic animal carcinogens or possible causative agents of other irreversible toxicity such as neurotoxicity or teratogenicity. Solvents suspected of other significant but reversible toxicities. Class 2 solvents are listed in Table 2.46-2.

(iii) Class 3 solvents: Solvents with low toxic potential
Solvents with low toxic potential to human; no health-based exposure limit is needed. Class 3 solvents are listed in Table 2.46-3 and have PDEs of 50 mg or more per day.

2.2. Option for describing limits of Class 2 solvents

Two options are available when setting limits for Class 2 solvents.

2.2.1. Option 1

The concentration limits in ppm can be calculated using equation (1) below by assuming a product mass of 10 g administered daily.

$$\text{Concentration limit (ppm)} = \frac{1000 \times PDE}{\text{dose}} \quad (1)$$

Here, PDE is given in terms of mg per day and dose is given in g per day.

These limits are considered acceptable for all substances, excipients, or products. Therefore this option may be applied if the daily dose is not known or fixed. If all excipients and drug substances in a formulation meet the limits given in Option 1, then these components may be used in any proportion. No further calculation is necessary provided the daily dose does not exceed 10 g. Products that are administered in doses greater than 10 g per day should be considered under Option 2.

2.2.2. Option 2

It is not considered necessary for each component of the drug product to comply with the limits given in Option 1. The PDE in terms of mg per day as stated in Table 2.46-2 can be used with the known maximum daily dose and equation (1) above to determine the concentration of residual solvent allowed in drug product. Such limits are considered acceptable provided that it has been demonstrated that the residual solvent has been reduced to the practical minimum. The limits should be realistic in relation to analytical precision, manufacturing capability, reasonable variation in the manufacturing process, and the limits should reflect contemporary manufacturing standards.

Option 2 may be applied by adding the amounts of a residual solvent present in each of the components of the drug product. The sum of the amounts of solvent per day should be less than that given by the PDE.

3. Analytical procedures

Residual solvents are typically determined using chromatographic techniques such as gas chromatography. If only Class 3 solvents are present, a nonspecific method such as loss on drying may be used. The analytical method should be validated adequately.

4. Reporting levels of residual solvents

Manufacturers of drug products need certain information about the content of residual solvents in excipients or drug substances. The following statements are given as acceptable examples of the information.

(i) Only Class 3 solvents are likely to be present. Loss on drying is not more than 0.5%.

(ii) Only Class 2 solvents are likely to be present. Name the Class 2 solvents that are present. All are not more than the Option 1 limit.

(iii) Only Class 2 solvents and Class 3 solvents are likely to be present. Residual Class 2 solvents are not more than the Option 1 limit and residual Class 3 solvents are not more than 0.5%.

If Class 1 solvents are likely to be present, they should be identified and quantified. "Likely to be present" refers to the solvents that were used in the final manufacturing step

and to the solvents that were used in earlier manufacturing steps and not always possible to be excluded even in a validated process.

If solvents of Class 2 or Class 3 are present at greater than their Option 1 limits or 0.5%, respectively, they should be identified and quantified.

5. Limits of residual solvents**5.1. Solvents to be avoided in manufacture of pharmaceuticals**

Solvents in Class 1 should not be employed in the manufacture of drug substances, excipients, and drug products because of their unacceptable toxicity or their deleterious environmental effect. However, if their use is unavoidable in order to produce a drug product with a significant therapeutic advance, then their levels should be restricted as shown in Table 2.46-1, unless otherwise justified. 1,1,1-Trichloroethane is included in Table 2.46-1 because it is an environmental hazard. The stated limit of 1500 ppm shown in Table 2.46-1 is based on a review of the safety data.

Table 2.46-1 Class 1 solvents in drug products (solvents that should be avoided)

Solvent	Concentration Limit (ppm)	Concern
Benzene	2	Carcinogen
Carbon tetrachloride	4	Toxic and environmental hazard
1,2-Dichloroethane	5	Toxic
1,1-Dichloroethene	8	Toxic
1,1,1-Trichloroethane	1500	Environmental hazard

5.2. Solvents to be limited in pharmaceuticals

Solvents in Table 2.46-2 should be limited in drug products because of their inherent toxicity.

PDEs are given to the nearest 0.1 mg per day, and concentrations are given to the nearest 10 ppm. The stated values do not reflect the necessary analytical precision of determination. Precision should be determined as part of the validation of the method.

5.3. Solvents with low toxic potential

Solvents in Class 3 shown in Table 2.46-3 may be regarded as less toxic and of lower risk to human health. Class 3 includes no solvent known as a human health hazard at levels normally accepted in pharmaceuticals. The amounts of these residual solvents of 50 mg per day or less (corresponding to 5000 ppm or 0.5% under Option 1) would be acceptable without justification. Higher amounts may also be acceptable provided they are realistic in relation to manufacturing capability and good manufacturing practice.

5.4 Solvents for which no adequate toxicological data was found

The following solvents (Table 2.46-4) may also be of interest to manufacturers of drug substances, excipients, or drug products. However, no adequate toxicological data on

Table 2.46-2 Class 2 Solvents which residual amount should be limited in drug products

Solvent	PDE (mg/day)	Concentration limit (ppm)
Acetonitrile	4.1	410
Chlorobenzene	3.6	360
Chloroform	0.6	60
Cumene	0.7	70
Cyclohexane	38.8	3880
1,2-Dichloroethene	18.7	1870
Dichloromethane	6.0	600
1,2-Dimethoxyethane	1.0	100
<i>N,N</i> -Dimethylacetamide	10.9	1090
<i>N,N</i> -Dimethylformamide	8.8	880
1,4-Dioxane	3.8	380
2-Ethoxyethanol	1.6	160
Ethylene glycol	3.1	310
Formamide	2.2	220
Hexane	2.9	290
Methanol	30.0	3000
2-Methoxyethanol	0.5	50
Methyl butyl ketone	0.5	50
Methylcyclohexane	11.8	1180
Methyl isobutyl ketone	45	4500
<i>N</i> -Methylpyrrolidone	5.3	530
Nitromethane	0.5	50
Pyridine	2.0	200
Sulfolane	1.6	160
Tetrahydrofuran	7.2	720
Tetralin	1.0	100
Toluene	8.9	890
1,1,2-Trichloroethene	0.8	80
Xylene*	21.7	2170

* Usually 60% *m*-xylene, 14% *p*-xylene, 9% *o*-xylene with 17% ethylbenzene

Table 2.46-3 Class 3 solvents which should be limited by GMP or other quality-based requirements

Acetic acid	Heptane
Acetone	Isobutyl acetate
Anisole	Isopropyl acetate
1-Butanol	Methyl acetate
2-Butanol	3-Methyl-1-butanol
<i>n</i> -Butyl acetate	Methyl ethyl ketone
<i>tert</i> -Butyl methyl ether	2-Methyl-1-propanol
Dimethylsulfoxide	Pentane
Ethanol	1-Pentanol
Ethyl acetate	1-Propanol
Diethyl ether	2-Propanol
Ethyl formate	Propyl acetate
Formic acid	Triethylamine

which to base a PDE was found. Manufacturers should supply justification for residual levels of these solvents in

Table 2.46-4 Solvents for which no adequate toxicological data was found

1,1-Diethoxypropane	Methyl isopropyl ketone
1,1-Dimethoxymethane	Methyltetrahydrofuran
2,2-Dimethoxypropane	Petroleum ether
Isooctane	Trichloroacetic acid
Isopropyl ether	Trifluoroacetic acid

drug products.

II. Identification and quantification of residual solvents

Whenever possible, the substance under test needs to be dissolved to release the residual solvent. Because drug products, as well as active ingredients and excipients are treated, it may be acceptable that in some cases, some of the components of the formulation will not dissolve completely. In those cases, the drug product may first need to be pulverized into a fine powder so that any residual solvent that may be present can be released. This operation should be performed as fast as possible to prevent the loss of volatile solvents during the procedure.

In the operating conditions of gas chromatography and headspace described below, parameters to be set and their description may be different depending on the apparatus. When setting these conditions, it is necessary to change them according to the apparatus used, if it is confirmed that they meet the system suitability.

In addition to the reagents specified to be used for the test, those that meet the purpose of the test can be used.

1. Class 1 and Class 2 residual solvents

The following procedures are useful to identify and quantify residual solvents when the information regarding which solvents are likely to be present in the material is not available. When the information about the presence of specific residual solvents are available, it is not necessary to perform Procedure A and Procedure B, and only Procedure C or other appropriate procedure is needed to quantify the amount of residual solvents.

A flow chart for the identification of residual solvents and the application of limit and quantitative tests is shown in Fig. 2.46-1.

1.1. Water-soluble articles

1.1.1. Procedure A

The test is performed by gas chromatography <2.02> according to the following conditions.

Class 1 standard stock solution: Pipet 1 mL of Residual Solvents Class 1 RS, dissolve in about 9 mL of dimethylsulfoxide, and add water to make exactly 100 mL. Pipet 1 mL of this solution in a volumetric flask, previously filled with about 50 mL of water and add water to make exactly 100 mL. Pipet 10 mL of this solution in a volumetric flask, previously filled with about 50 mL of water and add water to make exactly 100 mL.

Class 1 standard solution: Pipet 1 mL of Class 1 standard stock solution in an appropriate head space vial containing exactly 5 mL of water, apply the stopper, cap, and mix.




Fig. 2.46-1 Flow chart for the identification of residual solvents and the application of limit and qualification tests.

Class 2 standard stock solution A: Pipet 1 mL of Residual Solvents Class 2A RS, add water to make exactly 100 mL.

Class 2 standard stock solution B: Pipet 1 mL of Residual Solvents Class 2B RS, add water to make exactly 100 mL.

Class 2 standard stock solution C: Pipet 1 mL of Residual Solvents Class 2C RS, add water to make exactly 100 mL.

Class 2 standard solution A: Pipet 1 mL of Class 2 standard stock solution A in an appropriate headspace vial, add exactly 5 mL of water, apply the stopper, cap, and mix.

Class 2 standard solution B: Pipet 5 mL of Class 2 standard stock solution B in an appropriate headspace vial, add exactly 1 mL of water, apply the stopper, cap, and mix.

Class 2 standard solution C: Pipet 1 mL of Class 2 standard stock solution C in an appropriate headspace vial, add exactly 5 mL of water, apply the stopper, cap, and mix.

Test stock solution: Dissolve 0.25 g of the article under test in water, and add water to make exactly 25 mL.

Test solution: Pipet 5 mL of test stock solution in an appropriate headspace vial, add exactly 1 mL of water, and apply the stopper, cap, and mix.

Class 1 system suitability solution: Pipet 1 mL of Class 1 standard stock solution in an appropriate headspace vial, add exactly 5 mL of test stock solution, and apply the stopper, cap, and mix.

Operating conditions—

Detector: A hydrogen flame-ionization detector.

Column: A fused silica column (or a wide-bore column) 0.32 mm (or 0.53 mm) in inside diameter and 30 m in length, coated with 6% cyanopropylphenyl-94% dimethyl silicon polymer for gas chromatography in 1.8 μm (or 3.0 μm) thickness.

Column temperature: Maintain at 40°C for 20 minutes after injection, raise the temperature to 240°C at a rate of 10°C per minute, and maintain at 240°C for 20 minutes.

Injection port temperature: 140°C.

Detector temperature: 250°C.

Carrier gas: Nitrogen or Helium.

Flow rate: About 35 cm per second.

Split ratio: 1:5. (Note: The split ratio can be modified in order to optimize sensitivity.)

System suitability—

Test for required detectability: When the procedure is run with Class 1 standard solution and Class 1 system suitability solution under the above operating conditions, the SN ratio of the peak of 1,1,1-trichloroethane in Class 1 standard solution is not less than 5, and the SN ratio of each peak in Class 1 system suitability solution is not less than 3, respectively.

System performance: When the procedure is run with Class 2 standard solution A or the solution for system suitability under the above operating conditions, the resolution between acetonitrile and dichloromethane is not less than 1.0. Pipet 1 mL of a solution of Residual Solvents RS for System Suitability (1 in 100) in an appropriate headspace vial, add exactly 5 mL of water, and apply the stopper, cap, and mix, and use this solution as the solution for system suitability.

System repeatability: When the test is repeated 6 times with Class 1 standard solution under the above operating conditions, the relative standard deviation of each peak area is not more than 15%.

Separately inject (following one of the headspace operating parameter sets described in Table 2.46-5) equal volumes of headspace (about 1.0 mL) of Class 1 standard solution, Class 2 standard solution A, Class 2 standard solution B, Class 2 standard solution C and test solution into the chromatograph, record the chromatograms, and measure the responses for the major peaks. If a peak response of any peak, other than a peak for 1,1,1-trichloroethane, in the test solution is greater than or equal to a corresponding peak in either Class 1 standard solution, Class 2 standard solution A, Class 2 standard solution B or Class 2 standard solution C, or a peak response of 1,1,1-trichloroethane is greater than or equal to 150 times the peak response corresponding to 1,1,1-trichloroethane in Class 1 standard solution, proceed to Procedure B to verify the identity of the peak; otherwise the article meets the requirements of this test.

1.1.2. Procedure B

The test is performed by gas chromatography <2.02> according to the following conditions.

Class 1 standard stock solution, Class 1 standard solution, Class 1 system suitability solution, Class 2 standard

stock solutions A, B and C, Class 2 standard solutions A, B and C, test stock solution and test solution: Prepare as directed for Procedure A.

Operating conditions—

Detector: A hydrogen flame-ionization detector.

Column: A fused silica column (or a wide-bore column) 0.32 mm (or 0.53 mm) in inside diameter and 30 m in length, coated with polyethylene glycol for gas chromatography in 0.25 μ m thickness.

Column temperature: Maintain at 50°C for 20 minutes after injection, raise the temperature to 165°C at a rate of 6°C per minute, and maintain at 165°C for 20 minutes.

Injection port temperature: 140°C.

Detector temperature: 250°C.

Carrier gas: Nitrogen or Helium.

Flow rate: About 35 cm per second.

Split ratio: 1:5. (Note: The split ratio can be modified in order to optimize sensitivity.)

System suitability—

Test for required detectability: When the procedure is run with Class 1 standard solution and Class 1 system suitability solution under the above operating conditions, the SN ratio of the peak of benzene in Class 1 standard solution is not less than 5, and the SN ratio of each peak in Class 1 system suitability solution is not less than 3, respectively.

System performance: When the procedure is run with Class 2 standard solution A or the solution for system suitability under the above operating conditions, the resolution between acetonitrile and *cis*-1,2-dichloroethene is not less than 1.0. Pipet 1 mL of a solution of Residual Solvents RS for System Suitability (1 in 100) in an appropriate headspace vial, add exactly 5 mL of water, and apply the stopper, cap, and mix, and use this solution as the solution for system suitability.

System repeatability: When the test is repeated 6 times with Class 1 standard solution under the above operating conditions, the relative standard deviation of each peak area is not more than 15%.

Separately inject (following one of the headspace operating parameter sets described in Table 2.46-5) equal volumes of headspace (about 1.0 mL) of Class 1 standard solution, Class 2 standard solution A, Class 2 standard solution B, Class 2 standard solution C and test solution into the chromatograph, record the chromatograms, and measure the responses for the major peaks. If the peak response(s) in the test solution of the peak(s) identified in Procedure A is/are greater than or equal to a corresponding peak(s) in either Class 1 standard solution, Class 2 standard solution A, Class 2 standard solution B or Class 2 standard solution C, proceed to Procedure C to quantify the peak(s); otherwise the article meets the requirements of this test.

1.1.3. Procedure C

The test is performed by gas chromatography <2.02> according to the following conditions.

Class 1 standard stock solution, Class 1 standard solution, Class 2 standard stock solution A, Class 2 standard solution A, Class 2 standard stock solution C, Class 2 standard solution C and Class 1 system suitability solution:

Prepare as directed for Procedure A.

Standard stock solution (Note: Prepare a separate standard stock solution for each peak identified and verified by Procedures A and B. For Class 1 solvents other than 1,1,1-trichloroethane, prepare the first dilution as directed for the first dilution under Class 1 standard stock solution in Procedure A.): Transfer an accurately measured volume of each individual solvent corresponding to each residual solvent peak identified and verified by Procedures A and B to a suitable container, and dilute quantitatively and stepwise if necessary, with water to obtain a solution having a final concentration of 1/20 of the value stated in Table 2.46-1 or Table 2.46-2.

Standard solution: Pipet 1 mL of standard stock solution in an appropriate headspace vial, add exactly 5 mL of water, and apply the stopper, cap, and mix.

Test stock solution: Weigh accurately about 0.25 g of the article under test, dissolve in water, and add water to make exactly 25 mL.

Test solution: Pipet 5 mL of test stock solution in an appropriate headspace vial, add exactly 1 mL of water, and apply the stopper, cap, and mix.

Spiked test solution (Note: prepare a separate spiked test solution for each peak identified and verified by Procedure A and B): Pipet 5 mL of test stock solution in an appropriate headspace vial, add exactly 1 mL of standard stock solution, and apply the stopper, cap, and mix.

Operating conditions and system suitability fundamentally follow the procedure A. Test for required detectability is unnecessary, and use Standard solution instead of Class 1 standard solution for system repeatability. If the results of the chromatography from Procedure A are found to be inferior to those found with Procedure B, the operating conditions from Procedure B may be substituted.

Separately inject (following one of the headspace operating parameters described in Table 2.46-5) equal volumes of headspace (about 1.0 mL) of the standard solution, test solution, and spiked test solution into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the amount of each residual solvent found in the article under test by the formula:

$$\text{Residual solvent (ppm)} = 5 (C/M) \{A_T / (A_S - A_T)\}$$

C: Concentration (μ g/mL) of the appropriate Reference Standard in the standard stock solution

M: Amount (g) of the article under test taken to prepare the test stock solution

A_T: Peak responses of each residual solvent obtained from the test solution

A_S: Peak responses of each residual solvent obtained from the spiked test solution

1.2. Water-insoluble articles

1.2.1. Procedure A

The test is performed by gas chromatography <2.02> according to the following conditions. Dimethylsulfoxide may be substituted as an alternative solvent to *N,N*-dimethylformamide.

Class 1 standard stock solution: Pipet 1 mL of Residual Solvents Class 1 RS, dissolve in about 80 mL of *N,N*-dimethylformamide, and add *N,N*-dimethylformamide to make exactly 100 mL. Pipet 1 mL of this solution in a volumetric flask, previously filled with about 80 mL of *N,N*-dimethylformamide and add *N,N*-dimethylformamide to make exactly 100 mL (this solution is the intermediate dilution prepared from Residual Solvents Class 1 RS and use it for preparation of Class 1 system suitability solution). Pipet 1 mL of this solution, and add *N,N*-dimethylformamide to make exactly 10 mL.

Class 1 standard solution: Pipet 1 mL of Class 1 standard stock solution in an appropriate head space vial containing exactly 5 mL of water, apply the stopper, cap, and mix.

Class 2 standard stock solution A: Pipet 1 mL of Residual Solvents Class 2A RS, dissolve in about 80 mL of *N,N*-dimethylformamide, and add *N,N*-dimethylformamide to make exactly 100 mL.

Class 2 standard stock solution B: Pipet 0.5 mL of Residual Solvents Class 2B RS, add *N,N*-dimethylformamide to make exactly 10 mL.

Class 2 standard stock solution C: Pipet 1 mL of Residual Solvents Class 2C RS, dissolve in about 80 mL of *N,N*-dimethylformamide, and add *N,N*-dimethylformamide to make exactly 100 mL.

Class 2 standard solution A: Pipet 1 mL of Class 2 standard stock solution A in an appropriate headspace vial, add exactly 5 mL of water, and apply the stopper, cap, and mix.

Class 2 standard solution B: Pipet 1 mL of Class 2 standard stock solution B in an appropriate headspace vial, add exactly 5 mL of water, and apply the stopper, cap, and mix.

Class 2 standard solution C: Pipet 1 mL of Class 2 standard stock solution C in an appropriate headspace vial, add exactly 5 mL of water, and apply the stopper, cap, and mix.

Test stock solution: Dissolve 0.5 g of the article under test in *N,N*-dimethylformamide, and add *N,N*-dimethylformamide to make exactly 10 mL.

Test solution: Pipet 1 mL of test stock solution in an appropriate headspace vial, add exactly 5 mL of water, and apply the stopper, cap, and mix.

Class 1 system suitability solution: Pipet 5 mL of test stock solution and 0.5 mL of the intermediate dilution prepared from Residual Solvents Class 1 RS, and mix. Pipet 1 mL of this solution in an appropriate headspace vial, add exactly 5 mL of water, and apply the stopper, cap, and mix.

Operating conditions—

Detector: A hydrogen flame-ionization detector.

Column: A wide-bore column 0.53 mm in inside diameter and 30 m in length, coated with 6% cyanopropylphenyl-94% dimethyl silicon polymer for gas chromatography in 3.0 μm thickness.

Column temperature: Maintain at 40°C for 20 minutes after injection, raise the temperature to 240°C at a rate of 10°C per minute, and maintain at 240°C for 20 minutes.

Injection port temperature: 140°C.

Detector temperature: 250°C.

Carrier gas: Helium.

Flow rate: About 35 cm per second.

Split ratio: 1:3. (Note: The split ratio can be modified in order to optimize sensitivity.)

System suitability—

Test for required detectability: When the procedure is run with Class 1 standard solution and Class 1 system suitability solution under the above operating conditions, the SN ratio of the peak of 1,1,1-trichloroethane in Class 1 standard solution is not less than 5, and the SN ratio of each peak in Class 1 system suitability solution is not less than 3, respectively.

System performance: When the procedure is run with Class 2 standard solution A or the solution for system suitability under the above operating conditions, the resolution between acetonitrile and dichloromethane is not less than 1.0. Pipet 1 mL of the *N,N*-dimethylformamide solution of Residual Solvents RS for System Suitability (1 in 100) in an appropriate headspace vial, add exactly 5 mL of water, and apply the stopper, cap, and mix, and use this solution as the solution for system suitability.

System repeatability: When the test is repeated 6 times with Class 1 standard solution under the above operating conditions, the relative standard deviation of each peak areas is not more than 15%.

Separately inject (use headspace operating parameters in column 3 of Table 2.46-5) equal volumes of headspace (about 1.0 mL) of Class 1 standard solution, Class 2 standard solution A, Class 2 standard solution B, Class 2 standard solution C, and test solution into the chromatograph, record the chromatograms, and measure the responses for the major peaks. If a peak response of any peak, other than a peak for 1,1,1-trichloroethane, in the test solution is greater than or equal to a corresponding peak in either Class 1 standard solution, Class 2 standard solution A, Class 2 standard solution B or Class 2 standard solution C, or a peak response of 1,1,1-trichloroethane is greater than or equal to 150 times the peak response corresponding to 1,1,1-trichloroethane in Class 1 standard solution, proceed to Procedure B to verify the identity of the peak; otherwise, the article meets the requirements of this test.

1.2.2. Procedure B

The test is performed by gas chromatography <2.02> according to the following conditions.

Class 1 standard stock solution, Class 1 standard solution, Class 1 system suitability solution, Class 2 standard stock solutions A, B and C, Class 2 standard solutions A, B and C, test stock solution, and test solution: Proceed as directed for Procedure A.

Proceed as directed for Procedure B under Water-soluble articles with a split ratio of 1:3. (Note: The split ratio can be modified in order to optimize sensitivity.) The solution for system suitability: Proceed as directed for Procedure A.

Separately inject (use headspace operating parameters in Table 2.46-5) equal volumes of headspace (about 1.0 mL) of Class 1 standard solution, Class 2 standard solution A, Class 2 standard solution B, Class 2 standard solution C and test solution into the chromatograph, record the chromatograms, and measure the responses for the major peaks. If the peak response(s) in test solution of the peak(s) identi-

fied in Procedure A is/are greater than or equal to a corresponding peak(s) in either Class 1 standard solution, Class 2 standard solution A, Class 2 standard solution B or Class 2 standard solution C, proceed to Procedure C to quantify the peak; otherwise, the article meets the requirements of this test.

1.2.3 Procedure C

The test is performed by gas chromatography <2.02> according to the following conditions.

Class 1 standard stock solution, Class 1 standard solution, Class 1 system suitability solution, Class 2 standard stock solution A, Class 2 standard solution A, Class 2 standard stock solution C and Class 2 standard solution C: Proceed as directed for Procedure A.

Standard stock solution (Note: Prepare a separate standard stock solution for each peak identified and verified by Procedures A and B. For Class 1 solvents other than 1,1,1-trichloroethane, prepare the first dilution as directed for the first dilution under Class 1 standard stock solution in Procedure A.): Transfer an accurately measured volume of each individual solvent corresponding to each residual solvent peak identified and verified by Procedures A and B to a suitable container, and dilute quantitatively and stepwise if necessary, with water to obtain a solution having a final concentration of 1/20 of the value stated in Table 2.46-1 or Table 2.46-2.

Standard solution: Pipet 1 mL of standard stock solution in an appropriate headspace vial, add exactly 5 mL of water, and apply the stopper, cap, and mix.

Test stock solution: Weigh accurately about 0.5 g of the article under test, and add *N,N*-dimethylformamide to make exactly 10 mL.

Test solution: Pipet 1 mL of test stock solution in an appropriate headspace vial, add exactly 5 mL of water, and apply the stopper, cap, and mix.

Spiked test solution (Note: prepare a separate spiked test solution for each peak identified and verified by Procedure A and B): Pipet 1 mL of test stock solution in an appropriate headspace vial, add exactly 4 mL of water, and apply the stopper, cap, and mix.

Operating conditions and system suitability fundamentally follow the procedure A. Test for required detectability is unnecessary, and use Standard solution instead of Class 1 standard solution for system repeatability. If the results of the chromatography from Procedure A are found to be inferior to those found with Procedure B, the operating conditions from Procedure B may be substituted.

Separately inject (use headspace operating parameters in Table 2.46-5) equal volumes of headspace (about 1.0 mL) of the standard solution, test solution, and spiked test solution into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the amount of each residual solvent found in the article under test by the formula:

$$\text{Residual solvent (ppm)} = 10 (C/M) \{A_T / (A_S - A_T)\}$$

C: Concentration ($\mu\text{g/mL}$) of the appropriate Reference Standard in the standard stock solution

Table 2.46-5 Headspace operating parameters

	Headspace Operating Parameter Sets		
	1	2	3
Equilibration temperature ($^{\circ}\text{C}$)	80	105	80
Equilibration time (min.)	60	45	45
Transfer-line temperature ($^{\circ}\text{C}$)	85	110	105
Syringe temperature ($^{\circ}\text{C}$)	80 – 90	105 – 115	80 – 90
Carrier gas: nitrogen or helium at an appropriate pressure			
Pressurization time (s)	≥ 60	≥ 60	≥ 60
Injection volume (mL)*	1	1	1

* Or follow the instrument manufacture's recommendations, as long as the method criteria are met. Injecting less than this amount is allowed as long as adequate sensitivity is achieved.

M : Amount (g) of the article under test taken to prepare the test stock solution

A_T : Peak responses of each residual solvent obtained from the test solution

A_S : Peak responses of each residual solvent obtained from the spiked test solution

1.3. Headspace operating parameters and other considerations

Examples of headspace operating parameters are shown in Table 2.46-5.

These test methods describe the analytical methods using the headspace gas chromatography. The following Class 2 residual solvents are not readily detected by the headspace injection conditions: 2-ethoxyethanol, ethylene glycol, formamide, 2-methoxyethanol, *N*-methylpyrrolidone, and sulfolane. Other appropriate validated procedures are to be employed for the quantification of these residual solvents. In the headspace methods, *N,N*-dimethylformamide and *N,N*-dimethylacetamide are often used as solvents. As not only 6 solvents described above but these two solvents are not included in the Residual Solvents Class 2A RS, the Residual Solvents Class 2B RS and/or the Residual Solvents Class 2C RS, appropriate validated procedures are to be employed for these residual solvents as necessary.

2. Class 3 residual solvents

Perform the test according to 1. Otherwise an appropriate validated procedure is to be employed. Prepare appropriately standard solutions, etc. according to the residual solvent under test.

If only Class 3 solvents are present, the level of residual solvents may be determined by Loss on Drying <2.41>. However when the value of the loss on drying is more than 0.5%, or other solvents exist, the individual Class 3 residual solvent or solvents present in the article under test should be identified using the procedures as described above or other appropriate procedure, and quantified as necessary.

3. Reference Standards

(i) Residual Solvents Class 1 RS (A mixture of benzene, carbon tetrachloride, 1,2-dichloroethane, 1,1-dichloroethene and 1,1,1-trichloroethane)

(ii) Residual Solvents Class 2A RS (A mixture of acetonitrile, chlorobenzene, cumene, cyclohexane, 1,2-dichloroethene (*cis*-1,2-dichloroethene, *trans*-1,2-dichloroethene), dichloromethane, 1,4-dioxane, methanol, methylcyclohexane, tetrahydrofuran, toluene and xylene (*m*-xylene, *p*-xylene, *o*-xylene, ethylbenzene))

(iii) Residual Solvents Class 2B RS (A mixture of chloroform, 1,2-dimethoxyethane, hexane, methyl butyl ketone, nitromethane, pyridine, tetralin and 1,1,2-trichloroethene)

(iv) Residual Solvents Class 2C RS (Methyl isobutyl ketone)

(v) Residual Solvents RS for System Suitability (A mixture of acetonitrile, *cis*-1,2-dichloroethene and dichloromethane)

2.51 Conductivity Measurement

Change the following as follows:

This test is harmonized with the European Pharmacopoeia and the U. S. Pharmacopoeia.

The parts of the text that are not harmonized among the targeted texts for the harmonization are marked with symbols (◆ ◆), and the texts that are uniquely specified by the JP other than the targeted texts for the harmonization are marked with symbols (◇ ◇).

This chapter provides information on how to apply electrical conductivity measurements (hereafter referred to as "conductivity") of fluid solutions, including pure fluids. This chapter is intended for fluid applications when conductivity is used to measure, monitor, or control chemical dispensing, chemical purity, ionic concentration, and other applications where the ionic character of the fluid needs to be known or controlled.

Applications include, but are not limited to, solutions that may be used in clean-in-place, chromatography detection, ionic solution preparations, end point detection, dosing, fermentation, and buffer production. In some cases, conductivity measurements can be extended to pure organic fluids such as alcohols and glycols where a weak conductivity signal exists, and the signal can be significantly increased if the organics become contaminated with water or salts.

Conductivity is the measurement of the ability of a fluid to conduct electricity via its chemical ions. The ability of any ion to electrically conduct is directly related to its ion mobility. Conductivity is directly proportional to the concentrations of ions in the fluid, according to Equation (1):

$$\kappa = 100 \sum_i^{all\ ions} C_i \cdot \lambda_i \quad (1)$$

κ = conductivity (S/cm)

C_i = concentration of chemical ion i (mol/L)

λ_i = specific molar conductance of ion i (S·cm²/mol)

Although the SI unit S/m is the appropriate SI unit for conductivity, historically the unit S/cm has been selected by industry as the accepted unit.

On the basis of Equation (1), conductivity is not ion selective because it responds to all ions. Furthermore, the specific molar conductance of each ion is different. As a result, unless the percentage composition of ions of the solution is limited and known, the precise concentrations of ionic species cannot be determined from conductivity measurements. However, for examples such as a solution of a single salt or acid or base, such as a caustic solution used in cleaning, the precise concentration can be directly determined. Despite the lack of ionic specificity, conductivity is a valuable laboratory and process tool for measurement and control of total ionic content because it is proportional to the sum of the concentrations of all ionic species (anions and cations) for diluted solutions as described in Equation (1). At higher concentrations, conductivity measurements are not perfectly linear with concentration. Conductivity measurements cannot be applied to solids or gases, but they can be applied to the condensate of gases.

Another variable that influences conductivity measurements is the fluid temperature. As the fluid temperature increases, the ion conductance increases, making this physicochemical phenomenon the predominant reason for the temperature-compensation requirement when testing conductive fluids.

The conductivity, κ , is proportional to the conductance, G (S), of a fluid between two electrodes (Equation (2)):

$$\kappa = G \times (d/A) = G \times K \quad (2)$$

κ = conductivity (S/cm)

G = conductance (S)

d = distance between the electrodes (cm)

A = area of the conducting electrodes (cm²)

K = cell constant (cm⁻¹), which also equals the ratio of d/A

The resistivity ρ (Ω·cm) of the fluid is, by definition, the reciprocal of the conductivity (Equation (3)):

$$\rho = 1/\kappa = 1/(G \times K) = R/K \quad (3)$$

ρ = resistivity (Ω·cm)

κ = conductivity (S/cm)

G = conductance (S)

K = cell constant (cm⁻¹)

R = resistance (Ω), which is the reciprocal of the conductance, G

1. Apparatus

An electrical conductivity measurement consists of the determination of resistance of the fluid between and around the electrodes of the conductivity sensor. To achieve this measurement, the primary instrumentation is the resistance-measuring circuit and the conductivity sensor, and they are

usually connected by a cable when the sensor and the user interface are separated.

The resistance measurement is made by applying an alternating current (AC, meaning the flow of electric charge periodically reverses direction) voltage (or current) to the electrodes, measuring the current (or voltage), and calculating the resistance according to Ohm's Law. The alternating source is used to prevent the polarization (collection of ions) at the electrodes. Depending on the instrument, the measuring frequency of the measuring system adjusts automatically according to the measuring conditions of the instrument, and there may be multiple resistance-measuring circuits embedded in the measuring system. The resistance-measurement circuit may be embedded in the transmitter or in the sensor.

The conductivity sensor consists of at least two electrical conductors of a fixed size and geometry, separated by an electrical insulator. The electrodes, insulator, and any other wetted materials should be constructed of materials that are unreactive to fluids with which they may come into contact. Also, the sensor construction should withstand the environmental conditions (process or ambient temperature, pressure, cleaning applications) that it would be subjected to.

Most conductivity sensors have temperature devices such as a platinum resistance temperature device (RTD) or negative temperature coefficient (NTC) thermistor embedded inside the sensor, although external temperature measurement is possible. The purpose of the temperature measurement is for temperature compensation of the conductivity measurement.

2. Cell Constant Determination

The purpose of the sensor's cell constant is to normalize the conductance (or resistance) measurement for the geometrical construction of the two electrodes.

The cell constant is determined by immersing the conductivity sensor in a solution of known conductivity. Solutions of known conductivity can be obtained by preparation of specific mixtures according to national authoritative sources or procurement of commercially available certified and traceable standard solutions. These recipes or certified solutions can range from 5 to 200,000 $\mu\text{S}/\text{cm}$, depending on the level of accuracy desired. Alternatively the cell constant is determined by comparison to other reference conductivity measuring systems (also available as an accredited calibration service). [Note—Conductivity measurements are not perfectly linear with concentration.]

The measured cell constant of the conductivity sensor must be within 5% of the nominal value indicated by the sensor certificate, unless otherwise prescribed.

Modern conductivity sensors normally do not change their cell constant over their lifetime. If a change of the cell constant is detected during calibration, a cleaning of the sensor is appropriate according to the manufacturer's recommendations. Following that, the calibration procedure should be repeated. Sometimes "memory effects" appear, particularly when changing from high to low concentrations if the sensor is not well flushed.

3. Calibration of Temperature

In addition to verifying the sensor's cell constant, the embedded temperature device (or external temperature device) should be appropriately calibrated for the application to apply the temperature compensation algorithm accurately. The temperature accuracy that is required depends on the criticality of the temperature to the application. An accuracy of $\pm 1^\circ\text{C}$ typically suffices.

4. Calibration of Measurement Electronics

The measurement circuit of the system is fundamentally an AC resistance measuring device. Appropriate verification and/or calibration of the measuring circuit is required for measurement systems with signal transfer via analog cable. This is accomplished by disconnecting the measuring circuit from the sensor's electrodes, attaching traceable resistors of known value with the cable of the measurement system to the measuring circuit, and verifying that the measured resistance agrees with the resistor value to an acceptable level. A typical acceptance criterion for the resistance accuracy is $< 2\%$ of the reading at resistances $> 100 \Omega$, and increasing to 5% at lower resistances. However, the application criticality should ultimately determine the desired accuracy.

For conductivity systems that cannot have the resistance-measuring circuit disconnected from the electrodes (e.g., measurement circuit and electrodes in one mutual housing), it may be difficult to directly adjust or verify the circuit accuracy, depending on the sensor design. An alternative method of verifying the measurement system integrity is a system calibration according to the procedures for the cell constant determination for each measuring circuit that is intended to be used.

If verification/calibration of the sensor's cell constant, temperature device, and measuring circuit are done at the same service interval, the measuring circuit should be verified first, the temperature device next, and the cell constant last. Because all of these parameters are typically very stable due to modern electronics and stable sensor construction, frequent calibration (such as daily) is not usually required. Comparison to qualified reference systems is also a proper means of calibration. Calibration is performed at appropriate intervals as defined in the quality management system.

5. Temperature Compensation

Because the conductivity of a fluid is temperature dependent, temperature compensation of the conductivity measurement is necessary unless otherwise prescribed. An appropriate temperature compensation algorithm will ensure that changes in the conductivity measurement can be ascribed to concentration changes and not temperature changes. Conductivity measurements are normally referenced to 25°C . A common form of linear temperature compensation uses Equation (4):

$$\kappa_{25} = \frac{\kappa_T}{[1 + \alpha(T - 25)]} \quad (4)$$

κ_{25} = conductivity compensated to 25°C

κ_T = conductivity at T

α = temperature coefficient of the conductivity

T = measured temperature

A temperature coefficient of 2.1% per 1°C is commonly used for many salt solutions. Most salt-based solutions have linear compensation factors ranging from 1.9% to 2.2% per 1°C. Depending on the fluid samples, other forms of temperature compensation may be appropriate. ◇Non-linear temperature compensation will carry out temperature compensation using preprogrammed data in the instrument. Non-linear temperature compensation data for a variety of solutions is widely available, e.g. for natural waters, and for ultrapure water with traces of ammonia. ◇ In cases of very low conductivity ($< 10 \mu\text{S}/\text{cm}$), such as purified pharmaceutical waters, two compensations need to be made. One is for the intrinsic conductivity of water, and the other is for the other ionic species in water. These compensations are normally combined and embedded in the microprocessor-controlled conductivity measurement systems. This is not supplied in all conductivity measurement technologies.

6. Conductivity Measurement of Fluids

For off-line batch measurements, rinse the cleaned sensor with the fluid to be measured. Then immerse the sensor in the fluid to be measured, and record the temperature and the temperature-compensated conductivity as required. Be sure that the position of the sensor in the container does not affect the conductivity measurement, because the container walls can affect the measurement for some electrode designs.

For continuous on-line or ◇in-line◇ measurements, install the cleaned sensor into the pipe, tank, or other containment vessel, and flush, if necessary. Make sure proper installation procedures are applied to prevent bubbles or particles from collecting between the electrodes. Be sure that the position of the sensor in the pipe or tank does not affect the conductivity measurement, because the nearby surfaces can affect the measurement for some electrode designs.

Record the temperature and the temperature-compensated conductivity as required.

For all batch or continuous measurements, ensure that the wetted components of the sensor are compatible with the fluid and the temperature to be measured.

Add the following:

2.66 Elemental Impurities— Procedures

Procedures of Elemental Impurities are methods to control elemental impurities contained in drug products and their components, etc. This chapter describes two analytical procedures (Procedures 1 and 2) and validation criteria for the evaluation of the levels of elemental impurities. The chapter permits the use of any procedure that meets the validation criteria specified in this chapter. As the chemical composition of the considered substances and the specification limits for the element(s) of interest vary considerably, it

is difficult to describe all suitable sample preparation and measurement methods. By means of validation studies, analysts will confirm that the analytical procedure is suitable for use on specified material. It is not necessary to cross validate against either procedure 1 or 2 provided that requirements for procedure validation are met. As elemental impurities may be ubiquitous they have the potential to be present in trace amounts therefore special precautions may be necessary to avoid sample contamination. (Note: Methods such as atomic absorption spectrometry other than methods described in this chapter, if validated, can also be used without cross validation against analytical procedure 1 or 2.)

1. Sample Preparation

Forms of sample preparation include Neat, Direct aqueous solution, Direct organic solution, and Indirect solution. The selection of the appropriate sample preparation depends on the material under test and is the responsibility of the analyst. When a sample preparation is not indicated in the monograph, an analyst may use any appropriately validated sample preparation procedure, including but not limited to procedures described below. In cases where spiking of a material under test is necessary to provide an acceptable signal intensity, the blank should be spiked with the same Target elements, and where possible, using the same spiking solution. The material or mixture under test must be spiked before any sample preparation steps are performed. Standard solutions may contain multiple Target elements. (Note: If intended for a quantitative test, appropriate material handling procedures should be followed e.g. volatile liquids should be pipetted, viscous liquids should be weighed.)

Neat: Used for liquids or samples measurable without addition of solvent.

Direct aqueous solution: Used when the sample is soluble in an aqueous solvent.

Direct organic solution: Used when the sample is soluble in an organic solvent.

Indirect solution: Generally, an indirect solution is obtained when a material is not directly soluble in aqueous or organic solvents. Total metal extraction is the preferred sample preparation approach to obtain an indirect solution. Digest the sample using the Closed vessel digestion procedure provided below or one similar to it.

Closed vessel digestion: This sample preparation procedure is designed for samples that must be digested in a Concentrated acid using a closed vessel digestion apparatus. Closed vessel digestion minimizes the loss of volatile impurities. The choice of a Concentrated acid depends on the sample matrix. The use of any of the Concentrated acids may be appropriate, but each introduces inherent safety risks. Therefore, appropriate safety precautions should be used at all times. (Note: Weights and volumes provided may be adjusted to meet the requirements of the digestion apparatus used.)

An example procedure that has been shown to have broad applicability is the following. Dehydrate and predigest 0.5 g

of material under test in 5 mL of freshly prepared Concentrated acid. Allow to sit loosely covered for 30 minutes in a fume hood. Add an additional 10 mL of Concentrated acid, and digest, using a closed vessel technique, until digestion or extraction is complete. Repeat, if necessary, by adding an additional 5 mL of Concentrated acid. (Note: Where closed vessel digestion is necessary, follow the manufacturer's recommended procedures to ensure safe use.)

Clear solutions are expected in the validation. In those cases where a clear solution cannot be obtained, appropriate studies should ensure that the recovery is suitable for the intended use.

Reagents: All reagents used for the preparation of sample and standard solutions should be sufficiently pure for the intended purpose.

2. Analytical Procedures 1 and 2

System standardization and suitability evaluation using applicable reference materials should be performed for each analytical sequence.

2.1. Procedure and Detection Technique

Procedure 1 can be used for elemental impurities generally amenable to detection by inductively coupled plasma-atomic (optical) emission spectroscopy (ICP – AES or ICP – OES). Procedure 2 can be used for elemental impurities generally amenable to detection by inductively coupled plasma-mass spectrometry (ICP – MS). Before initial use, the analyst should verify that the procedure is appropriate for the instrument and sample used by meeting the procedure validation requirements below.

2.2. Procedure 1: ICP – OES

Standard solution 1: 1.5J of the Target element(s) in a Matrix matched solution

Standard solution 2: 0.5J of the Target element(s) in a Matrix matched solution

Sample stock solution: Proceed as directed in Sample Preparation above. Allow the sample to cool, if necessary. For mercury determination, add an appropriate stabilizer, if necessary.

Sample solution: Dilute the Sample stock solution with an appropriate solvent to obtain a final concentration of the Target element(s) within the calibrated range.

Blank: Matrix matched solution

Elemental spectrometric system

Mode: ICP

Detector: Optical detection system

Rinse: Generally, diluent used

Calibration: Standard solution 1, Standard solution 2, and Blank

System suitability Sample: Standard solution of the Target element(s) in a Matrix matched solution at a concentration within the calibrated range

Suitability requirements

Short term Instrumental Stability: Compare results obtained from System suitability sample before and after the analysis of the Sample solution.

Suitability criteria: NMT 20% deviation between both samples for each Target element. (Note: If samples are high

in mineral content, rinse the system well in order to minimize carryover and check it by measuring a blank solution before introducing the System Suitability Sample.)

Analysis: Analyze according to manufacturer's suggestions for wavelength. Calculate and report results on the basis of the original sample size. [Note: Appropriate measures must be taken to correct for matrix-induced interferences (e.g., wavelength overlaps).]

2.3. Procedure 2: ICP – MS

Standard solution 1: 1.5J of the Target element(s) in a Matrix matched solution

Standard solution 2: 0.5J of the Target element(s) in a Matrix matched solution

Sample stock solution: Proceed as directed in Sample Preparation above. Allow the sample to cool, if necessary. For mercury determination, add an appropriate stabilizer, if necessary.

Sample solution: Dilute the Sample stock solution with an appropriate solvent to obtain a final concentration of the Target element(s) within the calibrated range.

Blank: Matrix matched solution

Elemental spectrometric system

Mode: ICP. [Note: An instrument with a cooled spray chamber is recommended. (A collision cell or reaction cell may also be beneficial.)]

Detector: Mass spectrometer

Rinse: Generally, diluent used

Calibration: Standard solution 1, Standard solution 2, and Blank

System suitability Sample: Standard solution of the Target element(s) in a Matrix matched solution at a concentration within the calibrated range

Suitability requirements

Short term Instrumental Stability: Compare results obtained from system suitability sample before and after the analysis of the Sample solution.

Suitability criteria: NMT 20% deviation between both samples for each Target element. (Note: If samples are high in mineral content, rinse the system well in order to minimize carryover and check it by measuring a blank before introducing the System suitability sample.)

Analysis: Analyze according to the manufacturer's suggestions for program and *m/z*. Calculate and report results based on the original sample size. [Note: Appropriate measures must be taken to correct for matrix-induced interferences (e.g., argon chloride interference with arsenic determinations).]

3. Requirements for Procedure Validation

All procedures must be validated and shown to be acceptable, in accordance with the validation requirements described below. The level of validation necessary to ensure that a procedure is acceptable depends on whether a limit test or a quantitative determination is used. Any procedure that has been validated and meets the acceptance criteria that follow is considered to be suitable for use. If appropriate, the validation method and criteria may be changed according to the purpose of evaluating the levels of the con-

tent of elemental impurities. They may differ from the requirements to meet the system suitability criteria described in Inductively Coupled Plasma-Atomic Emission Spectrometry and Inductively Coupled Plasma-Mass Spectrometry <2.63>.

3.1. Procedures for Limits Tests

The following section defines the validation parameters for the acceptability of limit tests. Meeting these requirements must be demonstrated experimentally using an appropriate system suitability test and reference materials.

The suitability of the method must be determined by conducting studies with the material or mixture under test spiked with known concentrations of each Target element of interest at the appropriate Target concentration.

3.1.1. Detectability

Standard solution: A preparation of reference materials for the Target element(s) at 1.0J in a Matrix matched solution.

Spiked sample solution 1: Prepare a solution of the sample under test, spiked with appropriate reference materials for the Target element(s) at the Target concentration, solubilized or digested as described in Sample Preparation.

Spiked sample solution 2: Prepare a solution of the sample under test, spiked with appropriate reference materials for the Target element(s) at 80% of the Target concentration, solubilized or digested as described in Sample Preparation.

Unspiked sample solution: A sample of material under test, solubilized or digested in the same manner as the spiked Sample solutions

Acceptance criteria

Non-instrumental procedures: Spiked sample solution 1 provides a signal or intensity equivalent to or greater than that of the Standard solution. Spiked sample solution 2 must provide a signal or intensity less than that of Spiked sample solution 1. (Note: The signal from each Spiked sample solution is NLT the Unspiked sample solution determination.)

Instrumental procedures: The average value of the three replicate measurements of Spiked sample solution 1 is within $\pm 15\%$ of the average value obtained for the replicate measurements of the Standard solution. The average value of the replicate measurements of Spiked sample solution 2 must provide a signal intensity or value less than that of the Standard solution. (Note: Correct the values obtained for each of the spiked solutions using the Unspiked sample solution.)

3.1.2. Specificity

The procedure must be able to unequivocally assess each Target element in the presence of components that may be expected to be present, including other Target elements, and matrix components.

3.1.3. Precision, only for Instrumental Methods (Repeatability)

Sample solutions: Six independent samples of the material under test, spiked with appropriate reference materials for the Target elements at the Target concentration

Acceptance criteria

Relative standard deviation: NMT 20% for each Target element

3.2. Procedures for Quantitative Tests

The following section defines the validation parameters for the acceptability of procedures for quantitative tests. Meeting these requirements must be demonstrated experimentally, using an appropriate system suitability test and reference materials.

3.2.1. Accuracy

Standard solutions: Prepare solutions containing the Target element(s) at three concentrations ranging from 0.5 to 1.5J, using appropriate reference materials, in a Matrix matched solution and blank.

Test samples: Prepare samples of the material under test spiked with appropriate reference materials for the Target element(s) before any sample preparation steps (digestion or solubilization) at 3 concentrations ranging from 50% to 150% of the Target concentration. Spike concentrations should range from 0.5 to 1.5J, and should contain at least three individual concentrations.

Acceptance criteria

Spike recovery: 70% – 150% for the mean of three replicate preparations at each concentration

3.2.2. Precision

Repeatability

Test samples: Six independent samples of material under test (taken from the same lot) spiked with appropriate reference materials for the Target element(s) at the Target concentration. Or at least 9 determinations (e.g., 3 replicates of 3 concentrations) covering the specified range.

Acceptance criteria

Relative standard deviation: NMT 20% ($n = 6$) for each Target element

Intermediate precision (ruggedness)

Perform the Repeatability analysis again at least once either on a different day, with a different instrumentation, with a different analyst, or a combination thereof. Combine the results of this analysis with the Repeatability analysis so the total number of samples is at least 12.

Acceptance criteria

Relative standard deviation: NMT 25% ($n = 12$) for each Target element

3.2.3. Specificity

The procedure must be able to unequivocally assess each Target element in the presence of components that may be expected to be present, including other Target elements, and matrix components.

3.2.4. Range and Linearity

Demonstrated by meeting the Accuracy requirement.

3.2.5. Limit of Quantification

The Limit of Quantification is confirmed when the accuracy acceptance criteria for the corresponding spiked solution is met. The Limit of Quantification is smaller or equal to 50% of Target concentration.

4. Glossary

(i) **Concentrated acid:** Concentrated ultra-pure nitric, sulfuric, hydrochloric, or hydrofluoric acids or any other acid or mixture of acids that is demonstrated suitable.

(ii) **Matrix matched solution:** Solutions having the same

solvent composition as the Sample solution. In the case of an aqueous solution, Matrix matched solution would indicate that the same acids, acid concentrations and mercury stabilizer are used in both preparations.

(iii) **Target elements:** Elements whose levels in the drug product must be controlled within acceptable limits.

(iv) **Target limit or Target concentration:** The acceptance value for the elemental impurity being evaluated. Exceeding the Target limit indicates that a material under test exceeds the acceptable value. Target limits in the final drug product can be approximated by dividing the permitted daily exposures (PDEs) by the maximum daily dose of the drug product. When evaluating the significance of elemental impurity levels, it is possible to set the Target limits to the values obtained by dividing 30% of PDEs by the maximum daily dose of the drug product. Furthermore, when the permitted concentration limit of each element in the individual components of the drug product is set, it can be set as the Target concentration.

(v) **J:** The concentration (w/v) of the Target element(s) at the Target limit, appropriately diluted to the working range of the instrument. If a dilution is not necessary, *J* is equal to the Target concentration. For example, if the target elements are lead and arsenic for an analysis of an oral solid drug product with a daily dose of 10 g/day using inductively coupled plasma – mass spectrometry (ICP – MS), the target limit for these elements would be 0.5 µg/g and 1.5 µg/g. However, in both cases, the linear dynamic range of the ICP – MS is known to extend from 0.01 ng/mL to 0.1 µg/mL for these elements. Therefore, a dilution factor of at least 1:100 is required to ensure that the analysis occurs in the linear dynamic range of the instrument. *J* would thus equal 5 ng/mL and 15 ng/mL for lead and arsenic, respectively.

(vi) **Appropriate reference materials:** In principle, where Appropriate reference materials are specified in the chapter, certified reference materials (CRM) from a national metrology institute (NMI), or reference materials that are traceable to the CRM of an NMI should be used.

(vii) **Cross validation:** Verification whether or not the same result can be obtained from the corresponding analyses for the same sample.

Add the following:

6.16 Rheological Measurements for Semi-solid Preparations

Rheological measurements for semi-solid preparations are methods to measure fluidity and deformation by adding force to semi-solid preparations such as Semi-solid Preparations for Oro-mucosal Application, Ophthalmic Ointments, Ointments, Creams and Gels.

There are two methods, the first (spreadability test) and the second (penetrometry).

These methods are more practical to determine rheologi-

cal properties of semi-solid preparations, though Method II Viscosity measurement by rotational viscometer under Viscosity Determination <2.53> can evaluate precisely rheological properties of semi-solids.

1. Method 1 Spreadability test

Spreadability test is a method for measuring flowability of semi-solid preparations using a spread meter (also known as a parallel plate viscometer).

A spread meter measures a spreading diameter etc. of a sample by observing the characteristic of the concentric spreading over time when the sample is sandwiched between two parallel plates [glass (or plastic) plate and fixed plate] placed horizontally and pushed outward with the own weight of the glass plate.

Generally there is a reciprocal relationship between fluidity as an index of flowability and viscosity, however flowability measured by this method does not necessarily correlate with apparent viscosity (mPa·s) measured by the viscosity determination.

This method targets relatively soft preparations in particular among semi-solid preparations.

1.1. Apparatus

An example of spread meters is shown in Fig. 6.16-1.

There are two parallel plates placed horizontally. The fixed plate installed in the lower part has engraved scales at 1 mm intervals to measure the distance from the center and has a cylindrical hole (0.5 mL) at the center for inserting a sample. The weight-loading glass plate positioned in the upper part is made of transparent glass or acrylate resin etc. and has a mass of 115 g. The glass plate is supported by rods. Pushing the piston up raise the bottom of the hole to push the sample above the fixed plate. In connection with it the glass plate falls (20 mm, commonly) and the sample spreads concentrically on the fixed plate with the own weight of the glass plate. Measuring the extent of the spread provides the flowability of the sample.

1.2. Procedure and measurement conditions

Before measurement remove a glass plate from an apparatus and clean the glass plate, a fixed plate and a specimen hole. Fill a sample in the specimen hole at the center of the fixed plate and flatten the sample by a spatula etc. so that the upper face of the sample is flush with the fixed plate and become flat. Wipe the sample protruded off. Make sure that the apparatus is horizontal by a level and install the glass plate to the support rod. Push the piston up and start time measurement simultaneously. Measure the spread of the sample on the fixed plate by the scale in mm unit over time and record them.

A constant temperature is needed during measurement and it is preferable to perform the measurement in the room controlled at 25 ± 2°C.

Bring the temperature of samples equal to that of the measurement environment by allowing them to stand in the measurement environment.

1.3. Analysis

Characteristics of flowability obtained with the measurement using a spread meter are expressed as spread meter

diameter D and spread meter yield value YV in the case of the single-point method and as spread meter slope S and spread meter intercept IC in the case of the multi-point method. They are calculated by the following methods, respectively.

1.3.1. Single-point method

(i) Spread meter diameter D : Expressed as the spreading diameter (mm) after the specified time (usually, 60 seconds).

A larger spreading diameter indicates higher flowability.

(ii) Spread meter yield value YV : Calculate by the following equation.

$$YV = (4.8 \times W \times V \times g_n) / (\pi^2 \times D_{\infty}^5)$$

YV : Yield value (Pa)

W : Mass (kg) of glass plate

V : Sample volume (m³)

g_n : Standard acceleration due to gravity (m/s²)

D_{∞} : Maximum of spreading diameter (m)

The above equation is expressed in the International System of Units, however actual measurement is performed in the Centimeter-Gram-Second System of Units.

Many semi-solid preparations have no flowability when leave them as they are, however they flow by adding force. The limit value of the force is the yield value and a larger yield value indicates that a larger force is required for the flow of a sample.

1.3.2. Multi-point method

(i) Spread meter slope S : Calculate by the following equation.

$$S = (D_2 - D_1) / \log_{10}(T_2/T_1)$$

D_1 : Spreading diameter after T_1 seconds (mm)

D_2 : Spreading diameter after T_2 seconds (mm)

T_1, T_2 : Measurement time (seconds) $T_2 > T_1, 5 \leq T_1$ and $T_2 \leq 100, \Delta T = (T_2 - T_1) > 40$

In general, plot the spreading diameter measured each time on a semi-logarithmic graph to obtain an almost straight line connecting each point. Spread meter slope S corresponds to its slope.

A larger S indicates a larger flow of a sample.

(ii) Spread meter intercept IC : Plot logarithms of times (T_1, T_2) as abscissa against spreading diameters (D_1, D_2) as ordinate and draw a line connecting these two points. Obtain the intersection point ($T = 1$) of this extension line and the ordinate axis as spread meter IC .

A larger IC indicates higher flowability of a sample.

2. Method 2 Penetrometry

Penetrometry is a method for measuring hardness or softness of semi-solid preparations using a penetrometer.

A penetrometer is an apparatus for measuring the distance traveled by a cone penetrant inside a sample and the consistency is expressed as ten times of the value measured in units of 0.1 mm. A smaller value indicates a harder sample.

This method targets relatively hard preparations in particular among semi-solid preparations.




Fig. 6.16-1 Example of spread meter

2.1. Apparatus

2.1.1. Penetrometer

An example of penetrometers is shown in Fig. 6.16-2.

Adjust a penetrometer so that the position of the tip of a prescribed cone touches the surface of the sample filled in a sample container, penetrate the cone into the sample with its own weight for a certain time and calculate the consistency from the depth measured in units of 0.1 mm.

Adjust exactly the cone part or the sample stage of the penetrometer so that the position of the tip of the cone touches the horizontal surface of the sample keeping the reading of the dial gage zero. Adjust the cone in advance so that the cone falls more than 62 mm smoothly when released from the state fixed to the penetrometer and the top of the cone does not hit the bottom of the sample container after the fall. The penetrometer must be equipped with a screw for horizontal control and a level to maintain a cone holder being vertical.

2.1.2. Cone

A standard cone is a conical body made of magnesium or other suitable metal, which has a removable hardened steel needle. Fig. 6.16-3 shows the specifications of the standard cone.

The upper end of a holder is equipped with a stopper and the lower end is devised to connect a cone. The inner structure of the cone may be changed in order to conform to the prescribed mass as far as there is no change in shape and mass distribution of the cone. The outer surface of the cone must be without scratches and smooth enough.

Fig. 6.16-4, 6.16-5 and 6.16-6 show the specifications of an optional cone, a half-scale cone and a quarter-scale cone. The half-scale and quarter-scale cones are the prescribed cones that are scaled down to a half and a quarter of the




Fig. 6.16-2 Example of penetrometer




Fig. 6.16-4 Optional cone




Fig. 6.16-3 Standard cone




Fig. 6.16-5 Half-scale cone




Fig. 6.16-6 Quarter-scale cone

standard cone or the optional cone.

Select a suitable cone based on the sample volume and the consistency of the preparation to be tested and convert the measured consistency to the value equivalent to that measured using a standard cone.

An optional cone may be used to measure the sample having a consistency of not more than 400. Use a half-scale cone or a quarter-scale cone, when a sample has a consistency of 175 to 385 and a standard cone is not available because of small sample amounts.

2.2. Procedure and measurement conditions

2.2.1. Sample preparation

Stand a prepared empty container and a container with a lid containing a necessary amount of sample in a water bath at 25°C and bring the temperature of the sample at 25 ± 0.5°C. Transfer the sample in the container with a lid to the empty container at a time, if possible. Remove air bubbles mixed in the sample in the sample container by a suitable method and fill the container with an excessive amount of the sample using a spatula again. Be careful not to stir the sample and not to make vacant space inside the sample in this procedure. Flatten the surface of the sample by removal of the excessive sample by moving a spatula, of which surface is inclined about 45 degrees in the direction of the movement, along the upper edge of the container. Hereafter do not touch the surface of the sample before measurement. Perform the test promptly to keep the temperature of the sample evenly at 25 ± 0.5°C.

The consistency of soft samples is affected by the container diameter. With soft samples having a consistency of not less than 265, use a container with inside diameter of 76.2 mm (a half-scale cone: 38.1 mm, a quarter-scale cone: 19.0 mm). The consistency of relatively hard samples having a consistency of not more than 265 is hardly affected by the container diameter when using a container with inside diameter of not less than 76.2 mm.

The amount of sample required for the test depends on the sizes of the sample container and the cone, and the procedure specified according to the consistency.

2.2.2. Procedure

2.2.2.1. Standard cone

Stand a sample container gently on the sample stage of the penetrometer adjusted to horizontal position. After placing the position of the cone to the zero point of the dial gage adjust the cone so that the tip touches the surface of the sample at the position prescribed in (i), (ii) or (iii) by moving either the cone part or the sample stage up and down. Push the metal clamping tool immediately to penetrate the cone for 5 ± 0.1 seconds. The holder must move smoothly in the drop unit. Push the rack for measurement down gently until it stops and read the dial gage in first place after the decimal point.

(i) With a sample having a consistency of more than 400, only one test may be made in one container by placing the center of the sample container within 0.3 mm from the needle tip. Three tests may be made in three containers.

(ii) With a sample having a consistency of more than 200 and less than 400, perform carefully the centering of the

cone in the sample container. Only one test may be made with this sample. Three tests may be made in three containers.

(iii) With a sample having a consistency of not more than 200, three tests may be made in one container. The measurement points are the midpoints between the center and the edge of the sample container at about 120 degrees intervals on a concentric circle.

2.2.2.2. Half-scale cone and quarter-scale cone

Place a cone at the center of a sample surface and perform a penetration pretest. The pretest may be omitted if an approximate value of consistency is known. Perform the measurement of consistency according to the procedure in 2.2.2.1. and place the position of the tip according to the following (i) or (ii).

(i) With a sample having a consistency of more than 97 when using a half-scale cone or more than 47 when using a quarter-scale cone, only one test may be made in one container by placing carefully the needle tip at the center of the sample container. Three tests may be made in three containers.

(ii) With a sample having a consistency of not more than 97 when using a half-scale cone or not more than 47 when using a quarter-scale cone, three tests may be made in one sample container. The measurement points are the midpoints between the center and the edge of the sample container at about 120 degrees intervals on a concentric circle so that the cone does not collide with the edge of the sample container and the measurement position of previous tests.

2.3. Analysis

2.3.1. Conversion of consistency measured using a half-scale or quarter-scale cone

Convert the consistency obtained using a half-scale or quarter-scale cone to the value equivalent to that obtained using a standard cone by the following equation.

2.3.1.1. Conversion of consistency obtained using a half-scale cone

$$P = 2p_{1/2} + 5$$

P: Consistency converted to the value equivalent to that measured using the standard cone

*p*_{1/2}: Consistency measured using a half-scale cone

2.3.1.2. Conversion of consistency obtained using a quarter-scale cone

$$P = 3.75p_{1/4} + 24$$

P: Consistency converted to the value equivalent to that measured using a standard cone

*p*_{1/4}: Consistency measured using a quarter-scale cone

Add the following:

6.17 Insoluble Particulate Matter Test for Therapeutic Protein Injections

Insoluble particulate matters in injections consist of mobile undissolved particles other than gas bubbles in preparations. Extraneous substances, substances derived from manufacturing processes, protein aggregates and so on may be included in therapeutic protein injections. In this chapter, Method 1 (Light Obscuration Particle Count Test) under Insoluble Particulate Matter Test for Injections <6.07> is used for the determination of insoluble particulates in therapeutic protein injections. This test is applied to the injections whose active ingredients are peptides, proteins or their derivatives.

Since this test is a sampling test conducted on a part of samples, the test must be performed under a statistically sound sampling plan in order to estimate correctly the number of particles in the population.

1. Apparatus

Use a suitable apparatus based on the principle of light blockage which allows an automatic determination of the size of particles and the number of particles according to size. Calibration, and verification of sample volume accuracy, sample flow rate accuracy and counting accuracy are performed according to Method 1 under Insoluble Particulate Matter Test for Injections <6.07>. When one measurement is performed with volume less than 1 mL, confirm the sample volume accuracy separately by an appropriate method.

2. General precautions

The test is carried out under conditions limiting particulate contamination, preferably in a laminar-flow cabinet. Very carefully wash the glassware and filtration equipment used, except for the membrane filters, with a warm detergent solution and rinse with abundant amounts of water to remove all traces of detergent. Immediately before use, rinse the equipment from top to bottom, outside and then inside, with *particle-free water*. Take care not to introduce air bubbles into the preparation to be examined, especially when fractions of the preparation are being transferred to the container in which the determination is to be carried out. In order to check that the environment is suitable for the test, that the glassware is properly cleaned and that the number of particles in the *particle-free water* to be used is within specifications, the following test is carried out using 5 mL of the *particle-free water*. When one measurement is performed with volume less than 1 mL, 1 mL of *particle-free water* may be used. Determine the particulate contamination of 5 samples of *particle-free water*. If the number of particles of 10 μm or greater size exceeds 1 per 1 mL, the precautions taken for the test are not sufficient. In this case, the preparatory steps must be repeated until the environment, filtration equipment glassware and *particle-free water*

are suitable for the test.

3. Method

Treat a protein solution in an appropriate manner because of its tendency to generate air bubbles. In the case of an injection to be dissolved before use, use a specified solvent. When solvent is not specified, dissolve in *particle-free water* or use other suitable solvent comparable to *particle-free water*. Mix the appropriate contents of the sample gently and thoroughly by an appropriate procedure such as swirling the container slowly. If the container is sealed, cautiously remove the sealing closure. Clean the outer surfaces of the container opening using a jet of *particle-free water* and remove the closure, avoiding any contamination at the contents. For elimination of air bubbles, it is recommended to allow a container to stand under ambient pressure or reduced pressure. Other procedures are applicable if confirmed to be appropriate. Sonicating is not appropriate because it may aggregate or denature proteins. If necessary, after degassing, mix the contents gently and thoroughly by swirling slowly the container so as not to introduce air bubbles, and use it for the test. The measurement volume is 1 to 5 mL. The measurement volume can be reduced to 0.2 mL when the validity of the reduction is confirmed in considering the property of the sample and the tare volume of the apparatus. Set the volume necessary for the test in consideration of counting 4 portions.

In the case of injections where the volume necessary for the test can be obtained from one container, individual containers are tested. For injections with insufficient volume, combine the contents of several containers in one clean container to obtain the necessary volume after mixing the contents of containers gently and thoroughly. Where justified, the volume necessary for the test may be prepared by diluting the test solution with *particle-free water* or an appropriate solvent comparable to *particle-free water*. The validity of the dilution procedure and the solvent used for the dilution is confirmed by, for example, demonstrating consistent result regardless of the dilution. The number of test specimens must be adequate to provide a statistically sound assessment.

Take 4 portions and count the number of particles equal to or greater than 10 μm and 25 μm . Disregard the result obtained for the first portion, and calculate the mean number of particles for the preparation to be examined.

4. Evaluation

The preparation complies with the test if the average number of particles meets the following requirement.

A—Solutions for injection supplied in containers with a nominal content of equal to or more than 100 mL.

The average number of particles of equal to or greater than 10 μm does not exceed 25 per mL and that of particles of equal to or greater than 25 μm does not exceed 3 per mL.

B—Solutions for injection supplied in containers with a nominal content of less than 100 mL.

The average number of particles of equal to or greater than 10 μm does not exceed 6000 per container and that of particles of equal to or greater than 25 μm does not exceed

600 per container.

9.01 Reference Standards

Add the following to section (1):

Bromfenac Sodium RS
L-Carnosine RS
Doripenem RS
Gatifloxacin RS
Hydroxyethylcellulose RS for Identification
Lanocanazole RS
Microcrystalline Cellulose RS for Identification
Residual Solvents Class 2C RS
Sitagliptin Phosphate RS
Sitagliptin Phosphate RS for System Suitability

Move the following from section (2) to section (1):

Ampicillin RS
Azithromycin RS
Cefazolin RS
Cefmetazole RS
Fradomycin Sulfate RS
Meropenem RS

9.21 Standard Solutions for Volumetric Analysis

Add the following:

Cerium (IV) Sulfate, 0.1 mol/L

1000 mL of this solution contains 40.43 g of cerium (IV) sulfate tetrahydrate [Ce (SO₄)₂·4H₂O: 404.30].

Preparation—Dissolve 40.43 g of cerium sulfate (IV) tetrahydrate in water to make 1000 mL, and standardize the solution as follows:

Standardization—Weigh accurately about 0.2 g of sodium oxalate (standard reagent), previously dried between 150°C and 200°C for 1 to 1.5 hours, and allow to cool in a desiccator (silica gel), and dissolve in 75 mL of water. Add a mixture of 5 mL of water and 2 mL of sulfuric acid with stirring, add 10 mL of hydrochloric acid, and warm to 70–75°C. Titrate <2.50> the solution with 0.1 mol/L cerium (IV) sulfate VS until the solution shows a persistent slightly yellow color, and calculate the molarity factor.

Each mL of 0.1 mol/L cerium sulfate (IV) VS
= 6.700 mg of Na₂C₂O₄

Iodine, 0.025 mol/L

1000 mL of this solution contains 6.345 g of iodine (I:126.90).

Preparation—Before use, dilute 0.05 mol/L iodine VS with water to make exactly twice the initial volume.

9.22 Standard Solutions

Add the following:

Standard Chloride Solution Pipet 10 mL of Standard Chloride Stock Solution, add water to make exactly 1000 mL. Prepare before use. Each mL of this solution contains 5 μg of chloride (Cl).

Standard Chloride Stock Solution Weigh accurately 0.842 g of sodium chloride, previously dried at 130°C for 2 hours, and dissolve in water to make exactly 1000 mL.

Standard Glyoxal Solution Dilute Standard Glyoxal Stock Solution to 10 times with ethanol (99.5). Prepare before use. Each mL of this solution contains 2 μg of glyoxal (C₂H₂O₂).

Standard Glyoxal Stock Solution Transfer a quantity of 40% glyoxal TS, equivalent to 0.200 g of glyoxal, in a 100-mL volumetric flask, and dilute to 100 mL with ethanol (99.5). Dilute to 100-fold with ethanol (99.5) before use. Each mL of this solution contains 20 μg of glyoxal (C₂H₂O₂).

9.41 Reagents, Test Solutions

Add the following:

4-Amino-6-chlorobenzene-1,3-disulfonamide

C₆H₈ClN₃O₄S₂ White, crystals or crystalline powder.

Identification—Determine the infrared absorption spectrum of 4-amino-6-chlorobenzene-1,3-disulfonamide as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>: it exhibits absorption at the wave numbers of about 3380 cm⁻¹, 3250 cm⁻¹, 1638 cm⁻¹, 1597 cm⁻¹, 1544 cm⁻¹ and 1324 cm⁻¹.

Storage—Preserve in tight containers.

Bilirubin for assay C₃₃H₃₆N₄O₆ A red-orange powder. Very slightly soluble in dimethyl sulfoxide, and practically insoluble in water and in ethanol (99.5).

Identification Determine the infrared absorption spectrum of bilirubin for assay as directed in the ATR method under Infrared Spectrophotometry <2.25>: it exhibits absorption at the wave numbers of about 3400 cm⁻¹, 2910 cm⁻¹, 1686 cm⁻¹ and 1643 cm⁻¹.

Absorbance <2.24> E₁^{1%}_{cm} (453 nm): 970–1134 (1 mg, dimethyl sulfoxide, 200 mL). Conduct this procedure without exposure to light, using light-resistant vessels.

Purity Related substances—Conduct this procedure without exposure to light, using light-resistant vessels. The following sample solution and standard solution should be prepared before use. Dissolve 5 mg of bilirubin for assay in 50 mL of a warmed mixture of dimethyl sulfoxide and acetic acid (100) (9:1), cool and use this solution as the sample solution. Pipet 1 mL of the sample solution, add a mixture of dimethyl sulfoxide and acetic acid (100) (9:1) to

make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the total area of the peaks other than bilirubin obtained from the sample solution is not larger than the peak area of bilirubin from the standard solution. Operating conditions

Detector, column, column temperature, mobile phase and flow rate: Proceed as directed in the operating conditions in the Assay under Oriental Bezoar.

Time span of measurement: About 3 times as long as the retention time of bilirubin, beginning after the solvent peak. System suitability

System performance and system repeatability: Proceed as directed in the system suitability in the Assay under Oriental Bezoar.

Deuterated acetone for nuclear magnetic resonance spectroscopy CD_3COCD_3 Prepared for nuclear magnetic resonance spectroscopy.

Diclofenac sodium for assay $\text{C}_{14}\text{H}_{10}\text{Cl}_2\text{NNaO}_2$ [Same as the monograph Diclofenac Sodium. When dried, it contains not less than 99.0% of diclofenac sodium ($\text{C}_{14}\text{H}_{10}\text{Cl}_2\text{NNaO}_2$).]

Diisopropyl 1,3-dithiolan-2-ylidenemalonate

$\text{C}_{12}\text{H}_{18}\text{O}_4\text{S}_2$ White crystals.

Identification—Determine the absorption spectrum of a solution of diisopropyl 1,3-dithiolan-2-ylidenemalonate in methanol (1 in 125,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 304 nm and 308 nm.

Melting point <2.60>: 54 – 57°C

Dilute phenolphthalein TS See phenolphthalein TS, dilute.

Euodia fruit [Same as the namesake monograph]

Evodiamine for assay $\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}$ White to light yellow, crystals or crystalline powder. Very slightly soluble in methanol and in ethanol (99.5), and practically insoluble in water. Correct the content based on the amount (%) obtained in the Assay.

Identification—Proceed as directed in the Assay: it exhibits a double doublet-like signal equivalent to one proton around δ 2.82 ppm, signals equivalent to four protons which includes a singlet signal around δ 2.91 ppm and a multiplet signal around δ 2.90 ppm – δ 2.98 ppm, a double triplet-like signal equivalent to one proton around δ 3.23 ppm, a double doublet-like signal equivalent to one proton around δ 4.66 ppm, a singlet signal equivalent to one proton around δ 6.16 ppm, a triplet-like signal equivalent to one proton around δ 7.00 ppm, a triplet-like signal equivalent to one proton around δ 7.05 ppm, a doublet-like signal equivalent to one proton around δ 7.08 ppm, a triplet-like signal equivalent to one proton around δ 7.14 ppm, a doublet-like signal equivalent to one proton around δ 7.39 ppm, a

doublet-like signal equivalent to one proton around δ 7.51 ppm, a multiplet signal equivalent to one proton around δ 7.52 ppm and a double doublet-like signal equivalent to one proton around δ 7.83 ppm.

Unity of peak—Dissolve 1 mg of evodiamine for assay in 20 mL of methanol, and use this solution as the sample solution. Perform the test with 10 μ L of the sample solution as directed under Liquid Chromatography <2.01> according to the following conditions, and compare the absorption spectra of at least 3 points including the top of evodiamine peak and around the two middle peak heights of before and after the top: no difference in form is observed among their spectra.

Operating conditions

Column, column temperature, mobile phase and flow rate: Proceed as directed in the operating conditions in the Assay (1) under Goshuyuto Extract.

Detector: A photodiode array detector (wavelength: 282 nm; spectrum range of measurement: 220 – 400 nm).

System suitability

System performance: When the procedure is run with 10 μ L of the sample solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of evodiamine are not less than 5000 and not more than 1.5, respectively.

Assay—Weigh accurately 5 mg of evodiamine for assay and 1 mg of DSS- d_6 for nuclear magnetic resonance spectroscopy using an ultramicrobalance, dissolve them in 1 mL of deuterated dimethylsulfoxide for nuclear magnetic resonance spectroscopy, and use this solution as the sample solution. Transfer the sample solution into an NMR tube 5 mm in outer diameter, and measure ^1H -NMR as directed under Nuclear Magnetic Resonance Spectroscopy <2.21> and Crude Drugs Test <5.01> according to the following conditions, using DSS- d_6 for nuclear magnetic resonance spectroscopy as the internal reference compound. Calculate the resonance intensity A (equivalent to 1 hydrogen) of the signal around δ 6.16 ppm assuming the signal of the internal reference compound as δ 0 ppm.

$$\begin{aligned} \text{Amount (\%)} \text{ of evodiamine } (\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}) \\ = M_S \times I \times P / (M \times N) \times 1.3521 \end{aligned}$$

M : Amount (mg) of evodiamine for assay taken

M_S : Amount (mg) of DSS- d_6 for nuclear magnetic resonance spectroscopy taken

I : Signal resonance intensity A based on the signal resonance intensity of DSS- d_6 for nuclear magnetic resonance spectroscopy as 9.000

N : Number of the hydrogen derived from A

P : Purity (%) of DSS- d_6 for nuclear magnetic resonance spectroscopy

Operating conditions

Apparatus: A nuclear magnetic resonance spectrometer having ^1H resonance frequency of not less than 400 MHz.

Target nucleus: ^1H .

Digital resolution: 0.25 Hz or lower.

Measuring spectrum range: 20 ppm or upper, including

between -5 ppm and 15 ppm.

Spinning: off.

Pulse angle: 90° .

^{13}C decoupling: on.

Delay time: Repeating pulse waiting time not less than 60 seconds.

Integrating times: 8 or more times.

Dummy scanning: 2 or more times.

Measuring temperature: A constant temperature between 20°C and 30°C .

System suitability

Test for required detectability: When the procedure is run with the sample solution under the above operating conditions, the SN ratio of the signal around δ 6.16 ppm is not less than 100 .

System performance: When the procedure is run with the sample solution under the above operating conditions, the signals around δ 6.16 ppm is not overlapped with any signal of obvious foreign substance.

System repeatability: When the test is repeated 6 times with the sample solution under the above operating conditions, the relative standard deviation of the ratio of the resonance intensity A to that of the internal reference compound is not more than 1.0% .

Felodipine for assay [Same as the monograph Felodipine. It contains not less than 99.5% of ferodipine ($\text{C}_{18}\text{H}_{19}\text{Cl}_2\text{NO}_4$), calculated on the dried basis.]

40% glyoxal TS *Content*: $38 - 42\%$. *Assay*—Put 1.000 g of **40% glyoxal TS** in a glass-stoppered flask, add 20 mL of a solution of hydroxylammonium chloride (7 in 100) and 50 mL of water. Stopper tightly, allow to stand for 30 minutes, titrate $\langle 2.50 \rangle$ with 1 mol/L sodium hydroxide VS (indicator: 1.0 mL of methyl red-methylene blue TS). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 1 mol/L sodium hydroxide VS
= 29.02 mg of $\text{C}_2\text{H}_2\text{O}_2$

Iodoethane for assay $\text{C}_2\text{H}_5\text{I}$ Colorless to slightly yellow liquid, turning brown on exposure to air and light. Miscible with ethanol (95). Specific gravity d_{20}^{20} : about 1.95 ; Boiling point: about 72°C .

Refractive index $\langle 2.45 \rangle$ n_D^{20} : $1.509 - 1.515$.

Content: not less than 99.0% . *Assay*—Proceed as directed in the Assay under isopropyl iodide for assay.

Each mL of 0.1 mol/L silver nitrate VS
= 15.60 mg of $\text{C}_2\text{H}_5\text{I}$

Storage—Preserve in tight, light-resistant containers.

Iron (III) chloride-amidosulfuric acid TS Dissolve 10 g of iron (III) chloride hexahydrate and 16 g of amidosulfuric acid (standard reagent) in water to make 1000 mL.

Lanconazole $\text{C}_{14}\text{H}_{10}\text{ClN}_3\text{S}_2$ [Same as the namesake monograph]

(Z)-Ligustilide TS for thin-layer chromatography Dis-

solve 1 mg of (Z)-ligustilide for thin-layer chromatography in 10 mL of methanol.

Methyl 4-aminobenzoate $\text{H}_2\text{NC}_6\text{H}_4\text{COOCH}_3$ Pale yellow, crystals or crystalline powder.

Melting point $\langle 2.60 \rangle$: $111 - 114^\circ\text{C}$

3-Methyl-2-benzothiazolonehydrazone hydrochloride monohydrate $\text{C}_8\text{H}_{10}\text{ClN}_3\text{S}\cdot\text{H}_2\text{O}$ A white to light yellow-white crystalline powder. Melting point: about 270°C (with decomposition).

Methyl red-sodium hydroxide TS Dissolve 50 mg of methyl red in a mixture of 1.86 mL of 0.1 mol/L sodium hydroxide VS and 50 mL of ethanol (95), and add water to make 100 mL.

Nortriptyline hydrochloride $\text{C}_{19}\text{H}_{21}\text{N}\cdot\text{HCl}$ [Same as the namesake monograph]

Nortriptyline hydrochloride for assay $\text{C}_{19}\text{H}_{21}\text{N}\cdot\text{HCl}$ [Same as the monograph Nortriptyline Hydrochloride. When dried, it contains not less than 99.0% of nortriptyline hydrochloride ($\text{C}_{19}\text{H}_{21}\text{N}\cdot\text{HCl}$).]

Peucedanum ledebourielloides for purity Powder of the root and rhizome of *Peucedanum ledebourielloides* K. T. Fu (*Umbelliferae*).

Identification—Place 1.0 g of peucedanum·ledebourielloides for purity in a glass-stoppered centrifuge tube, add 5 mL of hexane, shake for 10 minutes, centrifuge, and use the supernatant liquid as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography $\langle 2.03 \rangle$. Spot 5 μL of the sample solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of hexane, ethyl acetate and acetic acid (100) ($20:10:1$) to a distance of about 7 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): blue fluorescent spots at R_f values of about 0.35 (agasyllin) and about 0.4 [xanthalin ($\text{C}_{24}\text{H}_{26}\text{O}_7$)] are observed.

Phenolphthalein TS, dilute Dissolve 0.1 g of phenolphthalein in 80 mL of ethanol (95), and add water to make 100 mL.

Platycodin D for thin-layer chromatography $\text{C}_{57}\text{H}_{92}\text{O}_{28}$ A white powder. Freely soluble in methanol.

Identification Determine the infrared absorption spectrum of platycodin D for thin-layer chromatography as directed in the potassium bromide disk method under Infrared Spectrophotometry $\langle 2.25 \rangle$: it exhibits absorption at the wave numbers of about 1734 cm^{-1} , 1637 cm^{-1} , 1385 cm^{-1} , 825 cm^{-1} and 783 cm^{-1} .

Purity Related substances—Dissolve 2 mg of platycodin D for thin-layer chromatography in 2 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 50 mL, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography $\langle 2.03 \rangle$. Spot 5 μL each of the sample solution and standard solution on a plate of silica gel for thin-layer chro-

matography. Develop the plate with a mixture of 1-propanol, ethyl acetate, water and acetic acid (100) (5:3:2:1) to a distance of about 10 cm, and air-dry the plate. Spray dilute sulfuric acid on the plate, and heat the plate at 105°C for 10 minutes: the spots other than the principal spot with an R_f value of about 0.5 from the sample solution are not more intense than the spot from the standard solution.

Sodium stearyl fumarate $C_{22}H_{39}NaO_4$ A white crystalline powder.

Identification (1) Determine the infrared absorption spectrum of sodium stearyl fumarate as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>: it exhibits absorption at the wave numbers of about 2950 cm^{-1} , 2920 cm^{-1} , 2850 cm^{-1} , 1720 cm^{-1} , 1610 cm^{-1} , 1313 cm^{-1} , 1186 cm^{-1} , 980 cm^{-1} , and 665 cm^{-1} .

(2) Sodium stearyl fumarate responds to Qualitative Tests <1.09> (1) for sodium salt.

Valsartan $C_{24}H_{29}N_5O_3$ [Same as the namesake monograph]

Change the following as follows:

Cineol for assay $C_{10}H_{18}O$ Clear and colorless liquid, having a characteristic aroma.

Refractive index <2.45> n_D^{20} : 1.457 – 1.459

Specific gravity <2.56> d_4^{20} : 0.920 – 0.930

Purity Related substances—Dissolve 0.10 g of cineol for assay in 25 mL of hexane and use this solution as the sample solution. Perform the test with 2 μL of the sample solution as directed under Gas Chromatography <2.02> according to the following conditions. Determine each peak area by the automatic integration method and calculate the amount of them by the area percentage method: the total amount of the peaks other than cineol is not more than 1.0%.

Operating conditions

Proceed the operating conditions in the Assay under Eucalyptus Oil except test for required detectability and time span of measurement.

Test for required detectability: To 1 mL of the sample solution add hexane to make 100 mL. Adjust so that the peak height of cineol obtained with 2 μL of this solution is 40 to 60% of the full scale.

Time span of measurement: About 3 times as long as the retention time of cineol, beginning after the solvent peak.

(E)-Ferulic acid for assay $C_{10}H_{10}O_4$ (*E*)-Ferulic acid. It meets the requirements of the following 1) (*E*)-ferulic acid for assay 1 or 2) (*E*)-ferulic acid for assay 2 (Purity value by quantitative NMR). The former is used after drying in a desiccator (silica gel) for 24 hours, and latter is used with correction for its amount based on the result obtained in the Assay.

1) (*E*)-Ferulic acid for assay 1

Absorbance <2.24> $E_{1\%}^{1\text{cm}}$ (320 nm): 878 – 969 (5 mg, methanol, 1000 mL).

Purity Related substances—Conduct this procedure without exposure to light, using light-resistant vessels. Dis-

solve 5 mg of (*E*)-ferulic acid for assay 1 in 10 mL of a mixture of water and methanol (1:1), and use this solution as the sample solution. Pipet 1 mL of the sample solution, add a mixture of water and methanol (1:1) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the total area of the peaks other than (*E*)-ferulic acid obtained from the sample solution is not larger than the peak area of (*E*)-ferulic acid from the standard solution.

Operating conditions

Detector, column, column temperature, mobile phase and flow rate: Proceed as directed in the operating conditions in the Assay (1) under Tokishakuyakusan Extract.

Time span of measurement: About 6 times as long as the retention time of (*E*)-ferulic acid, beginning after the solvent peak.

System suitability

Test for required detectability: Pipet 1 mL of the standard solution, and add a mixture of water and methanol (1:1) to make exactly 20 mL. Confirm that the peak area of (*E*)-ferulic acid obtained with 10 μL of this solution is equivalent to 3.5 to 6.5% of that with 10 μL of the standard solution.

System performance: When the procedure is run with 10 μL of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of (*E*)-ferulic acid are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of (*E*)-ferulic acid is not more than 1.5%.

2) (*E*)-Ferulic acid for assay 2 (Purity value by quantitative NMR)

Unity of peak—Conduct this procedure without exposure to light, using light-resistant vessels. Dissolve 5 mg of (*E*)-ferulic acid for assay 2 in 10 mL of a mixture of water and methanol (1:1), and use this solution as the sample solution. Perform the test with 10 μL of the sample solution as directed under Liquid Chromatography <2.01> according to the following conditions, and compare the absorption spectra of at least 3 points including the top of (*E*)-ferulic acid peak and around the two middle peak heights of before and after the top: no difference in form is observed among their spectra.

Operating conditions

Column, column temperature, mobile phase and flow rate: Proceed as directed in the operating conditions in the Assay (1) under Tokishakuyakusan Extract.

Detector: A photodiode array detector (wavelength: 320 nm, measuring range of spectrum: 220 – 400 nm).

System suitability

System performance: When the procedure is run with 10 μL of the sample solution under the above operating conditions, the number of theoretical plates and the symmetry

factor of the peak of (*E*)-ferulic acid are not less than 5000 and not more than 1.5, respectively.

Assay—Weigh accurately 5 mg of (*E*)-ferulic acid for assay 2 and 1 mg of 1,4-BTMSB-*d*₄ for nuclear magnetic resonance spectroscopy using an ultramicrobalance, dissolve in 1 mL of deuterated methanol for nuclear magnetic resonance spectroscopy, and use this solution as the sample solution. Transfer the sample solution into an NMR tube 5 mm in outer diameter, and measure ¹H-NMR as directed under Nuclear Magnetic Resonance Spectroscopy <2.21> and Crude Drugs Test <5.01> according to the following conditions, using 1,4-BTMSB-*d*₄ for nuclear magnetic resonance spectroscopy as the internal reference compound. Calculate the resonance intensity *A* (equivalent to 1 hydrogen) of the signal around δ 6.06 ppm assuming the signal of the internal reference compound as δ 0 ppm.

$$\begin{aligned} &\text{Amount (\% of } (E)\text{-ferulic acid (C}_{10}\text{H}_{10}\text{O}_4\text{))} \\ &= M_S \times I \times P / (M \times N) \times 0.8573 \end{aligned}$$

M: Amount (mg) of (*E*)-ferulic acid for assay 2 taken

*M*_S: Amount (mg) of 1,4-BTMSB-*d*₄ for nuclear magnetic resonance spectroscopy taken

I: Signal resonance intensity *A* based on the signal resonance intensity of 1,4-BTMSB-*d*₄ for nuclear magnetic resonance spectroscopy as 18.000

N: Number of hydrogen derived from *A*

P: Purity (%) of 1,4-BTMSB-*d*₄ for nuclear magnetic resonance spectroscopy

Operating conditions

Apparatus: A nuclear magnetic resonance spectrometer having ¹H resonance frequency of not less than 400 MHz.

Target nucleus: ¹H.

Digital resolution: 0.25 Hz or lower.

Measuring spectrum range: 20 ppm or upper, including between -5 ppm and 15 ppm.

Spinning: off.

Pulse angle: 90°.

¹³C decoupling: on.

Delay time: Repeating pulse waiting time not less than 60 seconds.

Integrating times: 8 or more times.

Dummy scanning: 2 or more times.

Measuring temperature: A constant temperature between 20°C and 30°C.

System suitability

Test for required detectability: When the procedure is run with the sample solution under the above operating conditions, the SN ratio of the signal around δ 6.06 ppm is not less than 100.

System performance: When the procedure is run with the sample solution under the above operating conditions, the signal around δ 6.06 ppm is not overlapped with any signal of obvious foreign substances.

System repeatability: When the test is repeated 6 times with the sample solution under the above operating conditions, the relative standard deviation of the ratio of the resonance intensity *A* to that of the internal reference com-

pound is not more than 1.0%.

10-Hydroxy-2-(*E*)-decenoic acid for assay C₁₀H₁₈O₃ 10-hydroxy-2-(*E*)-decenoic acid for thin-layer chromatography. It meets the requirement of the following 1) 10-Hydroxy-2-(*E*)-decenoic acid for assay 1 or 2) 10-Hydroxy-2-(*E*)-decenoic acid for assay 2 (Purity value by quantitative NMR). The latter is used with correction for its amount based on the result obtained in the Assay.

1) 10-Hydroxy-2-(*E*)-decenoic acid for assay 1

Purity Related substances—Dissolve 10 mg of 10-hydroxy-2-(*E*)-decenoic acid for assay 1 in 100 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: the total area of the peaks other than 10-hydroxy-2-(*E*)-decenoic acid obtained from the sample solution is not larger than the peak area of 10-hydroxy-2-(*E*)-decenoic acid from the standard solution.

Operating conditions

Detector, column, column temperature, mobile phase and flow rate: Proceed as directed in the operating conditions in the Assay under Royal Jelly.

Time span of measurement: About 4 times as long as the retention time of 10-hydroxy-2-(*E*)-decenoic acid, beginning after the solvent peak.

System suitability

Test for required detectability: Pipet 1 mL of the standard solution, and add methanol to make exactly 20 mL. Confirm that the peak area of 10-hydroxy-2-(*E*)-decenoic acid obtained with 10 μL of this solution is equivalent to 3.5 to 6.5% of that with 10 μL of the standard solution.

System performance: Dissolve 1 mg of propyl parahydroxybenzoate for resolution check in 10 mL of the sample solution. When the procedure is run with 10 μL of this solution under the above operating conditions, 10-hydroxy-2-(*E*)-decenoic acid and propyl parahydroxybenzoate are eluted in this order with the resolution between these peaks being not less than 6.

System repeatability: When the test is repeated 6 times with 10 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of 10-hydroxy-2-(*E*)-decenoic acid is not more than 1.5%.

2) 10-Hydroxy-2-(*E*)-decenoic acid for assay 2 (Purity value by quantitative NMR)

Unity of peak—Dissolve 1 mg of 10-hydroxy-2-(*E*)-decenoic acid for assay 2 in 50 mL of methanol, and use this solution as the sample solution. Perform the test with 10 μL of the sample solution as directed under Liquid Chromatography <2.01> according to the following conditions, and compare the absorption spectra of at least 3 points including the top of 10-hydroxy-2-(*E*)-decenoic acid peak and around the two middle peak heights of before and after the

top: no difference in form is observed among their spectra.
Operating conditions

Column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay under Royal Jelly.

Detector: A photodiode array detector (wavelength: 215 nm; spectrum range of measurement: 200 – 400 nm).

System suitability

System performance: Dissolve 1 mg each of 10-hydroxy-2-(*E*)-decenoic acid for assay 2 and propyl parahydroxybenzoate for resolution check in methanol to make 50 mL. When the procedure is run with 10 μ L of this solution under the above operating conditions, 10-hydroxy-2-(*E*)-decenoic acid and propyl parahydroxybenzoate are eluted in this order with the resolution between these peaks being not less than 6.

Assay—Weigh accurately 5 mg of 10-hydroxy-2-(*E*)-decenoic acid for assay 2 and 1 mg of 1,4-BTMSB-*d*₄ for nuclear magnetic resonance spectroscopy using an ultramicrobalance, dissolve in 1 mL of deuterated methanol for nuclear magnetic resonance spectroscopy, and use this solution as the sample solution. Transfer the sample solution into an NMR tube 5 mm in outer diameter, and measure ¹H-NMR as directed under Nuclear Magnetic Resonance Spectroscopy <2.21> and Crude Drugs Test <5.01> according to the following conditions, using 1,4-BTMSB-*d*₄ for nuclear magnetic resonance spectroscopy as the internal reference compound. Calculate the resonance intensities, *A*₁ (equivalent to 1 hydrogen) and *A*₂ (equivalent to 1 hydrogen), of the signals around δ 5.54 ppm and δ 6.70 ppm assuming the signal of the internal reference compound as δ 0 ppm.

Amount (%) of 10-hydroxy-2-(*E*)-decenoic acid (C₁₀H₁₈O₃)
= $M_S \times I \times P / (M \times N) \times 0.8223$

M: Amount (mg) of 10-hydroxy-2-(*E*)-decenoic acid for assay 2 taken

*M*_S: Amount (mg) of 1,4-BTMSB-*d*₄ for nuclear magnetic resonance spectroscopy taken

I: Sum of the signal resonance intensities, *A*₁ and *A*₂, based on the signal resonance intensity of 1,4-BTMSB-*d*₄ for nuclear magnetic resonance spectroscopy as 18.000

N: Sum of the numbers of the hydrogen derived from *A*₁ and *A*₂

P: Purity (%) of 1,4-BTMSB-*d*₄ for nuclear magnetic resonance spectroscopy

Operating conditions

Apparatus: A nuclear magnetic resonance spectrometer having ¹H resonance frequency of not less than 400 MHz.

Target nucleus: ¹H.

Digital resolution: 0.25 Hz or lower.

Measuring spectrum range: 20 ppm or upper, including between –5 ppm and 15 ppm.

Spinning: off.

Pulse angle: 90°.

¹³C decoupling: on.

Delay time: Repeating pulse waiting time not less than 60 seconds.

Integrating times: 8 or more times.

Dummy scanning: 2 or more times.

Measuring temperature: A constant temperature between 20°C and 30°C.

System suitability

Test for required detectability: When the procedure is run with the sample solution under the above operating conditions, the SN ratio of each signal around δ 5.54 ppm and δ 6.70 ppm is not less than 100.

System performance: When the procedure is run with the sample solution under the above operating conditions, the signals around δ 5.54 ppm and δ 6.70 ppm are not overlapped with any signal of obvious foreign substances, and the ratio of the resonance intensities, *A*₁/*A*₂, of each signal around δ 5.54 ppm and δ 6.70 ppm is between 0.99 and 1.01.

System repeatability: When the test is repeated 6 times with the sample solution under the above operating conditions, the relative standard deviations of the ratios of the resonance intensities, *A*₁ and *A*₂, to that of the internal reference are not more than 1.0%.

Limonene C₁₀H₁₆ Clear and colorless liquid, having a characteristic aroma and a bitter taste.

Refractive index <2.45> *n*_D²⁰: 1.472 – 1.474

Specific gravity <2.56> *d*₂₀²⁰: 0.841 – 0.846

Purity Related substances—Dissolve 0.1 g of limonene in 25 mL of hexane and use this solution as the sample solution. Perform the test with 2 μ L of the sample solution as directed under Gas Chromatography <2.02> according to the following conditions. Determine each peak area by the automatic integration method and calculate the amount of them by the area percentage method: the total amount of the peaks other than limonene is not more than 3.0%.

Operating conditions

Proceed the operating conditions in the Assay under Eucalyptus Oil except test for required detectability and time span of measurement.

Test for required detectability: To 1 mL of the sample solution add hexane to make 100 mL. Adjust so that the peak height of limonene obtained with 2 μ L of this solution is 40 to 60% of the full scale.

Time span of measurement: About 3 times as long as the retention time of limonene, beginning after the solvent peak.

Saikosaponin a for thin-layer chromatography A white, crystalline powder or powder. Freely soluble in methanol and in ethanol (99.5), and practically insoluble in water. Melting point: 225 – 232°C (with decomposition).

Absorbance <2.24> *E*_{1 cm}^{1%} (206 nm): 65 – 73 (15 mg, methanol, 200 mL). Previously dried in a desiccator (in vacuum, silica gel) for 24 hours.

Purity Related substances—Dissolve 1.0 mg of saikosaponin a for thin-layer chromatography in exactly 1 mL of methanol, and perform the test with 10 μ L of this solution as directed in the Identification (2) under Bupleurum

Root: any spot other than the principal spot at the *Rf* value of about 0.4 does not appear.

Saikosaponin d for assay $C_{42}H_{68}O_{13}$ A white, crystalline powder or powder. Freely soluble in methanol and in ethanol (99.5), and practically insoluble in water. Melting point: about 240°C.

Absorbance <2.24> $E_{1\text{cm}}^{1\%}$ (206 nm): 66 – 74 (15 mg, methanol, 200 mL). Previously dried in a desiccator (in vacuum, silica gel) for 24 hours.

Purity Related substances—

(1) Dissolve 2.0 mg of saikosaponin d for assay in 2 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 100 mL, and use this solution as the standard solution. Proceed the test with 10 μL each of the sample solution and standard solution as directed in the Identification (2) under Bupleurum Root: the spot other than the principal spot around *Rf* value of 0.4 obtained from the sample solution is not larger and not more intense than the spot from the standard solution.

(2) Dissolve 10 mg of saikosaponin d for assay in 20 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the total area of the peaks other than saikosaponin d obtained from the sample solution is not larger than the peak area of saikosaponin d from the standard solution.

Operating conditions

Detector and column: Proceed as directed in the operating conditions in the Assay under Bupleurum Root.

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of water and acetonitrile (11:9).

Flow rate: Adjust so that the retention time of saikosaponin d is about 13 minutes.

Time span of measurement: About 4 times as long as the retention time of saikosaponin d, beginning after the solvent peak.

System suitability

Test for required detectability: Pipet 1 mL of the standard solution, and add methanol to make exactly 20 mL. Confirm that the peak area of saikosaponin d obtained with 20 μL of this solution is equivalent to 3.5 to 6.5% of that with 20 μL of the standard solution.

System performance: Dissolve 6 mg each of saikosaponin d for assay and saikosaponin a for assay in methanol to make 100 mL. When the procedure is run with 20 μL of this solution under the above operating conditions, saikosaponin a and saikosaponin d are eluted in this order with the resolution between these peaks being not less than 1.5.

System repeatability: When the test is repeated 6 times with 20 μL of the standard solution under the above operat-

ing conditions, the relative standard deviation of the peak area of saikosaponin d is not more than 1.0%.

Sinomenine for assay $C_{19}H_{23}NO_4$ Sinomenine for thin-layer chromatography. It meets the requirements of the following 1) sinomenine for assay 1 or 2) sinomenine for assay 2 (Purity value by quantitative NMR). The former is used after drying in a desiccator (silica gel) for 24 hours, and latter is used with correction for its amount based on the result obtained in the Assay.

1) Sinomenine for assay 1

Identification Determine the absorption spectrum of a solution of sinomenine for assay in methanol (1 in 25,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits the maximum between 259 nm and 263 nm.

Purity Related substances—Dissolve 5 mg of sinomenine for assay 1 in 10 mL of a mixture of water and acetonitrile (7:3), and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mixture of water and acetonitrile (7:3) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the total area of the peaks other than sinomenine obtained from the sample solution is not larger than the peak area of sinomenine from the standard solution.

Operating conditions

Column, column temperature, mobile phase and flow rate: Proceed as directed in the operating conditions in the Assay (1) under Boiogito Extract.

Detector: An ultraviolet absorption photometer (wavelength: 261 nm).

Time span of measurement: About 3 times as long as the retention time of sinomenine, beginning after the solvent peak.

System suitability

Test for required detectability: Pipet 1 mL of the standard solution, and add a mixture of water and acetonitrile (7:3) to make exactly 20 mL. Confirm that the peak area of sinomenine obtained with 10 μL of this solution is equivalent to 3.5 to 6.5% of that with 10 μL of the standard solution.

System performance: When the procedure is run with 10 μL of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of sinomenine are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of sinomenine is not more than 1.5%.

2) Sinomenine for assay 2 (Purity value by quantitative NMR)

Unity of peak—Dissolve 5 mg of sinomenine for assay 2 in 10 mL of a mixture of water and acetonitrile (7:3), and

use this solution as the sample solution. Perform the test with 10 μL of the sample solution as directed under Liquid Chromatography <2.01> according to the following conditions, and compare the absorption spectra of at least 3 points including the top of sinomenine peak and around the two middle peak heights of before and after the top: no difference in form is observed among their spectra.

Operating conditions

Column, column temperature, mobile phase and flow rate: Proceed as directed in the operating conditions in the Assay (1) under Boiogito Extract.

Detector: A photodiode array detector (wavelength: 261 nm, spectrum range of requirement: 220 – 400 nm).

System suitability

System performance: When the procedure is run with 10 μL of the sample solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of sinomenine are not less than 5000 and not more than 1.5, respectively.

Assay—Weigh accurately 5 mg of sinomenine for assay 2 and 1 mg of 1,4-BTMSB- d_4 for nuclear magnetic resonance spectroscopy using an ultramicrobalance, dissolve in 1 mL of deuterated acetone for nuclear magnetic resonance spectroscopy, and use this solution as the sample solution. Transfer the sample solution into an NMR tube 5 mm in outer diameter, and measure $^1\text{H-NMR}$ as directed under Nuclear Magnetic Resonance Spectroscopy <2.21> and Crude Drugs Test <5.01> according to the following conditions, using 1,4-BTMSB- d_4 for nuclear magnetic resonance spectroscopy as the internal reference compound. Calculate the resonance intensity A (equivalent to 1 hydrogen) of the signal around δ 5.42 ppm assuming the signal of the internal reference compound as δ 0 ppm.

$$\begin{aligned} &\text{Amount (\%)} \text{ of sinomenine (C}_{19}\text{H}_{23}\text{NO}_4\text{)} \\ &= M_S \times I \times P / (M \times N) \times 1.4543 \end{aligned}$$

M : Amount (mg) of sinomenine for assay 2 taken

M_S : Amount (mg) of 1,4-BTMSB- d_4 for nuclear magnetic resonance spectroscopy taken

I : Signal resonance intensity A based on the signal resonance intensity of 1,4-BTMSB- d_4 for nuclear magnetic resonance spectroscopy as 18.000

N : Number of hydrogen derived from A

P : Purity (%) of 1,4-BTMSB- d_4 for nuclear magnetic resonance spectroscopy

Operating conditions

Apparatus: A nuclear magnetic resonance spectrometer having ^1H resonance frequency of not less than 400 MHz.

Target nucleus: ^1H .

Digital resolution: 0.25 Hz or lower.

Measuring spectrum range: 20 ppm or upper, including between -5 ppm and 15 ppm.

Spinning: off.

Pulse angle: 90° .

^{13}C decoupling: on.

Delay time: Repeating pulse waiting time not less than 60 seconds.

Integrating times: 8 or more times.

Dummy scanning: 2 or more times.

Measuring temperature: A constant temperature between 20°C and 30°C .

System suitability

Test for required detectability: When the procedure is run with the sample solution under the above operating conditions, the SN ratio of the signal around δ 5.42 ppm is not less than 100.

System performance: When the procedure is run with the sample solution under the above operating conditions, the signal around δ 5.42 ppm is not overlapped with any signal of obvious foreign substances.

System repeatability: When the test is repeated 6 times with the sample solution under the above operating conditions, the relative standard deviation of the ratio of the resonance intensity A to that of the internal reference compound is not more than 1.0%.

Starch, soluble [K 8659, Starch, soluble, First class]

9.42 Solid Supports/Column Packings for Chromatography

Add the following:

Amylose tris-(3,5-dimethylphenylcarbamate)-coated silica gel for liquid chromatography Prepared for liquid chromatography.

Octadecyl-strong anion exchange-silanized silica gel for liquid chromatography Prepared for liquid chromatography.

Porous silica gel for gas chromatography Prepared for gas chromatography.

Official Monographs

Amphotericin B Tablets

アムホテリシン B 錠

Add the following next to the Uniformity of dosage units:

Disintegration <6.09> Perform the test using the disk: it meets the requirement.

Beclomethasone Dipropionate

ベクロメタゾンプロピオン酸エステル

Change the Description and Optical rotation as follows:

Description Beclomethasone Dipropionate occurs as a white to pale yellow powder.

It is soluble in methanol, sparingly soluble in ethanol (99.5), and practically insoluble in water.

Melting point: about 208°C (with decomposition).

It shows crystal polymorphism.

Optical rotation <2.49> $[\alpha]_D^{25}$: +106 – +114° (after drying, 0.1 g, ethanol (99.5), 10 mL, 100 mm).

Betamethasone Dipropionate

ベタメタゾンジプロピオン酸エステル

Change the Description and Optical rotation as follows:

Description Betamethasone Dipropionate occurs as a white to pale yellow-white crystalline powder. It is odorless.

It is freely soluble in acetone and in chloroform, soluble in methanol and in ethanol (99.5), and practically insoluble in water.


It is gradually affected by light.

Optical rotation <2.49> $[\alpha]_D^{25}$: +84 – +89° (after drying, 50 mg, ethanol (99.5), 10 mL, 100 mm).

Add the following:

Bromfenac Sodium Hydrate

ブロムフェナクナトリウム水和物



$C_{15}H_{11}BrNNaO_3 \cdot 1/2H_2O$: 383.17

Sodium 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate sesquihydrate
[120638-55-3]

Bromfenac Sodium Hydrate contains not less than 97.5% and not more than 101.5% of bromfenac sodium ($C_{15}H_{11}BrNNaO_3$: 356.15), calculated on the anhydrous basis.

Description Bromfenac Sodium Hydrate occurs as a yellow to orange crystalline powder.

It is freely soluble in water, soluble in methanol, and slightly soluble in ethanol (99.5).

It dissolves in a solution of sodium hydrogen carbonate (21 in 2500).

Identification (1) Dissolve 10 mg of Bromfenac Sodium Hydrate in 500 mL of a solution of sodium hydrogen carbonate (21 in 2500). Determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Bromfenac Sodium RS prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Bromfenac Sodium Hydrate as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Bromfenac Sodium RS: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) A solution of Bromfenac Sodium Hydrate (1 in 20) responds to Qualitative Tests <1.09> (1) for sodium salt.

pH <2.54> Dissolve 1.0 g of Bromfenac Sodium Hydrate in 20 mL of water: the pH of the solution is between 8.4 and 10.2.

Purity (1) Heavy metals <1.07>—Proceed with 1.0 g of Bromfenac Sodium Hydrate according to Method 2, and perform the test. Prepare the control solution with 2.0 mL

of Standard Lead Solution (not more than 20 ppm).

(2) Related substances—Dissolve 50 mg of Bromfenac Sodium Hydrate in 100 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the area of the peak other than bromfenac obtained from the sample solution is not larger than 1/10 times the peak area of bromfenac from the standard solution, and the total area of the peaks other than bromfenac from the sample solution is not larger than the peak area of bromfenac from the standard solution.

Operating conditions—

Detector, column and column temperature: Proceed as directed in the operating conditions in the Assay.

Mobile phase: Dissolve 3.85 g of ammonium acetate in 1000 mL of water, and adjust to pH 4.0 with acetic acid (100). To 570 mL of this solution add 430 mL of acetonitrile.

Flow rate: Adjust so that the retention time of bromfenac is about 8 minutes.

Time span of measurement: About 3 times as long as the retention time of bromfenac, beginning after the solvent peak.

System suitability—

Test for required detectability: Pipet 2 mL of the standard solution, and add methanol to make exactly 20 mL. Confirm that the peak area of bromfenac obtained with 20 μ L of this solution is equivalent to 7 to 13% of that with 20 μ L of the standard solution.

System performance: When the procedure is run with 20 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of bromfenac are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 20 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of bromfenac is not more than 2.0%.

Water <2.48> 6.9 – 8.5% (0.15 g, volumetric titration, direct titration. Use a solution of imidazole for water determination in methanol for water determination (1 in 80) instead of methanol for water determination).

Assay Weigh accurately about 30 mg each of Bromfenac Sodium Hydrate and Bromfenac Sodium RS (separately determine the water <2.48> in the same manner as Bromfenac Sodium Hydrate), dissolve each in methanol to make exactly 50 mL. Pipet 5 mL each of these solutions, add the mobile phase to make them exactly 100 mL, and use these solutions as the sample solution and the standard solution, respectively. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following

conditions, and determine the peak areas, A_T and A_S , of bromfenac in each solution.

$$\begin{aligned} \text{Amount (mg) of bromfenac sodium (C}_{15}\text{H}_{11}\text{BrNNaO}_3) \\ = M_S \times A_T/A_S \end{aligned}$$

M_S : Amount (mg) of Bromfenac Sodium RS taken, calculated on the anhydrous basis

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 266 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 35°C.

Mobile phase: Dissolve 3.85 g of ammonium acetate in 1000 mL of water. To 600 mL of this solution add 250 mL of methanol and 150 mL of tetrahydrofuran.

Flow rate: Adjust so that the retention time of bromfenac is about 9 minutes.

System suitability—

System performance: When the procedure is run with 20 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of bromfenac are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 20 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of bromfenac is not more than 1.0%.

Containers and storage Containers—Tight containers.

Storage—Light-resistant.

Add the following:

Bromfenac Sodium Ophthalmic Solution

ブロムフェナクナトリウム点眼液

Bromfenac Sodium Ophthalmic Solution is an aqueous ophthalmic preparation.

It contains not less than 90.0% and not more than 110.0% of the labeled amount of Bromfenac Sodium Hydrate (C₁₅H₁₁BrNNaO₃·1½H₂O: 383.17).

Method of preparation Prepare as directed under Ophthalmic Liquids and Solutions, with Bromfenac Sodium Hydrate.

Description Bromfenac Sodium Ophthalmic Solution occurs as a clear and yellow liquid.

Identification To a volume of Bromfenac Sodium Ophthalmic Solution, equivalent to 1 mg of Bromfenac Sodium Hydrate, add a solution of sodium hydrogen carbonate (21

in 2500) to make 50 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 266 nm and 270 nm, and between 377 nm and 381 nm.

pH Being specified separately when the drug is granted approval based on the Law.

Purity Related substances—Being specified separately when the drug is granted approval based on the Law.

Foreign insoluble matter <6.11> It meets the requirement.

Insoluble particulate matter <6.08> It meets the requirement.

Sterility <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

Assay Pipet a volume of Bromfenac Sodium Ophthalmic Solution, equivalent to about 2 mg of bromfenac sodium hydrate ($C_{15}H_{11}BrNNaO_3 \cdot 1\frac{1}{2}H_2O$), add the mobile phase to make exactly 20 mL, and use this solution as the sample solution. Separately, weigh accurately about 20 mg of Bromfenac Sodium RS (separately determine the water <2.48> in the same manner as Bromfenac Sodium Hydrate), and dissolve in the mobile phase to make exactly 20 mL. Pipet 2 mL of this solution, add the mobile phase to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of bromfenac in each solution.

$$\begin{aligned} & \text{Amount (mg) of bromfenac sodium hydrate} \\ & (C_{15}H_{11}BrNNaO_3 \cdot 1\frac{1}{2}H_2O) \\ & = M_S \times A_T / A_S \times 1/10 \times 1.076 \end{aligned}$$

M_S : Amount (mg) of Bromfenac Sodium RS taken, calculated on the anhydrous basis

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 266 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: Dissolve 1.98 g of diammonium hydrogen phosphate in 750 mL of water, adjust to pH 7.3 with phosphoric acid, and add 250 mL of acetonitrile.

Flow rate: Adjust so that the retention time of bromfenac is about 18 minutes.

System suitability—

System performance: When the procedure is run with 10 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of bromfenac are not less than 13,000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of bromfenac is not more than 1.0%.

Containers and storage Containers—Tight containers.

Change the following as follows:

Anhydrous Dibasic Calcium Phosphate

無水リン酸水素カルシウム

CaHPO₄: 136.06
[7757-93-9]

This monograph is harmonized with the European Pharmacopoeia and the U.S. Pharmacopoeia.

The corresponding part of the attributes/provisions which are agreed as non-harmonized within the scope of the harmonization is marked with symbols (◆ ◆), and the corresponding parts which are agreed as the JP local requirement other than the scope of the harmonization are marked with symbols (◇ ◇).

Anhydrous Dibasic Calcium Phosphate contains not less than 97.5% and not more than 102.5% of dibasic calcium phosphate (CaHPO₄).

◆**Description** Anhydrous Dibasic Calcium Phosphate occurs as white, crystalline powder or granules.

It is practically insoluble in water and in ethanol (99.5).

It dissolves in dilute hydrochloric acid and in dilute nitric acid.◆

Identification (1) Dissolve 0.1 g of Anhydrous Dibasic Calcium Phosphate in 10 mL of 2 mol/L hydrochloric acid TS by warming, add 2.5 mL of ammonia TS dropwise with shaking, and add 5 mL of ammonium oxalate TS: a white precipitate is produced.

(2) Dissolve 0.1 g of Anhydrous Dibasic Calcium Phosphate in 5 mL of dilute nitric acid, and add 2 mL of hexaammonium heptamolybdate TS after warming at 70°C for 1 to 2 minutes: a yellow precipitate is produced.

Purity (1) Acid-insoluble substances—Dissolve 5.0 g of Anhydrous Dibasic Calcium Phosphate in 40 mL of water and 10 mL of hydrochloric acid, and boil gently for 5 minutes. After cooling, collect the insoluble substance using a filter paper for assay. Wash with water until no more turbidity of the washings is produced when silver nitrate TS is added. Ignite to incinerate the residue and the filter paper at 600 ± 50°C: the mass is not more than 10 mg (not more than 0.2%).

(2) Chloride—To 0.20 g of Anhydrous Dibasic Calcium Phosphate add 20 mL of water and 13 mL of dilute nitric acid, dissolve by warming, if necessary, add water to make

100 mL, and filter, if necessary. Put 50 mL of this solution in a Nessler tube, and use this as the sample solution. Separately, transfer 0.70 mL of 0.01 mol/L hydrochloric acid VS to another Nessler tube, add 6 mL of dilute nitric acid and water to make 50 mL, and use this solution as the control solution. Add 1 mL of silver nitrate TS to the sample solution and control solution, mix well, and allow to stand for 5 minutes protecting from light. Compare the opalescence developed in both solutions against a black background by viewing down-ward or transversely. The opalescence developed in the sample solution is not more than that of the control solution (not more than 0.25%).

(3) Sulfate—Dissolve 0.50 g of Anhydrous Dibasic Calcium Phosphate in 5 mL of water and 5 mL of dilute hydrochloric acid, add water to make 100 mL, and filter, if necessary. Put 20 mL of this solution in a Nessler tube, add 1 mL of dilute hydrochloric acid, and add water to make 50 mL, and use this as the sample solution. Transfer 1.0 mL of 0.005 mol/L sulfuric acid VS to another Nessler tube, add 1 mL of dilute hydrochloric acid and water to make 50 mL, and use this solution as the control solution. Add 2 mL of barium chloride TS to the sample solution and control solution, mix well, and allow to stand for 10 minutes. Compare the white turbidity produced in both solutions against a black background by viewing downward or transversely. The turbidity produced in the sample solution is not thicker than that of the control solution (not more than 0.48%).

(4) Carbonate—Mix 1.0 g of Anhydrous Dibasic Calcium Phosphate with 5 mL of freshly boiled and cooled water, and add immediately 2 mL of hydrochloric acid: no effervescence occurs.

◇(5) Heavy metals <1.07>—Dissolve 0.65 g of Anhydrous Dibasic Calcium Phosphate in a mixture of 5 mL of water and 5 mL of dilute hydrochloric acid by warming, cool, and add ammonia TS until precipitates begin to form in the solution. Dissolve the precipitates by adding a small amount of dilute hydrochloric acid dropwise, add 10 mL of hydrochloric acid-ammonium acetate buffer solution (pH 3.5) and water to make 50 mL, and perform the test using this solution as the sample solution. Prepare the control solution as follows: to 10 mL of hydrochloric acid-ammonium acetate buffer solution (pH 3.5) add 2.0 mL of Standard Lead Solution and water to make 50 mL (not more than 31 ppm).◇

(6) Barium—Heat 0.5 g of Anhydrous Dibasic Calcium Phosphate with 10 mL of water, add 1 mL of hydrochloric acid dropwise with stirring, and filter after cooling, if necessary. Add 2 mL of potassium sulfate TS to this solution, and allow to stand for 10 minutes: no turbidity forms.

◆(7) Arsenic <1.11>—Dissolve 1.0 g of Anhydrous Dibasic Calcium Phosphate in 5 mL of dilute hydrochloric acid, and perform the test with this solution as the test solution (not more than 2 ppm).◆

Loss on ignition <2.43> Not less than 6.6% and not more than 8.7% (1 g, 800 – 825°C, constant mass).

Assay Weigh accurately about 0.4 g of Anhydrous Dibasic Calcium Phosphate, dissolve in 12 mL of dilute hydrochloric

acid by heating on a water bath, if necessary, and add water to make exactly 200 mL. Pipet 20 mL of this solution, add exactly 25 mL of 0.02 mol/L disodium dihydrogen ethylenediamine tetraacetate VS, 50 mL of water and 5 mL of ammonia-ammonium chloride buffer solution (pH 10.7), and titrate <2.50> the excess disodium dihydrogen ethylenediamine tetraacetate with 0.02 mol/L zinc sulfate VS (indicator: 25 mg of eriochrome black T-sodium chloride indicator). Perform a blank determination in the same manner.

Each mL of 0.02 mol/L disodium dihydrogen ethylenediamine tetraacetate VS
= 2.721 mg of CaHPO₄

◆**Containers and storage** Containers—Well-closed containers.◆

Add the following:

Cefalotin Sodium for Injection

注射用セファロチンナトリウム

Cefalotin Sodium for Injection is a preparation for injection, which is dissolved before use.

It contains not less than 90.0% and not more than 110.0% of the labeled potency of cefalotin (C₁₆H₁₆N₂O₆S₂: 396.44).

Method of preparation Prepare as directed under Injections, with Cefalotin Sodium.

Description Cefalotin Sodium for Injection occurs as white to light yellow-white, crystals or crystalline powder.

Identification Determine the infrared absorption spectrum of Cefalotin Sodium for Injection as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum of Cefalotin Sodium or the spectrum of Cefalotin Sodium RS: both spectra exhibit similar intensities of absorption at the same wave numbers.

pH <2.54> Dissolve an amount of Cefalotin Sodium for Injection, equivalent to 0.5 g (potency) of Cefalotin Sodium, in 5 mL of water: the pH of the solution is between 4.5 and 7.0.

Purity (1) Clarity and color of solution—Dissolve 1.0 g of Cefalotin Sodium for Injection in 10 mL of water: the solution is clear. Perform the test with this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: the absorbance at 450 nm is not more than 0.20.

(2) Related substances—Dissolve an amount of Cefalotin Sodium for Injection, equivalent to 25 mg (potency), in the mobile phase to make 25 mL, and use this solution as the sample solution. Pipet 1 mL of the sample solution, and add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10 μL each of the sample solution and standard solu-

tion as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the area of the peak other than cefalotin obtained from the sample solution is not larger than the peak area of cefalotin from the standard solution, and the total area of the peaks other than cefalotin from the sample solution is not larger than 3 times the peak area of cefalotin from the standard solution.

Operating conditions—

Detector, column, column temperature, mobile phase and flow rate: Proceed as directed in the operating conditions in the Assay under Cefalotin Sodium.

Time span of measurement: About 4 times as long as the retention time of cefalotin.

System suitability—

Proceed as directed in the system suitability in the Purity (4) under Cefalotin Sodium.

Water <2.48> Not more than 1.0% (0.5 g, volumetric titration, back titration).

Bacterial endotoxins <4.01> Less than 0.2 EU/mg (potency).

Uniformity of dosage units <6.02> It meets the requirement of the Mass variation test.

Foreign insoluble matter <6.06> Perform the test according to Method 2: it meets the requirement.

Insoluble particulate matter <6.07> It meets the requirement.

Sterility <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

Assay Weigh accurately the mass of the contents of not less than 10 containers of Cefalotin Sodium for Injection. Weigh accurately an amount of the contents, equivalent to about 25 mg (potency) of Cefalotin Sodium, dissolve in the mobile phase to make exactly 25 mL, and use this solution as the sample solution. Separately, weigh accurately about 25 mg (potency) of Cefalotin Sodium RS, and dissolve in the mobile phase to make exactly 25 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Cefalotin Sodium.

$$\begin{aligned} & \text{Amount } [\mu\text{g}(\text{potency})] \text{ of cefalotin } (\text{C}_{16}\text{H}_{16}\text{N}_2\text{O}_6\text{S}_2) \\ & = M_S \times A_T/A_S \times 1000 \end{aligned}$$

M_S : Amount [mg(potency)] of Cefalotin Sodium RS taken

Containers and storage Containers—Hermetic containers.

Add the following:

Cefixime Fine Granules

セフィキシム細粒

Cefixime Fine Granules contain not less than 90.0% and not more than 105.0% of the labeled potency of cefixime ($\text{C}_{16}\text{H}_{15}\text{N}_3\text{O}_7\text{S}_2$; 453.45).

Method of preparation Prepare as directed under Granules, with Cefixime Hydrate.

Identification To a quantity of powdered Cefixime Fine Granules, equivalent to 2 mg (potency) of Cefixime Hydrate add 150 mL of 0.1 mol/L phosphate buffer solution (pH 7.0), and shake. If necessary, filter or centrifuge. Determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maximum between 286 nm and 290 nm.

Purity Related substances—To a quantity of powdered Cefixime Fine Granules, equivalent to 0.1 g (potency) of Cefixime Hydrate, add 100 mL of 0.1 mol/L phosphate buffer solution (pH 7.0), shake, filter through a membrane filter with a pore size not exceeding 0.45 μm , and use the filtrate as the sample solution. Perform the test with 10 μL of the sample solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method, and calculate their amounts by the area percentage method: the amount of the peak other than cefixime is not more than 1.0%, and the total amount of the peaks other than cefixime is not more than 2.5%.

Operating conditions—

Detector, column, column temperature, mobile phase and flow rate: Proceed as directed in the operating conditions in the Assay under Cefixime Hydrate.

Time span of measurement: Proceed as directed in the operating conditions in the Purity under Cefixime Hydrate.

System suitability—

Test for required detectability: To 1 mL of the sample solution add 0.1 mol/L phosphate buffer solution (pH 7.0) to make 100 mL, and use this solution as the solution for system suitability test. Pipet 1 mL of the solution for system suitability test, and add 0.1 mol/L phosphate buffer solution (pH 7.0) to make exactly 10 mL. Confirm that the peak area of cefixime obtained with 10 μL of this solution is equivalent to 7 to 13% of that with 10 μL of the solution for system suitability test.

System performance: When the procedure is run with 10 μL of the solution for system suitability test under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of cefixime are not less than 4000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 10 μL of the solution for system suitability test under the above operating conditions, the relative standard deviation of the peak area of cefixime is not more than 2.0%.

Water <2.48> Not more than 3.0% (1 g, volumetric titration, direct titration. Use a mixture of formamide for water determination and methanol for water determination (2:1) instead of methanol for water determination).

Uniformity of dosage units <6.02> Perform the test according to the following method: Cefixime Fine Granules in single-dose packages meet the requirement of the Content uniformity test.

To the total content of 1 package of Cefixime Fine Granules add 7 $V/10$ mL of 0.1 mol/L phosphate buffer solution (pH 7.0), shake, add 0.1 mol/L phosphate buffer solution (pH 7.0) to make exactly V mL so that each mL contains about 1 mg (potency) of Cefixime Hydrate. Centrifuge this solution, pipet 10 mL of the supernatant liquid, add 0.1 mol/L phosphate buffer solution (pH 7.0) to make exactly 50 mL, and use this solution as the sample solution. Separately, weigh accurately an amount of Cefixime RS, equivalent to about 20 mg (potency), dissolve in 0.1 mol/L phosphate buffer solution (pH 7.0) to make exactly 100 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Cefixime Hydrate.

$$\begin{aligned} & \text{Amount [mg (potency)] of cefixime (C}_{16}\text{H}_{15}\text{N}_5\text{O}_7\text{S}_2) \\ & = M_S \times A_T/A_S \times V/20 \end{aligned}$$

M_S : Amount [mg (potency)] of Cefixime RS taken

Dissolution <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of 2nd fluid for dissolution test as the dissolution medium, the dissolution rates in 30 minutes of Cefixime Fine Granules is not less than 75%.

Start the test with an accurately weighed amount of Cefixime Fine Granules, equivalent to about 0.1 g (potency) of Cefixime Hydrate, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45 μm . Discard not less than 10 mL of the first filtrate, and use the subsequent filtrate as the sample solution. Separately, weigh accurately an amount of Cefixime RS, equivalent to about 28 mg (potency), and dissolve in the dissolution medium to make exactly 50 mL. Pipet 4 mL of this solution, add the dissolution medium to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 20 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of cefixime in each solution.

$$\begin{aligned} & \text{Dissolution rate (\%)} \text{ with respect to the labeled amount} \\ & \text{of cefixime (C}_{16}\text{H}_{15}\text{N}_5\text{O}_7\text{S}_2) \\ & = M_S/M_T \times A_T/A_S \times 1/C \times 360 \end{aligned}$$

M_S : Amount [mg (potency)] of Cefixime RS taken

M_T : Amount (g) of Cefixime Fine Granules taken

C : Labeled amount [mg (potency)] of cefixime (C₁₆H₁₅N₅O₇S₂) in 1 g

Operating conditions—

Proceed as directed in the operating conditions in the Assay under Cefixime Hydrate.

System suitability—

System performance: When the procedure is run with 20 μL of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of cefixime are not less than 4000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 20 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of cefixime is not more than 2.0%.

Assay Weigh accurately an amount of powdered Cefixime Fine Granules, equivalent to about 0.1 g (potency) of Cefixime Hydrate, add 70 mL of 0.1 mol/L phosphate buffer solution (pH 7.0), shake, and add 0.1 mol/L phosphate buffer solution (pH 7.0) to make exactly 100 mL. Centrifuge this solution, pipet 10 mL of the supernatant liquid, add 0.1 mol/L phosphate buffer solution (pH 7.0) to make exactly 50 mL, and use this solution as the sample solution. Separately, weigh accurately an amount of Cefixime RS, equivalent to about 20 mg (potency), dissolve in 0.1 mol/L phosphate buffer solution (pH 7.0) to make exactly 100 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Cefixime Hydrate.

$$\begin{aligned} & \text{Amount [mg (potency)] of cefixime (C}_{16}\text{H}_{15}\text{N}_5\text{O}_7\text{S}_2) \\ & = M_S \times A_T/A_S \times 5 \end{aligned}$$

M_S : Amount [mg (potency)] of Cefixime RS taken

Containers and storage Containers—Tight containers.

Change the following as follows:

Microcrystalline Cellulose

結晶セルロース

[9004-34-6, cellulose]

This monograph is harmonized with the European Pharmacopoeia and the U.S. Pharmacopeia.

The corresponding part of the attributes/provisions which are agreed as non-harmonized within the scope of the harmonization is marked with symbols (\blacklozenge \blacklozenge), and the corresponding parts which are agreed as the JP local requirement other than the scope of the harmonization are marked with symbols (\blacklozenge \blacklozenge).

Microcrystalline Cellulose is purified, partially depolymerized α -cellulose, obtained as a pulp from fibrous plant material, with mineral acids.

The label indicates the \blacklozenge mean degree of polymerization, loss on drying, \blacklozenge and bulk density values with a range.

◆**Description** Microcrystalline Cellulose occurs as a white crystalline powder having fluidity.

It is practically insoluble in water, in ethanol (95) and in diethyl ether.

It swells with sodium hydroxide TS on heating.◆

Identification (1) Dissolve 20 g of zinc chloride and 6.5 g of potassium iodide in 10.5 mL of water, add 0.5 g of iodine, and shake for 15 minutes. Place about 10 mg of Microcrystalline Cellulose on a watch glass, and disperse in 2 mL of this solution: the substance develops a blue-violet color.

(2) Determine the infrared absorption spectrum of Microcrystalline Cellulose as directed in the ATR method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the spectrum of Microcrystalline Cellulose RS for Identification: both spectra exhibit similar intensities of absorption at the same wave numbers. If there are absorptions between 800 cm^{-1} and 825 cm^{-1} , and between 950 cm^{-1} and 1000 cm^{-1} , disregard the absorptions.

(3) Transfer about 1.3 g of Microcrystalline Cellulose, accurately weighed, to a 125-mL conical flask, and add exactly 25 mL each of water and 1 mol/L cupriethylenediamine TS. Immediately purge the solution with nitrogen, insert the stopper, and shake on a suitable mechanical shaker to dissolve. Perform the test with a suitable amount of this solution, taken exactly, according to Method 1 under Viscosity Determination <2.53> using a capillary viscometer having the viscosity constant (K) of approximately 0.03, at $25 \pm 0.1^\circ\text{C}$, and determine the kinematic viscosity, ν . Separately, perform the test with a mixture of exactly 25 mL each of water and 1 mol/L cupriethylenediamine TS in the same manner as above, using a capillary viscometer having K of approximately 0.01, and determine the kinematic viscosity, ν_0 .

Calculate the relative viscosity, η_{rel} , of Microcrystalline Cellulose by the following formula:

$$\eta_{\text{rel}} = \nu/\nu_0$$

Obtain the product, $[\eta]C$, of intrinsic viscosity $[\eta]$ (mL/g) and concentration C (g/100 mL) from the value η_{rel} of the table. When calculate the degree of polymerization, P , by the following formula, P is not more than 350 ◆and within the labeled range.◆

$$P = 95[\eta]C/M_T$$

M_T : Amount (g) of the Microcrystalline Cellulose taken, calculated on the dried basis

pH <2.54> Shake 5.0 g of Microcrystalline Cellulose with 40 mL of water for 20 minutes, and centrifuge: the pH of the supernatant liquid is between 5.0 and 7.5.

Purity ◆**(1)** Heavy metals <1.07>—Proceed with 2.0 g of Microcrystalline Cellulose according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).◆

(2) Water-soluble substances—Shake 5.0 g of Microcrystalline Cellulose with 80 mL of water for 10 minutes,

filter with the aid of vacuum through a filter paper for quantitative analysis (5C) into a vacuum flask. Evaporate the filtrate in a tared evaporating dish to dryness without charring, dry at 105°C for 1 hour, cool in a desiccator, and weigh: the difference between the mass of the residue and the mass obtained from a blank determination does not exceed 12.5 mg.


(3) Diethyl ether-soluble substances—Place 10.0 g of Microcrystalline Cellulose in a column having an internal diameter of about 20 mm, and pass 50 mL of peroxide-free diethyl ether through the column. Evaporate the eluate to dryness in a previously dried and tared evaporation dish. Dry the residue at 105°C for 30 minutes, allow to cool in a desiccator, and weigh: the difference between the mass of the residue and the mass obtained from a blank determination does not exceed 5.0 mg.

Conductivity <2.51> Perform the test as directed in the Conductivity Measurement with the supernatant liquid obtained in the pH as the sample solution, and determine the conductivity at $25 \pm 0.1^\circ\text{C}$. Determine in the same manner the conductivity of water used for the preparation of the sample solution: the difference between these conductivities is not more than $75\ \mu\text{S}\cdot\text{cm}^{-1}$.

Loss on drying <2.41> Not more than 7.0% ◆and within a range as specified on the label◆ (1 g, 105°C , 3 hours).

Residue on ignition <2.44> Not more than 0.1% (2 g).

Bulk density (i) Apparatus—Use a volumeter shown in the figure. Put a No.8.6 sieve (2000 μm) on the top of the volumeter. A funnel is mounted over a baffle box, having four glass baffle plates inside which the sample powder slides as it passes. At the bottom of the baffle box is a funnel that collect the powder, and allows it to pour into a sample receiving cup mounted directly below it.



(ii) Procedure—Weigh accurately the mass of a brass or stainless steel cup, which has a capacity of $25.0 \pm 0.05\text{ mL}$ and an inside diameter of $30.0 \pm 2.0\text{ mm}$, and put the cup directly below the funnel of the volumeter. Slowly pour Microcrystalline Cellulose 5.1 cm height from the upper part of the powder funnel through the sieve, at a rate suitable to prevent clogging, until the cup overflows. If the clogging occurs, take out the sieve. Level the excess powder with the aid of a slide glass, weigh the filled cup, and weigh accurately the content of the cup, and then calculate the bulk

Table for Conversion of Relative Viscosity (η_{rel}) into the Product of Limiting Viscosity and Concentration ($[\eta]C$)

η_{rel}	$[\eta]C$									
	0.00	0.01	0.02	0.03	0.04	0.05	0.06	0.07	0.08	0.09
1.1	0.098	0.106	0.115	0.125	0.134	0.143	0.152	0.161	0.170	0.180
1.2	0.189	0.198	0.207	0.216	0.225	0.233	0.242	0.250	0.259	0.268
1.3	0.276	0.285	0.293	0.302	0.310	0.318	0.326	0.334	0.342	0.350
1.4	0.358	0.367	0.375	0.383	0.391	0.399	0.407	0.414	0.422	0.430
1.5	0.437	0.445	0.453	0.460	0.468	0.476	0.484	0.491	0.499	0.507
1.6	0.515	0.522	0.529	0.536	0.544	0.551	0.558	0.566	0.573	0.580
1.7	0.587	0.595	0.602	0.608	0.615	0.622	0.629	0.636	0.642	0.649
1.8	0.656	0.663	0.670	0.677	0.683	0.690	0.697	0.704	0.710	0.717
1.9	0.723	0.730	0.736	0.743	0.749	0.756	0.762	0.769	0.775	0.782
2.0	0.788	0.795	0.802	0.809	0.815	0.821	0.827	0.833	0.840	0.846
2.1	0.852	0.858	0.864	0.870	0.876	0.882	0.888	0.894	0.900	0.906
2.2	0.912	0.918	0.924	0.929	0.935	0.941	0.948	0.953	0.959	0.965
2.3	0.971	0.976	0.983	0.988	0.994	1.000	1.006	1.011	1.017	1.022
2.4	1.028	1.033	1.039	1.044	1.050	1.056	1.061	1.067	1.072	1.078
2.5	1.083	1.089	1.094	1.100	1.105	1.111	1.116	1.121	1.126	1.131
2.6	1.137	1.142	1.147	1.153	1.158	1.163	1.169	1.174	1.179	1.184
2.7	1.190	1.195	1.200	1.205	1.210	1.215	1.220	1.225	1.230	1.235
2.8	1.240	1.245	1.250	1.255	1.260	1.265	1.270	1.275	1.280	1.285
2.9	1.290	1.295	1.300	1.305	1.310	1.314	1.319	1.324	1.329	1.333
3.0	1.338	1.343	1.348	1.352	1.357	1.362	1.367	1.371	1.376	1.381
3.1	1.386	1.390	1.395	1.400	1.405	1.409	1.414	1.418	1.423	1.427
3.2	1.432	1.436	1.441	1.446	1.450	1.455	1.459	1.464	1.468	1.473
3.3	1.477	1.482	1.486	1.491	1.496	1.500	1.504	1.508	1.513	1.517
3.4	1.521	1.525	1.529	1.533	1.537	1.542	1.546	1.550	1.554	1.558
3.5	1.562	1.566	1.570	1.575	1.579	1.583	1.587	1.591	1.595	1.600
3.6	1.604	1.608	1.612	1.617	1.621	1.625	1.629	1.633	1.637	1.642
3.7	1.646	1.650	1.654	1.658	1.662	1.666	1.671	1.675	1.679	1.683
3.8	1.687	1.691	1.695	1.700	1.704	1.708	1.712	1.715	1.719	1.723
3.9	1.727	1.731	1.735	1.739	1.742	1.746	1.750	1.754	1.758	1.762
4.0	1.765	1.769	1.773	1.777	1.781	1.785	1.789	1.792	1.796	1.800
4.1	1.804	1.808	1.811	1.815	1.819	1.822	1.826	1.830	1.833	1.837
4.2	1.841	1.845	1.848	1.852	1.856	1.859	1.863	1.867	1.870	1.874
4.3	1.878	1.882	1.885	1.889	1.893	1.896	1.900	1.904	1.907	1.911
4.4	1.914	1.918	1.921	1.925	1.929	1.932	1.936	1.939	1.943	1.946
4.5	1.950	1.954	1.957	1.961	1.964	1.968	1.971	1.975	1.979	1.982
4.6	1.986	1.989	1.993	1.996	2.000	2.003	2.007	2.010	2.013	2.017
4.7	2.020	2.023	2.027	2.030	2.033	2.037	2.040	2.043	2.047	2.050
4.8	2.053	2.057	2.060	2.063	2.067	2.070	2.073	2.077	2.080	2.083
4.9	2.087	2.090	2.093	2.097	2.100	2.103	2.107	2.110	2.113	2.116
5.0	2.119	2.122	2.125	2.129	2.132	2.135	2.139	2.142	2.145	2.148
5.1	2.151	2.154	2.158	2.160	2.164	2.167	2.170	2.173	2.176	2.180
5.2	2.183	2.186	2.190	2.192	2.195	2.197	2.200	2.203	2.206	2.209
5.3	2.212	2.215	2.218	2.221	2.224	2.227	2.230	2.233	2.236	2.240
5.4	2.243	2.246	2.249	2.252	2.255	2.258	2.261	2.264	2.267	2.270
5.5	2.273	2.276	2.279	2.282	2.285	2.288	2.291	2.294	2.297	2.300
5.6	2.303	2.306	2.309	2.312	2.315	2.318	2.320	2.324	2.326	2.329
5.7	2.332	2.335	2.338	2.341	2.344	2.347	2.350	2.353	2.355	2.358
5.8	2.361	2.364	2.367	2.370	2.373	2.376	2.379	2.382	2.384	2.387
5.9	2.390	2.393	2.396	2.400	2.403	2.405	2.408	2.411	2.414	2.417
6.0	2.419	2.422	2.425	2.428	2.431	2.433	2.436	2.439	2.442	2.444
6.1	2.447	2.450	2.453	2.456	2.458	2.461	2.464	2.467	2.470	2.472
6.2	2.475	2.478	2.481	2.483	2.486	2.489	2.492	2.494	2.497	2.500
6.3	2.503	2.505	2.508	2.511	2.513	2.516	2.518	2.521	2.524	2.526
6.4	2.529	2.532	2.534	2.537	2.540	2.542	2.545	2.547	2.550	2.553
6.5	2.555	2.558	2.561	2.563	2.566	2.568	2.571	2.574	2.576	2.579
6.6	2.581	2.584	2.587	2.590	2.592	2.595	2.597	2.600	2.603	2.605
6.7	2.608	2.610	2.613	2.615	2.618	2.620	2.623	2.625	2.627	2.630
6.8	2.633	2.635	2.637	2.640	2.643	2.645	2.648	2.650	2.653	2.655
6.9	2.658	2.660	2.663	2.665	2.668	2.670	2.673	2.675	2.678	2.680

η_{rel}	$[\eta]C$									
	0.00	0.01	0.02	0.03	0.04	0.05	0.06	0.07	0.08	0.09
7.0	2.683	2.685	2.687	2.690	2.693	2.695	2.698	2.700	2.702	2.705
7.1	2.707	2.710	2.712	2.714	2.717	2.719	2.721	2.724	2.726	2.729
7.2	2.731	2.733	2.736	2.738	2.740	2.743	2.745	2.748	2.750	2.752
7.3	2.755	2.757	2.760	2.762	2.764	2.767	2.769	2.771	2.774	2.776
7.4	2.779	2.781	2.783	2.786	2.788	2.790	2.793	2.795	2.798	2.800
7.5	2.802	2.805	2.807	2.809	2.812	2.814	2.816	2.819	2.821	2.823
7.6	2.826	2.828	2.830	2.833	2.835	2.837	2.840	2.842	2.844	2.847
7.7	2.849	2.851	2.854	2.856	2.858	2.860	2.863	2.865	2.868	2.870
7.8	2.873	2.875	2.877	2.879	2.881	2.884	2.887	2.889	2.891	2.893
7.9	2.895	2.898	2.900	2.902	2.905	2.907	2.909	2.911	2.913	2.915
8.0	2.918	2.920	2.922	2.924	2.926	2.928	2.931	2.933	2.935	2.937
8.1	2.939	2.942	2.944	2.946	2.948	2.950	2.952	2.955	2.957	2.959
8.2	2.961	2.963	2.966	2.968	2.970	2.972	2.974	2.976	2.979	2.981
8.3	2.983	2.985	2.987	2.990	2.992	2.994	2.996	2.998	3.000	3.002
8.4	3.004	3.006	3.008	3.010	3.012	3.015	3.017	3.019	3.021	3.023
8.5	3.025	3.027	3.029	3.031	3.033	3.035	3.037	3.040	3.042	3.044
8.6	3.046	3.048	3.050	3.052	3.054	3.056	3.058	3.060	3.062	3.064
8.7	3.067	3.069	3.071	3.073	3.075	3.077	3.079	3.081	3.083	3.085
8.8	3.087	3.089	3.092	3.094	3.096	3.098	3.100	3.102	3.104	3.106
8.9	3.108	3.110	3.112	3.114	3.116	3.118	3.120	3.122	3.124	3.126
9.0	3.128	3.130	3.132	3.134	3.136	3.138	3.140	3.142	3.144	3.146
9.1	3.148	3.150	3.152	3.154	3.156	3.158	3.160	3.162	3.164	3.166
9.2	3.168	3.170	3.172	3.174	3.176	3.178	3.180	3.182	3.184	3.186
9.3	3.188	3.190	3.192	3.194	3.196	3.198	3.200	3.202	3.204	3.206
9.4	3.208	3.210	3.212	3.214	3.215	3.217	3.219	3.221	3.223	3.225
9.5	3.227	3.229	3.231	3.233	3.235	3.237	3.239	3.241	3.242	3.244
9.6	3.246	3.248	3.250	3.252	3.254	3.256	3.258	3.260	3.262	3.264
9.7	3.266	3.268	3.269	3.271	3.273	3.275	3.277	3.279	3.281	3.283
9.8	3.285	3.287	3.289	3.291	3.293	3.295	3.297	3.298	3.300	3.302
9.9	3.304	3.305	3.307	3.309	3.311	3.313	3.316	3.318	3.320	3.321
10	3.32	3.34	3.36	3.37	3.39	3.41	3.43	3.45	3.46	3.48
11	3.50	3.52	3.53	3.55	3.56	3.58	3.60	3.61	3.63	3.64
12	3.66	3.68	3.69	3.71	3.72	3.74	3.76	3.77	3.79	3.80
13	3.80	3.83	3.85	3.86	3.88	3.89	3.90	3.92	3.93	3.95
14	3.96	3.97	3.99	4.00	4.02	4.03	4.04	4.06	4.07	4.09
15	4.10	4.11	4.13	4.14	4.15	4.17	4.18	4.19	4.20	4.22
16	4.23	4.24	4.25	4.27	4.28	4.29	4.30	4.31	4.33	4.34
17	4.35	4.36	4.37	4.38	4.39	4.41	4.42	4.43	4.44	4.45
18	4.46	4.47	4.48	4.49	4.50	4.52	4.53	4.54	4.55	4.56
19	4.57	4.58	4.59	4.60	4.61	4.62	4.63	4.64	4.65	4.66

density by the following expression: the bulk density is within the labeled specification.

$$\text{Bulk density (g/cm}^3\text{)} = A/25$$

A: Measured mass (g) of the content of the cup

Microbial limit <4.05> The acceptance criteria of TAMC and TYMC are 10^3 CFU/g and 10^2 CFU/g, respectively. *Escherichia coli*, *Salmonella*, *Pseudomonas aeruginosa* and *Staphylococcus aureus* are not observed.

◆**Containers and storage** Containers—Tight containers.◆

Chloramphenicol

クロラムフェニコール

Delete the Purity (2), move up (3) to (2) and change (2) as follows:

Purity

(2) Related substances—Dissolve 0.10 g of Chloramphenicol in 10 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 100 mL, and use this solution as the standard solution (1). Pipet 10 mL of the standard solution (1), add methanol to make exactly 20 mL, and use this

solution as the standard solution (2). Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 20 μ L each of the sample solution and standard solutions (1) and (2) on a plate of silica gel with fluorescent indicator for thin-layer chromatography, develop the plate with a mixture of ethyl acetate, methanol and acetic acid (100) (10:1:1) to a distance of about 15 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): the spots other than the principal spot and the spot of the starting point obtained from the sample solution are not more intense than the spot from the standard solution (1), and the total amount of these spots from the sample solution is not more than 2.0%.

Change the Assay as follows:

Assay Weigh accurately an amount of Chloramphenicol and Chloramphenicol RS, equivalent to about 50 mg (potency), dissolve each in 10 mL of methanol, and add water to make exactly 50 mL. Pipet 20 mL each of these solutions, and add water to make exactly 100 mL. Pipet 10 mL each of these solutions, add water to make exactly 100 mL, and use these solutions as the sample solution and standard solution. Determine the absorbances, A_T and A_S , of the sample solution and standard solution at 278 nm as directed under Ultraviolet-visible Spectrophotometry <2.24>.

Amount [μ g (potency)] of chloramphenicol ($C_{11}H_{12}Cl_2N_2O_5$)
 $= M_S \times A_T / A_S \times 1000$

M_S : Amount [mg (potency)] of Chloramphenicol RS taken

Chlorpromazine Hydrochloride

クロルプロマジン塩酸塩

Change the Melting point as follows:

Melting point <2.60> 196 – 200°C

Cholesterol

コレステロール

Change the Description and Optical rotation as follows:

Description Cholesterol occurs as white to pale yellow, crystals or grains. It is odorless, or has a slight odor. It is tasteless.

It is freely soluble in chloroform and in diethyl ether, sparingly soluble in ethanol (99.5) and in acetone, and practically insoluble in water.

It gradually changes to a yellow to light yellow-brown color by light.

Optical rotation <2.49> $[\alpha]_D^{25}$: –29 – –36° (after drying, 0.2 g, acetone, 10 mL, 100 mm).

Add the following:

Clarithromycin for Syrup

シロップ用クラリスロマイシン

Clarithromycin for Syrup is a preparation for syrup, which is suspended before use.

It contains not less than 90.0% and not more than 110.0% of the labeled potency of clarithromycin ($C_{38}H_{69}NO_{13}$; 747.95).

Method of preparation Prepare as directed under Preparations for Syrups, with Clarithromycin.

Identification To an amount of Clarithromycin for Syrup, equivalent to 0.1 g (potency) of Clarithromycin, add 5 mL of acetone, and sonicate. After cooling with ice, centrifuge, take the supernatant liquid, and evaporate the solvent. Dissolve 10 mg of the residue and 2 mg of Clarithromycin RS in separate 2 mL of acetone, and use these solutions as the sample solution and the standard solution, respectively. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of methanol, ethyl acetate and acetic acid (100) (90:10:1) to a distance of about 15 cm, and air-dry the plate. Spray evenly sulfuric acid on the plate, and heat the plate at 105°C for 10 minutes: the principal spot obtained from the sample solution and the spot from the standard solution show a black-purple color and the same R_f value.

Water <2.48> Not more than 3.0% (0.5 g, volumetric titration, direct titration).

Uniformity of dosage units <6.02> Perform the test according to the following method: Clarithromycin for Syrup in single-dose packages meet the requirement of the Content uniformity test.

To the total content of 1 package of Clarithromycin for Syrup add 3V/5 mL of ethanol (99.5), add exactly V/10 mL of the internal standard solution, sonicate with occasional vigorous shaking, and add ethanol (99.5) to make V mL so that each mL contains about 0.5 mg (potency) of Clarithromycin. Centrifuge this solution, and filter the supernatant liquid through a membrane filter with a pore size not exceeding 0.45 μ m. Discard the first 3 mL of the filtrate, and use the subsequent filtrate as the sample solution. Then, proceed as directed in the Assay.

Amount [mg (potency)] of clarithromycin ($C_{38}H_{69}NO_{13}$)
 $= M_S \times Q_T / Q_S \times V / 100$

M_S : Amount [mg (potency)] of Clarithromycin RS taken

Internal standard solution—A solution of butyl parahydroxybenzoate in ethanol (99.5) (1 in 12,500).

Dissolution <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of disodium hydrogen phosphate-citric acid buffer

solution (pH 5.5) as the dissolution medium, the dissolution rate in 90 minutes of Clarithromycin for Syrup is not less than 75%.

Start the test with an accurately weighed amount of Clarithromycin for Syrup, equivalent to about 50 mg (potency) of Clarithromycin, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45 μm . Discard not less than 10 mL of the first filtrate, pipet 10 mL of the subsequent filtrate, add the mobile phase to make exactly 20 mL, and use this solution as the sample solution. Separately, weigh accurately an amount of Clarithromycin RS, equivalent to about 28 mg (potency), and dissolve in acetonitrile for liquid chromatography to make exactly 100 mL. Pipet 5 mL of this solution, add the mobile phase to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 100 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of clarithromycin in each solution.

Dissolution rate (%) with respect to the labeled amount of clarithromycin ($\text{C}_{38}\text{H}_{69}\text{NO}_{13}$)

$$= M_S/M_T \times A_T/A_S \times 1/C \times 180$$

M_S : Amount [mg (potency)] of Clarithromycin RS taken

M_T : Amount (g) of Clarithromycin for Syrup taken

C : Labeled amount of [mg (potency)] of clarithromycin ($\text{C}_{38}\text{H}_{69}\text{NO}_{13}$) in 1 g

Operating conditions—

Proceed as directed in the operating conditions in the Assay.

System suitability—

System performance: When the procedure is run with 100 μL of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of clarithromycin are not less than 3000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 100 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of clarithromycin is not more than 2.0%.

Assay Weigh accurately an amount of crushed Clarithromycin for Syrup, equivalent to about 50 mg (potency) of Clarithromycin, add 60 mL of ethanol (99.5), add exactly 10 mL of the internal standard solution, sonicate with occasional vigorous shaking, and add ethanol (99.5) to make 100 mL. Centrifuge this solution, and filter the supernatant liquid through a membrane filter with a pore size not exceeding 0.45 μm . Discard the first 3 mL of the filtrate, and use the subsequent filtrate as the sample solution. Separately, weigh accurately an amount of Clarithromycin RS, equivalent about 50 mg (potency), and dissolve in ethanol (99.5) to make exactly 50 mL. Pipet 10 mL of this solution, add exactly 2 mL of the internal standard solution, add ethanol (99.5) to make 20 mL, and use this solution as the standard solution. Perform the test with 10 μL each of the sample so-

lution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of clarithromycin to that of the internal standard.

$$\begin{aligned} \text{Amount [mg (potency)] of clarithromycin } (\text{C}_{38}\text{H}_{69}\text{NO}_{13}) \\ = M_S \times Q_T/Q_S \end{aligned}$$

M_S : Amount [mg (potency)] of Clarithromycin RS taken

Internal standard solution—A solution of butyl parahydroxybenzoate in ethanol (99.5) (1 in 12,500).

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 210 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 50°C.

Mobile phase: A mixture of diluted 0.2 mol/L potassium dihydrogen phosphate TS (1 in 3) and acetonitrile for liquid chromatography (13:7).

Flow rate: Adjust so that the retention time of clarithromycin is about 8 minutes.

System suitability—

System performance: When the procedure is run with 10 μL of the standard solution under the above operating conditions, clarithromycin and the internal standard are eluted in this order with the resolution between these peaks being not less than 3.

System repeatability: When the test is repeated 6 times with 10 μL of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of clarithromycin to that of the internal standard is not more than 2.0%.

Containers and storage Containers—Tight containers.

Storage—Light-resistant.

Cloperastine Hydrochloride

クロペラスチン塩酸塩

Change the Melting point and Purity (2) as follows:

Melting point <2.60> 149 – 153°C

Purity

(2) Related substances—Dissolve 40 mg of Cloperastine Hydrochloride in 50 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mobile phase to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 20 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the area of

the peaks, having the relative retention times of about 0.8 and about 3.0 to cloperastine obtained from the sample solution are not larger than the peak area of cloperastine from the standard solution, and the area of the peak having the relative retention time about 2.0 from the sample solution is not larger than 5/3 times the peak area of cloperastine from the standard solution. The area of the peak other than cloperastine and the peaks mentioned above from the sample solution are not larger than 3/5 times the peak area of cloperastine from the standard solution, and the total area of these peaks is not larger than 2 times the peak area of cloperastine from the standard solution.

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 222 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: A mixture of methanol, 0.1 mol/L potassium dihydrogen phosphate TS and perchloric acid (500:250:1).

Flow rate: Adjust so that the retention time of cloperastine is about 7 minutes.

Time span of measurement: About 4 times as long as the retention time of cloperastine, beginning after the solvent peak.

System suitability—

Test for required detectability: Pipet 2 mL of the standard solution, add the mobile phase to make exactly 20 mL. Confirm that the peak area of cloperastine obtained with 20 μL of this solution is equivalent to 7 to 13% of that with 20 μL of the standard solution.

System performance: Dissolve 30 mg of Cloperastine Hydrochloride and 40 mg of benzophenone in 100 mL of the mobile phase. To 2 mL of this solution add the mobile phase to make 50 mL. When the procedure is run with 20 μL of this solution under the above operating conditions, cloperastine and benzophenone are eluted in this order with the resolution between these peaks being not less than 6.

System repeatability: When the test is repeated 6 times with 20 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of cloperastine is not more than 2.0%.

Dehydrocholic Acid

デヒドロコール酸

Change the Description and Optical rotation as follows:

Description Dehydrocholic Acid occurs as a white crystalline powder. It is odorless, and has a bitter taste.

It is sparingly soluble in acetone, slightly soluble in

ethanol (95), and practically insoluble in water.

It dissolves in sodium hydroxide TS.

Optical rotation <2.49> $[\alpha]_D^{25}$: +20 – +26° (after drying, 0.2 g, acetone, 10 mL, 100 mm).

Purified Dehydrocholic Acid

精製デヒドロコール酸

Change the Description and Optical rotation as follows:

Description Purified Dehydrocholic Acid occurs as a white crystalline powder. It is odorless, and has a bitter taste.

It is sparingly soluble in acetone, slightly soluble in ethanol (95), and practically insoluble in water.

It dissolves in sodium hydroxide TS.

Optical rotation <2.49> $[\alpha]_D^{25}$: +20 – +26° (after drying, 0.2 g, acetone, 10 mL, 100 mm).

Add the following:

Diclofenac Sodium Suppositories

ジクロフェナクナトリウム坐剤

Diclofenac Sodium Suppositories contain not less than 93.0% and not more than 107.0% of the labeled amount of diclofenac sodium (C₁₄H₁₀Cl₂NNaO₂: 318.13).

Method of preparation Prepare as directed under Suppositories for Rectal Application, with Diclofenac Sodium.

Identification To an amount of Diclofenac Sodium Suppositories, equivalent to 25 mg of Diclofenac Sodium, add 200 mL of a mixture of methanol and 0.01 mol/L sodium hydroxide TS (99:1), and dissolve by warming. Cool while shaking, add a mixture of methanol and 0.01 mol/L sodium hydroxide TS (99:1) to make 250 mL, and filter through a pledget of absorbent cotton if necessary. To 10 mL of this solution add a mixture of methanol and 0.01 mol/L sodium hydroxide TS (99:1) to make 100 mL. Determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 280 nm and 284 nm.

Uniformity of dosage unit <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 suppository of Diclofenac Sodium Suppositories add 5 mL of tetrahydrofuran, and sonicate to dissolve. Add a mixture of methanol and water (3:2) to make exactly 100 mL, shake, and filter through a membrane filter with a pore size not exceeding 0.5 μm. Discard the first 5 mL of the filtrate, pipet *V* mL of the subsequent filtrate, add a mixture of methanol and water (3:2) to make exactly *V'* mL so that

each mL contains about 0.125 mg of diclofenac sodium ($C_{14}H_{10}Cl_2NNaO_2$), and use this solution as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} \text{Amount (mg) of diclofenac sodium } (C_{14}H_{10}Cl_2NNaO_2) \\ = M_S \times A_T/A_S \times V'/V \times 1/4 \end{aligned}$$

M_S : Amount (mg) of diclofenac sodium for assay taken

Melting behavior of suppositories Perform the test according to Method 2 under Melting Point Determination <2.60>: the melting range is between 33°C and 36°C.

Assay Weigh accurately the mass of not less than 20 Diclofenac Sodium Suppositories, cut into small pieces carefully, and mix uniformly. Weigh accurately a portion of the pieces, equivalent to about 25 mg of diclofenac sodium ($C_{14}H_{10}Cl_2NNaO_2$), add 5 mL of tetrahydrofuran, and sonicate to dissolve. Add a mixture of methanol and water (3:2) to make exactly 100 mL, shake, and filter through a membrane filter with a pore size not exceeding 0.5 μ m. Discard the first 5 mL of the filtrate, pipet 10 mL of the subsequent filtrate, add a mixture of methanol and water (3:2) to make exactly 20 mL, and use this solution as the sample solution. Separately, weigh accurately about 50 mg of diclofenac sodium for assay, previously dried, and dissolve in a mixture of methanol and water (3:2) to make exactly 100 mL. Pipet 5 mL of this solution, add a mixture of methanol and water (3:2) to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of diclofenac in each solution.

$$\begin{aligned} \text{Amount (mg) of diclofenac sodium } (C_{14}H_{10}Cl_2NNaO_2) \\ = M_S \times A_T/A_S \times 1/2 \end{aligned}$$

M_S : Amount (mg) of diclofenac sodium for assay taken

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.0 mm in inside diameter and 12.5 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: Dissolve 13.6 g of sodium acetate trihydrate in water to make 1000 mL. To 200 mL of this solution add 300 mL of methanol.

Flow rate: Adjust so that the retention time of diclofenac is about 3.5 minutes.

System suitability—

System performance: When the procedure is run with 20 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of diclofenac are not less than 2000 and 0.7 to 1.5, respectively.

System repeatability: When the test is repeated 6 times

with 20 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of diclofenac is not more than 1.0%.


Containers and storage Containers—Tight containers.

Storage—In a cold place.

Add the following:

Doripenem Hydrate

ドリペネム水和物



$C_{15}H_{24}N_4O_6S_2 \cdot H_2O$: 438.52

(4*R*,5*S*,6*S*)-6-[(1*R*)-1-Hydroxyethyl]-4-methyl-7-oxo-3-[(3*S*,5*S*-5-[(sulfamoylamino)methyl]pyrrolidin-3-ylsulfanyl)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate [364622-82-2]

Doripenem Hydrate contains not less than 970 μ g (potency) and not more than 1020 μ g (potency) per mg, calculated on the anhydrous basis. The potency of Doripenem Hydrate is expressed as mass (potency) of doripenem ($C_{15}H_{24}N_4O_6S_2$: 420.50).

Description Doripenem Hydrate occurs as a white to pale yellow-brown-white crystalline powder.

It is sparingly soluble in water, slightly soluble in methanol, and practically insoluble in ethanol (99.5).

It is gradually colored to pale yellow-brown-white by light.

Identification (1) Determine the absorption spectrum of a solution of Doripenem Hydrate (1 in 50,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Doripenem RS prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Doripenem Hydrate as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Doripenem RS: both spectra exhibit similar intensities of absorption at the same wave numbers.

Optical rotation <2.49> $[\alpha]_D^{20}$: +33 – +38° (0.25 g calculated on the anhydrous basis, water, 25 mL, 100 mm).

pH <2.54> Dissolve 0.3 g of Doripenem Hydrate in 30 mL of water: the pH of the solution is between 4.5 and 6.0.

Purity (1) Clarity and color of solution—Dissolve 0.2 g of Doripenem Hydrate in 20 mL of water, and perform the test with this solution as directed under Turbidity Meas-

urement <2.61>: the solution is clear. Perform the test with this solution according to Method 2 under Methods for Color Matching <2.65>: the solution is not more colored than Matching Fluid Y4.

(2) Heavy metals <1.07>—Moisten 1.0 g of Doripenem Hydrate with sulfuric acid, cover loosely, and heat gently to carbonize. Then proceed according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

(3) Related substances (i)—Dissolve 20 mg of Doripenem Hydrate in 10 mL of water, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: the peak areas of related substance A, having the relative retention time of about 2.2 to doripenem, related substance B, having the relative retention time of about 2.5, and related substance C, having the relative retention time of about 3.2, obtained from the sample solution, are not larger than 1/10 times the peak area of doripenem from the standard solution, and the area of the peak other than doripenem, the peaks mentioned above and the peak having the relative retention time of about 2.1, from the sample solution, is not larger than 1/20 times the peak area of doripenem from the standard solution. Furthermore, the total area of the peaks other than doripenem and the peak having the relative retention time of about 2.1 from the sample solution is not larger than 1/2 times the peak area of doripenem from the standard solution.

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 230 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 30°C.

Mobile phase A: Dissolve 2.04 g of potassium dihydrogen phosphate in water to make 1000 mL, and adjust to pH 5.6–5.7 with a solution prepared by dissolving 2.61 g of dipotassium hydrogen phosphate in water to make 1000 mL. To 970 mL of this solution add 30 mL of acetonitrile for liquid chromatography.

Mobile phase B: Dissolve 2.04 g of potassium dihydrogen phosphate in water to make 1000 mL, and adjust to pH 5.6–5.7 with a solution prepared by dissolving 2.61 g of dipotassium hydrogen phosphate in water to make 1000 mL. To 700 mL of this solution add 300 mL of acetonitrile for liquid chromatography.

Flowing of mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 15	100	0
15 – 45	100 → 50	0 → 50
45 – 50	50 → 0	50 → 100
50 – 55	0	100

Flow rate: 1.0 mL per minute.

Time span of measurement: For 55 minutes after injection, beginning after the peak having the relative retention time of about 0.2 to doripenem.

System suitability—

Test for required detectability: Pipet 1.5 mL of the standard solution, and add water to make exactly 50 mL. Confirm that the peak area of doripenem obtained with 20 μ L of this solution is equivalent to 2.1 to 3.9% of that with 20 μ L of the standard solution.

System performance: When the procedure is run with 20 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of doripenem are not less than 5000 and not more than 1.3, respectively.

System repeatability: When the test is repeated 3 times with 20 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of doripenem is not more than 0.95%.

(ii) Dissolve 20 mg of Doripenem Hydrate in 10 mL of water, and use this solution as the sample solution. Pipet 1 mL of the sample solution, and add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: the peak area of related substance D, having the relative retention time of about 0.5 to doripenem, obtained from the sample solution is not larger than 2/5 times the peak area of doripenem from the standard solution.

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 215 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecyl-strong anion exchange-silanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: To 9 mL of phosphoric acid add 200 mL of water, add 20 mL of triethylamine, and add water to make 2000 mL. Adjust to pH 5.7–5.9 with phosphoric acid. To 950 mL of this solution add 50 mL of acetonitrile for liquid chromatography.

Flow rate: Adjust so that the retention time of doripenem is about 10 minutes.

System suitability—

Test for required detectability: Pipet 2 mL of the stand-

ard solution, and add water to make exactly 20 mL. Confirm that the peak area of doripenem obtained with 20 μ L of this solution is equivalent to 7 to 13% of that with 20 μ L of the standard solution.

System performance: To 1 mL of the sample solution add 1 mL of 0.1 mol/L hydrochloric acid TS, allow to stand at $25 \pm 5^\circ\text{C}$ for 15 minutes, and add water to make 100 mL. When the procedure is run with 20 μ L of this solution under the above operating conditions, related substance D and doripenem are eluted in this order with the resolution between these peaks being not less than 5. The number of theoretical plates and the symmetry factor of the peak of related substance D are not less than 300 and 0.7 to 1.3, respectively, and those of the peak of doripenem are not less than 5000 and 0.7 to 1.3, respectively.

System repeatability: When the test is repeated 6 times with 20 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of doripenem is not more than 2.0%.

(iii) Dissolve 20 mg of Doripenem Hydrate in 10 mL of water, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: the areas of the peaks, having the relative retention time of about 1.8, about 2.2 and about 2.3 to doripenem, obtained from the sample solution are not larger than 1/20, 7/100 and 1/20 times the peak area of doripenem from the standard solution, respectively.

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 310 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (3 μ m in particle diameter).

Column temperature: A constant temperature of about 30°C .

Mobile phase A: To 11 mL of perchloric acid add water to make 500 mL. To 100 mL of this solution add water to make 1000 mL. To 600 mL of this solution add 100 mL of water, and adjust to pH 1.9 – 2.0 with a solution prepared by adding water to 2.81 g of sodium perchlorate monohydrate to make 1000 mL. To 900 mL of this solution add 100 mL of acetonitrile.

Mobile phase B: To 11 mL of perchloric acid add water to make 500 mL. To 100 mL of this solution add water to make 1000 mL. To 600 mL of this solution add 100 mL of water, and adjust to pH 1.9 – 2.0 with a solution prepared by adding water to 2.81 g of sodium perchlorate monohydrate to make 1000 mL. To 300 mL of this solution add 200 mL of acetonitrile.

Flowing of mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 25	100	0
25 – 55	100 \rightarrow 0	0 \rightarrow 100
55 – 60	0	100

Flow rate: 0.8 mL per minute.

System suitability—

Test for required detectability: Pipet 2.5 mL of the standard solution, and add water to make exactly 50 mL. Confirm that the peak area of doripenem obtained with 20 μ L of this solution is equivalent to 3.5 to 6.5% of that with 20 μ L of the standard solution.

System performance: When the procedure is run with 20 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of doripenem are not less than 15,000 and not more than 1.3, respectively.

System repeatability: When the test is repeated 3 times with 20 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of doripenem is not more than 0.95%.

Water <2.48> 4.0 – 5.0% (0.3 g, volumetric titration, back titration).

Residue on ignition <2.44> Not more than 0.1% (1 g).

Assay Weigh accurately amounts of Doripenem Hydrate and Doripenem RS (separately determine the water <2.48> in the same manner as Doripenem Hydrate), equivalent to about 25 mg (potency), dissolve each in water to make exactly 200 mL, and use these solutions as the sample solution and the standard solution, respectively. Perform the test with exactly 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of doripenem in each solution.

$$\text{Amount } [\mu\text{g (potency)}] \text{ of doripenem (C}_{15}\text{H}_{24}\text{N}_4\text{O}_6\text{S}_2) = M_S \times A_T / A_S \times 1000$$

M_S : Amount [mg (potency)] of Doripenem RS taken, calculated on the anhydrous basis

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 300 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 25°C .

Mobile phase: Adjust the pH of 90 mL of 0.02 mol/L potassium dihydrogen phosphate TS to pH 5.6 – 5.7 with a solution prepared by dissolving 3.48 g of dipotassium hydrogen phosphate in water to make 1000 mL. To 100 mL of this solution add water to make exactly 1000 mL. To 970

mL of this solution add 30 mL of acetonitrile.

Flow rate: Adjust so that the retention time of doripenem is about 15 minutes.

System suitability—

System performance: When the procedure is run with 10 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of doripenem are not less than 5000 and not more than 1.3, respectively.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of doripenem is not more than 1.0%.


Containers and storage Containers—Tight containers.

Storage—At a temperature between 2°C and 8°C.

Others


Related substance A:

(4*R*,5*S*,6*S*)-3-[(3*S*,5*S*)-5-[[*N*-(*E*)-(Dimethylamino)methylene]sulfonyl]amino)methyl]pyrrolidin-3-ylsulfanyl]-6-[(1*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid




Related substance B:

(1*S*,4*S*,5*S*,6*R*)-4-[(1*R*)-1-Hydroxyethyl]-8-[(4*R*,5*S*,6*S*)-6-[(1*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3*S*,5*S*)-5-[(sulfonylamino)methyl]pyrrolidin-3-ylsulfanyl]-1-azabicyclo[3.2.0]hept-2-ene-2-carbonyl]-6-methyl-3-oxo-7-[(3*S*,5*S*)-5-[(sulfonylamino)methyl]pyrrolidin-3-ylsulfanyl]-2-oxa-8-azabicyclo[3.2.1]octane-1-carboxylic acid




Related substance C:

(4*R*,5*S*,6*S*)-3-[(3*S*,5*S*)-5-[[*N*-(1,1-Dimethylethyl)sulfonyl]amino)methyl]pyrrolidin-3-ylsulfanyl]-6-[(1*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid



Related substance D:

(2*S*,3*R*,4*S*)-2-[(1*S*,2*R*)-1-Carboxy-2-hydroxypropyl]-3-methyl-4-[(3*S*,5*S*)-5-[(sulfonylamino)methyl]pyrrolidin-3-ylsulfanyl]-3,4-dihydro-2*H*-pyrrole-5-carboxylic acid



Add the following:

Doripenem for Injection

注射用ドリペネム

Doripenem for Injection is a preparation for injection, which is dissolved before use.

It contains not less than 95.0% and not more than 105.0% of the labeled potency of doripenem (C₁₅H₂₄N₄O₆S₂: 420.50).

Method of preparation Prepare as directed under Injections, with Doripenem Hydrate.

Description Doripenem for Injection occurs as a white to pale yellow-brown-white crystalline powder.

Identification Proceed as directed in the Identification (2) under Doripenem Hydrate.

pH <2.54> Dissolve an amount of Doripenem for Injection, equivalent to 0.3 g (potency) of Doripenem Hydrate, in 30 mL of water: the pH of the solution is between 4.5 and 6.0.

Purity (1) Clarity and color of solution—Dissolve an amount of Doripenem for Injection, equivalent to 0.2 g (potency) of Doripenem Hydrate in 20 mL of water, and proceed as directed in the Purity (1) under Doripenem Hydrate.

(2) Related substances—(i) Dissolve an amount of Doripenem for Injection, equivalent to 20 mg (potency) of Doripenem Hydrate, in 10 mL of water, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the area of the peak other than doripenem and the peak, having the relative retention time of about 2.1 to doripenem, related substance A having the relative retention time of about 2.2, related substance B having the relative retention time of about 2.5 and related substance C having the relative retention time of about 3.2, obtained from the sample solution is not larger than 1/10 times the peak area of doripenem from the standard solution, and the total area of the peaks other than

doripenem and the peak mentioned above from the sample solution is not larger than 1/2 times the peak area of doripenem from the standard solution.

Operating conditions—

Proceed as directed in the operating conditions in the Purity (3) (i) under Doripenem Hydrate.

System suitability—

Test for required detectability: Pipet 2.5 mL of the standard solution, and add water to make exactly 50 mL. Confirm that the peak area of doripenem obtained with 20 μ L of this solution is equivalent to 3.5 to 6.5% of that with 20 μ L of the standard solution.

System performance: When the procedure is run with 20 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of doripenem are not less than 5000 and not more than 1.3, respectively.

System repeatability: When the test is repeated 3 times with 20 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of doripenem is not more than 0.95%.

(ii) Dissolve an amount of Doripenem for Injection, equivalent to 20 mg (potency) of Doripenem Hydrate, in 10 mL of water, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: the peak area of related substance D, having the relative retention time of about 0.5 to doripenem, obtained from the sample solution is not larger than the peak area of doripenem from the standard solution.

Operating conditions—

Proceed as directed in the operating conditions in the Purity (3) (ii) under Doripenem Hydrate.

System suitability—

System performance: To 1 mL of the sample solution add 1 mL of 0.1 mol/L hydrochloric acid TS, allow to stand at $25 \pm 5^\circ\text{C}$ for 15 minutes, and add water to make 100 mL. When the procedure is run with 20 μ L of this solution under the above operating conditions, related substance D and doripenem are eluted in this order with the resolution between these peaks being not less than 5. The number of theoretical plates and the symmetry factor of the peak of related substance D are not less than 300 and 0.7 to 1.3, respectively, and those of the peak of doripenem are not less than 5000 and 0.7 to 1.3, respectively.

System repeatability: When the test is repeated 6 times with 20 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of doripenem is not more than 2.0%.

Water <2.48> 4.0 – 5.0% (0.3 g, volumetric titration, back titration).

Bacterial endotoxins <4.01> Less than 0.25 EU/mg (potency).

Uniformity of dosage units <6.02> It meets the requirement of the Mass variation test.

Foreign insoluble matter <6.06> Perform the test according to Method 2: it meets the requirement.

Insoluble particulate matter <6.07> It meets the requirement.

Sterility <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

Assay Weigh accurately the mass of the contents of not less than 10 containers of Doripenem for Injection. Weigh accurately an amount of the contents, equivalent to about 25 mg (potency) of Doripenem Hydrate, dissolve in water to make exactly 200 mL, and use this solution as the sample solution. Separately, weigh accurately about 25 mg (potency) of Doripenem RS (separately determine the water <2.48> in the same manner as Doripenem Hydrate), dissolve in water to make exactly 200 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Doripenem Hydrate.

$$\begin{aligned} &\text{Amount } [\mu\text{g (potency)}] \text{ of doripenem } (\text{C}_{15}\text{H}_{24}\text{N}_4\text{O}_6\text{S}_2) \\ &= M_S \times A_T/A_S \times 1000 \end{aligned}$$

M_S : Amount [mg (potency)] of Doripenem RS taken, calculated on the anhydrous basis

Containers and storage Containers—Hermetic containers. Plastic containers for aqueous injections may be used.

Others

Related substances A, B, C and D: Refer to them described in Doripenem Hydrate.

Epirubicin Hydrochloride

エピルビシン塩酸塩

Delete the Purity (4):

Estriol

エストリオール

Change the Description and Optical rotation as follows:

Description Estriol occurs as a white crystalline powder. It is odorless.

It is sparingly soluble in methanol, slightly soluble in ethanol (99.5), and practically insoluble in water.

Optical rotation <2.49> $[\alpha]_D^{25}$: +55 – +65° (after drying, 40 mg, ethanol (99.5), 10 mL, 100 mm).

Add the following:**Ethylcellulose**

エチルセルロース

[9004-57-3]

This monograph is harmonized with the European Pharmacopoeia and the U. S. Pharmacopoeia.

The corresponding part of the attributes/provisions which are agreed as non-harmonized within the scope of the harmonization is marked with symbols (◆ ◆), and the corresponding parts which are agreed as the JP local requirement other than the scope of the harmonization are marked with symbols (◇ ◇).

Ethylcellulose is a partly *O*-ethylated cellulose.

It contains not less than 44.0% and not more than 51.0% of ethoxy group ($-\text{OC}_2\text{H}_5$; 45.06), calculated on the dried basis.

It may contain a suitable antioxidant.

The viscosity of Ethylcellulose is shown in millipascal second ($\text{mPa}\cdot\text{s}$) on the label.

◆**Description** Ethylcellulose occurs as a white to yellowish white, amorphous powder or grains.

It is soluble in dichloromethane.

It forms a slightly white-turbid or white-turbid, viscous liquid upon addition of ethanol (95).

To 1 g of Ethylcellulose add 100 mL of hot water, shake to become turbid, cool to room temperature, and add freshly boiled and cooled water to make 100 mL: the solution is neutral.◆

Identification Spread 2 drops of a solution of Ethylcellulose in dichloromethane (1 in 25) between sodium chloride plates, then remove one of the plates to evaporate the solvent, and determine the infrared absorption spectrum of the plate as directed in the film method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

Viscosity <2.53> Weigh exactly a quantity of Ethylcellulose, equivalent to 5.00 g calculated on the dried basis, add 95 g of a mixture of 80 g of toluene and 20 g of ethanol (95), and shake to dissolve. Perform the test with this solution at 25°C as directed in Method I: not less than 80.0% and not more than 120.0% of the labeled viscosity for a nominal viscosity more than 6 $\text{mPa}\cdot\text{s}$, and not less than 75.0% and not more than 140.0% of the labeled viscosity for a nominal viscosity not more than 6 $\text{mPa}\cdot\text{s}$.

Purity (1) Acidity or alkalinity—To 0.5 g of Ethylcellulose add 25 mL of freshly boiled and cooled water, shake for 15 minutes, filter through a glass filter (G3), and use the filtrate as the sample solution. To 10 mL of the sample solution add 0.1 mL of dilute phenolphthalein TS and 0.5 mL of 0.01 mol/L sodium hydroxide VS: a light red color

develops. To 10 mL of the sample solution add 0.1 mL of methyl red-sodium hydroxide TS and 0.5 mL of 0.01 mol/L hydrochloric acid VS: a red color develops.

(2) Chloride—Disperse 0.250 g of Ethylcellulose in 50 mL of water, and boil with occasional shaking. Allow to cool, and filter. Discard the first 10 mL of the filtrate, to 10 mL of the subsequent filtrate add water to make 15 mL, and use this solution as the sample solution. Separately, to 10 mL of Standard Chloride Solution add 5 mL of water, and use this solution as the control solution. To 15 mL each of the sample solution and control solution add 1 mL of 2 mol/L nitric acid TS, transfer to test tubes containing 1 mL of a solution of silver nitrate (17 in 1000), allow to stand for 5 minutes protecting from light, and compare the opalescence developed in the both solutions against a black background by viewing transversely: the opalescence developed in the sample solution is not more intense than that of the control solution (not more than 0.1%).

◇(3) Heavy metal <1.07>—Proceed with 1.0 g of Ethylcellulose according to Method 2, and perform the test. Prepare the control solution with 4.0 mL of Standard Lead Solution (not more than 40 ppm).◇

(4) Acetaldehyde—Introduce 3.0 g of Ethylcellulose into a 250-mL glass-stoppered conical flask, add 10 mL of water, and stir for 1 hour. Allow to stand for 24 hours, filter, add water to the filtrate to make 100 mL, and use this solution as the sample solution. Separately, dissolve 1.0 g of acetaldehyde for assay in water to make 100 mL. To 5 mL of this solution add water to make 500 mL. To 3 mL of this solution add water to make 100 mL, and use this solution as the control solution. Transfer 5 mL each of the sample solution and control solution to 25-mL volumetric flasks, add 5 mL of a solution of 3-methyl-2-benzothiazolonehydrazone hydrochloride monohydrate (1 in 2000), and heat in a water bath at 60°C for 5 minutes. Add 2 mL of iron (III) chloride-amidosulfuric acid TS, and warm again at 60°C for 5 minutes. After cooling, add water to make 25 mL, and compare the color of these solutions: the sample solution is not more intensely colored than the control solution (not more than 100 ppm).

Loss on drying <2.41> Not more than 3.0% (1 g, 105°C, 2 hours).

Residue on Ignition <2.44> Not more than 0.5% (1 g).

Assay Weigh accurately about 30 mg of Ethylcellulose, transfer to a 5-mL pressure-tight serum vial, add exactly 60 mg of adipic acid, 2 mL of the internal standard solution and 1 mL of hydroiodic acid, seal the vial immediately with a septum coated with fluororesin and an aluminum cap or any other sealing system providing a sufficient air-tightness, and weigh accurately the vial. Take care not to mix the contents in the vial before heating. Place the vial in an oven or heat in a suitable heater with continuous stirring, maintaining an internal temperature of about $115 \pm 2^\circ\text{C}$ for 70 min. Allow to cool, and weigh accurately the vial. If the difference of the mass between before heating and after heating is more than 10 mg, prepare a new sample solution. If the

difference of the mass between before heating and after heating is not more than 10 mg, after phase separation, pierce through the septum of the vial with a cooled syringe, and withdraw a sufficient volume of the upper phase as the sample solution. Separately, place exactly 60 mg of adipic acid, 2 mL of the internal standard solution and 1 mL of hydroiodic acid in another serum vial, and seal immediately. Weigh accurately the vial, inject 25 μ L of iodoethane for assay through the septum in the vial, and weigh again accurately. Shake thoroughly, after phase separation, pierce through the septum of the vial with a cooled syringe, withdraw a sufficient volume of the upper phase, and use this solution as the standard solution. Perform the test with 1 μ L each of the sample solution and standard solution as directed under Gas Chromatography <2.02> according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of iodoethane to that of the internal standard.

$$\begin{aligned} \text{Amount (\%)} & \text{ of ethoxy group (C}_2\text{H}_5\text{O)} \\ & = M_S/M_T \times Q_T/Q_S \times 28.89 \end{aligned}$$

M_S : Amount (mg) of iodoethane for assay taken

M_T : Amount (mg) of Ethylcellulose taken, calculated on the dried basis

Internal standard solution—A solution of *n*-octane in *o*-xylene (1 in 200).

Operating conditions—

Detector: A hydrogen flame-ionization detector.

Column: A fused silica column 0.53 mm in inside diameter and 30 m in length, coated with dimethylpolysiloxane for gas chromatography in 3 μ m thickness.

Column temperature: Maintain the temperature at 50°C for 3 minutes, raise to 100°C at a rate of 10°C per minute, then to 250°C at a rate of 35°C per minute, and maintain at 250°C for 8 minutes.

Injection port temperature: A constant temperature of about 250°C.

Detector temperature: A constant temperature of about 280°C.

Carrier gas: Helium.

Flow rate: 4.2 mL per minute (the retention time of the internal standard is about 10 minutes).

Split ratio: 1:40.

System suitability—

System performance: When the procedure is run with 1 μ L of the standard solution under the above operating conditions, iodoethane and the internal standard are eluted in this order with the relative retention time of iodoethane to the internal standard being about 0.6, and with the resolution between these peaks being not less than 5.0.

System repeatability: When the test is repeated 6 times with 1 μ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of iodoethane to that of the internal standard is not more than 2.0%.

◆**Containers and storage** Containers—Well-closed containers.◆

Etizolam

エチゾラム


Change the Melting point as follows:

Melting point <2.60> 147 – 151°C

Add the following:

Felodipine

フェロジピン



and enantiomer

$C_{18}H_{19}Cl_2NO_4$: 384.25

Ethyl methyl (4*RS*)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

[72509-76-3]

Felodipine contains not less than 99.0% and not more than 101.0% of felodipine ($C_{18}H_{19}Cl_2NO_4$), calculated on the dried basis.

Description Felodipine occurs as pale yellow-white to light yellow-white, crystals or crystalline powder.

It is freely soluble in methanol and in ethanol (99.5), and practically insoluble in water.

A solution of Felodipine in methanol (1 in 20) shows no optical rotation.

Identification (1) Determine the absorption spectrum of a solution of Felodipine in methanol (1 in 62,500) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Felodipine as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

Purity (1) Heavy metals—Being specified separately when the drug is granted approval based on the Law.

(2) Related substances—Dissolve 25 mg of Felodipine in 50 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, and add the mobile phase to make exactly 100 mL. Pipet 1 mL of this solution, add the mobile phase to make exactly 10 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard

solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: the area of the peak other than felodipine, related substance B, having the relative retention time of about 0.7 to felodipine, and related substance C, having the relative retention time of about 1.4, obtained from the sample solution is not larger than the peak area of felodipine from the standard solution. Furthermore, the total area of the peaks of related substances B and C from the sample solution is not larger than 10 times the peak area of felodipine from the standard solution, and the total area of the peaks other than felodipine and related substances mentioned above from the sample solution is not larger than 3 times the peak area of felodipine from the standard solution. For this calculation the peak area less than 1/5 times the peak area of felodipine from the standard solution is excluded.

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: Dissolve 3.2 g of sodium dihydrogen phosphate dihydrate in 400 mL of water, adjust to pH 3.0 with phosphoric acid, and add 200 mL of methanol and 400 mL of acetonitrile.

Flow rate: Adjust so that the retention time of felodipine is about 12 minutes.

Time span of measurement: About 2 times as long as the retention time of felodipine, beginning after the solvent peak.

System suitability—

Test for required detectability: When the procedure is run with 20 μL of the standard solution under the above operating conditions, the SN ratio of the peak of felodipine is not less than 30.

System performance: When the procedure is run with 20 μL of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of felodipine are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 20 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of felodipine is not more than 2.0%.

Loss on drying <2.41> Not more than 0.2% (1 g, 105°C, 3 hours).

Residue on ignition <2.44> Not more than 0.1% (1 g).

Assay Weigh accurately about 0.16 g of Felodipine, dissolve in 25 mL of t-butyl alcohol and 25 mL of diluted perchloric acid (17 in 200), and titrate <2.50> with 0.1 mol/L cerium (IV) sulfate VS (indicator: 50 μL of 1,10-

phenanthroline TS) until the color of the solution changes from orange to colorless. Perform a blank determination in the same manner, and make any necessary correction.


Each mL of 0.1 mol/L cerium (IV) sulfate VS
= 19.21 mg of C₁₈H₁₉Cl₂NO₄

Containers and storage Containers—Well-closed containers.

Others


Related substance B:

Dimethyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate



Related substance C:

Diethyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate



Add the following:

Felodipine Tablets

フェロジピン錠

Felodipine Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of felodipine (C₁₈H₁₉Cl₂NO₄: 384.25).

Method of preparation Prepare as directed under Tablets, with Felodipine.

Identification To a quantity of powdered Felodipine Tablets, equivalent to 4 mg of Felodipine, add 200 mL of methanol, shake thoroughly, add methanol to make 250 mL, and centrifuge. Determine the absorption spectrum of the supernatant liquid as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 235 nm and 239 nm, and between 357 nm and 363 nm.

Uniformity of dosage units <6.02> Perform the Mass variation test, or the Content uniformity test according to the following method: it meets the requirement.

To 1 tablet of Felodipine Tablets add 1 mL of water per 2.5 mg of felodipine (C₁₈H₁₉Cl₂NO₄), and shake thoroughly until the tablet is completely disintegrated. Add exactly 1 mL of the internal standard solution per 2.5 mg of felodipine (C₁₈H₁₉Cl₂NO₄), and add methanol to make V mL so

that each mL contains about 0.25 mg of felodipine ($C_{18}H_{19}Cl_2NO_4$). Centrifuge this solution, filter the supernatant liquid, and use this filtrate as the sample solution. Separately, weigh accurately about 25 mg of felodipine for assay (separately determine the loss on drying <2.41> in the same conditions as Felodipine), add 10 mL of water, and add exactly 10 mL of the internal standard solution. Add methanol to make 100 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay.

$$\begin{aligned} &\text{Amount (mg) of felodipine } (C_{18}H_{19}Cl_2NO_4) \\ &= M_S \times Q_T/Q_S \times V/100 \end{aligned}$$

M_S : Amount (mg) of felodipine for assay taken, calculated on the dried basis

Internal standard solution—A solution of butyl parahydroxybenzoate in methanol (1 in 3000).

Dissolution <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of a solution prepared by dissolving 1 g of polysorbate 80 in water to make 5000 mL, as the dissolution medium, the dissolution rates in 45 minutes of a 2.5-mg tablet and a 5-mg tablet are not less than 80% and not less than 75%, respectively.

Start the test with 1 tablet of Felodipine Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45 μm . Discard not less than 10 mL of the first filtrate, pipet V mL of the subsequent filtrate, add the dissolution medium to make exactly V' mL so that each mL contains about 2.8 μg of felodipine ($C_{18}H_{19}Cl_2NO_4$), and use this solution as the sample solution. Separately, weigh accurately about 28 mg of felodipine for assay (separately determine the loss on drying <2.41> in the same conditions as Felodipine), and dissolve in methanol to make exactly 200 mL. Pipet 2 mL of this solution, add the dissolution medium to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 50 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of felodipine in each solution.

Dissolution rate (%) with respect to the labeled amount of felodipine ($C_{18}H_{19}Cl_2NO_4$)

$$= M_S \times A_T/A_S \times V'/V \times 1/C \times 9$$

M_S : Amount (mg) of felodipine for assay taken, calculated on the dried basis

C : Labeled amount (mg) of felodipine ($C_{18}H_{19}Cl_2NO_4$) in 1 tablet

Operating conditions—

Column, column temperature, mobile phase and flow rate: Proceed as directed in the operating conditions in the Assay.

Detector: An ultraviolet absorption photometer (wavelength: 238 nm).

System suitability—

System performance: When the procedure is run with 50 μL of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of felodipine are not less than 3000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 50 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of felodipine is not more than 2.0%.

Assay Weigh accurately the mass of not less than 20 Felodipine Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 10 mg of felodipine ($C_{18}H_{19}Cl_2NO_4$), add 20 mL of water, add exactly 4 mL of the internal standard solution, add methanol to make 100 mL and shake. Centrifuge this solution, filter the supernatant liquid through a membrane filter with a pore size not exceeding 0.45 μm , and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of felodipine for assay (separately determine the loss on drying <2.41> in the same conditions as Felodipine), add 20 mL of water, add exactly 4 mL of the internal standard solution, add methanol to make 100 mL, and use this solution as the standard solution. Perform the test with 20 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of felodipine to that of the internal standard.

Amount (mg) of felodipine ($C_{18}H_{19}Cl_2NO_4$) = $M_S \times Q_T/Q_S$

M_S : Amount (mg) of felodipine for assay taken, calculated on the dried basis

Internal standard solution—A solution of butyl parahydroxybenzoate in methanol (1 in 6000).

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 264 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: A mixture of methanol, water, a solution of sodium perchlorate monohydrate (281 in 2000) and diluted perchloric acid (17 in 200) (65:25:8:2).

Flow rate: Adjust so that the retention time of felodipine is about 12 minutes.

System suitability—

System performance: When the procedure is run with 20 μL of the standard solution under the above operating conditions, the internal standard and felodipine are eluted in this order with the resolution between these peaks being not less than 5.


System repeatability: When the test is repeated 6 times with 20 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of felodipine is not more than 1.0%.

Containers and storage Containers—Tight containers.

Add the following:

Gatifloxacin Hydrate

ガチフロキサシン水和物



$C_{19}H_{22}FN_3O_4 \cdot 1\frac{1}{2}H_2O$: 402.42

1-Cyclopropyl-6-fluoro-8-methoxy-7-[(3*RS*)-3-methylpiperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid sesquihydrate

[180200-66-2]

Gatifloxacin Hydrate contains not less than 98.5% and not more than 101.5% of gatifloxacin ($C_{19}H_{22}FN_3O_4$: 375.39), calculated on the anhydrous basis.

Description Gatifloxacin Hydrate occurs as white to pale yellow, crystals or crystalline powder.

It is slightly soluble in methanol and in ethanol (99.5), and very slightly soluble in water.

It dissolves in sodium hydroxide TS.

It is gradually colored to pale yellow by light.

A solution of Gatifloxacin Hydrate in dilute sodium hydroxide TS (1 in 100) shows no optical rotation.

Identification (1) Determine the absorption spectrum of a solution of Gatifloxacin Hydrate in dilute sodium hydroxide TS (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Gatifloxacin RS prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Gatifloxacin Hydrate as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Gatifloxacin RS: both spectra exhibit similar intensities of absorption at the same wave numbers.

Purity (1) Clarity and color of solution—Dissolve 1.0 g of Gatifloxacin Hydrate in 10 mL of sodium hydroxide TS: the solution is clear. Perform the test with the solution as directed under Methods for Color Matching <2.65>: the solution is not more colored than diluted Matching Fluid O (1 in 5).

(2) Heavy metals <1.07>—Proceed with 1.0 g of Gatifloxacin Hydrate according to Method 4, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

(3) Related substances—Dissolve 20 mg of Gatifloxacin Hydrate in 50 mL of the dissolving solution, and use this solution as the sample solution. Pipet 1 mL of the sample solution, and add the dissolving solution to make exactly 100 mL. Pipet 2 mL of this solution, add the dissolving solution to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: the peak area of the related substance A, having the relative retention time of about 1.2 to gatifloxacin, obtained from the sample solution is not larger than 2 times the peak area of gatifloxacin from the standard solution, and the area of the peak other than gatifloxacin and the peak mentioned above from the sample solution is not larger than the peak area of gatifloxacin from the standard solution. Furthermore, the total area of the peaks other than gatifloxacin from the sample solution is not larger than 3 times the peak area of gatifloxacin from the standard solution.

Dissolving solution: A mixture of diluted phosphoric acid (1 in 1000) and acetonitrile (4:1).

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 325 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 35°C.

Mobile phase A: A mixture of diluted triethylamine (1 in 100), adjusted to pH 4.3 with phosphoric acid, and acetonitrile (22:3).

Mobile phase B: A mixture of diluted triethylamine (1 in 100), adjusted to pH 4.3 with phosphoric acid, and acetonitrile (1:1).

Flowing of mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 15	100	0
15 – 30	100 → 0	0 → 100
30 – 40	0	100

Flow rate: 1.0 mL per minute (the retention time of gatifloxacin is about 16 minutes).

Time span of measurement: About 2.5 times as long as the retention time of gatifloxacin, beginning after the solvent peak.

System suitability—

Test for required detectability: Pipet 5 mL of the standard solution, and add the dissolving solution to make exactly 10 mL. Confirm that the peak area of gatifloxacin ob-

tained with 20 μL of this solution is equivalent to 40 to 60% of that with 20 μL of the standard solution.

System performance: Dissolve 20 mg of methyl 4-aminobenzoate in 50 mL of the dissolving solution. To 5 mL of this solution add 1 mL of the sample solution and the dissolving solution to make 100 mL. When the procedure is run with 20 μL of this solution under the above operating conditions, gatifloxacin and methyl 4-aminobenzoate are eluted in this order with the resolution between these peaks being not less than 4.

System repeatability: When the test is repeated 6 times with 20 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of gatifloxacin is not more than 3.0%.

Water <2.48> 6.0 – 9.0% (0.1 g, volumetric titration, direct titration).

Residue on ignition <2.44> Not more than 0.1% (1 g).

Assay Weigh accurately about 50 mg of Gatifloxacin Hydrate and Gatifloxacin RS (separately determine the water <2.48> in the same manner as Gatifloxacin Hydrate), and dissolve each in the dissolving solution to make exactly 100 mL. Pipet 2 mL each of these solution, add exactly 2 mL of the internal standard solution to them, add the dissolving solution to make 25 mL, and use these solutions as the sample solution and standard solutions. Perform the test with 20 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of gatifloxacin to that of the internal standard.

$$\begin{aligned} \text{Amount (mg) of gatifloxacin (C}_{19}\text{H}_{22}\text{FN}_3\text{O}_4) \\ = M_S \times Q_T/Q_S \end{aligned}$$

M_S : Amount (mg) of Gatifloxacin RS taken, calculated on the anhydrous basis

Internal standard solution—A solution of methyl 4-aminobenzoate in the dissolving solution (1 in 4000).

Dissolving solution: A mixture of diluted phosphoric acid (1 in 1000) and acetonitrile (4:1).

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 280 nm).

Column: A stainless steel column 4 mm in inside diameter and 12.5 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of diluted triethylamine (1 in 100), adjusted to pH 4.5 with phosphoric acid, and acetonitrile (87:13).

Flow rate: Adjust so that the retention time of gatifloxacin is about 5 minutes.

System suitability—

System performance: When the procedure is run with 20 μL of the standard solution under the above operating conditions, gatifloxacin and the internal standard are eluted in

this order with the resolution between these peaks being not less than 4.

System repeatability: When the test is repeated 6 times with 20 μL of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of gatifloxacin to that of the internal standard is not more than 1.0%.


Containers and storage Containers—Tight containers.

Storage—Light-resistant.

Others

Related substance A:

1-Cyclopropyl-6-fluoro-8-methoxy-7-[(2*RS*)-2-methylpiperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid



Add the following:

Gatifloxacin Ophthalmic Solution

ガチフロキサシン点眼液

Gatifloxacin Ophthalmic Solution is an aqueous ophthalmic preparation.

It contains not less than 95.0% and not more than 107.0% of the labeled amount of gatifloxacin ($\text{C}_{19}\text{H}_{22}\text{FN}_3\text{O}_4$; 375.39).

Method of preparation Prepare as directed under Ophthalmic Liquids and Solutions, with Gatifloxacin Hydrate.

Description Gatifloxacin Ophthalmic Solution is a clear, pale yellow liquid.

Identification To a volume of Gatifloxacin Ophthalmic Solution, equivalent to 6 mg of gatifloxacin ($\text{C}_{19}\text{H}_{22}\text{FN}_3\text{O}_4$), add diluted sodium hydroxide TS (1 in 10) to make 30 mL. To 1 mL of this solution add diluted sodium hydroxide TS (1 in 10) to make 20 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 238 nm and 242 nm, between 287 nm and 291 nm, and between 336 nm and 340 nm.

Osmotic pressure ratio Being specified separately when the drug is granted approval based on the Law.

pH Being specified separately when the drug is granted approval based on the Law.

Purity Related substance—To a volume of Gatifloxacin Ophthalmic Solution, equivalent to 6 mg of gatifloxacin ($\text{C}_{19}\text{H}_{22}\text{FN}_3\text{O}_4$), add the diluting solution to make 30 mL, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the diluting solution to make exactly 100 mL. Pipet 2 mL of this solution, add the diluting

solution to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 40 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: the peak area of the related substance A, having the relative retention time of about 1.2 to gatifloxacin, obtained from the sample solution is not larger than 2 times the peak area of gatifloxacin from the standard solution, and the area of the peak other than gatifloxacin and the peak mentioned above from the sample solution is not larger than the peak area of gatifloxacin from the standard solution. Furthermore, the total area of the peaks other than gatifloxacin from the sample solution is not larger than 3 times the peak area of gatifloxacin from the standard solution.

Diluting solution: A mixture of diluted phosphoric acid (1 in 1000) and acetonitrile (4:1).

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 325 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase A: A mixture of diluted triethylamine (1 in 100) and acetonitrile (22:3), adjusted to pH 4.3 with phosphoric acid.

Mobile phase B: A mixture of diluted triethylamine (1 in 100) and acetonitrile (1:1), adjusted to pH 4.3 with phosphoric acid.

Flowing of mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 15	100	0
15 – 30	100 → 0	0 → 100
30 – 40	0	100

Flow rate: 0.9 mL per minute (the retention time of gatifloxacin is about 16 minutes).

Time span of measurement: For 40 minutes after injection, beginning after the solvent peak.

System suitability—

Test for required detectability: Pipet 5 mL of the standard solution, and add the diluting solution to make exactly 10 mL. Confirm that the peak area of gatifloxacin obtained with 40 μ L of this solution is equivalent to 40 to 60% of that with 40 μ L of the standard solution.

System performance: Dissolve 20 mg of methyl 4-aminobenzoate in 100 mL of the diluting solution. To 5 mL of this solution and 1 mL of the sample solution add the diluting solution to make 100 mL. When the procedure is

run with 40 μ L of this solution under the above operating conditions, gatifloxacin and methyl 4-aminobenzoate are eluted in this order with the resolution between these peaks being not less than 4.

System repeatability: When the test is repeated 6 times with 40 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of gatifloxacin is not more than 3.0%.

Foreign insoluble matter <6.11> It meets the requirement.

Insoluble particulate matter <6.08> It meets the requirement.

Sterility <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

Assay Pipet a volume of Gatifloxacin Ophthalmic Solution, equivalent to about 6 mg of gatifloxacin (C₁₉H₂₂FN₃O₄), and add the diluting solution to make exactly 30 mL. Pipet 2 mL of this solution, add exactly 3 mL of the internal standard solution, add the diluting solution to make 20 mL, and use this solution as the sample solution. Separately, weigh accurately about 22 mg of Gatifloxacin RS (separately determine the water <2.48> in the same manner as Gatifloxacin Hydrate), and dissolve in the diluting solution to make exactly 100 mL. Pipet 2 mL of this solution, add exactly 3 mL of the internal standard solution, add the diluting solution to make 20 mL, and use this solution as the standard solution. Perform the test with 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of gatifloxacin to that of the internal standard.

$$\begin{aligned} &\text{Amount (mg) of gatifloxacin (C}_{19}\text{H}_{22}\text{FN}_3\text{O}_4) \\ &= M_S \times Q_T/Q_S \times 3/10 \end{aligned}$$

M_S : Amount (mg) of Gatifloxacin RS taken, calculated on the anhydrous basis

*Internal standard solution—*A solution of methyl 4-aminobenzoate in the diluting solution (1 in 10,000).

Diluting solution: A mixture of diluted phosphoric acid (1 in 1000) and acetonitrile (4:1).

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 280 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of water, acetonitrile and triethylamine (81:18:1), adjusted to pH 4.5 with phosphoric acid.

Flow rate: Adjust so that the retention time of gatifloxacin is about 6 minutes.

System suitability—

System performance: When the procedure is run with 20 μL of the standard solution under the above operating conditions, gatifloxacin and the internal standard are eluted in this order with the resolution between these peaks being not less than 10.

System repeatability: When the test is repeated 6 times with 20 μL of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of gatifloxacin to that of the internal standard is not more than 1.0%.

Containers and storage Containers—Tight containers.

Others

Related substances A: Refer to it described in Gatifloxacin Hydrate.

Add the following:**Gentamicin Sulfate Injection**

ゲンタマイシン硫酸塩注射液

Gentamicin Sulfate Injection is an aqueous injection.

It contains not less than 90.0% and not more than 110.0% of the labeled potency of gentamicin C_1 ($\text{C}_{21}\text{H}_{43}\text{N}_5\text{O}_7$: 477.60).

Method of preparation Prepare as directed under Injections, with Gentamicin Sulfate.

Description Gentamicin Sulfate Injection is a clear and colorless liquid.

Identification To a volume of Gentamicin Sulfate Injection, equivalent to 40 mg (potency) of Gentamicin Sulfate, add water to make 10 mL, and use this solution as the sample solution. Separately, dissolve an amount of Gentamicin Sulfate RS, equivalent to 20 mg (potency), in 5 mL of water, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5 μL each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with the lower layer of a mixture of chloroform, ammonia solution (28) and methanol (2:1:1) to a distance of about 15 cm, and air-dry the plate. Spray evenly 0.2% ninhydrin-water saturated 1-butanol TS on the plate, and heat the plate at 100°C for 10 minutes: three principal spots obtained from the sample solution are the same with the corresponding spots from the standard solution in color tone and the R_f value, respectively.

Osmotic pressure ratio Being specified separately when the drug is granted approval based on the Law.

pH <2.54> 4.0 – 6.0

Bacterial endotoxins <4.01> Less than 0.50 EU/mg (po-

tency).

Extractable volume <6.05> It meets the requirement.

Foreign insoluble matter <6.06> Perform the test according to Method 1: it meets the requirement.

Insoluble particulate matter <6.07> It meets the requirement.

Sterility <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

Assay Perform the test according to the Cylinder-plate method as directed under Microbial Assay for Antibiotics <4.02> according to the following conditions.

(i) Test organism, agar media for base and seed layer, agar medium for transferring test organisms, and standard solutions—Proceed as directed in the Assay under Gentamicin Sulfate.

(ii) Sample solutions—Pipet a volume of Gentamicin Sulfate Injection, equivalent to about 40 mg (potency) of Gentamicin Sulfate, add 0.1 mol/L phosphate buffer solution (pH 8.0) to make exactly 200 mL. Pipet a suitable volume of this solution, add 0.1 mol/L phosphate buffer solution (pH 8.0) to make solutions so that each mL contains 4 μg (potency) and 1 μg (potency), and use these solutions as the high concentration sample solution and the low concentration sample solution, respectively.

Containers and storage Containers—Hermetic containers.

Add the following:**Gentamicin Sulfate Ointment**

ゲンタマイシン硫酸塩軟膏

Gentamicin Sulfate Ointment contains not less than 90.0% and not more than 110.0% of the labeled potency of gentamicin C_1 ($\text{C}_{21}\text{H}_{43}\text{N}_5\text{O}_7$: 477.60).

Method of preparation Prepare as directed under Ointments, with Gentamicin Sulfate.

Identification To an amount of Gentamicin Sulfate Ointment, equivalent to 5 mg (potency) of Gentamicin Sulfate, add 10 mL of diethyl ether, and shake in lukewarm water, if necessary, to dissolve. Add 5 mL of water, shake for 10 minutes, centrifuge, and use the water layer as the sample solution. Separately, dissolve an amount of Gentamicin Sulfate RS, equivalent to 10 mg (potency), in 10 mL of water, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μL each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with the lower layer of a mixture of chloroform, ammonia solution (28) and methanol (2:1:1) to a distance of about 15 cm, and air-dry the plate. Spray evenly 0.2% ninhydrin-water saturated 1-butanol TS on the plate, and heat the plate at 100°C for 10

minutes: three principal spots obtained from the sample solution are the same with the corresponding spots from the standard solution in color tone and the *R_f* value, respectively.

Assay Perform the test according to the Cylinder-plate method as directed under Microbial Assay for Antibiotics <4.02> according to the following conditions.

(i) Test organism, agar media for base and seed layer, agar medium for transferring test organisms, and standard solutions—Proceed as directed in the Assay under Gentamicin Sulfate.

(ii) Sample solutions—Weigh accurately an amount of Gentamicin Sulfate Ointment, equivalent to about 1 mg (potency) of Gentamicin Sulfate, transfer to a separator, add 50 mL of diethyl ether, and shake until the solution becomes uniform. Add 25 mL of 0.1 mol/L phosphate buffer solution (pH 8.0), shake, and collect the water layer. Repeat the same procedure with 25 mL of 0.1 mol/L phosphate buffer solution (pH 8.0), and combine the water layers. To this solution add 0.1 mol/L phosphate buffer solution (pH 8.0) to make exactly 100 mL. Pipet a suitable volume of this solution, add 0.1 mol/L phosphate buffer solution (pH 8.0) to make solutions so that each mL contains 4 μg (potency) and 1 μg (potency), and use these solutions as the high concentration sample solution and the low concentration sample solution, respectively.

Containers and storage Containers—Tight containers.

Delete the following Monograph:

Adsorbed Habu-venom Toxoid

沈降はぶトキソイド

Haloperidol

ハロペリドール

Change the Melting point as follows:

Melting point <2.60> 150 – 154°C

Hydrocortisone

ヒドロコルチゾン

Change the Description and Optical rotation as follows:

Description Hydrocortisone occurs as a white crystalline powder.

It is sparingly soluble in methanol and in ethanol (99.5), and very slightly soluble in water.

Melting point: 212 – 220°C (with decomposition).

It shows crystal polymorphism.

Optical rotation <2.49> $[\alpha]_D^{25}$: +160 – +170° (after drying, 0.1 g, ethanol (99.5), 10 mL, 100 mm).

Hydrocortisone Acetate

ヒドロコルチゾン酢酸エステル

Change the Description and Optical rotation as follows:

Description Hydrocortisone Acetate occurs as white, crystals or crystalline powder.

It is freely soluble in dimethylsulfoxide, slightly soluble in methanol and in ethanol (95), and practically insoluble in water.

Melting point: about 220°C (with decomposition).

It shows crystal polymorphism.

Optical rotation <2.49> $[\alpha]_D^{25}$: +154 – +164° (after drying, 50 mg, dimethylsulfoxide, 10 mL, 100 mm).

Hydrocortisone and Diphenhydramine Ointment

ヒドロコルチゾン・ジフェンヒドラミン軟膏

Change the Identification (3) as follows:

Identification

(3) To 0.2 g of Hydrocortisone and Diphenhydramine Ointment add 0.5 mL of methanol, warm, and shake. After cooling, separate the methanol layer, and use this layer as the sample solution. Dissolve 10 mg each of hydrocortisone acetate and diphenhydramine in 10 mL each of methanol, and use these solutions as standard solutions (1) and (2). Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5 μL each of the sample solution and standard solutions (1) and (2) on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate and diethyl ether (4:1) to a distance of about 5 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): two spots obtained from the sample solution show the same *R_f* value as the corresponding spots from standard solutions (1) and (2).

Add the following:

Hydroxyethylcellulose

ヒドロキシエチルセルロース

[9004-62-0]

This monograph is harmonized with the European Pharmacopoeia and the U. S. Pharmacopoeia.

The corresponding part of the attributes/provisions which are agreed as non-harmonized within the scope of the harmonization is marked with symbols (◆ ◆), and the corresponding parts which are agreed as the JP local requirement other than the scope of the harmonization are marked with symbols (◇ ◇).

Hydroxyethylcellulose is partly *O*-(2-hydroxyethylated) cellulose.

It contains not less than 30.0% and not more than 70.0% of hydroxyethoxy group (-OC₂H₄OH: 61.06), calculated on the dried basis.

It may contain suitable pH-adjusting agents such as phosphates.

◆The viscosity is shown in millipascal second (mPa·s) on the label.◆

◆**Description** Hydroxyethylcellulose occurs as a white to yellowish white, powder or grains.

It is practically insoluble in ethanol (95).

It forms a viscous liquid upon addition of water.

It is hygroscopic.◆

Identification (1) Determine the infrared absorption spectrum of Hydroxyethylcellulose as directed in the ATR method under Infrared Spectrophotometry <2.25> and compare the spectrum with the spectrum of Hydroxyethylcellulose RS for Identification: both spectra exhibit similar intensities of absorption at the same wave numbers.

(2) Disperse 1.0 g of Hydroxyethylcellulose, calculated on the dried basis, in 50 mL of freshly boiled and cooled water. After 10 minutes, add freshly boiled and cooled water to make 100 mL, stir to dissolve completely, and use this solution as the sample solution. Boil 10 mL of the sample solution: the solution is clear.

◆**Viscosity** <2.53> Weigh exactly a quantity of Hydroxyethylcellulose, equivalent to 10.00 g calculated on the dried basis, add 400 mL of water, stir to dissolve, and add water to make exactly 500.0 g. Remove air bubbles, and use this solution as the sample solution. Perform the test with the sample solution at 20 ± 0.1°C as directed in Method II under Viscosity Determination, using a beaker with an inside diameter of not less than 70 mm and a single cylinder-type rotational viscometer, according to the following operating conditions: not less than 75% and not more than 140% of the labeled viscosity.

Operating conditions—

Apparatus: Brookfield type viscometer LV or RV model.

Rotor No., rotation frequency and calculation multiplier: According to the following table, depending on the labeled viscosity.

Labeled viscosity (mPa·s)	Model	Rotor No.	Rotation frequency /min	Calculation multiplier
less than 200	LV	1	30	2
Not less than 200 and less than 4000	LV	3	30	40
" 4000 " 10,000	LV	4	30	200
" 10,000 " 50,000	RV	6	20	500
" 50,000	RV	7	20	2000

Procedure of apparatus: Read a value after 2 minutes of rotation, and stop the rotation for at least 2 minutes. Repeat this procedure more two times, and average the three observed values.◆

pH <2.54> The pH of the sample solution obtained in the Identification (2) is between 5.5 and 8.5.

Purity (1) Chloride—To 1 mL of the sample solution obtained in the Identification (2) add water to make 30 mL, and use this solution as the sample solution. Separately, to 10 mL of Standard Chloride Solution add 5 mL of water, and use this solution as the control solution. To 15 mL each of the sample solution and control solution add 1 mL of diluted nitric acid (1 in 5), transfer to test tubes containing 1 mL of a solution of silver nitrate (17 in 1000), allow to stand for 5 minutes protecting from light, and compare the opalescence developed in the both solutions against a black background by viewing transversely: the opalescence developed in the sample solution is not more intense than that of the control solution (not more than 1.0%).

(2) Nitrate—Prepare the solutions before use. Dissolve 0.50 g of Hydroxyethylcellulose in the diluting solution to make exactly 100 mL, and use this solution as the sample solution. Separately, dissolve 0.8154 g of potassium nitrate in the diluting solution to make 1000 mL, and use this solution as the standard nitrate stock solution. If the viscosity of Hydroxyethylcellulose is not more than 1000 mPa·s, pipet 10 mL, 20 mL and 40 mL of the standard nitrate stock solution, add the diluting solution to each to make exactly 100 mL, and use these solutions as the standard solutions. If the viscosity of Hydroxyethylcellulose is more than 1000 mPa·s, pipet 1 mL, 2 mL and 4 mL of the standard nitrate stock solution, add the diluting solution to each to make exactly 100 mL, and use these solutions as the standard solutions. Perform the test with the sample solution and standard solutions using a nitrate-selective electrode as an indicator electrode, a silver-silver chloride electrode as a reference electrode and diluted ammonium sulfate TS (1 in 30) as reference electrolyte. Calculate the concentration of nitrates in the sample solution using a calibration curve obtained from the potential differences of the standard solutions: not more than 3.0%, calculated on the dried basis, if Hydroxyethylcellulose has a viscosity of not more than 1000 mPa·s, and not more than 0.2%, calculated on the dried basis, if Hydroxyethylcellulose has a viscosity of more than 1000 mPa·s.

Diluting solution: To a mixture of 50 mL of 1 mol/L sulfuric acid TS and 800 mL of water add 135 g of potassium

dihydrogen phosphate, and add water to make 1000 mL. To this solution add water to make exactly 25 times the initial volume.

In order to determine the applicable limit, determine the viscosity using the following procedure.

Introduce a quantity of Hydroxyethylcellulose, equivalent to 2.00 g calculated on the dried basis, into 50 g of water, stir, add water to make 100 g, and stir to dissolve completely. Determine the viscosity using a rotating viscometer at 25°C and at a shear rate of 100 s⁻¹ for substances with an expected viscosity less than 100 mPa·s, at a shear rate of 10 s⁻¹ for substances with an expected viscosity not less than 100 mPa·s and not more than 20,000 mPa·s, and at a shear rate of 1 s⁻¹ for substances with an expected viscosity more than 20,000 mPa·s. If it is impossible to obtain a shear rate of exactly 10 s⁻¹ or 100 s⁻¹ respectively, use a rate slightly higher and a rate slightly lower and interpolate.

◇(3) Heavy metal <1.07>—Proceed with 1.0 g of Hydroxyethylcellulose according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).◇

(4) Aldehydes—Introduce 1.0 g of Hydroxyethylcellulose into a glass-stoppered test tube, add 10 mL of ethanol (99.5), stopper the tube tightly, and stir for 30 minutes. Centrifuge, and use the supernatant liquid as the sample solution. Use Standard Glyoxal Solution as the control solution. Pipet 2 mL each of the sample solution and control solution, to each add 5 mL of a solution prepared by dissolving 4 g of 3-methyl-2-benzothiazolonehydrazone hydrochloride monohydrate in diluted acetic acid (100) (4 in 5) to make 1000 mL, shake to homogenize, and allow to stand for 2 hours. Compare the color of these solutions: the sample solution is not more intensely colored than the control solution (not more than 20 ppm).

Loss on drying <2.41> Not more than 10.0% (1 g, 105°C, 3 hours).

Residue on Ignition <2.44> Not more than 4.0% if the viscosity of Hydroxyethylcellulose is not more than 1000 mPa·s, and not more than 1.0% if the viscosity of Hydroxyethylcellulose is more than 1000 mPa·s (1 g). In order to determine the applicable limit, determine the viscosity according to the method in the Purity (2).

Assay Weigh accurately about 30 mg of Hydroxyethylcellulose, transfer to a 5-mL pressure-tight serum vial, add exactly 60 mg of adipic acid, 2 mL of the internal standard solution and 1 mL of hydroiodic acid, seal the vial immediately with a septum coated with fluororesin and an aluminum cap or any other sealing system providing a sufficient air-tightness, and weigh accurately the vial. Take care not to mix the content of the vial before heating. Place the vial in an oven or heat in a suitable heater with continuous stirring, maintaining the internal temperature of about 165 ± 2°C for 2.5 hours. Allow to cool and weigh accurately the vial. If the difference of the mass between before heating and after heating is more than 10 mg, prepare a new sample solution. If the difference of the mass between before heating

and after heating is not more than 10 mg, after phase separation, pierce through the septum of the vial with a cooled syringe, and withdraw a sufficient volume of the upper phase as the sample solution. Separately, place exactly 60 mg of adipic acid, 2 mL of the internal standard solution and 1 mL of hydroiodic acid in another serum vial, and seal immediately. Weigh accurately the vial, inject 55 μL of iodoethane for assay through the septum in the vial, and weigh again accurately. Shake thoroughly, after phase separation, pierce through the septum of the vial with a cooled syringe, and withdraw a sufficient volume of the upper phase as the standard solution. Perform the test with 1 μL each of the sample solution and standard solution as directed under Gas Chromatography <2.02> according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of iodoethane to that of the internal standard.

$$\begin{aligned} \text{Amount (\% of hydroethoxy group (C}_2\text{H}_5\text{O}_2\text{))} \\ = M_S/M_T \times Q_T/Q_S \times 39.15 \end{aligned}$$

M_S : Amount (mg) of iodoethane for assay taken

M_T : Amount (mg) of Hydroxyethylcellulose taken, calculated on the dried basis

Internal standard solution—A solution of *n*-octane in *o*-xylene (1 in 200).

Operating conditions—

Detector: A hydrogen flame-ionization detector.

Column: A fused silica column 0.53 mm in inside diameter and 30 m in length, coated with dimethylpolysiloxane for gas chromatography in 3 μm thickness.

Column temperature: Maintain the temperature at 50°C for 3 minutes, raise to 100°C at a rate of 10°C per minute, then raise to 250°C at a rate of 35°C per minute, and maintain at 250°C for 8 minutes.

Injection port temperature: A constant temperature of about 250°C.

Detector temperature: A constant temperature of about 280°C.

Carrier gas: Helium.

Flow rate: 4.2 mL per minutes (the retention time of the internal standard is about 10 minutes).

Split ratio: 1:40.

System suitability—

System performance: When the procedure is run with 1 μL of the standard solution under the above operating conditions, iodoethane and the internal standard are eluted in this order with the relative retention time of iodoethane to the internal standard being about 0.6 and the resolution between these peaks being not less than 5.0.

System repeatability: When the test is repeated 6 times with 1 μL of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of iodoethane to that of the internal standard is not more than 2.0%.

◆**Containers and storage** Containers—Tight containers.◆

Change the following as follows:

Hydroxypropylcellulose

ヒドロキシプロピルセルロース

[9004-64-2]

This monograph is harmonized with the European Pharmacopoeia and the U. S. Pharmacopoeia.

The corresponding part of the attributes/provisions which are agreed as non-harmonized within the scope of the harmonization is marked with symbols (◆ ◆), and the corresponding parts which are agreed as the JP local requirement other than the scope of the harmonization are marked with symbols (◇ ◇).

Hydroxypropylcellulose is partially *O*-(2-hydroxypropylated) cellulose.

It contains not less than 53.4% and not more than 80.5% of hydroxypropoxy group (-OC₃H₆OH: 75.09), calculated on the dried basis.

It may contain silicon dioxide as anti-caking agent.

◆The label states the addition in the case where silicon dioxide is added as anti-caking agent.◆

◆**Description** Hydroxypropylcellulose occurs as a white to yellowish white powder.

It forms a viscous liquid upon addition of water or ethanol (95).◆

Identification (1) Dissolve 1 g of Hydroxypropylcellulose in 100 mL of water, transfer 1 mL of the solution to a glass plate, and allow the water to evaporate: a thin film is formed.

(2) Determine the infrared absorption spectrum of Hydroxypropylcellulose as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers. If there are an absorption at about 1719 cm⁻¹, disregard the absorption.

pH <2.54> Disperse evenly 1.0 g of Hydroxypropylcellulose in 100 mL of freshly boiled water, and allow to cool the mixture while stirring with a magnetic stirrer: the pH of the solution is between 5.0 and 8.0.

Purity

◇(1) Heavy metals<1.07>—Proceed with 1.0 g of Hydroxypropylcellulose according to Method 2 and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).◇

(2) Silicon dioxide—Apply to Hydroxypropylcellulose, if the addition of silicon dioxide is stated on the label and if more than 0.2% residue is found in the Residue on ignition test. Weigh accurately the crucible containing the residue tested in the Residue on ignition of Hydroxypropylcellulose (*a* (g)). Moisten the residue with water, and add 5 mL of hydrofluoric acid, in small portions. Evaporate it on a

steam bath to dryness and cool. Add 5 mL of hydrofluoric acid and 0.5 mL of sulfuric acid, and evaporate to dryness. Slowly increase the temperature until all the acids have been volatilized, and ignite at 1000 ± 25°C. Cool the crucible in a desiccator, and weigh (*b* (g)). Calculate the amount of silicon dioxide by the following equation: not more than 0.6%.

$$\begin{aligned} \text{Amount (\% of silicon dioxide (SiO}_2\text{))} \\ = (a - b)/M \times 100 \end{aligned}$$

M: Amount (g) of Hydroxypropylcellulose used for residue on ignition test

Loss on drying <2.41> Not more than 5.0% (1 g, 105°C, 4 hours).

Residue on ignition <2.44> Not more than 0.8% (1 g, platinum crucible).

Assay Weigh accurately about 30 mg of Hydroxypropylcellulose, transfer to a reaction vial, add exactly 60 mg of adipic acid, 2 mL of the internal standard solution and 1 mL of hydriodic acid, stopper the vial tightly, and weigh accurately. Place the vial in an oven or heat by a suitable heater with continuous stirring, maintaining the internal temperature of 115 ± 2°C for 70 minutes. Allow the vial to cool and weigh accurately. If the difference of the mass between before heating and after heating is more than 10 mg, prepare a new test solution. If the difference of the mass between before heating and after heating is not more than 10 mg, after phase separation by allowing the vial to stand, pierce through the septum of the vial with a cooled syringe, and withdraw a sufficient volume of the upper phase as the sample solution. Separately, place exactly 60 mg of adipic acid, 2 mL of internal standard solution and 1 mL of hydriodic acid in another reaction vial, stopper tightly, and weigh accurately. Inject 25 μL of isopropyl iodide for assay through the septum, and again weigh accurately. Shake the vial thoroughly, and after phase separation by allowing the vial to stand, pierce through the septum of the vial with a cooled syringe, and withdraw a sufficient volume of the upper phase as the standard solution. Perform the test with 2 μL each of the sample solution and standard solution as directed under Gas Chromatography <2.02> according to the following conditions, and calculate the ratios, *Q_T* and *Q_S*, of the peak area of isopropyl iodide to that of the internal standard.

$$\begin{aligned} \text{Amount (\% of hydroxypropoxy group (C}_3\text{H}_7\text{O}_2\text{))} \\ = M_S/M_T \times Q_T/Q_S \times 1.15 \times 44.17 \end{aligned}$$

M_S: Amount (mg) of isopropyl iodide for assay taken

M_T: Amount (mg) of Hydroxypropylcellulose taken, calculated on the dried basis

1.15: Correction factor

Internal standard solution—A solution of methylcyclohexane in *o*-xylene (1 in 50).

Operating conditions—

Detector: A hydrogen flame-ionization detector.

Column: A fused silica tube 0.53 mm in diameter and 30

m in length, coated with methylsilicone polymer for gas chromatography in 3 μm thickness.

Column Temperature: Maintain the temperature at 40°C for 3 minutes, raise to 100°C at a rate of 10°C per minute, then raise to 250°C at a rate of 50°C per minute, and maintain at 250°C for 3 minutes.

Injection port temperature: A constant temperature of about 180°C.

Detector temperature: A constant temperature of about 280°C.

Carrier gas: Helium.

Flow rate: 52 cm per second (the retention time of the internal standard is about 8 minutes).

Split ratio: 1:50.

System suitability—

System performance: When the procedure is run with 2 μL of the standard solution under the above operating conditions, isopropyl iodide and the internal standard are eluted in this order with the relative retention time of isopropyl iodide to the internal standard being about 0.8, and with the resolution between these peaks being not less than 2.0.

System repeatability: When the test is repeated 6 times with 2 μL of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of isopropyl iodide to that of the internal standard is not more than 2.0%.

◆Containers and storage Containers—Well-closed containers.◆

Change the following as follows:

Hypromellose

ヒプロメロース

[9004-65-3]

This monograph is harmonized with the European Pharmacopoeia and the U.S. Pharmacopoeia.

The corresponding part of the attributes/provisions which are agreed as non-harmonized within the scope of the harmonization is marked with symbols (◆ ◆), and the corresponding parts which are agreed as the JP local requirement other than the scope of the harmonization are marked with symbols (◇ ◇).

Hypromellose is a methyl and hydroxypropyl mixed ether of cellulose.

There are four substitution types of Hypromellose, 1828, 2208, 2906 and 2910. They contain methoxy (-OCH₃: 31.03) and hydroxypropoxy (-OC₃H₆OH: 75.09) groups conforming to the limits for the types of Hypromellose shown in the table below, calculated on the dried basis.

The viscosity is shown in millipascal second (mPa·s) on the label, together with the substitution

type.

Substitution Type	Methoxy Group (%)		Hydroxypropoxy Group (%)	
	Min.	Max.	Min.	Max.
1828	16.5	20.0	23.0	32.0
2208	19.0	24.0	4.0	12.0
2906	27.0	30.0	4.0	7.5
2910	28.0	30.0	7.0	12.0

◆Description Hypromellose occurs as a white to yellowish white, powder or grains.

It is practically insoluble in ethanol (99.5).

It swells with water and becomes a clear or slightly turbid, viscous solution.◆

Identification (1) Disperse evenly 1.0 g of Hypromellose over the surface of 100 mL of water in a beaker, while gently tapping the top of the beaker, if necessary, and allow the beaker to stand: it aggregates on the surface of water.

(2) Add 1.0 g of Hypromellose to 100 mL of hot water, and stir: it becomes a suspension. Cool the suspension to 10°C, and stir: the resulting liquid is a clear or a slightly cloudy, viscous fluid.

(3) To 0.1 mL of the viscous fluid obtained in (2) add 9 mL of diluted sulfuric acid (9 in 10), shake, heat in a water bath for exactly 3 minutes, and immediately cool in ice water. Add carefully 0.6 mL of ninhydrin TS, shake, and allow to stand at 25°C: the solution shows a red color first, then changes to purple color within 100 minutes.

(4) Pour and spread out 2 to 3 mL of the viscous fluid obtained in (2) onto a glass plate, and allow the water to evaporate: a transparent film results.

(5) Pipet 50 mL of water, add exactly 50 mL of the viscous fluid obtained in (2), and warm to raise the temperature at a rate of 2 to 5°C per minute while stirring: the temperature, when a white turbidity of the solution starts to increase, is not less than 50°C.

Viscosity <2.53> (i) Method I: Apply to Hypromellose having a labeled viscosity of less than 600 mPa·s. Put an exact amount of Hypromellose, equivalent to 4.000 g calculated on the dried basis, in a tared, wide-mouth bottle, add water (between 90°C and 99°C) to make 200 g, stopper the bottle, stir by mechanical means at 350 to 450 revolutions per minute for 10 to 20 minutes to get a homogeneous dispersion. If necessary, take off the sample attached on the walls of the bottle, put them in the dispersed solution, and dissolve by continuing the stirring in a water bath at not exceeding 10°C for 20 to 40 minutes. Add cold water, if necessary, to make 200 g, and use this solution as the sample solution. Centrifuge the solution if necessary to expel any entrapped air bubbles. Perform the test with the sample solution at 20 ± 0.1°C as directed in Method I under Viscosity Determination: not less than 80% and not more than 120% of the labeled viscosity.

(ii) Method II: Apply to Hypromellose having a labeled

viscosity of not less than 600 mPa·s. Put an exact amount of Hypromellose, equivalent to 10.00 g calculated on the dried basis, in a tared, wide-mouth bottle, add water (between 90°C and 99°C) to make 500 g, and prepare the sample solution in the same manner as directed in Method I. Perform the test with the sample solution at $20 \pm 0.1^\circ\text{C}$ as directed in Method II under Viscosity Determination, using a single cylinder-type rotational viscometer, according to the following operating conditions: not less than 75% and not more than 140% of the labeled viscosity.

Operating conditions—

Apparatus: Brookfield type viscometer LV model or an equivalent apparatus.

Rotor No., rotation frequency, and calculation multiplier: According to the following table, depending on the labeled viscosity.

Labeled viscosity (mPa·s)	Rotor No.	Rotation frequency /min	Calculation multiplier
Not less than 600 and less than 1400	3	60	20
// 1400 //	3500	3	12
// 3500 //	9500	4	60
// 9500 //	99,500	4	6
// 99,500	4	3	1000
			2000

Procedure of apparatus: Read the value after 2 minutes of rotation, and stop the rotation for at least 2 minutes. Repeat this procedure more two times, and average the three observed values.

pH <2.54> The pH of the sample solution obtained in the Viscosity, measured after 5 minutes immersing the electrode in the sample solution, is between 5.0 and 8.0.

◇**Purity** Heavy metals—Put 1.0 g of Hypromellose in a 100-mL Kjeldahl flask, add a sufficient amount of a mixture of nitric acid and sulfuric acid (5:4) to wet the sample, and heat gently. Repeat this procedure until to use totally 18 mL of the mixture of nitric acid and sulfuric acid (5:4). Then boil gently until the solution changes to black. After cooling, add 2 mL of nitric acid, and heat until the solution changes to black. Repeat this procedure until the solution no longer changes to black, and heat strongly until dense white fumes are evolved. After cooling, add 5 mL of water, boil gently until dense white fumes are evolved, then heat until the volume of the solution becomes to 2 to 3 mL. After cooling, if the solution reveals yellow color by addition of 5 mL of water, add 1 mL of hydrogen peroxide (30), and heat until the volume of the solution becomes to 2 to 3 mL. After cooling, dilute the solution with 2 to 3 mL of water, transfer to a Nessler tube, add water to make 25 mL, and use this solution as the sample solution. Separately, put 2.0 mL of Standard Lead Solution in a 100-mL Kjeldahl flask, add 18 mL of the mixture of nitric acid and sulfuric acid (5:4) and an amount of nitric acid equal to that used for preparation of the sample solution, and heat until white fumes are evolved. After cooling, add 10 mL of water. In the case where hydrogen peroxide (30) is added for the preparation

of the sample solution, add the same amount of hydrogen peroxide (30), then proceed in the same manner for preparation of the sample solution, and use so obtained solution as the control solution. Adjust the sample solution and the control solution to pH 3.0 to 4.0 with ammonia solution (28), and add water to make 40 mL, respectively. To these solutions add 1.2 mL of thioacetamide-alkaline glycerin TS, 2 mL of acetate buffer solution (pH 3.5) and water to make 50 mL, separately. After allowing to stand for 5 minutes, observe vertically both tubes on a white background: the color obtained with the sample solution is not more intense than that with the control solution (not more than 20 ppm).◇

Loss on drying <2.41> Not more than 5.0% (1 g, 105°C, 1 hour).

Residue on ignition <2.44> Not more than 1.5% (1 g).

Assay (i) Apparatus—Reaction vial: A 5-mL pressure-tight serum vial, having 20 mm in outside diameter and 50 mm in height, the neck 20 mm in outside diameter and 13 mm in inside diameter, equipped with a septum of butyl-rubber processed the surface with fluoroplastics, which can be fixed tightly to vial with aluminum cap, or equivalent.

Heater: A square-shaped aluminum block, having holes 20 mm in diameter and 32 mm in depth, adopted to the reaction vial. Capable of stirring the content of the reaction vial by means of magnetic stirrer or of reciprocal shaker about 100 times per minute.

(ii) Procedure—Weigh accurately about 65 mg of Hypromellose, transfer to the reaction vial, add 60 to 100 mg of adipic acid, 2.0 mL of the internal standard solution and 2.0 mL of hydroiodic acid, immediately stopper the vial tightly, and weigh accurately. Using a magnetic stirrer equipped in the heating module, or using a shaker, stir for 60 minutes while heating so that the temperature of the vial content is $130 \pm 2^\circ\text{C}$. In the case when a magnetic stirrer or shaker is not available, heat for 30 minutes with repeated shaking at 5-minute intervals by hand, and continue heating for an additional 30 minutes. Allow the vial to cool, and again weigh accurately. If the mass loss is not more than 26 mg and there is no evidence of a leak of the content, use the upper layer of the mixture as the sample solution. Separately, put 60 to 100 mg of adipic acid, 2.0 mL of the internal standard solution and 2.0 mL of hydroiodic acid in a reaction vial, immediately stopper the vial tightly, and weigh accurately. Add 45 μL of iodomethane for assay and 15 to 22 μL of isopropyl iodide for assay through the septum using a micro-syringe with weighing accurately every time, shake thoroughly, and use the upper layer of the content as the standard solution. Perform the test with 1 to 2 μL each of the sample solution and standard solution as directed under Gas Chromatography <2.02> according to the following conditions, and calculate the ratios, Q_{Ta} and Q_{Tb} , of the peak area of iodomethane and isopropyl iodide to that of the internal standard obtained from the sample solution, and Q_{Sa} and Q_{Sb} , of the peak area of iodomethane and isopropyl iodide to that of the internal standard from the

standard solution.

$$\begin{aligned} \text{Content (\% of methoxy group (CH}_3\text{O)} \\ = M_{\text{Sa}}/M \times Q_{\text{Ta}}/Q_{\text{Sa}} \times 21.86 \end{aligned}$$

$$\begin{aligned} \text{Content (\% of hydroxypropoxy group (C}_3\text{H}_7\text{O}_2) \\ = M_{\text{Sb}}/M \times Q_{\text{Tb}}/Q_{\text{Sb}} \times 44.17 \end{aligned}$$

M_{Sa} : Amount (mg) of iodomethane for assay taken

M_{Sb} : Amount (mg) of isopropyl iodide for assay taken

M : Amount (mg) of Hypromellose taken, calculated on the dried basis

Internal standard solution—A solution of *n*-octane in *o*-xylylene (3 in 100).

Operating conditions—

Detector: A thermal conductivity detector or hydrogen flame-ionization detector.

Column: A fused silica column 0.53 mm in inside diameter and 30 m in length, coated with dimethylpolysiloxane for gas chromatography in 3 μm thickness. Use a guard column, if necessary.

Column temperature: Maintain the temperature at 50°C for 3 minutes, raise to 100°C at a rate of 10°C per minute, then raise to 250°C at a rate of 35°C per minute, and maintain at 250°C for 8 minutes.

Injection port temperature: A constant temperature of about 250°C.

Detector temperature: A constant temperature of about 280°C.

Carrier gas: Helium.

Flow rate: 4.3 mL per minute (the retention time of the internal standard is about 10 minutes).

Split ratio: 1:40.

System suitability—

System performance: When the procedure is run with 1 – 2 μL of the standard solution under the above operating conditions, iodomethane, isopropyl iodide and the internal standard are eluted in this order with the resolution between these peaks being not less than 5.

System repeatability: When the test is repeated 6 times with 1 – 2 μL of the standard solution under the above operating conditions, the relative standard deviations of the ratio of the peak area of iodomethane and isopropyl iodide to that of the internal standard are not more than 2.0%, respectively.

◆**Containers and storage** Containers—Well-closed containers.◆

Imipramine Hydrochloride

イミプラミン塩酸塩

Change the Melting point as follows:

Melting point <2.60> 172 – 176°C (with decomposition).

Imipramine Hydrochloride Tablets


イミプラミン塩酸塩錠

Delete the Identification (3):

Add the following:

Irinotecan Hydrochloride Hydrate

イリノテカン塩酸塩水和物



$\text{C}_{33}\text{H}_{38}\text{N}_4\text{O}_6 \cdot \text{HCl} \cdot 3\text{H}_2\text{O}$: 677.18

(4*S*)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate monohydrochloride trihydrate [136572-09-3]

Irinotecan Hydrochloride Hydrate contains not less than 99.0% and not more than 102.0% of irinotecan hydrochloride ($\text{C}_{33}\text{H}_{38}\text{N}_4\text{O}_6 \cdot \text{HCl}$: 623.14), calculated on the anhydrous basis.

Description Irinotecan Hydrochloride Hydrate occurs as pale yellow to light yellow, crystals or crystalline powder.

It is sparingly soluble in methanol, and slightly soluble in water and in ethanol (99.5).

It is gradually colored to yellow-brown and decomposed by light.

Melting point: about 255°C (with decomposition).

It shows crystal polymorphism.

Identification (1) Determine the absorption spectrum of a solution of Irinotecan Hydrochloride Hydrate in methanol (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Irinotecan Hydrochloride Hydrate as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) To 1 g of Irinotecan Hydrochloride Hydrate add 50 mL of water, dissolve by heating, and cool: the solution responds to Qualitative Tests <1.09> (2) for chloride.

Optical rotation <2.49> $[\alpha]_{\text{D}}^{20}$: + 64 – + 69° (0.5 g calculated on the anhydrous basis, water, heat, after cooling, 50 mL, 100 mm).

pH <2.54> Dissolve 1 g of Irinotecan Hydrochloride Hy-

drate in 50 mL of water by heating, and cool: the pH of this solution is between 3.5 and 4.5.

Purity (1) Heavy metals <1.07>—Proceed with 2.0 g of Irinotecan Hydrochloride Hydrate according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Related substances—Dissolve 50 mg of Irinotecan Hydrochloride Hydrate in a suitable amount of a mixture of diluted 0.1 mol/L potassium dihydrogen phosphate TS (1 in 10), methanol and acetonitrile (6:4:3) and 1 mL of 1 mol/L hydrochloric acid TS, and add a mixture of diluted 0.1 mol/L potassium dihydrogen phosphate TS (1 in 10), methanol and acetonitrile (6:4:3) to make 20 mL, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add a mixture of diluted 0.1 mol/L potassium dihydrogen phosphate TS (1 in 10), methanol and acetonitrile (6:4:3) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: the peak areas of related substances A and B, having the relative retention time of about 0.8 to irinotecan, and related substances C and D, having the relative retention time of about 1.6, obtained from the sample solution are not larger than 1/5 times the peak area of irinotecan from the standard solution, and the area of the peak other than irinotecan and the peaks mentioned above from the sample solution is not larger than 1/10 times the peak area of irinotecan from the standard solution. Furthermore, the total area of the peaks other than irinotecan from the sample solution is not larger than 4/5 times the peak area of irinotecan from the standard solution.

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: Dissolve 1.22 g of sodium 1-decanesulfonate in a mixture of diluted 0.1 mol/L potassium dihydrogen phosphate TS (1 in 10), methanol and acetonitrile (6:4:3) to make 1000 mL.

Flow rate: Adjust so that the retention time of irinotecan is about 12 minutes.

Time span of measurement: About 3 times as long as the retention time of irinotecan.

System suitability—

Test for required detectability: Pipet 1 mL of the standard solution, and add a mixture of diluted 0.1 mol/L potassium dihydrogen phosphate TS (1 in 10), methanol and acetonitrile (6:4:3) to make exactly 20 mL. Confirm that the peak area of irinotecan obtained with 20 μ L of this solution

is equivalent to 3.5 to 6.5% of that with 20 μ L of the standard solution.

System performance: When the procedure is run with 20 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of irinotecan are not less than 6000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 20 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of irinotecan is not more than 2.0%.

(3) Enantiomer—Being specified separately when the drug is granted approval based on the Law.

Water <2.48> 7.5 – 9.5% (0.1 g, volumetric titration, direct titration).

Residue on ignition <2.44> Not more than 0.1% (1 g).

Assay Weigh accurately about 0.44 g of Irinotecan Hydrochloride Hydrate, dissolve in 120 mL of a mixture of acetic anhydride and acetic acid (100) (7:3), and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS
= 31.16 mg of C₃₃H₃₈N₄O₆·HCl


Containers and storage Containers—Tight containers.

Storage—Light-resistant.

Others


Related substance A:

(4S)-4,11-Diethyl-4,12-dihydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate




Related substance B:

(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 2'-hydroxy-[1,4'-bipiperidine]-1'-carboxylate




Related substance C:

(4S)-4,8,11-Triethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate



Related substance D:

(4*S*)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-yl 2'-ethoxy-[1,4'-bipiperidine]-1'-carboxylate




Isomalt Hydrate

Isomalt

イソマル水和物

Change as follows:



6-*O*- α -D-Glucopyranosyl-D-glucitol $C_{12}H_{24}O_{11}$: 344.31

1-*O*- α -D-Glucopyranosyl-D-mannitol dihydrate

$C_{12}H_{24}O_{11} \cdot 2H_2O$: 380.34

6-*O*- α -D-Glucopyranosyl-D-glucitol—1-*O*- α -D-glucopyranosyl-D-mannitol dihydrate

[64519-82-0]

This monograph is harmonized with the European Pharmacopoeia and the U.S. Pharmacopoeia.

The corresponding part of the attributes/provisions which are agreed as non-harmonized within the scope of the harmonization is marked with symbols (◆ ◆), and the corresponding parts which are agreed as the JP local requirement other than the scope of the harmonization are marked with symbols (◇ ◇).

Isomalt Hydrate is a mixture of 6-*O*- α -D-glucopyranosyl-D-sorbitol and 1-*O*- α -D-glucopyranosyl-D-mannitol.

It contains not less than 98.0% and not more than 102.0% as the mixture of 6-*O*- α -D-glucopyranosyl-D-sorbitol ($C_{12}H_{24}O_{11}$) and 1-*O*- α -D-glucopyranosyl-D-mannitol ($C_{12}H_{24}O_{11}$), calculated on the anhydrous basis, and the amount of each component is not less

than 3.0%, respectively.

The label states the contents (%) of 6-*O*- α -D-glucopyranosyl-D-sorbitol and 1-*O*- α -D-glucopyranosyl-D-mannitol.

◆**Description** Isomalt Hydrate occurs as a white, powder or grains.

It is freely soluble in water, and practically insoluble in ethanol (95).

Optical rotation $[\alpha]_D^{20}$: about + 92° (1 g calculated on the anhydrous basis, water, 100 mL, 100 mm).◆

◇**Identification** (1) To 1 mL of a solution of Isomalt Hydrate (1 in 100) add 1 mL of a solution of catechol (1 in 10) prepared before use, shake thoroughly, add 2 mL of sulfuric acid rapidly, and shake: a reddish purple to red-purple color develops.◇

(2) Perform the test with 20 μ L each of the sample solution and standard solution obtained in the Assay as directed under Liquid Chromatography <2.01> according to the following conditions, and compare the chromatograms obtained from these solutions: the two principal peaks in the chromatogram obtained from the sample solution are similar in retention time to respective two peaks from the standard solution.

Operating conditions—

Proceed as directed in the operating conditions in the Assay.

System suitability—

Proceed as directed in the system suitability in the Assay.

◇**Purity** (1) Heavy metals <1.07>—Proceed with 2.0 g of Isomalt Hydrate according to Method 1, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).◇

(2) Nickel—Weigh exactly an amount of Isomalt Hydrate, equivalent to 10.0 g calculated on the anhydrous basis, dissolve in 30 mL of 2 mol/L acetic acid TS, and add water to make exactly 100 mL. Add exactly 2 mL of a solution of ammonium pyrrolidinedithiocarbamate (1 in 100) and exactly 10 mL of water-saturated 4-methyl-2-pentanone, and shake for 30 seconds protected from light. Allow the layers to separate, and use the 4-methyl-2-pentanone layer as the sample solution. Separately, take in three vessels three exact portions of Isomalt Hydrate, each equivalent to 10.0 g calculated on the anhydrous basis, dissolve in 30 mL of 2 mol/L acetic acid TS, then add exactly 0.5 mL, 1.0 mL and 1.5 mL respectively of Standard Nickel Solution for Atomic Absorption Spectrophotometry, and add water to make them exactly 100 mL. Then, proceed in the same manner as the sample solution, and use the solutions so obtained as the standard solutions. Separately, prepare 4-methyl-2-pentanone layer by proceeding in the same manner as the sample solution but omitting the substance to be examined, and use this solution as the blank solution. Perform the test with the sample solution and standard solution as directed in the standard addition method under Atomic Absorption Spectrophotometry <2.23> according to the following conditions. The blank solution is used to set the zero of

the instrument, and to ascertain that the readings return to zero after rinsing the sample introduction system with water between each measurement: the amount of nickel is not more than 1 ppm.

Gas: Combustible gas—Acetylene.

Supporting gas—Air.

Lamp: Nickel hollow-cathode lamp.

Wavelength: 232.0 nm.

(3) Related substances—Weigh exactly 0.20 g of Isomalt Hydrate, dissolve in water to make exactly 10 mL, and use this solution as the sample solution. Separately, weigh exactly 10.0 mg of D-sorbitol and 10.0 mg of D-mannitol, dissolve in water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the peak areas of D-mannitol, having a relative retention time of about 1.6 to 1-O- α -D-glucopyranosyl-D-mannitol, and D-sorbitol, having a relative retention time of about 2.0, obtained from the sample solution are not larger than the area of the corresponding peak from the standard solution (not more than 0.5%), and the area of the peak other of 1-O- α -D-glucopyranosyl-D-mannitol and 6-O- α -D-glucopyranosyl-D-sorbitol having a relative retention time of about 1.2 and the peaks mentioned above from the sample solution is not larger than the peak area of D-sorbitol from the standard solution (not more than 0.5%). In addition, the total area of the peaks other than 1-O- α -D-glucopyranosyl-D-mannitol and 6-O- α -D-glucopyranosyl-D-sorbitol from the sample solution is not larger than 4 times the peak area of D-sorbitol from the standard solution (not more than 2.0%). However, the peaks which area is not larger than 1/5 times the peak area of D-sorbitol from the standard solution are disregarded (not more than 0.1%).

Operating conditions—

Detector, column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay.

Time span of measurement: About 2.5 times as long as the retention time of 1-O- α -D-glucopyranosyl-D-mannitol.

System suitability—

System performance: Proceed as directed in the system suitability in the Assay.

◇ Test for required detectability: Pipet 2 mL of the standard solution, and add water to make exactly 10 mL. Confirm that the peak area of D-sorbitol obtained with 20 μ L of this solution is equivalent to 14 to 26% of that with 20 μ L the standard solution.◇

◇ System repeatability: When the test is repeated 6 times with 20 μ L of the standard solution under the above operating conditions, the relative standard deviations of the peak area of D-mannitol and D-sorbitol are not more than 2.0%, respectively.◇

(4) Reducing sugars—Dissolve 3.3 g of Isomalt Hydrate in 10 mL of water with the aid of gentle heat, cool, and add 20 mL of copper (II) citrate TS. Add a few amount of boil-

ing chips, heat so that the boiling begins after 4 minutes, and maintain boiling for 3 minutes. Cool rapidly, add 100 mL of a solution of acetic acid (100) (3 in 125) and exactly 20 mL of 0.025 mol/L iodine VS. With continuous shaking, add 25 mL of a mixture of water and hydrochloric acid (47:3). When the precipitate has dissolved, titrate <2.50> the excess of iodine with 0.05 mol/L sodium thiosulfate VS, until the blue color due to 1 mL of soluble starch TS added at near of the end point disappears: not less than 12.8 mL of 0.05 mol/L sodium thiosulfate VS is required (not more than 0.3% as glucose).

Conductivity <2.51> Dissolve 20 g of Isomalt Hydrate in a suitable amount of freshly boiled and cooled water with the aid of gentle heat at 40 – 50°C, cool, add the same water to make exactly 100 mL, and use this solution as the sample solution. Measure the conductivity (25°C) of the sample solution at 25 \pm 0.1°C while gently stirring with a magnetic stirrer: not more than 20 μ S \cdot cm⁻¹.

Water <2.48> Not more than 7.0% (0.3 g, volumetric titration, direct titration. Use a mixture of methanol for water determination and formamide for water determination (1:1) heated at 50 \pm 5°C instead of methanol for water determination).

Assay Weight accurately about 0.2 g of Isomalt Hydrate, dissolve in water to make exactly 10 mL, and use this solution as the sample solution. Separately, weigh accurately about 0.2 g of Isomalt RS (separately determine the water <2.48> in the same manner as Isomalt Hydrate), dissolve in water to make exactly 10 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_{Ta} and A_{Tb} , and A_{Sa} and A_{Sb} , of 1-O- α -D-glucopyranosyl-D-mannitol and 6-O- α -D-glucopyranosyl-D-sorbitol in each solution.

$$\begin{aligned} & \text{Amount (g) of 1-O-}\alpha\text{-D-glucopyranosyl-D-mannitol} \\ & (\text{C}_{12}\text{H}_{24}\text{O}_{11}) \\ & = M_S \times K_a / 100 \times A_{Ta} / A_{Sa} \end{aligned}$$

$$\begin{aligned} & \text{Amount (g) of 6-O-}\alpha\text{-D-glucopyranosyl-D-sorbitol} \\ & (\text{C}_{12}\text{H}_{24}\text{O}_{11}) \\ & = M_S \times K_b / 100 \times A_{Tb} / A_{Sb} \end{aligned}$$

M_S : Amount (g) of Isomalt RS taken, calculated on the anhydrous basis

K_a : Content (%) of 1-O- α -D-glucopyranosyl-D-mannitol (C₁₂H₂₄O₁₁) in Isomalt RS

K_b : Content (%) of 6-O- α -D-glucopyranosyl-D-sorbitol (C₁₂H₂₄O₁₁) in Isomalt RS

Operating conditions—

Detector: A differential refractometer maintained at a constant temperature (40°C for example).

Column: Two stainless steel columns, 4.6 mm in inside diameter and 3 cm in length, and 7.8 mm in inside diameter and 30 cm in length, both packed with strongly acidic ion-

exchange resin (Ca type) for liquid chromatography with sulfonic acid groups attached to a polymer lattice consisting of polystyrene cross-linked with divinylbenzene (degree of cross-linkage: 8%) (9 μm in particle diameter). These are used as the pre-column and the separation column, respectively.

Column temperature: $80 \pm 3^\circ\text{C}$.

Mobile phase: Water.

Flow rate: 0.5 mL per minute (retention time of 1-*O*- α -D-glucopyranosyl-D-mannitol is about 12 minutes).

System suitability—

System performance: When the procedure is run with 20 μL of the standard solution under the above operating conditions, 1-*O*- α -D-glucopyranosyl-D-mannitol and 6-*O*- α -D-glucopyranosyl-D-sorbitol are eluted in this order with the resolution between these peaks being not less than 2.0.


◇System repeatability: When the test is repeated 6 times with 20 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of 1-*O*- α -D-glucopyranosyl-D-mannitol and 6-*O*- α -D-glucopyranosyl-D-sorbitol is not more than 2.0%, respectively.◇

◆**Containers and storage** Containers—Well-closed containers.◆

Add the following:

Lanoconazole

ラノコナゾール



$\text{C}_{14}\text{H}_{10}\text{ClN}_3\text{S}_2$: 319.83

(2*E*)-2-[(4*RS*)-4-(2-Chlorophenyl)-1,3-dithiolan-2-ylidene]-2-(1*H*-imidazol-1-yl)acetonitrile
[101530-10-3]

Lanoconazole, when dried, contains not less than 98.0% and not more than 102.0% of lanoconazole ($\text{C}_{14}\text{H}_{10}\text{ClN}_3\text{S}_2$).

Description Lanoconazole occurs as white to pale yellow, crystals or crystalline powder.

It is soluble in acetone, sparingly soluble in methanol and in ethanol (99.5), and practically insoluble in water.

It is gradually colored to yellow by light.

A solution of Lanoconazole in acetone (1 in 25) shows no optical rotation.

Identification (1) To 0.1 g of Lanoconazole add 0.5 g of sodium hydroxide, heat gradually to melt, and carbonize. After cooling, add 10 mL of dilute hydrochloric acid: the gas evolved darkens moistened lead (II) acetate paper.

(2) Perform the test with Lanoconazole as directed

under Flame Coloration Test <1.04> (2): a green color appears.

(3) Determine the absorption spectrum of a solution of Lanoconazole in methanol (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Lanoconazole RS prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

(4) Determine the infrared absorption spectrum of Lanoconazole, previously dried, as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of previously dried Lanoconazole RS: both spectra exhibit similar intensities of absorption at the same wave numbers.

Melting point <2.60> 141 – 146°C

Purity (1) Heavy metals <1.07>—Proceed with 2.0 g of Lanoconazole according to Method 4, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Related substances—Conduct this procedure using light-resistant vessels. Dissolve 0.10 g of Lanoconazole in 100 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 5 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: the total area of the peaks other than lanoconazole obtained from the sample solution is not larger than 1/2 times the peak area of lanoconazole from the standard solution.

Operating conditions—

Detector, column, and column temperature: Proceed as directed in the operating conditions in the Assay.

Mobile phase: Dissolve 0.576 g of sodium 1-nonanesulfonate in 1000 mL of a mixture of methanol, water and acetic acid (100) (55:44:1).

Flow rate: Adjust so that the retention time of lanoconazole is about 7 minutes.

Time span of measurement: About 3 times as long as the retention time of lanoconazole, beginning after the solvent peak.

System suitability—

Test for required detectability: Pipet 2.5 mL of the standard solution, and add methanol to make exactly 50 mL. Confirm that the peak area of lanoconazole obtained with 5 μL of this solution is equivalent to 3.5 to 6.5% of that with 5 μL of the standard solution.

System performance: Put 20 mL of the sample solution in a colorless vessel, and expose to ultraviolet light (main wavelength: 365 nm) for 30 minutes. When the procedure is run with 5 μL of this solution under the above operating conditions, the resolution between the peak having the relative retention time of about 0.8 to lanoconazole and the

peak of lanoconazole is not less than 1.5.

System repeatability: When the test is repeated 6 times with 5 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of lanoconazole is not more than 1.0%.

Loss on drying <2.41> Not more than 0.4% (1 g, 105°C, 2 hours).

Residue on ignition <2.44> Not more than 0.1% (1 g).

Assay Conduct this procedure using light-resistant vessels. Weigh accurately about 50 mg each of Lanoconazole and Lanoconazole RS, both previously dried, and dissolve each in methanol to make exactly 50 mL. Pipet 5 mL each of these solutions, add exactly 5 mL of the internal standard solution, add methanol to make 50 mL, and use these solutions as the sample solution and the standard solution, respectively. Perform the test with 5 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of lanoconazole to that of the internal standard.

$$\begin{aligned} &\text{Amount (mg) of lanoconazole (C}_{14}\text{H}_{10}\text{ClN}_3\text{S}_2) \\ &= M_S \times Q_T / Q_S \end{aligned}$$

M_S : Amount (mg) of Lanoconazole RS taken

Internal standard solution—A solution of diisopropyl 1,3-dithiolan-2-ylidenemalonate in methanol (1 in 1000).

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 295 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 50°C.

Mobile phase: A mixture of methanol and water (11:9).

Flow rate: Adjust so that the retention time of lanoconazole is about 9 minutes.

System suitability—

System performance: When the procedure is run with 5 μL of the standard solution under the above operating conditions, lanoconazole and the internal standard are eluted in this order with the resolution between these peaks being not less than 3.

System repeatability: When the test is repeated 6 times with 5 μL of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of lanoconazole to that of the internal standard is not more than 1.0%.

Containers and storage Containers—Well-closed containers.

Storage—Light-resistant.

Add the following:

Lanoconazole Cream

ラノコナゾールクリーム

Lanoconazole Cream contains not less than 95.0% and not more than 105.0% of the labeled amount of lanoconazole (C₁₄H₁₀ClN₃S₂: 319.83).

Method of preparation Prepare as directed under Creams, with Lanoconazole.

Identification Warm Lanoconazole Cream to soften, if necessary. To a quantity of Lanoconazole Cream, equivalent to 50 mg of Lanoconazole, add 10 mL of diluted hydrochloric acid (1 in 6) saturated with sodium chloride, previously warmed, shake vigorously for 15 minutes to disperse, and centrifuge. Filter the supernatant liquid, wash the residue with 1.5 mL of diluted hydrochloric acid (1 in 6) saturated with sodium chloride, filter, and combine the washing with the filtrate. To the combined filtrate add 2.5 g of sodium hydrogen carbonate to dissolve, and extract with 10 mL of diethyl ether. Wash the diethyl ether layer with three 10-mL portions of water, and dry under reduced pressure. Dissolve the residue in 15 mL of acetone, and use this solution as the sample solution. Separately, dissolve 10 mg of lanoconazole in 10 mL of acetone, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μL each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, toluene, methanol and ammonia solution (28) (400:400:20:1) to a distance of about 15 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): the principal spot obtained from the sample solution and the spot from the standard solution show the same R_f value.

Assay Conduct this procedure using light-resistant vessels. Weigh accurately a quantity of Lanoconazole Cream, equivalent to about 15 mg of lanoconazole (C₁₄H₁₀ClN₃S₂), add 80 mL of methanol, sonicate to disperse, and add exactly 10 mL of the internal standard solution. Add methanol to make 100 mL, filter through a membrane filter with a pore size of 0.45 μm if necessary, and use this solution as the sample solution. Separately, weigh accurately about 15 mg of Lanoconazole RS, previously dried at 105°C for 2 hours, dissolve in methanol, and add exactly 10 mL of the internal standard solution. Add methanol to make 100 mL, and use this solution as the standard solution. Perform the test with 10 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of lanoconazole to that of the internal standard.

$$\begin{aligned} &\text{Amount (mg) of lanoconazole (C}_{14}\text{H}_{10}\text{ClN}_3\text{S}_2) \\ &= M_S \times Q_T / Q_S \end{aligned}$$

M_S : Amount (mg) of Lanconazole RS taken

Internal standard solution—A solution of diisopropyl 1,3-dithiolan-2-ylidenemalonate in methanol (1 in 1000).

Operating conditions—

Proceed as directed in the operating conditions in the Assay under Lanconazole.

System suitability—

System performance: When the procedure is run with 10 μ L of the standard solution under the above operating conditions, lanconazole and the internal standard are eluted in this order with the resolution between these peaks being not less than 3.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of lanconazole to that of the internal standard is not more than 1.0%.

Containers and storage Containers—Tight containers.

Storage—Light-resistant.

Add the following:

Lanconazole Cutaneous Solution

ラノコナゾール外用液

Lanconazole Cutaneous Solution is a liquid for external use.

It contains not less than 95.0% and not more than 105.0% of the labeled amount of lanconazole ($C_{14}H_{10}ClN_3S_2$; 319.83).

Method of preparation Prepare as directed under Liquids and Solutions for Cutaneous Application, with Lanconazole.

Identification To a volume of Lanconazole Cutaneous Solution, equivalent to 50 mg of Lanconazole, add water enough to produce precipitate, and shake vigorously. Filter this solution, rinse the vessel with a suitable amount of water, and collect the precipitates. Wash the precipitates with 100 mL of water, dissolve in acetone, and dry under reduced pressure. If there are water droplets in the residue, dissolve the residue in 40 mL of acetone, and dry again under reduced pressure. Dissolve the residue in 30 mL of acetone, and use this solution as the sample solution. Separately, dissolve 10 mg of lanconazole in 10 mL of acetone, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, toluene, methanol and ammonia solution (28) (400:400:20:1) to a distance of about 15 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): the principal spot obtained from the sample solution and the spot from the standard so-

lution show the same R_f value.

Assay Conduct this procedure using light-resistant vessels. Pipet a volume of Lanconazole Cutaneous Solution, equivalent to about 50 mg of lanconazole ($C_{14}H_{10}ClN_3S_2$), and add methanol to make exactly 50 mL. Pipet 15 mL of this solution, add exactly 10 mL of the internal standard solution, add methanol to make 100 mL, and use this solution as the sample solution. Separately, weigh accurately about 15 mg of Lanconazole RS, previously dried at 105°C for 2 hours, dissolve in methanol, and add exactly 10 mL of the internal standard solution. Add methanol to make 100 mL, and use this solution as the standard solution. Perform the test with 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of lanconazole to that of the internal standard.

$$\begin{aligned} & \text{Amount (mg) of lanconazole (C}_{14}\text{H}_{10}\text{ClN}_3\text{S}_2) \\ & = M_S \times Q_T / Q_S \times 10/3 \end{aligned}$$

M_S : Amount (mg) of Lanconazole RS taken

Internal standard solution—A solution of diisopropyl 1,3-dithiolan-2-ylidenemalonate in methanol (1 in 1000).

Operating conditions—

Proceed as directed in the operating conditions in the Assay under Lanconazole.

System suitability—

System performance: When the procedure is run with 10 μ L of the standard solution under the above operating conditions, lanconazole and the internal standard are eluted in this order with the resolution between these peaks being not less than 3.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of lanconazole to that of the internal standard is not more than 1.0%.

Containers and storage Containers—Tight containers.

Storage—Light-resistant.

Add the following:

Lanconazole Ointment

ラノコナゾール軟膏

Lanconazole Ointment contains not less than 93.0% and not more than 107.0% of the labeled amount of lanconazole ($C_{14}H_{10}ClN_3S_2$; 319.83).

Method of preparation Prepare as directed under Ointments, with Lanconazole.

Identification To a quantity of Lanconazole Ointment, equivalent to 50 mg of Lanconazole, add 15 mL of hexane, sonicate to disperse, add 10 mL of methanol, and shake for 10 minutes. Centrifuge this solution, discard the hexane

layer, and take the methanol layer. Wash the residue with a small amount of methanol if necessary, and combine the washing with the methanol layer. Dry the combined methanol layer under reduced pressure, dissolve the residue in 40 mL of acetone, and use this solution as the sample solution. Separately, dissolve 10 mg of lanoconazole in 10 mL of acetone, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, toluene, methanol and ammonia solution (28) (400:400:20:1) to a distance of about 15 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): the principal spot obtained from the sample solution and the spot from the standard solution show the same R_f value.

Assay Conduct this procedure using light-resistant vessels. Weigh accurately a quantity of Lanoconazole Ointment, equivalent to about 15 mg of lanoconazole ($C_{14}H_{10}ClN_3S_2$), add 20 mL of tetrahydrofuran, sonicate to disperse, and add exactly 10 mL of the internal standard solution. Add methanol to make 100 mL, and use this solution as the sample solution. Separately, weigh accurately about 15 mg of Lanoconazole RS, previously dried at 105°C for 2 hours, dissolve in methanol, and add exactly 10 mL of the internal standard solution. Add methanol to make 100 mL, and use this solution as the standard solution. Perform the test with 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of lanoconazole to that of the internal standard.

$$\begin{aligned} \text{Amount (mg) of lanoconazole (C}_{14}\text{H}_{10}\text{ClN}_3\text{S}_2) \\ = M_S \times Q_T/Q_S \end{aligned}$$

M_S : Amount (mg) of Lanoconazole RS taken

Internal standard solution—A solution of diisopropyl 1,3-dithiolan-2-ylidenemalonate in methanol (1 in 1000).

Operating conditions—

Proceed as directed in the operating conditions in the Assay under Lanoconazole.

System suitability—

System performance: When the procedure is run with 10 μ L of the standard solution under the above operating conditions, lanoconazole and the internal standard are eluted in this order with the resolution between these peaks being not less than 3.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of lanoconazole to that of the internal standard is not more than 1.0%.

Containers and storage Containers—Tight containers.

Storage—Light-resistant.

Mestranol

メストラノール

Change the Description and Optical rotation as follows:

Description Mestranol occurs as a white to pale yellow-white crystalline powder. It is odorless.

It is freely soluble in chloroform, sparingly soluble in ethanol (99.5), and practically insoluble in water.

Optical rotation <2.49> $[\alpha]_D^{25}$: +1 – +6° (after drying, 0.1 g, ethanol (99.5), 10 mL, 100 mm).

Change the following as follows:

Methylcellulose

メチルセルロース

[9004-67-5]

This monograph is harmonized with the European Pharmacopoeia and the U.S. Pharmacopoeia.

The corresponding part of the attributes/provisions which are agreed as non-harmonized within the scope of the harmonization is marked with symbols (◆ ◆), and the corresponding parts which are agreed as the JP local requirement other than the scope of the harmonization are marked with symbols (◇ ◇).

Methylcellulose is a methyl ether of cellulose.

It contains not less than 26.0% and not more than 33.0% of methoxy group ($-OCH_3$: 31.03), calculated on the dried basis.

The viscosity of Methylcellulose is shown in millipascal second ($mPa \cdot s$).

◆**Description** Methylcellulose occurs as a white to yellowish white, powder or grains.

It is practically insoluble in ethanol (99.5).

It swells, when water is added, and forms a clear or slightly turbid, viscous liquid.◆

Identification (1) Disperse evenly 1.0 g of Methylcellulose over the surface of 100 mL of water in a beaker, while gently tapping the top of the beaker, if necessary, and allow the beaker to stand: it aggregates on the surface of water.

(2) Add 1.0 g of Methylcellulose to 100 mL of hot water, and stir: it becomes a suspension. Cool the suspension to 5°C, and stir: the resulting liquid is a clear or a slightly cloudy, viscous fluid.

(3) To 0.1 mL of the viscous fluid obtained in (2) add 9 mL of diluted sulfuric acid (9 in 10), shake, heat in a water bath for exactly 3 minutes, and immediately cool in ice water. Add carefully 0.6 mL of ninhydrin TS, shake, and allow to stand at 25°C: the solution shows a red color, and

it does not change to purple color within 100 minutes.

(4) Pour and spread out 2 to 3 mL of the viscous fluid obtained in (2) onto a glass plate, and allow the water to evaporate: a transparent film results.

(5) Pipet 50 mL of water, add exactly 50 mL of the viscous fluid obtained in (2), and warm to raise the temperature at a rate of 2 to 5°C per minute while stirring: the temperature, when a white turbidity of the solution starts to increase, is not less than 50°C.

Viscosity <2.53> (i) Method I: Apply to Methylcellulose having a labeled viscosity of less than 600 mPa·s. Put an exact amount of Methylcellulose, equivalent to 4.000 g, calculated on the dried basis, in a tared, wide-mouth bottle, add water (between 90°C and 99°C) to make 200 g, stopper the bottle, stir by mechanical means at 350 to 450 revolutions per minute for 10 to 20 minutes to get a homogeneous dispersion. If necessary, take off the sample attached on the walls of the bottle, put them in the dispersed solution, and dissolve by continuing the stirring in a water bath at not exceeding 5°C for 20 to 40 minutes. Add cold water, if necessary, to make 200 g, and use this solution as the sample solution. Centrifuge the solution if necessary to expel any entrapped air bubbles. Perform the test with the sample solution at 20 ± 0.1°C as directed in Method I under Viscosity Determination: not less than 80% and not more than 120% of the labeled viscosity.

(ii) Method II: Apply to Methylcellulose having a labeled viscosity of not less than 600 mPa·s. Put an exact amount of Methylcellulose, equivalent to 10.00 g, calculated on the dried basis, in a tared, wide-mouth bottle, add water (between 90°C and 99°C) to make 500 g, and prepare the sample solution in the same manner as directed in Method I. Perform the test with the sample solution at 20 ± 0.1°C as directed in Method II under Viscosity Determination, using a single cylinder-type rotational viscometer, according to the following operating conditions: not less than 75% and not more than 140% of the labeled viscosity.
Operating conditions—

Apparatus: Brookfield type viscometer LV model or an equivalent apparatus.

Rotor No., rotation frequency, and calculation multiplier: According to the following table, depending on the labeled viscosity.

Labeled viscosity (mPa·s)	Rotor No.	Rotation frequency /min	Calculation multiplier
Not less than 600 and less than 1400	3	60	20
" 1400 "	3500	3	12
" 3500 "	9500	4	60
" 9500 "	99,500	4	6
" 99,500 "	4	3	2000

Procedure of apparatus: Read the value after 2 minutes of rotation, and stop the rotation for at least 2 minutes. Repeat this procedure more two times, and average the three observed values.

pH <2.54> The pH of the sample solution obtained in the Viscosity, measured after 5 minutes immersing the electrode in the sample solution, is between 5.0 and 8.0.

◇**Purity** Heavy metals—Put 1.0 g of Methylcellulose in a 100-mL Kjeldahl flask, add a sufficient amount of a mixture of nitric acid and sulfuric acid (5:4) to wet the sample, and heat gently. Repeat this procedure until to use totally 18 mL of the mixture of nitric acid and sulfuric acid (5:4). Then boil gently until the solution changes to black. After cooling, add 2 mL of nitric acid, and heat until the solution changes to black. Repeat this procedure until the solution no longer changes to black, and heat strongly until dense white fumes are evolved. After cooling, add 5 mL of water, boil gently until dense white fumes are evolved, then heat until the volume of the solution becomes to 2 to 3 mL. After cooling, if the solution reveals yellow color by addition of 5 mL of water, add 1 mL of hydrogen peroxide (30), and heat until the volume of the solution becomes to 2 to 3 mL. After cooling, dilute the solution with 2 to 3 mL of water, transfer to a Nessler tube, add water to make 25 mL, and use this solution as the sample solution. Separately, put 2.0 mL of Standard Lead Solution in a 100-mL Kjeldahl flask, add 18 mL of the mixture of nitric acid and sulfuric acid (5:4) and an amount of nitric acid equal to that used for preparation of the sample solution, and heat until dense white fumes are evolved. After cooling, add 10 mL of water. In the case where hydrogen peroxide (30) is added for the preparation of the sample solution, add the same amount of hydrogen peroxide (30), then proceed in the same manner for preparation of the sample solution, and use so obtained solution as the control solution. Adjust the sample solution and the control solution to pH 3.0 to 4.0 with ammonia solution (28), and add water to make 40 mL, respectively. To these solutions add 1.2 mL of thioacetamide-alkaline glycerin TS, 2 mL of acetate buffer solution (pH 3.5) and water to make 50 mL, separately. After allowing to stand for 5 minutes, observe vertically both tubes on a white background: the color obtained with the sample solution is not more intense than that with the control solution (not more than 20 ppm).◇

Loss on drying <2.41> Not more than 5.0% (1 g, 105°C, 1 hour).

Residue on ignition <2.44> Not more than 1.5% (1 g).

Assay (i) Apparatus—Reaction vial: A 5-mL pressure-tight serum vial, having 20 mm in outside diameter and 50 mm in height, the neck 20 mm in outside diameter and 13 mm in inside diameter, equipped with a septum of butyl-rubber processed the surface with fluoroplastics, which can be fixed tightly to vial with aluminum cap, or equivalent.

Heater: A square-shaped aluminum block, having holes 20 mm in diameter and 32 mm in depth, adopted to the reaction vial. Capable of stirring the content of the reaction vial by means of magnetic stirrer or of reciprocal shaker about 100 times per minute.

(ii) Procedure—Weigh accurately about 65 mg of Methylcellulose, transfer to the reaction vial, add 60 to 100

mg of adipic acid, 2.0 mL of the internal standard solution and 2.0 mL of hydroiodic acid, immediately stopper the vial tightly, and weigh accurately. Using a magnetic stirrer equipped in the heating module, or using a shaker, stir for 60 minutes while heating so that the temperature of the vial content is $130 \pm 2^\circ\text{C}$. In the case when a magnetic stirrer or shaker is not available, heat for 30 minutes with repeated shaking at 5-minute intervals by hand, and continue heating for an additional 30 minutes. Allow the vial to cool, and again weigh accurately. If the mass loss is not more than 26 mg and there is no evidence of a leak of the content, use the upper layer of the mixture as the sample solution. Separately, put 60 to 100 mg of adipic acid, 2.0 mL of the internal standard solution and 2.0 mL of hydroiodic acid in a reaction vial, immediately stopper the vial tightly, and weigh accurately. Add 45 μL of iodomethane for assay through the septum using a micro-syringe, weigh accurately, shake, and use the upper layer of the mixture as the standard solution. Perform the test with 1 to 2 μL each of the sample solution and standard solution as directed under Gas Chromatography <2.02> according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of iodomethane to that of the internal standard.

$$\begin{aligned} \text{Content (\% of methoxy group (CH}_3\text{O)} \\ = M_S/M \times Q_T/Q_S \times 21.86 \end{aligned}$$

M_S : Amount (mg) of iodomethane for assay taken

M : Amount (mg) of Methylcellulose taken, calculated on the dried basis

Internal standard solution—A solution of *n*-octane in *o*-xylene (3 in 100).

Operating conditions—

Detector: A thermal conductivity detector or hydrogen flame-ionization detector.

Column: A fused silica column 0.53 mm in inside diameter and 30 m in length, coated with dimethylpolysiloxane for gas chromatography in 3 μm thickness. Use a guard column, if necessary.

Column temperature: Maintain the temperature at 50°C for 3 minutes, raise to 100°C at a rate of 10°C per minute, then raise to 250°C at a rate of 35°C per minute, and maintain at 250°C for 8 minutes.

Injection port temperature: A constant temperature of about 250°C .

Detector temperature: A constant temperature of about 280°C .

Carrier gas: Helium.

Flow rate: 4.3 mL per minute (the retention time of the internal standard is about 10 minutes).

Split ratio: 1:40.

System suitability—

System performance: When the procedure is run with 1 – 2 μL of the standard solution under the above operating conditions, iodomethane and the internal standard are eluted in this order with the resolution between these peaks being not less than 5

System repeatability: When the test is repeated 6 times

with 1 – 2 μL of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of iodomethane to that of the internal standard is not more than 2.0%.

◆**Containers and storage** Containers—Well-closed containers.◆

Methylprednisolone

メチルプレドニゾロン

Change the Description and Optical rotation as follows:

Description Methylprednisolone occurs as a white crystalline powder. It is odorless.

It is sparingly soluble in methanol and in ethanol (99.5), and practically insoluble in water.

Melting point: $232 - 240^\circ\text{C}$ (with decomposition).

Optical rotation <2.49> $[\alpha]_D^{25}$: $+93 - +103^\circ$ (after drying, 0.1 g, ethanol (99.5), 10 mL, 100 mm).

Add the following:

Minocycline Hydrochloride Granules

ミノサイクリン塩酸塩顆粒

Minocycline Hydrochloride Granules contain not less than 90.0% and not more than 110.0% of the labeled potency of minocycline ($\text{C}_{23}\text{H}_{27}\text{N}_3\text{O}_7$; 457.48).

Method of preparation Prepare as directed under Granules, with Minocycline Hydrochloride.

Identification To a quantity of Minocycline Hydrochloride Granules, equivalent to 10 mg (potency) of Minocycline Hydrochloride, add 625 mL of a solution of hydrochloric acid in methanol (19 in 20,000), shake thoroughly, and filter. Determine the absorption spectrum of the filtrate as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 221 nm and 225 nm, between 261 nm and 265 nm, and between 354 nm and 358 nm.

Purity Related substances—Conduct this procedure within 30 minutes after the preparation of the sample solution. To a quantity of Minocycline Hydrochloride Granules, equivalent to 50 mg (potency) of Minocycline Hydrochloride, add 60 mL of the mobile phase, shake vigorously, add the mobile phase to make 100 mL. Centrifuge this solution, and use the supernatant liquid as the sample solution. Perform the test with 20 μL of the sample solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic in-

tegration method, and calculate their amounts by the area percentage method: the amount of the peak of epiminocycline, having the relative retention time of about 0.83 to minocycline, is not more than 4.0%.

Operating conditions—

Detector, column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay under Minocycline Hydrochloride.

Time span of measurement: About 2.5 times as long as the retention time of minocycline, beginning after the solvent peak.

System suitability—

System performance: Proceed as directed in the system suitability in the Assay under Minocycline Hydrochloride.

Test for required detectability: To 2 mL of the standard solution obtained in the Assay add the mobile phase to make 100 mL, and use this solution as the solution for system suitability test. Pipet 5 mL of the solution for system suitability test, and add the mobile phase to make exactly 100 mL. Confirm that the peak area of minocycline obtained with 20 μ L of this solution is equivalent to 3.5 to 6.5% of that with 20 μ L of the solution for system suitability test.

System repeatability: When the test is repeated 6 times with 20 μ L of the solution for system suitability test under the above operating conditions, the relative standard deviation of the peak area of minocycline is not more than 2.0%.

Water <2.48> Not more than 2.0% (4 g of powdered Minocycline Hydrochloride Granules, volumetric titration, back titration).

Uniformity of dosage units <6.02> Perform the test according to the following method: Minocycline Hydrochloride Granules in single-dose packages meet the requirement of the Content uniformity test.

To the total content of 1 package of Minocycline Hydrochloride Granules add water to disintegrate, shake thoroughly, add water to make exactly 100 mL, and filter through a membrane filter with a pore size not exceeding 0.45 μ m. Discard the first 10 mL of the filtrate, pipet V mL of the subsequent filtrate, add water to make exactly V' mL so that each mL contains about 20 μ g (potency) of minocycline ($C_{23}H_{27}N_3O_7$), and use this solution as the sample solution. Separately, weigh accurately an amount of Minocycline Hydrochloride RS, equivalent to about 20 mg (potency), dissolve in water to make exactly 100 mL. Pipet 5 mL of this solution, add water to make exactly 50 mL, and use this solution as the standard solution. Determine the absorbances, A_T and A_S , of the sample solution and standard solution at 348 nm as directed under Ultraviolet-visible Spectrophotometry <2.24>.

$$\begin{aligned} &\text{Amount [mg (potency)] of minocycline } (C_{23}H_{27}N_3O_7) \\ &= M_S \times A_T/A_S \times V'/V \times 1/10 \end{aligned}$$

M_S : Amount [mg (potency)] of Minocycline Hydrochloride RS taken

Dissolution <6.10> When the test is performed at 50 revo-

lutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate in 15 minutes of Minocycline Hydrochloride Granules is not less than 85%.

Start the test with an accurately weighed amount of Minocycline Hydrochloride Granules, equivalent to about 20 mg (potency) of Minocycline Hydrochloride, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45 μ m. Discard not less than 10 mL of the first filtrate, and use the subsequent filtrate as the sample solution. Separately, weigh accurately an amount of Minocycline Hydrochloride RS, equivalent to about 22 mg (potency), and dissolve in water to make exactly 100 mL. Pipet 5 mL of this solution, add water to make exactly 50 mL, and use this solution as the standard solution. Determine the absorbances, A_T and A_S , of the sample solution and standard solution at 348 nm as directed under Ultraviolet-visible Spectrophotometry <2.24>.

Dissolution rate (%) with respect to the labeled amount of minocycline ($C_{23}H_{27}N_3O_7$)

$$= M_S/M_T \times A_T/A_S \times 1/C \times 90$$

M_S : Amount [mg (potency)] of Minocycline Hydrochloride RS taken

M_T : Amount (g) of Minocycline Hydrochloride Granules taken

C : Labeled amount [mg (potency)] of minocycline ($C_{23}H_{27}N_3O_7$) in 1 g

Assay Weigh accurately an amount of powdered Minocycline Hydrochloride Granules, equivalent to about 50 mg (potency) of Minocycline Hydrochloride, add the mobile phase, shake vigorously, and add the mobile phase to make exactly 100 mL. Centrifuge this solution, and use the supernatant liquid as the sample solution. Separately, weigh accurately an amount of Minocycline Hydrochloride RS, equivalent to about 25 mg (potency), dissolve in the mobile phase to make exactly 50 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Minocycline Hydrochloride.

$$\begin{aligned} &\text{Amount [mg (potency)] of minocycline } (C_{23}H_{27}N_3O_7) \\ &= M_S \times A_T/A_S \times 2 \end{aligned}$$

M_S : Amount [mg (potency)] of Minocycline Hydrochloride RS taken

Containers and storage Containers—Tight containers.

Storage—Light-resistant.

Add the following:

Nortriptyline Hydrochloride Tablets

ノルトリプチリン塩酸塩錠

Nortriptyline Hydrochloride Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of nortriptyline ($C_{19}H_{21}N$; 263.38).

Method of preparation Prepare as directed under Tablets, with Nortriptyline Hydrochloride.

Identification (1) Determine the absorption spectrum of the sample solution obtained in the Assay as directed under Ultraviolet-visible Spectrophotometry <2.24>, using diluted 0.1 mol/L hydrochloric acid TS (1 in 50) as the blank: it exhibits a maximum between 237 nm and 241 nm.

(2) To a quantity of powdered Nortriptyline Hydrochloride Tablets, equivalent to 10 mg of nortriptyline ($C_{19}H_{21}N$), add 10 mL of ethanol (99.5), shake thoroughly, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 11 mg of nortriptyline hydrochloride in 10 mL of ethanol (99.5), and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of 1-butanol, water and acetic acid (100) (4:1:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): the principal spot obtained from the sample solution and the spot from the standard solution show the same *R_f* value.

Uniformity of dosage units <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Nortriptyline Hydrochloride Tablets add a suitable volume of 0.1 mol/L hydrochloric acid TS, disperse the fine particles by sonicating, add a suitable volume of 0.1 mol/L hydrochloric acid TS, sonicate, extract for 15 minutes while occasional shaking. Shake for 15 minutes, and add 0.1 mol/L hydrochloric acid TS to make exactly *V* mL so that each mL contains about 0.5 mg of nortriptyline ($C_{19}H_{21}N$). Centrifuge this solution, pipet 2 mL of the supernatant liquid, add water to make exactly 100 mL, and use this solution as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} & \text{Amount (mg) of nortriptyline (C}_{19}\text{H}_{21}\text{N)} \\ & = M_S \times A_T/A_S \times V/50 \times 0.878 \end{aligned}$$

M_S: Amount (mg) of nortriptyline hydrochloride for assay taken

Dissolution <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution

rates in 30 minutes of a 10-mg tablet and a 25-mg tablet are not less than 70% and not less than 80%, respectively.

Start the test with 1 tablet of Nortriptyline Hydrochloride Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45 μ m. Discard not less than 10 mL of the first filtrate, pipet *V* mL of the subsequent filtrate, add water to make exactly *V'* mL so that each mL contains about 11 μ g of nortriptyline ($C_{19}H_{21}N$), and use this solution as the sample solution. Separately, weigh accurately about 25 mg of nortriptyline hydrochloride for assay, previously dried at 105°C for 2 hours, and dissolve in water to make exactly 100 mL. Pipet 5 mL of this solution, add water to make exactly 100 mL, and use this solution as the standard solution. Determine the absorbances, *A_T* and *A_S*, of the sample solution and standard solution at 239 nm as directed under Ultraviolet-visible Spectrophotometry <2.24>.

Dissolution rate (%) with respect to the labeled amount of nortriptyline ($C_{19}H_{21}N$)

$$= M_S \times A_T/A_S \times V'/V \times 1/C \times 45 \times 0.878$$

M_S: Amount (mg) of nortriptyline hydrochloride for assay taken

C: Labeled amount (mg) of nortriptyline ($C_{19}H_{21}N$) in 1 tablet

Assay Weigh accurately the mass of not less than 20 tablets of Nortriptyline Hydrochloride Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 50 mg of nortriptyline ($C_{19}H_{21}N$), add 50 mL of 0.1 mol/L hydrochloric acid TS, sonicate, and extract for 15 minutes while occasional shaking. Shake for 15 minutes, and add 0.1 mol/L hydrochloric acid TS to make exactly 100 mL. Centrifuge this solution, pipet 2 mL of the supernatant liquid, add water to make exactly 100 mL, and use this solution as the sample solution. Separately, weigh accurately about 28 mg of nortriptyline hydrochloride for assay, previously dried at 105°C for 2 hours, and dissolve in 0.1 mol/L hydrochloric acid TS to make exactly 50 mL. Pipet 2 mL of this solution, add water to make exactly 100 mL, and use this solution as the standard solution. Determine the absorbances, *A_T* and *A_S*, of the sample solution and standard solution at 239 nm as directed under Ultraviolet-visible Spectrophotometry <2.24>, using diluted 0.1 mol/L hydrochloric acid TS (1 in 50) as the blank.

$$\begin{aligned} & \text{Amount (mg) of nortriptyline (C}_{19}\text{H}_{21}\text{N)} \\ & = M_S \times A_T/A_S \times 2 \times 0.878 \end{aligned}$$

M_S: Amount (mg) of nortriptyline hydrochloride for assay taken

Containers and storage Containers—Tight containers.

Pioglitazone Hydrochloride and Glimepiride Tablets

ピオグリタゾン塩酸塩・グリメピリド錠

Change the Identification (2) as follows:


Identification

(2) Wash the membrane filter obtained in (1) with 100 mL of 0.1 mol/L hydrochloric acid TS, and extract with methanol so that each mL contains about 10 µg of glimepiride (C₂₄H₃₄N₄O₅S). Determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 227 nm and 231 nm.

Add the following:

Polaprezinc

ポラプレジンク



(C₉H₁₂N₄O₃Zn)_n

catena-Poly{zinc-μ-[β-alanyl-L-histidinato(2-)-N,N',O:N^T]}

[107667-60-7]

Polaprezinc contains not less than 98.0% and not more than 102.0% of polaprezinc (C₉H₁₂N₄O₃Zn: 289.60), and contains not less than 21.5% and not more than 23.0% of zinc (Zn: 65.38), calculated on the anhydrous basis.

Description Polaprezinc occurs as a white to pale yellow-white crystalline powder.

It is practically insoluble in water, in methanol and in ethanol (99.5).

It dissolves in dilute hydrochloric acid.

Identification (1) To 2 mL of a solution of Polaprezinc in 0.2 mol/L hydrochloric acid TS (1 in 1000) add 0.5 mL of a solution of sulfanilic acid in 1 mol/L hydrochloric acid TS (1 in 200), 0.5 mL of a solution of sodium nitrite (1 in 20) and 3 mL of sodium carbonate TS: a red color is produced.

(2) A solution of Polaprezinc in 0.2 mol/L hydrochloric acid TS (1 in 1000) responds to Qualitative Tests <1.09> for zinc salt.

(3) Determine the infrared absorption spectrum of Polaprezinc as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

Optical rotation <2.49> [α]_D²⁰: +8 – +9° (1 g calculated on the anhydrous basis, 3 mol/L hydrochloric acid TS, 50 mL, 100 mm).

Purity (1) Lead—Weigh accurately about 0.5 g of Polaprezinc, dissolve in 3 mL of dilute nitric acid, add water to make exactly 10 mL, and use this solution as the sample solution. Separately, pipet 0.5 mL, 1.0 mL, 1.5 mL and 2.0 mL of Standard Lead Solution, to each solution add 3 mL of dilute nitric acid and water to make exactly 10 mL, and use these solutions as the standard solutions. Perform the test with the sample solution and standard solutions as directed under Atomic Absorption Spectrophotometry <2.23> according to the following conditions, and calculate the amount of lead in the sample solution using a calibration curve obtained from the absorbances of the standard solutions: not more than 10 ppm.

Gas: Combustible gas—Acetylene.

Supporting gas—Air.

Lamp: Lead hollow-cathode lamp.

Wavelength: 283.3 nm.

(2) Related substances—Dissolve 50 mg of Polaprezinc in 10 mL of 0.1 mol/L hydrochloric acid TS, add the mobile phase to make 100 mL, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10 µL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: the peak area of L-histidine, having the relative retention time of about 0.38 to L-carnosine, obtained from the sample solution is not larger than 1/5 times of the peak area of L-carnosine from the standard solution, the area of the peak other than L-carnosine and the peak mentioned above from the sample solution is not larger than 1/10 times of the peak area of L-carnosine from the standard solution. Furthermore, the total area of the peaks other than L-carnosine from the sample solution is not larger than the peak area of L-carnosine from the standard solution.

Operating conditions—

Detector, column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay.

Time span of measurement: About 4 times as long as the retention time of L-carnosine, beginning after the solvent peak.

System suitability—

Test for required detectability: Pipet 2 mL of the standard solution, add the mobile phase to make exactly 20 mL. Confirm that the peak area of L-carnosine obtained with 10 µL of this solution is equivalent to 7 to 13% of that with 10 µL of the standard solution.

System performance: Dissolve 50 mg each of Polaprezinc and L-histidine in 10 mL of 0.1 mol/L hydrochloric acid TS, and add the mobile phase to make 100 mL. When the procedure is run with 10 µL of this solution under the above

operating conditions, L-histidine and L-carnosine are eluted in this order with the resolution between these peaks being not less than 12.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of L-carnosine is not more than 2.0%.

Water <2.48> Not more than 5.0% (0.2 g, volumetric titration, direct titration, stir for 30 minutes).

Assay (1) Polaprezinc—Weigh accurately about 25 mg of Polaprezinc, dissolve in 5 mL of 0.1 mol/L hydrochloric acid TS, add the mobile phase to make exactly 100 mL, and use this solution as the sample solution. Separately, weigh accurately about 20 mg of L-Carnosine RS, previously dried at 105°C for 3 hours, dissolve in 5 mL of 0.1 mol/L hydrochloric acid TS, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine the peak areas, A_T and A_S , of L-carnosine in each solution.

$$\begin{aligned} \text{Amount (mg) of polaprezinc (C}_9\text{H}_{12}\text{N}_4\text{O}_3\text{Zn)} \\ = M_S \times A_T / A_S \times 1.292 \end{aligned}$$

M_S : Amount (mg) of L-Carnosine RS taken

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 210 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 45°C.

Mobile phase: Dissolve 1.4 g of potassium dihydrogen phosphate in 1000 mL of water, adjust to pH 3.5 with diluted phosphoric acid (1 in 100). Dissolve 2 g of sodium 1-octane sulfonate in 900 mL of this solution, and add 100 mL of acetonitrile for liquid chromatography.

Flow rate: Adjust so that the retention time of L-carnosine is about 15 minutes.

System suitability—

System performance: Dissolve 5 mg of L-histidine in 20 mL of the standard solution. When the procedure is run with 10 μ L of this solution under the above operating conditions, L-histidine and L-carnosine are eluted in this order with the resolution between these peaks being not less than 12.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of L-carnosine is not more than 1.0%.

(2) Zinc—Weigh accurately about 0.2 g of Polaprezinc, dissolve in 3 mL of dilute hydrochloric acid, and add water to make exactly 100 mL. Pipet 25 mL of this solution, add 10 mL of ammonia-ammonium chloride buffer solution (pH

10.7), and titrate <2.50> with 0.01 mol/L disodium dihydrogen ethylenediamine tetraacetate VS (indicator: 40 mg of eriochrome black T-sodium chloride indicator).

$$\begin{aligned} \text{Each mL of 0.01 mol/L disodium dihydrogen} \\ \text{ethylenediamine tetraacetate VS} \\ = 0.6538 \text{ mg Zn} \end{aligned}$$

Containers and storage Containers—Tight containers.

Add the following:

Polaprezinc Granules

ポラプレジンク顆粒

Polaprezinc Granules contain not less than 95.0% and not more than 105.0% of the labeled amount of polaprezinc [(C₉H₁₂N₄O₃Zn)_n].

Method of preparation Prepare as directed under Granules, with Polaprezinc.

Identification (1) To a quantity of Polaprezinc Granules, equivalent to 20 mg of Polaprezinc, add 20 mL of 0.2 mol/L hydrochloric acid TS, shake for 10 minutes, centrifuge, and use the supernatant liquid as the sample solution. To 2 mL of the sample solution add 0.5 mL of a solution of sulfanilic acid in 1 mol/L hydrochloric acid TS (1 in 200), 0.5 mL of a solution of sodium nitrite (1 in 20) and 3 mL of sodium carbonate TS: a red color develops.

(2) The sample solution obtained in (1) responds to Qualitative Tests <1.09> for zinc salt.

Uniformity of dosage units <6.02> Perform the test according to the following method: Polaprezinc Granules in single-dose packages meet the requirement of the Content uniformity test.

To the total content of 1 package of Polaprezinc Granules add exactly V mL of 0.2 mol/L hydrochloric acid TS so that each mL contains about 5 mg of polaprezinc [(C₉H₁₂N₄O₃Zn)_n], shake vigorously for 10 minutes, and centrifuge. Pipet 5 mL of the supernatant liquid, add exactly 5 mL of the internal standard solution, add the mobile phase to make 50 mL, and use this solution as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} \text{Amount (mg) of polaprezinc [(C}_9\text{H}_{12}\text{N}_4\text{O}_3\text{Zn)}_n] \\ = M_S \times Q_T / Q_S \times V / 5 \times 1.292 \end{aligned}$$

M_S : Amount (mg) of L-Carnosine RS taken

Dissolution <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of 0.05 mol/L acetic acid-sodium acetate buffer solution (pH 4.0) as the dissolution medium, the dissolution rate in 15 minutes of Polaprezinc Granules is not less than 80%.

Start the test with an accurately weighed amount of Polaprezinc Granules, equivalent to about 75 mg of polaprezinc [(C₉H₁₂N₄O₃Zn)_n], withdraw not less than 20

mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45 μm . Discard not less than 10 mL of the first filtrate, pipet 1 mL of the subsequent filtrate, add diluted nitric acid (77 in 10,000) to make exactly 25 mL, and use this solution as the sample solution. Separately, pipet suitable volumes of Standard Zinc Stock Solution, to each solution add diluted nitric acid (77 in 10,000) so that each mL contains 0.4 to 0.8 μg of zinc (Zn: 65.38), and use these solutions as the standard solutions. Perform the test with the sample solution and standard solutions as directed under Atomic Absorption Spectrophotometry <2.23> according to the following conditions, and calculate the amount of zinc in the sample solution using a calibration curve obtained from the absorbances of the standard solutions.

Dissolution rate (%) with respect to the labeled amount of polaprezinc $[(\text{C}_9\text{H}_{12}\text{N}_4\text{O}_3\text{Zn})_n]$

$$= \text{Content } (\mu\text{g}/\text{mL}) \text{ of zinc in the sample solution} / M_T \times 1/C \times 2250 \times 4.429$$

M_T : Amount (g) of Polaprezinc Granules taken

C: Labeled amount (mg) of polaprezinc $[(\text{C}_9\text{H}_{12}\text{N}_4\text{O}_3\text{Zn})_n]$ in 1 g

Gas: Combustible gas—Acetylene.

Supporting gas—Air.

Lamp: Zinc hollow-cathode lamp.

Wavelength: 213.9 nm.

Assay Weigh accurately an amount of Polaprezinc Granules, equivalent to about 0.1 g of polaprezinc $[(\text{C}_9\text{H}_{12}\text{N}_4\text{O}_3\text{Zn})_n]$, add exactly 20 mL of 0.2 mol/L hydrochloric acid TS, shake vigorously for 10 minutes, and centrifuge. Pipet 5 mL of the supernatant liquid, add exactly 5 mL of the internal standard solution, add the mobile phase to make 50 mL, and use this solution as the sample solution. Separately, weigh accurately about 20 mg of L-Carnosine RS, previously dried at 105°C for 3 hours, dissolve in 5 mL of 0.2 mol/L hydrochloric acid TS, add exactly 5 mL of the internal standard solution, add the mobile phase to make 50 mL, and use this solution as the standard solution. Perform the test with 5 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of L-carnosine to that of the internal standard.

$$\begin{aligned} &\text{Amount (mg) of polaprezinc } [(\text{C}_9\text{H}_{12}\text{N}_4\text{O}_3\text{Zn})_n] \\ &= M_S \times Q_T / Q_S \times 4 \times 1.292 \end{aligned}$$

M_S : Amount (mg) of L-Carnosine RS taken

Internal standard solution—Dissolve 0.25 g of 4-aminoacetophenone in 5 mL of acetonitrile, and add the mobile phase to make 100 mL.

Operating conditions—

Proceed as directed in the operating conditions in the Assay (1) under Polaprezinc.

System suitability—

System performance: When the procedure is run with 5 μL of the standard solution under the above operating conditions, 4-aminoacetophenone and L-carnosine are eluted in this order with the resolution between these peaks being not less than 6.

System repeatability: When the test is repeated 6 times with 5 μL of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of L-carnosine to that of the internal standard is not more than 1.0%.

Containers and storage Containers—Tight containers.

Add the following:

Ritodrine Hydrochloride Injection

リトドリン塩酸塩注射液

Ritodrine Hydrochloride Injection is an aqueous injection.

It contains not less than 95.0% and not more than 105.0% of the labeled amount of ritodrine hydrochloride ($\text{C}_{17}\text{H}_{21}\text{NO}_3 \cdot \text{HCl}$: 323.81).

Method of preparation Prepare as directed under Injections, with Ritodrine Hydrochloride.

Manufacture Ritodrine Hydrochloride Injection is produced by the formulation and the manufacturing method to ensure that the amounts of related substances do not exceed the limit values of related substances under Ritodrine Hydrochloride.

Description Ritodrine Hydrochloride Injection is a clear and colorless liquid.

Identification To a volume of Ritodrine Hydrochloride Injection, equivalent to 50 mg of Ritodrine Hydrochloride, add 0.01 mol/L hydrochloric acid TS to make 100 mL. To 10 mL of this solution add 0.01 mol/L hydrochloric acid TS to make 100 mL. Determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 272 nm and 276 nm.

pH Being specified separately when the drug is granted approval based on the Law.

Bacterial endotoxins <4.01> Less than 25 EU/mg.

Extractable volume <6.05> It meets the requirement.

Foreign insoluble matter <6.06> Perform the test according to Method 1: it meets the requirement.

Insoluble particulate matter <6.07> It meets the requirement.

Sterility <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

Assay Pipet a volume of Ritodrine Hydrochloride Injection, equivalent to about 20 mg of ritodrine hydrochloride ($C_{17}H_{21}NO_3 \cdot HCl$), and add a mixture of 0.02 mol/L sodium dihydrogen phosphate dihydrate solution and methanol (7:3) to make exactly 250 mL, and use this solution as the sample solution. Separately, weigh accurately about 20 mg of Ritodrine Hydrochloride RS, previously dried at 105°C for 2 hours, dissolve in a mixture of 0.02 mol/L sodium dihydrogen phosphate dihydrate solution and methanol (7:3) to make exactly 250 mL, and use this solution as the standard solution. Perform the test with exactly 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine the peak areas, A_T and A_S , of ritodrine in each solution.

$$\text{Amount (mg) of ritodrine hydrochloride } (C_{17}H_{21}NO_3 \cdot HCl) = M_S \times A_T / A_S$$

M_S : Amount (mg) of Ritodrine Hydrochloride RS taken

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 220 nm).

Column: A stainless steel column 6 mm in inside diameter and 15 cm in length, packed with octylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: Dissolve 6.6 g of diammonium hydrogen phosphate and 1.1 g of sodium 1-heptansulfonate in 840 mL of water, add 160 mL of acetonitrile for liquid chromatography, and adjust to pH 3.0 with phosphoric acid.

Flow rate: Adjust so that the retention time of ritodrine is about 19 minutes.

System Suitability—

System performance: Dissolve 10 mg of ritodrine hydrochloride in 50 mL of dilute sulfuric acid. Heat a portion of this solution in a water bath for about 30 minutes, and allow to cool. Measure a portion of this solution, and add the same volume of 2 mol/L sodium hydroxide TS. Dissolve 2 mg of ritodrine hydrochloride in 10 mL of this solution, and add a mixture of 0.02 mol/L sodium dihydrogen phosphate dihydrate solution and methanol (7:3) to make 25 mL. When the procedure is run with 10 μ L of this solution under the above operating conditions, ritodrine and ritodrine threo-isomer are eluted in this order with the resolution between these peaks being not less than 3.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of ritodrine is not more than 1.0%.

Containers and storage Containers—Hermetic containers.

Storage—At a temperature between 2°C and 8°C.

Saccharin

サッカリン

Delete the description of harmonization in the beginning and symbols (◆ ◆) in the Description, Melting point, Purity (2) and (4), and Containers and storage.

Saccharin Sodium Hydrate

サッカリンナトリウム水和物

Delete the description of harmonization in the beginning and symbols (◆ ◆) in the Description, Purity (3) and (5), and Containers and storage.

Light Anhydrous Silicic Acid


軽質無水ケイ酸

Delete the Volume test:

Add the following:

Sitagliptin Phosphate Hydrate

シタグリプチンリン酸塩水和物



$C_{16}H_{15}F_6N_5O \cdot H_3PO_4 \cdot H_2O$: 523.32

(3*R*)-3-Amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one monophosphate monohydrate [654671-77-9]

Sitagliptin Phosphate Hydrate contains not less than 98.0% and not more than 102.0% of sitagliptin phosphate ($C_{16}H_{15}F_6N_5O \cdot H_3PO_4$: 505.31), calculated on the anhydrous basis.

Description Sitagliptin Phosphate Hydrate occurs as a white powder.

It is soluble in water, sparingly soluble in methanol, very slightly soluble in acetonitrile and in ethanol (99.5).

Identification (1) Determine the absorption spectrum of a solution of Sitagliptin Phosphate Hydrate (1 in 10,000) as directed under Ultraviolet-visible Spectrophotometry

<2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Sitagliptin Phosphate RS prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Sitagliptin Phosphate Hydrate as directed in the paste method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Sitagliptin Phosphate RS: both spectra exhibit similar intensities of absorption at the same wave numbers. Alternatively, perform the test by the potassium bromide disk method or the ATR method, and compare the spectrum with the spectrum of Sitagliptin Phosphate RS: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) A solution of Sitagliptin Phosphate Hydrate (1 in 25) responds to Qualitative Tests <1.09> (1) for phosphate.

Purity (1) Heavy metals—Being specified separately when the drug is granted approval based on the Law.

(2) Related substances—Use the sample solution obtained in the Assay as the sample solution. Pipet 1 mL of the sample solution, add a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile for liquid chromatography (19:1) to make exactly 1000 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: the area of the peak other than sitagliptin obtained from the sample solution is not larger than the peak area of sitagliptin from the standard solution, and the total area of the peaks other than sitagliptin from the sample solution is not larger than 5 times the peak area of sitagliptin from the standard solution. For this calculation the peak area not larger than 1/2 times the peak area of sitagliptin from the standard solution is excluded.

Operating conditions—

Detector, column, column temperature, mobile phase and flow rate: Proceed as directed in the operating conditions in the Assay.

Time span of measurement: About 5.5 times as long as the retention time of sitagliptin, beginning after the solvent peak.

System suitability—

System performance: Proceed as directed in the system suitability in the Assay.

Test for required detectability: Pipet 5 mL of the standard solution, and add a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile for liquid chromatography (19:1) to make exactly 10 mL. When the procedure is run with 20 μ L of this solution under the above operating conditions, the SN ratio of the peak of sitagliptin is not less than 10.

System repeatability: When the test is repeated 6 times with 20 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak

area of sitagliptin is not more than 2.0%.

(3) Enantiomer—Dissolve 80 mg of Sitagliptin Phosphate Hydrate in a mixture of methanol and water (9:1) to make 10 mL, and use this solution as the sample solution. Perform the test with 10 μ L of the sample solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine the total peak area, A_T , of sitagliptin and related substance A (enantiomer), having the relative retention time of about 0.9 to sitagliptin and the peak area, A_S , of related substance A (enantiomer), and calculate the amount of the enantiomer by the following equation: not more than 0.5%.

$$\text{Amount (\% of enantiomer)} = A_S/A_T \times 100$$

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 268 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with amylose tris-(3,5-dimethylphenylcarbamate)-coated silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 35°C.

Mobile phase: A mixture of ethanol (99.5), heptane, water and diethylamine (600:400:1:1).

Flow rate: 0.8 mL per minute.

System suitability—

Test for required detectability: Pipet 1 mL of the sample solution, and dissolve in a mixture of methanol and water (9:1) to make exactly 100 mL. Pipet 1 mL of this solution, add a mixture of methanol and water (9:1) to make exactly 10 mL. When the procedure is run with 10 μ L of this solution under the above operating conditions, the SN ratio of the peak of sitagliptin is not less than 10.

System performance: Dissolve 8 mg of Sitagliptin Phosphate RS for System Suitability in 1 mL of a mixture of methanol and water (9:1). When the procedure is run with 10 μ L of this solution under the above operating conditions, the resolution between the peaks of related substance A (enantiomer) and sitagliptin is not less than 1.5.

Water <2.48> 3.3 – 3.7% (0.3 g, volumetric titration, direct titration).

Residue on ignition <2.44> Not more than 0.2% (1 g, platinum crucible).

Assay Weigh accurately about 20 mg each of Sitagliptin Phosphate Hydrate and Sitagliptin Phosphate RS (separately determine the water <2.48> in the same manner as Sitagliptin Phosphate Hydrate), dissolve each in a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile for liquid chromatography (19:1) to make exactly 200 mL, and use these solutions as the sample solution and the standard solution, respectively. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of sitagliptin in each solution.

$$\begin{aligned} & \text{Amount (mg) of sitagliptin phosphate} \\ & (\text{C}_{16}\text{H}_{15}\text{F}_6\text{N}_5\text{O} \cdot \text{H}_3\text{PO}_4) \\ & = M_S \times A_T/A_S \end{aligned}$$

M_S : Amount (mg) of Sitagliptin Phosphate RS taken, calculated on the anhydrous basis

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 205 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with cyanopropylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 30°C.

Mobile phase: Dissolve 1.36 g of potassium dihydrogen phosphate in 900 mL of water, adjust to pH 2.0 with phosphoric acid, and add water to make 1000 mL. To 850 mL of this solution add 150 mL of acetonitrile for liquid chromatography.

Flow rate: 1.0 mL per minute.

System suitability—

System performance: Place 10 mg of Sitagliptin Phosphate RS and 1 mg of sodium stearyl fumarate in a vial, and add 1 mL of water. Stopper the vial tightly, and heat at 80°C for 20 to 48 hours. Take out the contents of the vial, wash the vial 3 times with a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile for liquid chromatography (19:1), combine the washings and the content, and add a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile for liquid chromatography (19:1) to make 100 mL. Stir this solution for 1 hour, and centrifuge for 10 minutes or until the solution becomes clear. Use the supernatant liquid as the solution for system suitability test. When the procedure is run with 20 μL of the solution for system suitability test under the above operating conditions, the resolution between sitagliptin and the peak having the relative retention time of about 1.2 to sitagliptin is not less than 1.5.


System repeatability: When the test is repeated 6 times with 20 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of sitagliptin is not more than 1.0%.

Containers and storage Containers—Tight containers.

Others

Related substance A (enantiomer):

(3*S*)-3-Amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one



Add the following:

Sitagliptin Phosphate Tablets

シタグリプチンリン酸塩錠

Sitagliptin Phosphate Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of sitagliptin ($\text{C}_{16}\text{H}_{15}\text{F}_6\text{N}_5\text{O}$: 407.31).

Method of preparation Prepare as directed under Tablets, with Sitagliptin Phosphate Hydrate.

Manufacture The management strategy of Sitagliptin Phosphate Tablets is based on systematic development methods, which put emphasis on prior setting targets, understanding of products and processes, and process control, and which is based on quality risk management and proven science. In addition when it can be scientifically possible to explain that a disintegration test ensure quality with distinguishability equal or better than a dissolution test, the following disintegration is alternative for the estimation of dissolution.

Disintegration <6.09> Perform the test for 5 minutes: it meets the requirement.

Identification (1) To 1 tablet of Sitagliptin Phosphate Tablets add water so that each mL contains about 0.2 mg of sitagliptin ($\text{C}_{16}\text{H}_{15}\text{F}_6\text{N}_5\text{O}$), and shake thoroughly to disintegrate. Centrifuge this solution. Determine the absorption spectrum of the supernatant liquid as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 265 nm and 269 nm.

(2) Perform the test with 20 μL of the sample solution and standard solution obtained in the Assay as directed under Liquid Chromatography <2.01> according to the operating conditions in the Assay: the retention times of the principal peaks in the chromatograms obtained from the sample solution and the standard solution are the same.

Purity Related substances—Use the sample solution obtained in the Assay as the sample solution. Separately, pipet 1 mL of the standard solution obtained in the Assay, add a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile for liquid chromatography (19:1) to make exactly 500 mL, and use this solution as the standard solution. Perform the test with exactly 20 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine the peak area, A_T , of related substance obtained from the sample solution and the peak area, A_S , of sitagliptin from the standard solution, and calculate the amount of related substances by the following equation: the total amount of related substances is not more than 0.2%. For this calculation the amount of related substance not more than 0.1% is excluded.

$$\begin{aligned} & \text{Amount (\%)} \text{ of related substance} \\ & = M_S \times A_T/A_S \times V'/V \times 1/C \times 1/50 \times 0.806 \end{aligned}$$

M_S : Amount (mg) of Sitagliptin Phosphate RS taken, cal-

culated on the anhydrous basis

V'/V : Dilution factor for the sample solution in the Assay

C : Labeled amount (mg) of sitagliptin ($C_{16}H_{15}F_6N_5O$) in 1 tablet

Operating conditions—

Detector, column, column temperature, mobile phase and flow rate: Proceed as directed in the operating conditions in the Assay.

Time span of measurement: About 5.5 times as long as the retention time of sitagliptin, beginning after the solvent peak.

System suitability—

System performance and system repeatability: Proceed as directed in the system suitability in the Assay.

Test for required detectability: To 5 mL of the standard solution add a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile for liquid chromatography (19:1) to make exactly 10 mL. When the procedure is run with 20 μ L of this solution under the above operating conditions, the SN ratio of the peak of sitagliptin is not less than 10.

Uniformity of dosage units <6.02> Perform the Mass variation test, or the Content uniformity test according to the following method: it meets the requirement.

To 1 tablet of Sitagliptin Phosphate Tablets add a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile for liquid chromatography (19:1) to make exactly 25 mL, and stir thoroughly. Pipet V mL of this solution, and add a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile for liquid chromatography (19:1) to make exactly V' mL so that each mL contains about 80 μ g of sitagliptin ($C_{16}H_{15}F_6N_5O$). Centrifuge this solution, and use the supernatant liquid as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} &\text{Amount (mg) of sitagliptin (C}_{16}\text{H}_{15}\text{F}_6\text{N}_5\text{O)} \\ &= M_S \times A_T/A_S \times V'/V \times 1/10 \times 0.806 \end{aligned}$$

M_S : Amount (mg) of Sitagliptin Phosphate RS taken, calculated on the anhydrous basis

Dissolution <6.10> When the test is performed at 100 revolutions per minute according to the Basket method, using 900 mL of water as the dissolution medium, the dissolution rate in 15 minutes of Sitagliptin Phosphate Tablets is not less than 85%.

Start the test with 1 tablet of Sitagliptin Phosphate Tablets, withdraw not less than 4 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size of 0.45 μ m. Discard not less than 2 mL of the first filtrate, pipet V mL of the subsequent filtrate, add water to make exactly V' mL so that each mL contains about 14 μ g of sitagliptin ($C_{16}H_{15}F_6N_5O$), and use this solution as the sample solution. Separately, weigh accurately about 29 mg of Sitagliptin Phosphate RS (separately determine the water <2.48> in the same manner as Sitagliptin Phosphate Hydrate), and dissolve in a solution of sodium chloride (37 in 25,000) to make exactly 100

mL. Pipet 6 mL of this solution, and add a solution of sodium chloride (37 in 25,000) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of sitagliptin in each solution.

Dissolution rate (%) with respect to the labeled amount of sitagliptin ($C_{16}H_{15}F_6N_5O$)

$$= M_S \times A_T/A_S \times V'/V \times 1/C \times 54 \times 0.806$$

M_S : Amount (mg) of Sitagliptin Phosphate RS taken, calculated on the anhydrous basis

C : Labeled amount (mg) of sitagliptin ($C_{16}H_{15}F_6N_5O$) in 1 tablet

Operating conditions—

Column, column temperature and flow rate: Proceed as directed in the operating conditions in the Assay.

Detector: An ultraviolet absorption photometer (wavelength: 267 nm).

Mobile phase: Dissolve 1.36 g of potassium dihydrogen phosphate in 900 mL of water, adjust to pH 2.0 with phosphoric acid, and add water to make 1000 mL. To 750 mL of this solution add 250 mL of acetonitrile for liquid chromatography.

System suitability—

System performance: When the procedure is run with 20 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of sitagliptin are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 20 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of sitagliptin is not more than 1.0%.

Assay To 10 Sitagliptin Phosphate Tablets add a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile for liquid chromatography (19:1) to make exactly 250 mL, and stir thoroughly. Pipet V mL of this solution, and add a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile for liquid chromatography (19:1) to make exactly V' mL so that each mL contains about 80 μ g of sitagliptin ($C_{16}H_{15}F_6N_5O$). Centrifuge this solution, and use the supernatant liquid as the sample solution. Separately, weigh accurately about 26 mg of Sitagliptin Phosphate RS (separately determine the water <2.48> in the same manner as Sitagliptin Phosphate Hydrate), dissolve in a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile for liquid chromatography (19:1) to make exactly 250 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of sitagliptin in each solution.

Amount (mg) of sitagliptin (C₁₆H₁₅F₆N₅O) in 1 tablet of Sitagliptin Phosphate Tablets

$$= M_S \times A_T/A_S \times V'/V \times 1/10 \times 0.806$$

M_S : Amount (mg) of Sitagliptin Phosphate RS taken, calculated on the anhydrous basis

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 205 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with cyanopropylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 30°C.

Mobile phase: Dissolve 1.36 g of potassium dihydrogen phosphate in 900 mL of water, adjust to pH 2.0 with phosphoric acid, and add water to make 1000 mL. To 850 mL of this solution add 150 mL of acetonitrile for liquid chromatography.

Flow rate: 1.0 mL per minute.

System suitability—

System performance: Proceed as directed in the system suitability in the Assay under Sitagliptin Phosphate Hydrate. The following method can be applied when sodium stearyl fumarate is contained in the additive of the tablet.

Crush 1 tablet of Sitagliptin Phosphate Tablets, transfer to a vial, and add 1 mL of water. Stopper the vial tightly, and heat at 80°C for 20 to 48 hours. Take out the contents of the vial, wash the vial 3 times with a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile for liquid chromatography (19:1), combine the washings and the content, and add a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile for liquid chromatography (19:1) to make 100 mL. Stir this solution for 1 hour, and centrifuge for 10 minutes or until the solution becomes clear. When the procedure is run with 20 μL of the supernatant liquid under the above operating conditions, the resolution between sitagliptin and the peak having the relative retention time of about 1.2 to sitagliptin is not less than 1.5.


System repeatability: When the test is repeated 6 times with 20 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of sitagliptin is not more than 1.0%.

Containers and storage Containers—Tight containers.

Sodium Fusidate

フシジン酸ナトリウム

Change the Structural formula as follows:



Change the purity as follows:

Purity (1) Heavy metals <1.07>—Proceed with 2.0 g of Sodium Fusidate according to Method 4, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Related substances—Dissolve 25 mg of Sodium Fusidate in a mixture of acetonitrile for liquid chromatography, diluted phosphoric acid (3 in 1000) and methanol (5:4:1) to make 10 mL, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: the peak area of related substance A, having the relative retention time of about 0.4 to fusidic acid, obtained from the sample solution is not larger than 3/10 times the peak area of fusidic acid from the standard solution, the peak area of related substance B, having the relative retention time of about 0.5, from the sample solution is not larger than 2/5 times the peak area of fusidic acid from the standard solution, the peak areas of related substance C having the relative retention time of about 0.6, related substance D having the relative retention time of about 0.63, an unknown substance having the relative retention time of about 0.65, related substance E having the relative retention time of about 0.7, related substance G having the relative retention time of about 0.96 and related substance H having the relative retention time of about 1.18, from the sample solution are not larger than 1/5 times the peak area of fusidic acid from the standard solution, the peak area of related substance F, having the relative retention time of about 0.82, from the sample solution is not larger than 7/10 times the peak area of fusidic acid from the standard solution, the peak area of related substance I, having the relative retention time of about 1.23, from the sample solution is not larger than 1/2 times the peak area of fusidic acid from the standard solution, the peak area of related substance J, having the relative retention time of about 1.4, from the sample solution is not larger than the peak area of

fusidic acid from the standard solution, the area of the peak other than fusidic acid and the peaks mentioned above from the sample solution is not larger than 1/10 times the peak area of fusidic acid from the standard solution. Furthermore, the total area of the peaks other than fusidic acid from the sample solution is not larger than 2 times the peak area of fusidic acid from the standard solution. For the areas of the peaks, related substances C, D, E, G and H, multiply their relative response factors, 0.7, 0.7, 0.3, 0.6 and 0.6, respectively.

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 235 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (3.5 μm in particle diameter).

Column temperature: A constant temperature of about 30°C.

Mobile phase A: A mixture of diluted phosphoric acid (3 in 1000), acetonitrile for liquid chromatography and methanol (2:2:1).

Mobile phase B: A mixture of acetonitrile for liquid chromatography, methanol and diluted phosphoric acid (3 in 1000) (7:2:1).

Flowing of mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 3	100	0
3 – 28	100 → 0	0 → 100
28 – 33	0	100

Flow rate: 1.0 mL per minute.

Time span of measurement: For 33 minutes after injection, beginning after the solvent peak.

System suitability—

Test for required detectability: Pipet 1 mL of the standard solution, and add a mixture of acetonitrile for liquid chromatography, diluted phosphoric acid (3 in 1000) and methanol (5:4:1) to make exactly 20 mL. Confirm that the peak area of fusidic acid obtained with 20 μL of this solution is equivalent to 3.5 to 6.5% of that with 20 μL of the standard solution.

System performance: When the procedure is run with 20 μL of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of fusidic acid are not less than 43,000 and not more than 1.5, respectively.


System repeatability: When the test is repeated 6 times with 20 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of fusidic acid is not more than 2.0%.

Add the following next to the Containers and storage:

Others


Related substance A:

(24*RS*,17*Z*)-*ent*-16 α -Acetoxy-3 β ,11 β ,24,25-tetrahydroxy-4 β ,8 β ,14 α -trimethyl-18-nor-5 β ,10 α -cholest-17(20)-en-21-oic acid




Related substance B:

(17*Z*)-*ent*-3 β ,11 β -Dihydroxy-17-[(6*SR*)-6-hydroxy-7,7-dimethyl-2-oxooxepan-3-ylidene]-4 β ,8 β ,14 α -trimethyl-18-nor-5 β ,10 α -androstan-16 α -yl acetate




Related substance C:

(17*Z*)-*ent*-3 β ,11 β -Dihydroxy-17-[(6*S*)-6-(2-hydroxypropan-2-yl)-2-oxodihydro-2*H*-pyran-3(4*H*)-ylidene]-4 β ,8 β ,14 α -trimethyl-18-nor-5 β ,10 α -androstan-16 α -yl acetate




Related substance D:

(17*Z*)-*ent*-3 β ,11 β -Dihydroxy-17-[(6*R*)-6-(2-hydroxypropan-2-yl)-2-oxodihydro-2*H*-pyran-3(4*H*)-ylidene]-4 β ,8 β ,14 α -trimethyl-18-nor-5 β ,10 α -androstan-16 α -yl acetate




Related substance E:

(17*Z*,24*EZ*)-*ent*-16 α -Acetoxy-3 β ,11 β -dihydroxy-4 β ,8 β ,14 α -trimethyl-26-oxo-18-nor-5 β ,10 α -cholesta-17(20),24-dien-21-oic acid




Related substance F:

(17*Z*)-*ent*-16 α -Acetoxy-11 β -hydroxy-4 β ,8 β ,14 α -trimethyl-3-oxo-18-nor-5 β ,10 α -cholesta-17(20),24-dien-21-oic acid




Related substance G:

(17*Z*)-*ent*-3 β ,11 β ,16 β -Trihydroxy-4 β ,8 β ,14 α -trimethyl-18-nor-5 β ,10 α -cholesta-17(20),24-dien-21-oic acid




Related substance H:

(17*Z*)-*ent*-3 β ,11 β -Dihydroxy-4 β ,8 β ,14 α -trimethyl-18-nor-5 β ,10 α -cholesta-17(20),24-dieno-21,16 α -lactone




Related substance I:

(17*Z*)-*ent*-16 α -Acetoxy-3 β -hydroxy-4 β ,8 β ,14 α -trimethyl-18-nor-5 β ,10 α -cholesta-9(11),17(20),24-trien-21-oic acid



Related substance J:

(17*Z*)-*ent*-16 α -Acetoxy-3 β -hydroxy-4 β ,8 β ,14 α -trimethyl-18-nor-5 β ,10 α -cholesta-17(20),24-dien-21-oic acid



Add the following:

Sodium Valproate Extended-release Tablets A

バルプロ酸ナトリウム徐放錠 A

Sodium Valproate Extended-release Tablets A contain not less than 95.0% and not more than 105.0% of the labeled amount of sodium valproate (C₈H₁₅NaO₂; 166.19).

Method of preparation Prepare as directed under Tablets, with Sodium Valproate.

Identification To a quantity of powdered Sodium Valproate Extended-release Tablets A, equivalent to 0.2 g of Sodium Valproate, add 20 mL of water, shake thoroughly, and centrifuge. To 2 mL of the supernatant liquid add 1 mL of a solution of cobalt (II) nitrate hexahydrate (1 in 20), and heat on a water bath: a purple precipitate is formed.

Uniformity of dosage units <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Crush 1 tablet of Sodium Valproate Extended-release Tablets A, add exactly $V/40$ mL of the internal standard solution, add $4V/5$ mL of a mixture of methanol and water (3:2), shake vigorously, add a mixture of methanol and water (3:2) to make V mL so that each mL contains about 1 mg of sodium valproate (C₈H₁₅NaO₂), and filter through a membrane filter with a pore size not exceeding 0.45 μ m. Discard the first 5 mL of the filtrate, and use the subsequent filtrate as the sample solution. Separately, weigh accurately about 0.1 g of sodium valproate for assay, previously dried at 105°C for 3 hours, add exactly 2.5 mL of the internal standard solution, add a mixture of methanol and water

(3:2) to make 100 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay.

$$\begin{aligned} & \text{Amount (mg) of sodium valproate (C}_8\text{H}_{15}\text{NaO}_2\text{)} \\ & = M_S \times Q_T/Q_S \times V/100 \end{aligned}$$

M_S : Amount (mg) of sodium valproate for assay taken

Internal standard solution—A solution of ethyl parahydroxybenzoate in a mixture of methanol and water (3:2) (1 in 5000).

Dissolution <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rates of a 100-mg tablet in 4 hours, in 6 hours and in 12 hours are 15 to 45%, 40 to 70%, and not less than 75%, respectively, and those of a 200-mg tablet in 4 hours, in 6 hours and in 12 hours are 15 to 45%, 35 to 65%, and not less than 75%, respectively.

Start the test with 1 tablet of Sodium Valproate Extended-release Tablets A, withdraw exactly 20 mL of the medium at the specified minutes after starting the test and supply exactly 20 mL of water warmed to $37 \pm 0.5^\circ\text{C}$ immediately after withdrawing of the medium every time. Filter the media through a membrane filter with a pore size not exceeding $0.45 \mu\text{m}$. Discard not less than 10 mL of the first filtrate, pipet V mL of the subsequent filtrate, add water to make exactly V' mL so that each mL contains about 0.11 mg of sodium valproate ($\text{C}_8\text{H}_{15}\text{NaO}_2$), and use these solutions as the sample solutions. Separately, weigh accurately about 56 mg of sodium valproate for assay, previously dried at 105°C for 3 hours, and dissolve in water to make exactly 50 mL. Pipet 5 mL of this solution, add water to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly $50 \mu\text{L}$ each of the sample solutions and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, $A_{T(n)}$ and A_S , of valproic acid in each solution.

Dissolution rate (%) with respect to the labeled amount of sodium valproate ($\text{C}_8\text{H}_{15}\text{NaO}_2$) on the n th medium withdrawing ($n = 1, 2, 3$)

$$= M_S \times \left\{ \frac{A_{T(n)}}{A_S} + \sum_{i=1}^{n-1} \left(\frac{A_{T(i)}}{A_S} \times \frac{1}{45} \right) \right\} \times \frac{V'}{V} \times \frac{1}{C} \times 180$$

M_S : Amount (mg) of sodium valproate for assay taken

C : Labeled amount (mg) of sodium valproate ($\text{C}_8\text{H}_{15}\text{NaO}_2$) in 1 tablet

Operating conditions—

Proceed as directed in the operating conditions in the Assay.

System suitability—

System performance: When the procedure is run with $50 \mu\text{L}$ of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of valproic acid are not less than 3000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times

with $50 \mu\text{L}$ of the standard solution under the above operating conditions, the relative standard deviation of the peak area of valproic acid is not more than 1.5%.

Assay Weigh accurately the mass of not less than 20 Sodium Valproate Extended-release Tablets A, and powder. Weigh accurately a portion of the powder, equivalent to about 0.1 g of sodium valproate ($\text{C}_8\text{H}_{15}\text{NaO}_2$), add about 80 mL of the mobile phase, shake thoroughly, add the mobile phase to make exactly 100 mL, and centrifuge. Pipet 20 mL of the supernatant liquid, add exactly 5 mL of the internal standard solution, and use this solution as the sample solution. Separately, weigh accurately about 0.1 g of sodium valproate for assay, previously dried at 105°C for 3 hours, dissolve in the mobile phase to make exactly 100 mL. Pipet 20 mL of this solution, add exactly 5 mL of the internal standard solution, and use this solution as the standard solution. Perform the test with $10 \mu\text{L}$ each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of valproic acid to that of the internal standard.

$$\begin{aligned} & \text{Amount (mg) of sodium valproate (C}_8\text{H}_{15}\text{NaO}_2\text{)} \\ & = M_S \times Q_T/Q_S \end{aligned}$$

M_S : Amount (mg) of sodium valproate for assay taken

Internal standard solution—A solution of ethyl parahydroxybenzoate in the mobile phase (1 in 50,000).

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 210 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography ($5 \mu\text{m}$ in particle diameter).

Column temperature: A constant temperature of about 25°C .

Mobile phase: A mixture of 0.05 mol/L sodium dihydrogen phosphate TS (pH 3.0) and acetonitrile for liquid chromatography (1:1).

Flow rate: Adjust so that the retention time of valproic acid is about 6 minutes.

System suitability—

System performance: When the procedure is run with $10 \mu\text{L}$ of the standard solution under the above operating conditions, the internal standard and valproic acid are eluted in this order with the resolution between these peaks being not less than 7.

System repeatability: When the test is repeated 6 times with $10 \mu\text{L}$ of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of valproic acid to that of the internal standard is not more than 1.0%.

Containers and storage Containers—Tight containers.

Add the following:

Sodium Valproate Extended-release Tablets B

バルプロ酸ナトリウム徐放錠 B

Sodium Valproate Extended-release Tablets B contain not less than 95.0% and not more than 105.0% of the labeled amount of sodium valproate ($C_8H_{15}NaO_2$; 166.19).

Method of preparation Prepare as directed under Tablets, with Sodium Valproate.

Identification To a quantity of the powdered Sodium Valproate Extended-release Tablets B, equivalent to 1.0 g of Sodium Valproate, add 10 mL of water, heat on a water bath for 30 minutes, and filter. To 2.5 mL of the filtrate add 2.5 mL of water and 1 mL of a solution of cobalt (II) nitrate hexahydrate (1 in 20), and heat on a water bath: a purple precipitate is formed.

Uniformity of dosage units <6.02> Perform the Mass variation test, or the Content uniformity test according to the following method: it meets the requirement.

To 1 tablet of Sodium Valproate Extended-release Tablets B add 150 mL of the mobile phase, allow to stand for not less than 16 hours, shake until the film is disintegrated, and add the mobile phase to make exactly 200 mL. Pipet V mL of this solution, and add the mobile phase to make exactly V' mL so that each mL contains about 1 mg of sodium valproate ($C_8H_{15}NaO_2$). Centrifuge this solution, and filter the supernatant liquid through a membrane filter with a pore size not exceeding $0.45 \mu\text{m}$. Discard the first 5 mL of the filtrate, pipet 20 mL of the subsequent filtrate, add exactly 5 mL of the internal standard solution, and use this solution as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} &\text{Amount (mg) of sodium valproate (} C_8H_{15}NaO_2 \text{)} \\ &= M_S \times Q_T/Q_S \times V'/V \times 2 \end{aligned}$$

M_S : Amount (mg) of sodium valproate for assay taken

Internal standard solution—A solution of methyl parahydroxybenzoate in the mobile phase (1 in 50,000).

Dissolution <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rates of a 200-mg tablet in 8 hours, in 11 hours and in 20 hours are 15 to 45%, 35 to 65%, and not less than 70%, respectively, and those of a 400-mg tablet in 9 hours, in 12 hours and in 21 hours are 15 to 45%, 35 to 65%, and not less than 70%, respectively.

Start the test with 1 tablet of Sodium Valproate Extended-release Tablets B, withdraw exactly 20 mL of the medium at the specified minutes after starting the test and supply exactly 20 mL of water warmed to $37 \pm 0.5^\circ\text{C}$ immediately after withdrawing of the medium every time.

Filter the media through a membrane filter with a pore size not exceeding $0.45 \mu\text{m}$. Discard not less than 2 mL of the first filtrate, pipet V mL of the subsequent filtrate, add water to make exactly V' mL so that each mL contains about 0.22 mg of sodium valproate ($C_8H_{15}NaO_2$), and use these solutions as the sample solutions. Separately, weigh accurately about 55 mg of sodium valproate for assay, previously dried at 105°C for 3 hours, dissolve in water to make exactly 250 mL, and use this solution as the standard solution. Perform the test with exactly $20 \mu\text{L}$ each of the sample solutions and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, $A_{T(n)}$ and A_S , of valproic acid in each solution.

Dissolution rate (%) with respect to the labeled amount of sodium valproate ($C_8H_{15}NaO_2$) on the n th medium with-drawing ($n = 1, 2, 3$)

$$= M_S \times \left\{ \frac{A_{T(n)}}{A_S} + \sum_{i=1}^{n-1} \left(\frac{A_{T(i)}}{A_S} \times \frac{1}{45} \right) \right\} \times \frac{V'}{V} \times \frac{1}{C} \times 360$$

M_S : Amount (mg) of sodium valproate for assay taken

C : Labeled amount (mg) of sodium valproate ($C_8H_{15}NaO_2$) in 1 tablet

Operating conditions—

Proceed as directed in the operating conditions in the Assay.

System suitability—

System performance: When the procedure is run with $20 \mu\text{L}$ of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of valproic acid are not less than 3000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with $20 \mu\text{L}$ of the standard solution under the above operating conditions, the relative standard deviation of the peak area of valproic acid is not more than 1.0%.

Assay To 20 Sodium Valproate Extended-release Tablets B add 150 mL of the mobile phase, allow to stand for not less than 16 hours, shake until the film is disintegrated, and add the mobile phase to make exactly 200 mL. Pipet 5 mL of this solution, add the mobile phase to make exactly V mL so that each mL contains about 1 mg of sodium valproate ($C_8H_{15}NaO_2$). Centrifuge this solution, and filter the supernatant liquid through a membrane filter with a pore size not exceeding $0.45 \mu\text{m}$. Discard the first 5 mL of the filtrate, pipet 20 mL of the subsequent filtrate, add exactly 5 mL of the internal standard solution, and use this solution as the sample solution. Separately, weigh accurately about 0.1 g of sodium valproate for assay, previously dried at 105°C for 3 hours, dissolve in the mobile phase to make exactly 100 mL. Pipet 20 mL of this solution, add exactly 5 mL of the internal standard solution, and use this solution as the standard solution. Perform the test with $10 \mu\text{L}$ each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of valproic acid to that of the internal standard.

Amount (mg) of sodium valproate ($C_8H_{15}NaO_2$) in 1 tablet
 $= M_S \times Q_T/Q_S \times V/50$

M_S : Amount (mg) of sodium valproate for assay taken

Internal standard solution—A solution of methyl para-hydroxybenzoate in the mobile phase (1 in 50,000).

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 210 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: A mixture of 0.05 mol/L sodium dihydrogen phosphate TS (pH 3.0) and acetonitrile for liquid chromatography (1:1).

Flow rate: Adjust so that the retention time of valproic acid is about 6 minutes.

System suitability—

System performance: When the procedure is run with 10 μ L of the standard solution under the above operating conditions, the internal standard and valproic acid are eluted in this order with the resolution between these peaks being not less than 7.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of valproic acid to that of the internal standard is not more than 1.0%.

Containers and storage Containers—Tight containers.

Teicoplanin

テイコプラニン

Change the Purity (4) as follows:

Purity

(4) Arsenic <1.11>—Prepare the test solution with 1.0 g of Teicoplanin according to Method 3, and perform the test (not more than 2 ppm).

Add the following:

Telmisartan and Hydrochlorothiazide Tablets

テルミサルタン・ヒドロクロロチアジド錠

Telmisartan and Hydrochlorothiazide Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of telmisartan ($C_{33}H_{30}N_4O_2$; 514.62) and hydrochlorothiazide ($C_7H_8ClN_3O_4S_2$;

297.74).

Method of preparation Prepare as directed under Tablets, with Telmisartan and Hydrochlorothiazide.

Identification (1) Perform the test with 5 μ L each of the sample solution and standard solution obtained in the Assay (1) as directed under Liquid Chromatography <2.01> according to the following conditions: the retention times of the peaks of telmisartan in the chromatograms obtained from the sample solution and standard solution are the same, and absorption spectra of these peaks exhibit similar intensities of absorption at the same wavelengths.

Operating conditions—

Column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay (1).

Detector: A photodiode array detector (wavelength: 270 nm, spectrum range of measurement: 210 – 400 nm).

System suitability—

System performance: Proceed as directed in the system suitability in the Assay (1).

(2) Perform the test with 5 μ L each of the sample solution and standard solution obtained in the Assay (2) as directed under Liquid Chromatography <2.01> according to the following conditions: the retention times of the peaks of hydrochlorothiazide in the chromatograms obtained from the sample solution and standard solution are the same, and absorption spectra of these peaks exhibit similar intensities of absorption at the same wavelengths.

Operating conditions—

Column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay (1).

Detector: A photodiode array detector (wavelength: 270 nm, spectrum range of measurement: 210 – 400 nm).

System suitability—

System performance: Proceed as directed in the system suitability in the Assay (2).

Purity Related substances—To a quantity of powdered Telmisartan and Hydrochlorothiazide Tablets, equivalent to 12.5 mg of Hydrochlorothiazide, add 40 mL of the dissolving solution, disperse by sonicating, add the dissolving solution to make exactly 50 mL. Centrifuge this solution, and use the supernatant liquid as the sample solution. Pipet 1 mL of the sample solution, add the dissolving solution to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the area of the peak having the relative retention time of about 0.9 to hydrochlorothiazide, obtained from the sample solution is not larger than the peak area of hydrochlorothiazide from the standard solution.

Dissolving solution: Dissolve 2 g of ammonium dihydrogen phosphate in 1000 mL of water, and adjust to pH 1.8 with phosphoric acid. To 1000 mL of this solution add 1000

mL of acetonitrile.

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 270 nm).

Column: A stainless steel column 4.0 mm in inside diameter and 15 cm in length, packed with octylsilanized silica gel for liquid chromatography (3 μ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase A: Dissolve 2 g of ammonium dihydrogen phosphate in 1000 mL of water, and adjust to pH 3.5 with phosphoric acid.

Mobile phase B: Acetonitrile.

Flowing of mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 8	90 → 50	10 → 50
8 – 12	50	50
12 – 18	50 → 20	50 → 80
18 – 20	20	80

Flow rate: 1.0 mL per minute.

System suitability—

Test for required detectability: Pipet 5 mL of the standard solution and add the dissolving solution to make exactly 50 mL. Confirm that the peak area of hydrochlorothiazide obtained with 20 μ L of this solution is equivalent to 7 to 13% of that with 20 μ L of the standard solution.

System performance: When the procedure is run with 20 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of hydrochlorothiazide are not less than 6000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 20 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of hydrochlorothiazide is not more than 2.0%.

Uniformity of dosage units <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

(1) **Telmisartan**—To 1 tablet of Telmisartan and Hydrochlorothiazide Tablets add 4V/5 mL of the dissolving solution, disintegrate by sonicating, add the dissolving solution to make exactly V mL so that each mL contains about 1.6 mg of telmisartan (C₃₃H₃₀N₄O₂). Centrifuge this solution, pipet 5 mL of the supernatant liquid, add the buffer solution to make exactly 25 mL, and use this solution as the sample solution. Proceed as directed in the Assay (1).

$$\begin{aligned} &\text{Amount (mg) of telmisartan (C}_{33}\text{H}_{30}\text{N}_4\text{O}_2) \\ &= M_S \times A_T/A_S \times V/50 \end{aligned}$$

M_S: Amount (mg) of telmisartan for assay taken

Dissolving solution: Dissolve 2 g of ammonium dihydro-

gen phosphate in 1000 mL of water, and adjust to pH 1.8 with phosphoric acid. To 1000 mL of this solution add 1000 mL of acetonitrile.

Buffer solution: Dissolve 2 g of ammonium dihydrogen phosphate in 1000 mL of water, and adjust to pH 1.8 with phosphoric acid.

(2) **Hydrochlorothiazide**—To 1 tablet of Telmisartan and Hydrochlorothiazide Tablets add 4V/5 mL of the dissolving solution, disintegrate by sonicating, add the dissolving solution to make exactly V mL so that each mL contains about 0.25 mg of hydrochlorothiazide (C₇H₈ClN₃O₄S₂). Centrifuge this solution, pipet 5 mL of the supernatant liquid, add the buffer solution to make exactly 25 mL, and use this solution as the sample solution. Proceed as directed in the Assay (2).

$$\begin{aligned} &\text{Amount (mg) of hydrochlorothiazide (C}_{7}\text{H}_8\text{ClN}_3\text{O}_4\text{S}_2) \\ &= M_S \times A_T/A_S \times V/50 \end{aligned}$$

M_S: Amount (mg) of Hydrochlorothiazide RS taken

Dissolving solution: Dissolve 2 g of ammonium dihydrogen phosphate in 1000 mL of water, and adjust to pH 1.8 with phosphoric acid. To 1000 mL of this solution add 1000 mL of acetonitrile.

Buffer solution: Dissolve 2 g of ammonium dihydrogen phosphate in 1000 mL of water, and adjust to pH 1.8 with phosphoric acid.

Dissolution <6.10> (1) **Telmisartan**—When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of 2nd fluid for dissolution test as the dissolution medium, the dissolution rates in 45 minutes of a telmisartan 40-mg and hydrochlorothiazide 12.5-mg tablet and a telmisartan 80-mg and hydrochlorothiazide 12.5-mg tablet are not less than 85% and not less than 80%, respectively.

Start the test with 1 tablet of Telmisartan and Hydrochlorothiazide Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45 μ m. Discard not less than 15 mL of the first filtrate, pipet V mL of the subsequent filtrate, add the dissolution medium to make exactly V' mL so that each mL contains about 44 μ g of telmisartan (C₃₃H₃₀N₄O₂), and use this solution as the sample solution. Separately, weigh accurately about 44 mg of telmisartan for assay, previously dried at 105°C for 4 hours, dissolve in 10 mL of a solution of meglumine in methanol (1 in 250), and add methanol to make exactly 50 mL. Pipet 5 mL of this solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 25 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S, of telmisartan in each solution.

$$\begin{aligned} &\text{Dissolution rate (\%)} \text{ with respect to the labeled amount of } \\ &\text{telmisartan (C}_{33}\text{H}_{30}\text{N}_4\text{O}_2) \\ &= M_S \times A_T/A_S \times V'/V \times 1/C \times 90 \end{aligned}$$

M_S : Amount (mg) of telmisartan for assay taken
 C: Labeled amount (mg) of telmisartan ($C_{33}H_{30}N_4O_2$) in 1 tablet

Operating conditions—

Proceed as directed in the operating conditions in the Assay (1).

System suitability—

System performance: When the procedure is run with 25 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of telmisartan are not less than 25,000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 25 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of telmisartan is not more than 2.0%.

(2) Hydrochlorothiazide—When the test is performed at 75 revolutions per minute according to the Paddle method, using 900 mL of 2nd fluid for dissolution test as the dissolution medium, the dissolution rate in 45 minutes of Telmisartan and Hydrochlorothiazide Tablets is not less than 80%.

Start the test with 1 tablet of Telmisartan and Hydrochlorothiazide Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45 μ m. Discard not less than 15 mL of the first filtrate, pipet V mL of the subsequent filtrate, add the dissolution medium to make exactly V' mL so that each mL contains about 14 μ g of hydrochlorothiazide ($C_7H_8ClN_3O_4S_2$), and use this solution as the sample solution. Separately, weigh accurately about 14 mg of Hydrochlorothiazide RS, previously dried at 105°C for 2 hours, and dissolve in methanol to make exactly 50 mL. Pipet 5 mL of this solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 25 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of hydrochlorothiazide in each solution.

Dissolution rate (%) with respect to the labeled amount of hydrochlorothiazide ($C_7H_8ClN_3O_4S_2$)

$$= M_S \times A_T / A_S \times V' / V \times 1 / C \times 90$$

M_S : Amount (mg) of Hydrochlorothiazide RS taken
 C: Labeled amount (mg) of hydrochlorothiazide ($C_7H_8ClN_3O_4S_2$) in 1 tablet

Operating conditions—

Proceed as directed in the operating conditions in the Assay (1).

System suitability—

System performance: When the procedure is run with 25 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of hydrochlorothiazide are not less than 1000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 25 μ L of the standard solution under the above operat-

ing conditions, the relative standard deviation of the peak area of hydrochlorothiazide is not more than 2.0%.

Assay (1) Telmisartan—Weigh accurately the mass of not less than 20 Telmisartan and Hydrochlorothiazide Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 80 mg of telmisartan ($C_{33}H_{30}N_4O_2$), add 40 mL of the dissolving solution, sonicate, and add the dissolving solution to make exactly 50 mL. Centrifuge this solution, pipet 5 mL of the supernatant liquid, add the buffer solution to make exactly 25 mL, and use this solution as the sample solution. Separately, weigh accurately about 80 mg of telmisartan for assay, previously dried at 105°C for 4 hours, and dissolve in the dissolving solution to make exactly 50 mL. Pipet 5 mL of this solution, add the buffer solution to make exactly 25 mL, and use this solution as the standard solution. Perform the test with exactly 5 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of telmisartan in each solution.

$$\begin{aligned} &\text{Amount (mg) of telmisartan (} C_{33}H_{30}N_4O_2 \text{)} \\ &= M_S \times A_T / A_S \end{aligned}$$

M_S : Amount (mg) of telmisartan for assay taken

Dissolving solution: Dissolve 2 g of ammonium dihydrogen phosphate in 1000 mL of water, and adjust to pH 1.8 with phosphoric acid. To 1000 mL of this solution add 1000 mL of acetonitrile.

Buffer solution: Dissolve 2 g of ammonium dihydrogen phosphate in 1000 mL of water, and adjust to pH 1.8 with phosphoric acid.

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 270 nm).

Column: A stainless steel column 3.0 mm in inside diameter and 7.5 cm in length, packed with octylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase A: Dissolve 2 g of ammonium dihydrogen phosphate in 1000 mL of water, and adjust to pH 3.5 with phosphoric acid.

Mobile phase B: Acetonitrile.

Flowing of mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 2	90	10
2 – 7	90 → 20	10 → 80
7 – 8	20	80

Flow rate: 0.8 mL per minute.

System suitability—

System performance: When the procedure is run with 5

μL of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of telmisartan are not less than 15,000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 5 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of telmisartan is not more than 1.0%.

(2) Hydrochlorothiazide—Weigh accurately the mass of not less than 20 Telmisartan and Hydrochlorothiazide Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 12.5 mg of hydrochlorothiazide ($\text{C}_7\text{H}_8\text{ClN}_3\text{O}_4\text{S}_2$), add 40 mL of the dissolving solution, sonicate, and add the dissolving solution to make exactly 50 mL. Centrifuge this solution, pipet 5 mL of the supernatant liquid, add the buffer solution to make exactly 25 mL, and use this solution as the sample solution. Separately, weigh accurately about 12.5 mg of Hydrochlorothiazide RS, previously dried at 105°C for 2 hours, and dissolve in the dissolving solution to make exactly 50 mL. Pipet 5 mL of this solution, add the buffer solution to make exactly 25 mL, and use this solution as the standard solution. Perform the test with exactly 5 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of hydrochlorothiazide in each solution.

$$\begin{aligned} \text{Amount (mg) of hydrochlorothiazide (C}_7\text{H}_8\text{ClN}_3\text{O}_4\text{S}_2) \\ = M_S \times A_T/A_S \end{aligned}$$

M_S : Amount (mg) of Hydrochlorothiazide RS taken

Dissolving solution: Dissolve 2 g of ammonium dihydrogen phosphate in 1000 mL of water, and adjust to pH 1.8 with phosphoric acid. To 1000 mL of this solution add 1000 mL of acetonitrile.

Buffer solution: Dissolve 2 g of ammonium dihydrogen phosphate in 1000 mL of water, and adjust to pH 1.8 with phosphoric acid.

Operating conditions—

Proceed as directed in the operating conditions in (1).

System suitability—

System performance: When the procedure is run with 5 μL of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of hydrochlorothiazide are not less than 1500 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 5 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of hydrochlorothiazide is not more than 1.0%.

Containers and storage Containers—Tight containers.

Testosterone Enanthate

テストステロンエナント酸エステル

Change the Description and Optical rotation as follows:

Description Testosterone Enanthate occurs as white to pale yellow, crystals or crystalline powder, or a pale yellow-brown viscous liquid. It is odorless or has a slight, characteristic odor.

It is freely soluble in ethanol (99.5), and practically insoluble in water.

Melting point: about 36°C

Optical rotation <2.49> $[\alpha]_D^{25}$: +76 – +86° (after drying, 0.1 g, ethanol (99.5), 10 mL, 100 mm).

Delete the following Monograph:

Freeze-dried Tetanus Antitoxin, Equine

乾燥破傷風ウマ抗毒素

Tipecidine Hibenzate Tablets

チペピジンヒベンズ酸塩錠

Change the Identification (2) as follows:

Identification

(2) To a quantity of powdered Tipecidine Hibenzate Tablets, equivalent to 11 mg of Tipecidine Hibenzate, add 30 mL of ethanol (99.5), and warm for 10 minutes with occasional shaking. After cooling, add ethanol (99.5) to make 50 mL, and filter. To 1 mL of the filtrate add ethanol (99.5) to make 20 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 280 nm and 286 nm.

Triamcinolone Acetonide

トリアムシノロンアセトニド

Change the Description and Optical rotation as follows:

Description Triamcinolone Acetonide occurs as a white crystalline powder.

It is sparingly soluble in ethanol (99.5) and in acetone, slightly soluble in methanol, and practically insoluble in water.

Melting point: about 290°C (with decomposition).

It shows crystal polymorphism.

Optical rotation <2.49> $[\alpha]_D^{25}$: +110 – +120° (after drying, 0.1 g, ethanol (99.5), 10 mL, 100 mm).

Ursodeoxycholic Acid

ウルソデオキシコール酸

Change the Melting point as follows:

Melting point <2.60> 201 – 205°C

Add the following:

Valsartan and Hydrochlorothiazide Tablets

バルサルタン・ヒドロクロロチアジド錠

Valsartan and Hydrochlorothiazide Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of valsartan ($C_{24}H_{29}N_5O_3$; 435.52) and hydrochlorothiazide ($C_7H_8ClN_3O_4S_2$; 297.74).

Method of preparation Prepare as directed under Tablets, with Valsartan and Hydrochlorothiazide.

Identification (1) To a quantity of powdered Valsartan and Hydrochlorothiazide Tablets, equivalent to 80 mg of Valsartan, add 5 mL of acetone, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 16 mg of valsartan in 1 mL of acetone, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5 μ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, hexane and acetic acid (100) (15:5:2) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): one of the two spots obtained from the sample solution and the spot from the standard solution show the same *R_f* value.

(2) To a quantity of powdered Valsartan and Hydrochlorothiazide Tablets, equivalent to 6.25 mg of Hydrochlorothiazide, add 5 mL of acetone, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 12.5 mg of hydrochlorothiazide in 10 mL of acetone, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5 μ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, hexane and acetic acid (100) (15:5:2) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): one of the two spots obtained from

the sample solution and the spot from the standard solution show the same *R_f* value.

Uniformity of dosage units <6.02> (1) Valsartan—Perform the Mass variation test, or the Content uniformity test according to the following method: it meets the requirement.

To 1 tablet of Valsartan and Hydrochlorothiazide Tablets add 10 mL of water, and shake until the tablet is disintegrated. Add 10 mL of acetonitrile, shake thoroughly, and add a mixture of water and acetonitrile (1:1) to make exactly 50 mL. Centrifuge this solution, pipet *V* mL of the supernatant liquid, add a mixture of water and acetonitrile (1:1) to make exactly *V'* mL so that each mL contains about 0.4 mg of valsartan ($C_{24}H_{29}N_5O_3$), and use this solution as the sample solution. Proceed as directed in the Assay (1).

$$\begin{aligned} & \text{Amount (mg) of valsartan } (C_{24}H_{29}N_5O_3) \\ & = M_S \times A_T/A_S \times V'/V \times 1/2 \end{aligned}$$

M_S: Amount (mg) of Valsartan RS taken, calculated on the anhydrous and residual solvent-free basis

(2) Hydrochlorothiazide—Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Valsartan and Hydrochlorothiazide Tablets add 10 mL of water, and shake until the tablet is disintegrated. Add 10 mL of acetonitrile, shake thoroughly, and add a mixture of water and acetonitrile (1:1) to make exactly 50 mL. Centrifuge this solution, pipet *V* mL of the supernatant liquid, add a mixture of water and acetonitrile (1:1) to make exactly *V'* mL so that each mL contains about 31 μ g of hydrochlorothiazide ($C_7H_8ClN_3O_4S_2$), and use this solution as the sample solution. Proceed as directed in the Assay (2).

$$\begin{aligned} & \text{Amount (mg) of hydrochlorothiazide } (C_7H_8ClN_3O_4S_2) \\ & = M_S \times A_T/A_S \times V'/V \times 1/8 \end{aligned}$$

M_S: Amount (mg) of Hydrochlorothiazide RS taken

Dissolution <6.10> (1) Valsartan—When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate in 30 minutes of Valsartan and Hydrochlorothiazide Tablets is not less than 75%.

Start the test with 1 tablet of Valsartan and Hydrochlorothiazide Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45 μ m. Discard not less than 5 mL of the first filtrate, pipet *V* mL of the subsequent filtrate, and add water to make exactly *V'* mL so that each mL contains about 89 μ g of valsartan ($C_{24}H_{29}N_5O_3$). Pipet 5 mL of this solution, add methanol to make exactly 10 mL, and use this solution as the sample solution. Separately, weigh accurately about 45 mg of Valsartan RS (separately determine the water <2.48> and the residual solvent in the same manner as Valsartan), and dissolve in methanol to make exactly 50 mL. Pipet 10 mL of this solution, add exactly 100 mL of water, then add

methanol to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of valsartan in each solution.

Dissolution rate (%) with respect to the labeled amount of valsartan ($C_{24}H_{29}N_5O_3$)

$$= M_S \times A_T/A_S \times V'/V \times 1/C \times 180$$

M_S : Amount (mg) of Valsartan RS taken, calculated on the anhydrous and residual solvent-free basis

C: Labeled amount (mg) of valsartan ($C_{24}H_{29}N_5O_3$) in 1 tablet

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 225 nm).

Column: A stainless steel column 3.0 mm in inside diameter and 12.5 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: Dissolve 14.68 g of disodium hydrogen phosphate dodecahydrate and 3.81 g of potassium dihydrogen phosphate in 1000 mL of water. To 4 volumes of this solution add 1 volume of acetonitrile.

Flow rate: Adjust so that the retention time of valsartan is about 6 minutes.

System suitability—

System performance: When the procedure is run with 10 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of valsartan are not less than 500, and not less than 0.7 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of valsartan is not more than 1.0%.

(2) Hydrochlorothiazide—When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate in 15 minutes of Valsartan and Hydrochlorothiazide Tablets is not less than 85%.

Start the test with 1 tablet of Valsartan and Hydrochlorothiazide Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45 μ m. Discard the first 5 mL of the filtrate, pipet V mL of the subsequent filtrate, add water to make exactly V' mL so that each mL contains about 6.9 μ g of hydrochlorothiazide ($C_7H_8ClN_3O_4S_2$), and use this solution as the sample solution. Separately, weigh accurately about 14 mg of Hydrochlorothiazide RS, previously dried at 105°C for 2 hours, and dissolve in methanol to make exactly 100 mL. Pipet 5 mL of this solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform

the test with exactly 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of hydrochlorothiazide in each solution.

Dissolution rate (%) with respect to the labeled amount of hydrochlorothiazide ($C_7H_8ClN_3O_4S_2$)

$$= M_S \times A_T/A_S \times V'/V \times 1/C \times 45$$

M_S : Amount (mg) of Hydrochlorothiazide RS taken

C: Labeled amount (mg) of hydrochlorothiazide ($C_7H_8ClN_3O_4S_2$) in 1 tablet

Operating conditions—

Proceed as directed in the operating conditions in (1).

System suitability—

System performance: When the procedure is run with 10 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of hydrochlorothiazide are not less than 3000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of hydrochlorothiazide is not more than 1.0%.

Assay (1) Valsartan—Weigh accurately the mass of not less than 20 tablets of Valsartan and Hydrochlorothiazide Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 80 mg of valsartan ($C_{24}H_{29}N_5O_3$), add 10 mL of water, and shake. Add 10 mL of acetonitrile, shake thoroughly, add a mixture of water and acetonitrile (1:1) to make exactly 50 mL, and centrifuge. Pipet 5 mL of the supernatant liquid, add a mixture of water and acetonitrile (1:1) to make exactly 20 mL, and use this solution as the sample solution. Separately, weigh accurately about 40 mg of Valsartan RS (separately determine the water <2.48> and the residual solvent in the same manner as Valsartan), dissolve in a mixture of water and acetonitrile (1:1) to make exactly 25 mL, and use this solution as the valsartan standard stock solution. Pipet 5 mL of the valsartan standard stock solution, add a mixture of water and acetonitrile (1:1) to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of valsartan in each solution.

$$\text{Amount (mg) of valsartan (C}_{24}\text{H}_{29}\text{N}_5\text{O}_3) \\ = M_S \times A_T/A_S \times 2$$

M_S : Amount (mg) of Valsartan RS taken, calculated on the anhydrous and residual solvent-free basis

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 271 nm).

Column: A stainless steel column 3.0 mm in inside diameter and 12.5 cm in length, packed with octadecylsilanized

silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase A: A mixture of water, acetonitrile and trifluoroacetic acid (900:100:1).

Mobile phase B: A mixture of acetonitrile, water and trifluoroacetic acid (900:100:1).

Flowing of mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 25	90 → 10	10 → 90

Flow rate: Adjust so that the retention time of valsartan is about 16 minutes.

System suitability—

System performance: Dissolve 1 mg of 4-amino-6-chlorobenzene-1,3-disulfonamide in a mixture of water and acetonitrile (1:1) to make 200 mL. To 1 mL of this solution, 5 mL of the valsartan standard stock solution and 5 mL of the hydrochlorothiazide standard stock solution in (2) add a mixture of water and acetonitrile (1:1) to make 20 mL. When the procedure is run with 10 μL of this solution under the above operating conditions, 4-amino-6-chlorobenzene-1,3-disulfonamide, hydrochlorothiazide and valsartan are eluted in this order with the resolution between the peaks of 4-amino-6-chlorobenzene-1,3-disulfonamide and hydrochlorothiazide being not less than 1.5.

System repeatability: When the test is repeated 6 times with 10 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of valsartan is not more than 1.0%.

(2) Hydrochlorothiazide—Weigh accurately the mass of not less than 20 tablets of Valsartan and Hydrochlorothiazide Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 6.25 mg of hydrochlorothiazide ($\text{C}_7\text{H}_8\text{ClN}_3\text{O}_4\text{S}_2$), add 10 mL of water, and shake. Add 10 mL of acetonitrile, shake thoroughly, add a mixture of water and acetonitrile (1:1) to make exactly 50 mL, and centrifuge. Pipet 5 mL of the supernatant liquid, add a mixture of water and acetonitrile (1:1) to make exactly 20 mL, and use this solution as the sample solution. Separately, weigh accurately about 12.5 mg of Hydrochlorothiazide RS, previously dried at 105°C for 2 hours, and dissolve in a mixture of water and acetonitrile (1:1) to make exactly 50 mL, and use this solution as the hydrochlorothiazide standard stock solution. Pipet 2.5 mL of the hydrochlorothiazide standard stock solution, add a mixture of water and acetonitrile (1:1) to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 10 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of hydrochlorothiazide in each solution.

Amount (mg) of hydrochlorothiazide ($\text{C}_7\text{H}_8\text{ClN}_3\text{O}_4\text{S}_2$)
 $= M_S \times A_T/A_S \times 1/2$

M_S : Amount (mg) of Hydrochlorothiazide RS taken

Operating conditions—

Proceed as directed in the operating conditions in (1).

System suitability—

System performance: Dissolve 1 mg of 4-amino-6-chlorobenzene-1,3-disulfonamide in a mixture of water and acetonitrile (1:1) to make 200 mL. To 1 mL of this solution, 5 mL of the valsartan standard stock solution in (1) and 5 mL of the hydrochlorothiazide standard stock solution add a mixture of water and acetonitrile (1:1) to make 20 mL. When the procedure is run with 10 μL of this solution under the above operating conditions, 4-amino-6-chlorobenzene-1,3-disulfonamide, hydrochlorothiazide and valsartan are eluted in this order with the resolution between the peaks of 4-amino-6-chlorobenzene-1,3-disulfonamide and hydrochlorothiazide being not less than 1.5.

System repeatability: When the test is repeated 6 times with 10 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of hydrochlorothiazide is not more than 1.0%.

Add the following:

Verapamil Hydrochloride Injection

ベラパミル塩酸塩注射液

Verapamil Hydrochloride Injection is an aqueous injection.

It contains not less than 93.0% and not more than 107.0% of the labeled amount of verapamil hydrochloride ($\text{C}_{27}\text{H}_{38}\text{N}_2\text{O}_4 \cdot \text{HCl}$: 491.06).

Method of preparation Prepare as directed under Injections, with Verapamil Hydrochloride.

Description Verapamil Hydrochloride Injection is a clear, colorless liquid.

Identification To 1 mL of the sample solution obtained in the Assay, add 0.02 mol/L hydrochloric acid TS to make 50 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 227 nm and 231 nm, and between 276 nm and 280 nm.

pH Being specified separately when the drug is granted approval based on the Law.

Bacterial endotoxins <4.01> Less than 12 EU/mg.

Extractable volume <6.05> It meets the requirement.

Foreign insoluble matter <6.06> Perform the test according to Method 1: it meets the requirement.

Insoluble particulate matter <6.07> It meets the requirement.

Sterility <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

Assay Pipet a volume of Verapamil Hydrochloride Injection, equivalent to about 10 mg of verapamil hydrochloride ($C_{27}H_{38}N_2O_4 \cdot HCl$), add 0.02 mol/L hydrochloric acid TS to make exactly 10 mL, and use this solution as the sample solution. Separately, weigh accurately about 50 mg of verapamil hydrochloride for assay, previously dried at 105°C for 2 hours, dissolve in 0.02 mol/L hydrochloric acid TS to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of verapamil in each solution.

$$\begin{aligned} & \text{Amount (mg) of verapamil hydrochloride} \\ & (C_{27}H_{38}N_2O_4 \cdot HCl) \\ & = M_S \times A_T / A_S \times 1/5 \end{aligned}$$

M_S : Amount (mg) of verapamil hydrochloride for assay taken

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 279 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of methanol, water and perchloric acid (550:450:1).

Flow rate: Adjust so that the retention time of verapamil is about 5 minutes.

System Suitability—

System performance: When the procedure is run with 10 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of verapamil are not less than 2000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of verapamil is not more than 1.0%.

Containers and storage Containers—Hermetic containers, and colored containers may be used.

Storage—Light-resistant.

Delete the following Monograph:

Compound Vitamin B Powder

複方ビタミンB散

Crude Drugs and Related Drugs

Amomum Seed

シュクシャ

Change the Origin/limits of content as follows:

Amomum Seed is the seed mass of *Amomum villosum* Loureiro var. *xanthioides* T. L. Wu & S. J. Chen, *Amomum villosum* Loureiro var. *villosum* or *Amomum longiligulare* T. L. Wu (*Zingiberaceae*).

Artemisia Capillaris Flower

インチンコウ

Change the Description as follows:

Description Capitulum, of ovoid to spherical, about 1.5 – 2 mm in length, about 2 mm in diameter, with linear leaves and pedicels. Outer surface of capitulum, light green to light yellow-brown in color; outer surface of leaf, green to green-brown; outer surface of pedicel, green-brown to dark brown. Under a magnifying glass, at the capitulum, involucre scale in 3 – 4 succubous rows; outer scale, of ovate with obtuse; inner scale, of elliptical, 1.5 mm in length, longer than outer one, with keel midrib and thin membranous margin. Floret, tubular; marginal flower, of female; disk flower, of hermaphrodite. Achene, of obovoid, 0.8 mm in length. Light in texture.

Odor, characteristic, slight; taste, slightly acrid, which gives slightly numbing sensation to the tongue.

Belladonna Root

ベラドンナコン

Change the Description as follows:

Description Cylindrical root, usually 10 – 30 cm in length, 0.5 – 4 cm in diameter; often cut crosswise or lengthwise; externally grayish brown to grayish yellow-brown, with longitudinal wrinkles; periderm often removed; fractured surface is light yellow to light yellow-brown in color and is powdery.

Almost odorless.

Bitter Tincture

苦味チンキ

Change the Identification (2) as follows:

Identification

(2) Use Bitter Tincture as the sample solution. Separately, to 0.5 g of pulverized Bitter Orange Peel add 10 mL of methanol, shake for 5 minutes, filter, and use the filtrate as the standard solution (1). Proceed with 0.5 g each of pulverized Swertia Herb and Japanese Zanthoxylum Peel in the same manner, and use the solutions so obtained as the standard solution (2) and the standard solution (3). Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μ L of the sample solution and 5 μ L each of standard solutions (1), (2) and (3) on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, ethanol (99.5) and water (8:2:1) to a distance of about 7 cm, and air-dry the plate. Examine the plate under ultraviolet light (main wavelength: 254 nm): one of the several spots obtained from the sample solution has the same *R_f* value with the clear spot at an *R_f* value of about 0.7 from the standard solution (3). Spray evenly vanillin-sulfuric acid-ethanol TS for spraying on the plate, and heat the plate at 105°C for 5 minutes: two of the several spots from the sample solution show the same color tone and *R_f* with the clear spot at an *R_f* value of about 0.4 from the standard solution (1), and the clear spot at an *R_f* value of about 0.35 from the standard solution (2).

Bofutsushosan Extract

防風通聖散エキス

Change the Identification (1) as follows:

Identification (1) To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 10 mL of water, shake, then add 10 mL of diethyl ether, shake, and centrifuge. Separate the diethyl ether layer, add 10 mL of sodium hydroxide TS, shake, centrifuge, separate the diethyl ether layer, and use this solution as the sample solution. Separately, use (*Z*)-ligustilide TS for thin-layer chromatography as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 20 μ L of the sample solution and 10 μ L of the standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of butyl acetate and hexane (2:1) to a distance of about 7 cm, and air-dry the plate. Examine

under ultraviolet light (main wavelength: 365 nm): one of the several spots obtained from the sample solution has the same color tone and *R_f* value with the blue-white fluorescent spot from the standard solution (Japanese Angelica Root; Cnidium Rhizome).

Boiogito Extract

防己黄耆湯エキス

Change the Assay (1) as follows:

Assay (1) Sinomenine—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add 20 mL of diethyl ether, shake, then add 5.0 mL of 0.1 mol/L hydrochloric acid TS, and shake for 10 minutes, centrifuge, and remove the upper layer. Add 20 mL of diethyl ether, proceed in the same manner as described above, and remove the upper layer. To the aqueous layer add 5.0 mL of diluted sodium hydroxide TS (1 in 10) and 10 mL of methanol, shake for 15 minutes, centrifuge, and take the supernatant liquid. To the residue add 20 mL of diluted methanol (1 in 2), shake for 15 minutes, centrifuge, and take the supernatant liquid. Combine all the supernatant liquids, add diluted methanol (1 in 2) to make exactly 50 mL, and use this solution as the sample solution. Separately, weigh accurately about 5 mg of sinomenine for assay, dissolve in diluted methanol (1 in 2) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, *A_T* and *A_S*, of sinomenine in each solution.

$$\text{Amount (mg) of sinomenine} = M_S \times A_T/A_S \times 1/2$$

M_S: Amount (mg) of sinomenine for assay taken

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 30°C.

Mobile phase: To 3 g of sodium lauryl sulfate add 350 mL of acetonitrile, shake, then add 650 mL of water and 1 mL of phosphoric acid to dissolve lauryl sulfate.

Flow rate: 1.0 mL per minute (the retention time of sinomenine is about 18 minutes).

System suitability—

System performance: When the procedure is run with 10 μ L each of the sample solution, the standard solution of sinomenine and the standard solution of glycyrrhizic acid obtained in Assay (2) under the above operating conditions, peaks of sinomenine and glycyrrhizic acid are observed in

the sample solution, glycyrrhizic acid and sinomenine are eluted in this order with the resolution between these peaks being not less than 4.5. Furthermore, except for the peak of glycyrrhizic acid, distinct peaks are observed before and after the peak of sinomenine, and the resolutions between sinomenine and these peaks are respectively not less than 1.5.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of sinomenine is not more than 1.5%.

Calumba

コロンボ

Change the Purity (1) as follows:

Purity (1) Heavy metals <1.07>—Proceed with 2.0 g of pulverized Calumba according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 15 ppm).

Powdered Calumba

コロンボ末

Change the Purity (1) as follows:

Purity (1) Heavy metals <1.07>—Proceed with 2.0 g of Powdered Calumba according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 15 ppm).

Cassia Seed

ケツメイシ

Change the Identification as follows:

Identification To 1.0 g of pulverized Cassia Seed add 10 mL of diluted methanol (4 in 5), heat on a water bath for 5 minutes, and filter. Evaporate the solvent of the filtrate, dissolve the residue in 5 mL of water, add 2 mL of ethyl acetate, and shake for 10 minutes. Centrifuge this solution, and use the upper layer as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 10 μ L of the sample solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of diethyl ether, cyclohexane and formic acid (5:5:1) to a distance of about 7 cm, and air-dry the plate. Spray evenly potassium hydroxide-ethanol TS on the plate: an orange to yellow-brown spot appears at an *R_f* value of about 0.35.

Chrysanthemum Flower

キクカ

Change the Description as follows:

Description 1) *Chrysanthemum morifolium* origin—Capitulum, 15 – 40 mm in diameter; involucre, consisting of 3 to 4 rows of involucre scales, often with peduncle; the outer involucre scale, linear to lanceolate; inner involucre scale, narrow ovate to ovate; ligulate flowers, numerous, white to yellow in color; tubular flowers, small in number, light yellow-brown, occasionally degenerate; outer surface of involucre, green-brown to brown; light in texture and easy to break.

Odor, characteristic; taste, slightly bitter.

2) *Chrysanthemum indicum* origin—Capitulum, 3 – 10 mm in diameter; involucre, consisting of 3 to 5 rows of involucre scales, often with peduncle; the outer involucre scale, linear to lanceolate; inner involucre scale, narrow ovate to ovate; ligulate flower, in a single circle, yellow to light yellow-brown in color; tubular flowers, numerous, light yellow-brown; outer surface of involucre, yellow-brown to brown; light in texture and easy to break.

Odor, characteristic; taste, slightly bitter.

Eucalyptus Oil

ユーカリ油

Change the Assay as follows:

Assay Weigh accurately about 0.1 g each of Eucalyptus Oil and cineol for assay, and dissolve each in hexane to make exactly 25 mL. Pipet 5 mL each of these solutions, add exactly 5 mL of the internal standard solution to each, then add hexane to make 100 mL, and use these solutions as the sample solution and the standard solution, respectively. Perform the test with 2 μ L each of the sample solution and standard solution as directed under Gas Chromatography <2.02> according to the following conditions. Calculate the ratios, Q_T and Q_S , of the peak area of cineol to that of the internal standard.

$$\text{Amount (mg) of cineol (C}_{10}\text{H}_{18}\text{O)} = M_S \times Q_T/Q_S$$

M_S : Amount (mg) of cineol for assay taken

Internal standard solution—A solution of anisol in hexane (1 in 250).

Operating conditions—

Detector: A hydrogen flame-ionization detector.

Column: A glass column 3 mm in inside diameter and 5 m in length, packed with silanized porous silica gel for gas chromatography coated in 5% with alkylene glycol phthalate ester for gas chromatography (150 to 180 μ m in particle diameter).

Column temperature: A constant temperature of about

120°C.

Carrier gas: Nitrogen.

Flow rate: Adjust so that the retention time of cineol is about 11 minutes.

System suitability—

System performance: Dissolve 0.1 g each of cineol for assay and limonene in 25 mL of hexane. To 1 mL of this solution add hexane to make 20 mL. When the procedure is run with 2 μ L of this solution under the above operating conditions, limonene and cineol are eluted in this order with the resolution between these peaks being not less than 1.5.

System repeatability: When the test is repeated 6 times with 2 μ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of cineol to that of the internal standard is not more than 1.0%.

Gastrodia Tuber

テンマ

Change the origin/limits of content as follows:

Gastrodia Tuber is the tuber of *Gastrodia elata* Blume (*Orchidaceae*), after being passed through hot water or steamed.

Glycyrrhiza Extract

カンゾウエキス

Change the Method of preparation as follows:

Method of preparation

1) To 1 kg of fine cuttings of Glycyrrhiza or the root and stolon of *Glycyrrhiza glabra* Linné (*Leguminosae*) which meets the requirement of Glycyrrhiza add 5 L of Water, Purified Water or Purified Water in Containers, and macerate for 2 days. Filter the macerated solution through a cloth filter. Add 3 L of Water, Purified Water or Purified Water in Containers to the residue, macerate again for 12 hours, and filter through a cloth filter. Evaporate the combined filtrates until the whole volume becomes 3 L. After cooling, add 1 L of Ethanol, and allow to stand in a cold place for 2 days. Filter, and evaporate the filtrate to a viscous extract.

2) Take Glycyrrhiza or the root and stolon of *Glycyrrhiza glabra* Linné (*Leguminosae*) which meets the requirement of Glycyrrhiza, pulverized to suitable sizes, and prepare the viscous extract as directed under Extracts using Water, Purified Water or Purified Water in Containers as the solvent. Immediately before making a millet jelly-like consistency for the viscous extract, add Ethanol, Anhydrous Ethanol or ethanol (99.5) to the extract, allow it to stand in a cold place, filter, and concentrate the filtrate to prepare.

Crude Glycyrrhiza Extract

カンゾウ粗エキス

Change the Method of preparation as follows:

Method of preparation Take Glycyrrhiza or the root and stolon of *Glycyrrhiza glabra* Linné (*Leguminosae*) which meets the requirement of Glycyrrhiza, pulverized to suitable sizes, and prepare the dry extracts as directed under Extracts using Water, Purified Water or Purified Water in Containers as the solvent.

Add the following:

Goshuyuto Extract

呉茱萸湯エキス

Goshuyuto Extract contains not less than 0.3 mg (for preparation prescribed 3 g of Euodia Fruit) or not less than 0.4 mg (for preparation prescribed 4 g of Euodia Fruit) of evodiamine, and not less than 0.5 mg and not more than 2.0 mg (for preparation prescribed 1 g of Ginger) or not less than 0.7 mg and not more than 2.8 mg (for preparation prescribed 1.5 g of Ginger) of [6]-gingerol, per extract prepared with the amount specified in the Method of preparation.

Method of preparation

	1)	2)	3)
Euodia Fruit	3 g	4 g	3 g
Ginger	1 g	1.5 g	1.5 g
Ginseng	2 g	3 g	2 g
Jujube	4 g	3 g	4 g

Prepare a dry extract or viscous extract as directed under Extracts, according to the prescription 1) to 3), using the crude drugs shown above.

Description Goshuyuto Extract occurs as a light brown to light red-yellow powder, or a black-brown viscous extract. It has a slight odor and a hot and bitter taste.

Identification (1) To 1.0 g of the dry extract (or 3.0 g of the viscous extract) add 10 mL of sodium hydroxide TS, shake, add 5 mL of 1-butanol, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, to 1 g of pulverized euodia fruit add 10 mL of methanol, shake, centrifuge, and use the supernatant liquid as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 1 μ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of acetone, 2-propanol, water and formic acid (7:7:1:1) to a distance of about 7 cm, and air-dry the plate. Examine under ultraviolet light (main

wavelength: 365 nm): one of the several spots obtained from the sample solution has the same color tone and *R_f* value with the blue-white fluorescent spot (*R_f* value: about 0.5) from the standard solution (Euodia Fruit).

(2) To 1.0 g of the dry extract (or 3.0 g of the viscous extract) add 10 mL of water, shake, add 25 mL of diethyl ether, and shake. Separate the diethyl ether layer, evaporate the solvent under reduced pressure, add 2 mL of diethyl ether to the residue, and use this solution as the sample solution. Separately, dissolve 1 mg of [6]-gingerol for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μ L of the sample solution and 5 μ L of the standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 7 cm, and air-dry the plate. Spray evenly 4-dimethylaminobenzaldehyde TS for spraying on the plate, heat the plate at 105°C for 5 minutes, allow to cool, and spray water: one of the several spots obtained from the sample solution has the same color tone and *R_f* value with the blue-green to grayish green spot from the standard solution (Ginger).

(3) To 1.0 g of the dry extract (or 3.0 g of the viscous extract) add 10 mL of sodium hydroxide TS, shake, add 5 mL of 1-butanol, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of ginsenoside R_{b1} for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5 μ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, 1-propanol, water and acetic acid (100) (7:5:4:1) to a distance of about 7 cm, and air-dry the plate. Spray evenly vanillin-sulfuric acid-ethanol TS for spraying on the plate, heat the plate at 105°C for 5 minutes, and allow to cool: one of the several spots obtained from the sample solution has the same color tone and *R_f* value with the blue-purple spot from the standard solution (Ginseng).

Purity (1) Heavy metals <1.07>—Prepare the test solution with 1.0 g of the dry extract (or an amount of the viscous extract, equivalent to 1.0 g of the dried substance) as directed under Extracts (4), and perform the test (not more than 30 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.67 g of the dry extract (or an amount of the viscous extract, equivalent to 0.67 g of the dried substance) according to Method 3, and perform the test (not more than 3 ppm).

Loss on drying <2.41> The dry extract: Not more than 11.0% (1 g, 105°C, 5 hours).

The viscous extract: Not more than 66.7% (1 g, 105°C, 5 hours).

Total ash <5.01> Not more than 10.0%, calculated on the dried basis.

Assay (1) Evodiamine—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of diluted methanol (7 in 10), shake for 30 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of evodiamine for assay, and dissolve in methanol to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of evodiamine in each solution.

$$\text{Amount (mg) of evodiamine} = M_S \times A_T/A_S \times 1/4$$

M_S : Amount (mg) of evodiamine for assay taken, calculated on the basis of the content obtained by qNMR

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 282 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of water, acetonitrile and phosphoric acid (620:380:1).

Flow rate: 1.0 mL per minute (the retention time of evodiamine is about 18 minutes).

System suitability—

System performance: When the procedure is run with 10 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of evodiamine are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of evodiamine is not more than 1.5%.

(2) [6]-Gingerol—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of diluted methanol (7 in 10), shake for 30 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of [6]-gingerol for assay, dissolve in methanol to make exactly 100 mL. Pipet 5 mL of this solution, add methanol to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, A_T and A_S , of [6]-gingerol in each solution.

$$\text{Amount (mg) of [6]-gingerol} = M_S \times A_T/A_S \times 1/20$$

M_S : Amount (mg) of [6]-gingerol for assay taken

Operating conditions—

Detector, column, column temperature and mobile phase:

Proceed as directed in the operating conditions in (1).

Flow rate: 1.0 mL per minute (the retention time of [6]-gingerol is about 14 minutes).

System suitability—

System performance: When the procedure is run with 10 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of [6]-gingerol are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of [6]-gingerol is not more than 1.5%.

Containers and storage Containers—Tight containers.

Hochuekkito Extract

補中益気湯エキス

Change the Identification (5) as follows:

Identification

(5) To 3.0 g of the dry extract (or 9.0 g of the viscous extract) add 30 mL of water, shake, then add 50 mL of diethyl ether, shake, and separate the diethyl ether layer. Evaporate the layer under reduced pressure, add 1 mL of diethyl ether to the residue, and use this solution as the sample solution. Separately, use (*Z*)-ligustilide TS for thin-layer chromatography as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 7 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): one of the several spots obtained from the sample solution has the same color tone and *R_f* value with the blue-white fluorescent spot from the standard solution (Japanese Angelica Root).

Japanese Angelica Root

トウキ

Add the following next to the Description as follows:

Identification To 1.0 g of pulverized Japanese Angelica Root add 5 mL of methanol, shake for 10 minutes, centrifuge, and use the supernatant liquid as the sample solution. Separately, use (*Z*)-ligustilide TS for thin-layer chromatography as the standard solution (1). Dissolve 1 mg of scopoletin for thin-layer chromatography in 10 mL of methanol, and use this solution as the standard solution (2). Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μ L of the sam-

ple solution and 5 μL each of the standard solutions (1) and (2) on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of hexane, acetone and acetic acid (100) (30:25:1) to a distance of about 7 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): two of the several spots obtained from the sample solution have the same color tones and *R_f* values with the corresponding blue-white fluorescent spots from the standard solutions (1) and (2).

Powdered Japanese Angelica Root

トウキ末

Add the following next to the Description as follows:

Identification To 1.0 g of Powdered Japanese Angelica Root add 5 mL of methanol, shake for 10 minutes, centrifuge, and use the supernatant liquid as the sample solution. Separately, use (*Z*)-ligustilide TS for thin-layer chromatography as the standard solution (1). Dissolve 1 mg of scopoletin for thin-layer chromatography in 10 mL of methanol, and use this solution as the standard solution (2). Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μL of the sample solution and 5 μL each of the standard solutions (1) and (2) on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of hexane, acetone and acetic acid (100) (30:25:1) to a distance of about 7 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): two of the several spots obtained from the sample solution have the same color tones and *R_f* values with the corresponding blue-white fluorescent spots from the standard solutions (1) and (2).

Juzentaihoto Extract

十全大補湯エキス

Change the Identification (5) as follows:

Identification

(5) Shake 1.0 g of the dry extract (or 3.0 g of the viscous extract) with 15 mL of water and 5 mL of 0.1 mol/L hydrochloric acid TS, add 25 mL of diethyl ether, and shake. Separate the diethyl ether layer, evaporate the layer under reduced pressure, then add 2 mL of diethyl ether to the residue, and use this solution as the sample solution. Separately, use (*Z*)-ligustilide TS for thin-layer chromatography as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μL each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 7 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength:

365 nm): one of the several spots obtained from the sample solution has the same color tone and *R_f* value with the blue-white fluorescent spot from the standard solution (Cnidium Rhizome; Japanese Angelica Root).

Kakkontokasenkyushin'i Extract

葛根湯加川芎辛夷エキス

Change the Identification (7) as follows:

Identification

(7) Shake 1.0 g of the dry extract (or 3.0 g of the viscous extract) with 15 mL of water and 5 mL of 0.1 mol/L hydrochloric acid TS, and then shake with 25 mL of diethyl ether. Separate the diethyl ether layer, evaporate the solvent under reduced pressure, then dissolve the residue in 2 mL of diethyl ether, and use this solution as the sample solution. Separately, use (*Z*)-ligustilide TS for thin-layer chromatography as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μL each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 7 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): one of the several spots obtained from the sample solution has the same color tone and *R_f* value with the blue-white fluorescent spot from the standard solution (Cnidium Rhizome).

Kamikihito Extract

加味帰脾湯エキス

Change the Identification (5) as follows:

Identification

(5) To 3.0 g of the dry extract (or 9.0 g of the viscous extract) add 15 mL of water, shake, then add 25 mL of diethyl ether, and shake. Separate the diethyl ether layer, evaporate the solvent under reduced pressure, then add 2 mL of diethyl ether to the residue, and use the solution as the sample solution. Separately, use (*Z*)-ligustilide TS for thin-layer chromatography as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μL of the sample solution and 2 μL of the standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of butyl acetate and hexane (2:1) to a distance of about 7 cm, and air-dry the plate. Examine the plate under ultraviolet light (main wavelength: 365 nm): one of the several spots obtained from the sample solution has the same color tone and *R_f* value with the blue-white fluorescent spot from the standard solution (Japanese Angelica Root).

Kamishoyosan Extract

加味逍遙散エキス

Change the Identification (1) as follows:

Identification (1) To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 10 mL of water, shake, then add 5 mL of diethyl ether, shake, centrifuge, and use the diethyl ether layer as the sample solution. Separately, use (*Z*)-ligustilide TS for thin-layer chromatography as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 7 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): one of the several spots obtained from the sample solution has the same color tone and *R_f* value with the blue-white fluorescent spot from the standard solution (Japanese Angelica Root).

Lithospermum Root

シコン

Change the Purity (1) as follows:

Purity (1) Heavy metals <1.07>—Proceed with 2.0 g of pulverized Lithospermum Root according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 15 ppm).

Lycium Bark

ジコッピ

Change the Purity (1) as follows:

Purity (1) Heavy metals <1.07>—Proceed with 2.0 g of pulverized Lycium Bark according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 15 ppm).

Nux Vomica

ホミカ

Change the Description as follows:

Description Disk, often slightly bent, 1–3 cm in diameter, 0.3–0.5 cm in thickness; externally light grayish yellow-green to light grayish brown, covered densely with lustrous appressed hairs radiating from the center to the circumference; on both sides, the margin and the central part

bulged a little; the dot-like micropyle situated at one point on the margin, and from which usually a raised line runs to the center on one side; extremely hard in texture; when cracked upon soaking in water, the seed coat thin, the interior consisting of two horny, light grayish yellow endosperms, and leaving a central narrow cavity at the center; a white embryo, about 0.7 cm in length, situated at one end between the inner surfaces of the endosperms.

Odorless.

Oriental Bezoar

ゴオウ

Change the origin/limits of content:

Oriental Bezoar is a stone formed in the gall sac of *Bos taurus* Linné var. *domesticus* Gmelin (*Bovidae*).

It contains not less than 10.0% of bilirubin.

Delete the Identification (2):

Add the following next to the Total ash:

Assay Conduct this procedure without exposure to light using light-resistant vessels. The following sample solution and standard solution should be prepared before use. Weigh accurately about 10 mg of pulverized Oriental Bezoar, add 10 mL of a mixture of dimethyl sulfoxide and acetic acid (100) (9:1), warm at 60°C for 20 minutes, and add a mixture of dimethyl sulfoxide and acetic acid (100) (9:1) to make exactly 50 mL. Pipet 5 mL of this solution, add the mobile phase to make exactly 50 mL, filter through a membrane filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of bilirubin for assay, add about 350 mg of L-ascorbic acid, and dissolve in a mixture of dimethyl sulfoxide and acetic acid (100) (9:1) to make exactly 100 mL. Pipet 5 mL of this solution, add the mobile phase to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, *A_T* and *A_S*, of bilirubin in each solution.

$$\text{Amount (mg) of bilirubin} = M_S \times A_T/A_S \times 1/2$$

M_S: Amount (mg) of bilirubin for assay taken

Operating conditions—

Detector: A visible absorption photometer (wavelength: 450 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 30°C.

Mobile phase: A mixture of acetonitrile and diluted acetic

acid (100) (1 in 100) (19:1).

Flow rate: Adjust so that the retention time of bilirubin is about 10 minutes.

System suitability—

System performance: When the procedure is run with 10 μL of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of bilirubin are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of bilirubin is not more than 1.5%.

Delete the Content of the active principle:

Otsujito Extract

乙字湯エキス

Change the Identification (1) as follows:

Identification (1) Shake 2.0 g of the dry extract (or 6.0 g of the viscous extract) with 10 mL of water, add 10 mL of diethyl ether, shake, and centrifuge. Separate the diethyl ether layer, add 10 mL of sodium hydroxide TS, shake, centrifuge, separate the diethyl ether layer, and use this layer as the sample solution. Separately, use (*Z*)-ligustilide TS for thin-layer chromatography as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μL each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of butyl acetate and hexane (2:1) to a distance of about 7 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): one of the several spots obtained from the sample solution has the same color tone and *R_f* value with the blue-white fluorescent spot from the standard solution (Japanese Angelica Root).

Platycodon Root

キキヨウ

Delete the Identification (1), move up (2) to (1) and add the following next to (1):

Identification

(2) To 2.0 g of pulverized Platycodon Root add 20 mL of sodium carbonate TS, and shake. Add 5 mL of 1-butanol, shake for 10 minutes, centrifuge, and use the 1-butanol layer as the sample solution. Separately, dissolve 1 mg of platycodin D for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5 μL each of the sample solution and standard solution on a plate of silica

gel for thin-layer chromatography. Develop the plate with a mixture of 1-propanol, ethyl acetate, water and acetic acid (100) (5:3:2:1) to a distance of about 7 cm, and air-dry the plate. Spray evenly dilute sulfuric acid on the plate, and heat the plate at 105°C for 5 minutes: one of the several spots obtained from the sample solution and a spot from the standard solution show the same color tone and the same *R_f* value.

Powdered Platycodon Root

キキヨウ末

Delete the Identification (1), move up (2) to (1) and add the following next to (1):

Identification

(2) To 2.0 g of Powdered Platycodon Root add 20 mL of sodium carbonate TS, and shake. Add 5 mL of 1-butanol, shake for 10 minutes, centrifuge, and use the 1-butanol layer as the sample solution. Separately, dissolve 1 mg of platycodin D for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5 μL each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of 1-propanol, ethyl acetate, water and acetic acid (100) (5:3:2:1) to a distance of about 7 cm, and air-dry the plate. Spray evenly dilute sulfuric acid on the plate, and heat the plate at 105°C for 5 minutes: one of the several spots obtained from the sample solution and a spot from the standard solution show the same color tone and the same *R_f* value.

Platycodon Fluidextract

キキヨウ流エキス

Change the Method of preparation and Identification as follows:

Method of preparation 1) Take coarse powder of Platycodon Root, and prepare the fluidextract as directed under Fluidextracts using 25 vol% ethanol. An appropriate quantity of Ethanol and Purified Water or Purified Water in Containers may be used in place of 25 vol% ethanol.

2) Take Platycodon Root pulverized to suitable sizes, and prepare the fluidextract as directed under Fluidextracts using 25 vol% ethanol or diluted ethanol (1 in 4) as the solvent.

Identification To 2 mL of Platycodon Fluidextract add 20 mL of water and 5 mL of 1-butanol, mix, shake for 10 minutes, centrifuge, and use the 1-butanol layer as the sample solution. Separately, dissolve 1 mg of platycodin D for thin-layer chromatography in 1 mL of methanol, and use

this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5 μL each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of 1-propanol, ethyl acetate, water and acetic acid (100) (5:3:2:1) to a distance of about 7 cm, and air-dry the plate. Spray evenly dilute sulfuric acid on the plate, and heat the plate at 105°C for 5 minutes: one of the several spots obtained from the sample solution has the same color tone and R_f value with the spot from the standard solution.

Add the following next to the Identification:

Alcohol number <1.01> Apply to Platycodon Fluidextract prepared by the Method of preparation 2). 2.0–3.0 (Method 1).

Change the Content of the active principle as follows:

Content of the active principle Transfer exactly 5 mL of Platycodon Fluidextract to a tared beaker or porcelain dish, evaporate to dryness on a water bath, and dry at 105°C for 5 hours: the mass of the residue is not less than 0.50 g.

Polygala Root

オンジ

Change the Identification (2) as follows:

Identification

(2) To 1.0 g of pulverized Polygala Root add 10 mL of a solution of sodium hydroxide (1 in 10), and heat under a reflux condenser on a water bath for 20 minutes. After cooling, add 10 mL of dilute hydrochloric acid, and shake. After cooling, add 10 mL of 1-butanol, shake for 10 minutes, centrifuge, and use the upper layer as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 5 μL of the sample solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol, water and acetic acid (100) (20:4:2:1) to a distance of about 7 cm, and air-dry the plate. Spray evenly dilute sulfuric acid on the plate, and heat the plate at 105°C for 10 minutes: a red-brown to light brown spot appears at an R_f value of about 0.35.

Powdered Polygala Root

オンジ末

Change the Identification (2) as follows:

Identification

(2) To 1.0 g of Powdered Polygala Root add 10 mL of a solution of sodium hydroxide (1 in 10), and heat under a

reflux condenser on a water bath for 20 minutes. After cooling, add 10 mL of dilute hydrochloric acid, and shake. After cooling, add 10 mL of 1-butanol, shake for 10 minutes, centrifuge, and use the upper layer as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 5 μL of the sample solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol, water and acetic acid (100) (20:4:2:1) to a distance of about 7 cm, and air-dry the plate. Spray evenly dilute sulfuric acid on the plate, and heat the plate at 105°C for 10 minutes: a red-brown to light brown spot appears at an R_f value of about 0.35.

Safflower

コウカ

Change the Identification as follows:

Identification To 1.0 g of pulverized Safflower add 10 mL of a mixture of acetone and water (4:1), shake for 10 minutes, filter, and use the filtrate as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 5 μL of the sample solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, water, formic acid and methanol (35:15:10:2) to a distance of about 7 cm, and air-dry the plate: a red spot appears at an R_f value of about 0.5.

Saposhnikovia Root and Rhizome

ボウフウ

Change the Purity (1) as follows:

Purity (1) Heavy metals <1.07>—Proceed with 2.0 g of pulverized Saposhnikovia Root and Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 15 ppm).

Add the following next to the Purity (3):

Purity

(4) Peucedanum ledebourielloides—Place 1.0 g of pulverized Saposhnikovia Root and Rhizome in a glass-stoppered centrifuge tube, add 5 mL of hexane, shake for 10 minutes, centrifuge, and use the supernatant liquid as the sample solution. Separately, place 1.0 g of peucedanum-ledebourielloides for purity in a glass-stoppered centrifuge tube, add 5 mL of hexane, shake for 10 minutes, centrifuge, and use the supernatant liquid as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5 μL each of the sample solution and standard solution on a plate of silica gel for

thin-layer chromatography. Develop the plate with a mixture of hexane, ethyl acetate and acetic acid (100) (20:10:1) to a distance of about 7 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): the sample solution shows no spot corresponding to the blue fluorescent spot at an *R_f* value of about 0.4 obtained from the standard solution.

Scopolia Rhizome

ロートコン

Change the Description as follows:

Description Chiefly irregularly branched, slightly curved rhizome, about 15 cm in length, about 3 cm in diameter, occasionally longitudinally cut; externally grayish brown, with wrinkles; constrictions make the rhizome appear nodular; rarely, stem base at one end; stem scars at upper side of each node; roots or root scars on both sides and lower surface of rhizome; fractured surface granular, grayish white to light brown in color, with lighter colored cortex.

Odor characteristic.

Under a microscope <5.01>, xylem reveals groups of vessels arranged stepwise, and accompanied with xylem sieve tubes in medullary rays; parenchyma cells contain starch grains, and sometimes sand crystals of calcium oxalate.

Sinomenium Stem and Rhizome

ボウイ

Change the Identification as follows:

Identification To 1.0 g of pulverized Sinomenium Stem and Rhizome add 5 mL of methanol, shake for 10 minutes, filter, and use the filtrate as the sample solution. Separately, dissolve 1 mg of sinomenine for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μ L of the sample solution and 5 μ L of the standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl formate, 1-propanol, water and acetic acid (100) (3:3:2:2) to a distance of about 7 cm, and air-dry the plate. Spray evenly Dragendorff's TS for spraying on the plate, air-dry the plate, and spray evenly sodium nitrite TS on the plate: one of the several spots obtained from the sample solution and the spot from the standard solution show the same color tone and the same *R_f* value. Further, a spot with the same color tone appears immediately below the spot.

Swertia Herb

センブリ

Change the Identification as follows:

Identification To 0.5 g of pulverized Swertia Herb add 10 mL of methanol, shake for 5 minutes, filter, and use the filtrate as the sample solution. Separately, dissolve 1 mg of Swertiamarin RS or swertiamarin for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5 μ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, ethanol (99.5) and water (8:2:1) to a distance of about 7 cm, and air-dry the plate. Spray evenly vanillin-sulfuric acid-ethanol TS for spraying on the plate, and heat the plate at 105°C for 5 minutes: one of the several spots obtained from the sample solution and the spot from the standard solution show the same color tone and *R_f* value.

Powdered Swertia Herb

センブリ末

Change the Identification as follows:

Identification To 0.5 g of Powdered Swertia Herb add 10 mL of methanol, shake for 5 minutes, filter, and use the filtrate as the sample solution. Separately, dissolve 1 mg of Swertiamarin RS or swertiamarin for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5 μ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, ethanol (99.5) and water (8:2:1) to a distance of about 7 cm, and air-dry the plate. Spray evenly vanillin-sulfuric acid-ethanol TS for spraying on the plate, and heat the plate at 105°C for 5 minutes: one of the several spots obtained from the sample solution and the spot from the standard solution show the same color tone and *R_f* value.

Swertia and Sodium Bicarbonate Powder

センブリ・重曹散

Change the Identification (1) as follows:

Identification (1) To 10 g of Swertia and Sodium Bicarbonate Powder add 10 mL of ethanol (95), shake for 15 minutes, filter, and use the filtrate as the sample solution.

Separately, dissolve 2 mg of Swertiamarin RS or swertiamarin for thin-layer chromatography in 1 mL of ethanol (95), and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μ L of the sample solution and 5 μ L of the standard solution on a plate of silica gel for thin-layer chromatography. Proceed as directed in the Identification under Powdered Swertia Herb.

Toad Cake

センソ

Change the Description as follows:

Description A round disk with slightly dented bottom and protuberant surface, about 8 cm in diameter, about 1.5 cm in thickness, the mass of one disk being about 80 to 90 g; or a round disk with almost flattened surfaces on both sides, about 3 cm in diameter, and about 0.5 cm in thickness, the mass of one disk being about 8 g; externally red-brown to black-brown, somewhat lustrous, approximately uniform and horny, hard in texture, and difficult to break; fractured surface nearly flat, and edges of broken pieces red-brown and translucent.

Odorless.

Tokishakuyakusan Extract

当帰芍薬散エキス

Change the Identification (1) as follows:

Identification (1) Shake 1.0 g of the dry extract (or 3.0 g of the viscous extract) with 15 mL of water and 5 mL of 0.1 mol/L hydrochloric acid TS, then add 25 mL of diethyl ether, and shake. Separate the diethyl ether layer, evaporate the layer under reduced pressure, add 2 mL of diethyl ether to the residue, and use this solution as the sample solution. Separately, use (*Z*)-ligustilide TS for thin-layer chromatography as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography, develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 7 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): one of the several spots obtained from the sample solution has the same color tone and *R_f* value with the blue-white fluorescent spot from the standard solution (Japanese Angelica Root; Cnidium Rhizome).

Change the Assay (1) as follows:

Assay (1) (*E*)-Ferulic acid—Conduct this procedure without exposure to light, using light-resistant vessels. Weigh accurately about 0.5 g of the dry extract (or an

amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of diluted methanol (1 in 2), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of (*E*)-ferulic acid for assay, and dissolve in diluted methanol (1 in 2) to make exactly 100 mL. Pipet 2 mL of this solution, add diluted methanol (1 in 2) to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 10 μ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, *A_T* and *A_S*, of (*E*)-ferulic acid in each solution.

$$\text{Amount (mg) of (E)-ferulic acid} = M_S \times A_T/A_S \times 1/50$$

M_S: Amount (mg) of (*E*)-ferulic acid for assay taken

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 320 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: Dissolve 7.8 g of sodium dihydrogen phosphate in 1000 mL of water, and add 2 mL of phosphoric acid. To 850 mL of this solution add 150 mL of acetonitrile.

Flow rate: 1.0 mL per minute [the retention time of (*E*)-ferulic acid is about 10 minutes].

System suitability—

System performance: When the procedure is run with 10 μ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of (*E*)-ferulic acid are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of (*E*)-ferulic acid is not more than 1.5%.

Yokukansan Extract

抑肝散エキス

Change the Identification (1) as follows:


Identification (1) To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 10 mL of water, shake, then add 10 mL of diethyl ether, shake, and centrifuge. Separate the diethyl ether layer, add 10 mL of sodium hydroxide TS, shake, centrifuge, separate the diethyl ether layer, and use this layer as the sample solution. Separately, use (*Z*)-ligustilide TS for thin-layer chromatography as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 μ L each of the sample solution and standard solution on a plate of

silica gel for thin-layer chromatography. Develop the plate with a mixture of butyl acetate and hexane (2:1) to a distance of about 7 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): one of the several spots obtained from the sample solution has the same color tone and *R_f* value with the blue-white fluorescent spot from the standard solution (Japanese Angelica Root; Cnidium Rhizome).


Infrared Reference Spectra

Add the following spectra:


Bromfenac Sodium Hydrate






Doripenem Hydrate






Ethylcellulose



The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)


Felodipine**Gatifloxacin Hydrate****Irinotecan Hydrochloride Hydrate**

Lanocnazole**Polaprezinc****Sitagliptin Phosphate Hydrate**


Ultraviolet-visible Reference Spectra

Add the following spectra:


Bromfenac Sodium Hydrate






Doripenem Hydrate




Felodipine



The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)

Gatifloxacin Hydrate**Irinotecan Hydrochloride Hydrate****Lanconazole**



General Information

GENERAL INFORMATION

G1 Physics and Chemistry

Add the following:

Control of Elemental Impurities in Drug Products

1. Introduction

Elemental impurities in drug products may arise from several sources; they may be residues intentionally added such as catalysts in the synthetic process of drug substances, drug substances being components of the drug product, impurities from natural products contained in additives, etc., and contaminants from manufacturing equipment and container/closure systems. The amounts of these impurities in drug products should be controlled within acceptable limits, except when they are stipulated in monographs.

The permitted daily exposures (PDEs) of elemental impurities are established to protect the health of all patients based on the evaluation of the toxic data of elemental impurities, and more strict limits are not needed if elemental impurities in drug products do not exceed the PDEs. In some cases, lower level of elemental impurities may be warranted when it is known that elemental impurities have been shown to have an impact on the quality attributes of the drug product (e.g., element catalyzed degradation of drug substances).

Elemental impurities in drug products are assessed and controlled based on a risk management approach.

2. Scope

The acceptable limit of elemental impurities apply to drug products, and also apply to drug products containing purified proteins and polypeptides (including proteins and polypeptides produced from genetic recombinant or non-recombinant origins), their derivatives, and drug products which they are components (e.g., conjugates) are within the scope of this guideline, as are drug products containing synthetic polypeptides, polynucleotides, and oligosaccharides.

It does not apply to crude drugs, radiopharmaceuticals, vaccines, cell metabolites, DNA products, allergenic extracts, cells, whole blood, cellular blood components, blood derivatives including plasma and plasma preparations, dialysate solutions not intended for systematic circulation, and drug products based on genes (gene therapy), cells (cell therapy) and tissues (tissue engineering). Also, it does not apply to elements that are intentionally included in the drug product for therapeutic benefit.

3. The PDEs for Elemental Impurities for Oral, Parenteral and Inhalation Routes of Administration, and Element Classification

The PDEs of elemental impurities established for preparations for oral, parenteral and inhalation routes of administration are shown in Table 1. If the PDEs for the other administration route are necessary, generally consider the oral PDE as a starting point in the establishment, and assess if the elemental impurity is expected to have local effects when administered by the intended route of administration.

Parenteral drug products with maximum daily volumes up to 2 L may use the maximum daily volume to calculate permissible concentrations from PDEs. For products whose daily volumes or general clinical practice may exceed 2 L (e.g., saline, dextrose, total parenteral nutrition, solutions for irrigation), a 2-L volume is used to calculate permissible concentrations from PDEs.

As shown in Table 1, elemental impurities are divided into three classes based on their toxicity (PDE) and likelihood of occurrence in the drug product. The likelihood of occurrence is judged from several factors, such as probab-

Table 1 PDEs for Elemental Impurities

Element	Class	Oral PDE ($\mu\text{g}/\text{day}$)	Parenteral PDE ($\mu\text{g}/\text{day}$)	Inhalation PDE ($\mu\text{g}/\text{day}$)
Cd	1	5	2	2
Pb	1	5	5	5
As	1	15	15	2
Hg	1	30	3	1
Co	2A	50	5	3
V	2A	100	10	1
Ni	2A	200	20	5
Tl	2B	8	8	8
Au	2B	100	100	1
Pd	2B	100	10	1
Ir	2B	100	10	1
Os	2B	100	10	1
Rh	2B	100	10	1
Ru	2B	100	10	1
Se	2B	150	80	130
Ag	2B	150	10	7
Pt	2B	100	10	1
Li	3	550	250	25
Sb	3	1200	90	20
Ba	3	1400	700	300
Mo	3	3000	1500	10
Cu	3	3000	300	30
Sn	3	6000	600	60
Cr	3	11000	1100	3

ity of use in pharmaceutical processes, impurities in materials used in pharmaceutical processes, the observed natural abundance and environmental distribution of the element.

Class 1: The elements, As, Cd, Hg, and Pb, are classified as this category and are human toxicant elements. As these elements are limited in the manufacture of pharmaceuticals, they are rarely used. Their presence in drug products usually comes from used materials such as mined excipients. These four elements require evaluation during the risk assessment, across all sources and routes of administration having possibility of contamination. Testing should only be applied when the risk assessment identifies it necessary to ensure that the PDE will be met, however it is not necessary for all components to determine for Class 1 elemental impurities.

Class 2: Elemental impurities classified as Class 2 have lower toxicity than the elements in Class 1, and are route-dependent human toxicants. These elements are further divided in 2A and 2B based on their relative likelihood of occurrence in the drug products. The class 2A elements are Co, Ni and V, which are known to exist naturally. These elements have relatively high probability of occurrence in drug products, and thus require evaluation during the risk assessment, across all sources and routes of administration having possibility of contamination. Because the Class 2B elements have the low probability of their existence in natural, they may be excluded from the risk assessment unless they are intentionally added during the manufacture of drug substances, excipients or other components of the drug product. The elemental impurities in Class 2B include Ag, Au, Ir, Os, Pd, Pt, Rh, Ru, Se and Tl.

Class 3: The elements in this class have relatively low toxicities by the oral route of administration, and their oral PDEs are more than 500 $\mu\text{g}/\text{day}$. For oral routes of administration, unless these elements are intentionally added, they do not need to be considered during the risk assessment. For parenteral and inhalation products, the potential for inclusion of these elemental impurities should be evaluated even in the case where they are not intentionally added, unless the route specific PDE is above 500 $\mu\text{g}/\text{day}$. The elements in this class include Ba, Cr, Cu, Li, Mo, Sb and Sn.

4. Risk Assessment and Control of Elemental Impurities

The technique of quality risk management should be considered in controls for elemental impurities in drug products, and the risk assessment should be based on scientific knowledge and principles. The risk assessment would be focused on assessing the levels of elemental impurities in a drug product in relation to the PDEs. Useful information for this risk assessment includes measured data of drug products and components, measured data and the risk assessment result supplied by drug substance and/or excipient manufacturers, and/or data available in published literature, but is not limited to them.

The risk assessment should be performed depending on the level of risk, and do not always require a formal risk management process. The use of informal risk management processes may also be considered acceptable.

4.1. General Principles

The risk assessment process consists of the following three steps.

1) Identify known and potential sources of elemental impurities that may find their way into the drug product.

2) Evaluate the presence of a particular elemental impurity in the drug product by determining the observed or predicted level of the impurity and comparing with the established PDE.

3) Summarize the risk assessment, and identify if controls built into the process are sufficient. Identify additional controls to be considered to limit elemental impurities in the drug product.

In many cases, the steps are considered simultaneously. The risk assessment may be iterated to develop a final approach to ensure the elemental impurities do not exceed the PDE certainly.

4.2. Source of Elemental Impurities

In considering the production of a drug product, there are broad categories of potential sources of elemental impurities.

- Residual impurities resulting from elements intentionally added (e.g., metal catalysts) in the formation of the drug substance, excipients or other components. The risk assessment of the drug substance should be studied about the potential for inclusion of elemental impurities in the drug product.
- Elemental impurities that are not intentionally added and are potentially present in the drug substance, water or excipients used in the preparation of the drug product.
- Elemental impurities that are potentially introduced into the drug substance and/or drug product from manufacturing equipment.
- Elemental impurities that have the potential to be leached into the drug substance and drug product from container closure systems.

During the risk assessment, the potential contributions from each of these sources should be considered to determine the overall contribution of elemental impurities to the drug product.

4.3. Identification of Potential Elemental Impurities

Potential elemental impurities derived from intentionally added catalysts and inorganic reagents: If any element is intentionally added, it should be considered in the risk assessment.

Potential elemental impurities that may be present in drug substances and excipients: While not intentionally added, some elemental impurities may be present in some drug substances and excipients. The possibility for inclusion of these elements in the drug product should be reflected in the risk assessment.

Potential elemental impurities derived from manufacturing equipment: The contribution of elemental impurities from this source may be limited and the subset of elemental impurities that should be considered in the risk assessment will depend on the manufacturing equipment used in the production of the drug product. The specific elemental

impurities of concern should be assessed based on the knowledge of the composition of the components of the manufacturing equipment that come in contact with components of the drug product. The risk assessment of this source of elemental impurities is one that can potentially be utilized for many drug products using similar process trains or processes.

In general, the processes used to prepare a given drug substance are considerably more aggressive than processes used in preparing the drug product when assessed relative to the potential to leach or remove elemental impurities from manufacturing equipment. Contributions of elemental impurities from drug product processing equipment would be expected to be lower than contributions observed for the drug substance. However, when this is not the case based on process knowledge or understanding, the potential for incorporation of elemental impurities from the drug product manufacturing equipment in the risk assessment (e.g., hot melt extrusion) should be considered.

Elemental impurities leached from container closure systems: The identification of potential elemental impurities that may be introduced from container closure systems should be based on a scientific understanding of likely interactions between a particular drug product type and its packaging. When a review of the materials of construction demonstrates that the container closure system does not contain elemental impurities, no additional risk assessment needs to be performed. It is recognized that the probability of elemental leaching into solid dosage forms is minimal and does not require further consideration in the risk assessment. For liquid and semi-solid dosage forms there is a higher probability that elemental impurities could leach from the container closure system during the shelf-life of the drug product. Studies to understand potential leachables from the container closure system (after washing, sterilization, irradiation, etc.) should be performed.

Factors that should be considered (for liquid and semi-solid dosage forms) are shown as follows, but are not limited.

- Hydrophilicity/hydrophobicity, Ionic content, pH, Temperature (cold chain vs room temperature and processing conditions), Contact surface area, Container/material composition, Terminal sterilization, Packaging process, Material sterilization, Duration of storage

Table 2 provides recommendations for inclusion of elemental impurities in the risk assessment. This can be applied to all sources of elemental impurities in the drug product.

4.4. Evaluation

As the potential elemental impurity identification process is concluded, there are following two possible outcomes.

- 1) The risk assessment process does not identify any potential elemental impurities.
- 2) The risk assessment process identifies one or more potential elemental impurities. For any elemental impurities identified in the process, the risk assessment should consider if there are multiple sources of the identified elemental im-

Table 2 Elements to be Considered in the Risk Assessment

Element	Class	If intentionally added (all routes)	If not intentionally added		
			Oral	Parenteral	Inhalation
Cd	1	○	○	○	○
Pb	1	○	○	○	○
As	1	○	○	○	○
Hg	1	○	○	○	○
Co	2A	○	○	○	○
V	2A	○	○	○	○
Ni	2A	○	○	○	○
TI	2B	○	×	×	×
Au	2B	○	×	×	×
Pd	2B	○	×	×	×
Ir	2B	○	×	×	×
Os	2B	○	×	×	×
Rh	2B	○	×	×	×
Ru	2B	○	×	×	×
Se	2B	○	×	×	×
Ag	2B	○	×	×	×
Pt	2B	○	×	×	×
Li	3	○	×	○	○
Sb	3	○	×	○	○
Ba	3	○	×	×	○
Mo	3	○	×	×	○
Cu	3	○	×	○	○
Sn	3	○	×	×	○
Cr	3	○	×	×	○

○: necessary ×: unnecessary

purity or impurities.

During the risk assessment, a number of factors that can influence the level of the potential elemental impurity in the drug product should be considered.

4.5. Summary of Risk Assessment Process

The risk assessment is summarized by reviewing relevant product or component specific data combined with information and knowledge gained across products or processes to identify the significant probable elemental impurities that may be observed in the drug product.

The significance of the observed or predicted level of the elemental impurity should be considered in relation to the PDE of the elemental impurity. As a measure of the significance of the observed elemental impurity level, a control threshold is defined as a level that is 30% of the established PDE in the drug product. The control threshold may be used to determine if additional controls may be required.

If the total elemental impurity level from all sources in the drug product is expected to be consistently less than 30% of the PDE, then additional controls are not required, provided adequate controls on elemental impurities are demonstrated by the appropriate assessment of the data.

If the risk assessment fails to demonstrate that an elemental impurity level is consistently less than the control threshold, controls should be established to ensure that the

elemental impurity level does not exceed the PDE in the drug product.

The variability of the level of an elemental impurity should be factored into the application of the control threshold to drug products. Sources of variability may include the following.

- Variability of the analytical method
- Variability of the elemental impurity level in the specific sources
- Variability of the elemental impurity level in the drug product

For some components that have inherent variability (e.g., mined excipients), additional data may be needed to apply the control threshold.

5. Converting between PDEs and Concentration Limits

The PDEs reported in μg per day ($\mu\text{g}/\text{day}$) give the maximum permitted quantity of each element that may be contained in the maximum daily dose of a drug product. Because the PDE reflects total exposure from the drug product, it is useful to convert the PDE into concentrations as a tool in evaluating elemental impurities in drug products or their components. Any of the following options may be selectable as long as the resulting permitted concentrations assure that the drug product does not exceed the PDEs. In the choice of a specific option the daily dose of the drug product needs to be determined or assumed.

Option 1: Common permitted concentration limits of elements across drug product components for drug products with daily doses of not more than 10 g: This option is not intended to imply that all elements are present at the same concentration, but rather provides a simplified approach to the calculations. The option assumes the daily dose of the drug product is 10 g or less, and that elemental impurities identified in the risk assessment (the target elements) are present in all components of the drug product. Using Equation (1) below and a daily dose of 10 g of drug product, this option calculates a common permissible target elemental concentration for each component in the drug product.

$$\text{Concentration } (\mu\text{g}/\text{g}) = \frac{\text{PDE}(\mu\text{g}/\text{day})}{\text{daily dose of drug product (g/day)}} \quad (1)$$

This approach, for each target element, allows determination of a fixed common maximum concentration in μg per g in each component. The permitted concentrations are provided in Table 3.

If all the components in a drug product do not exceed the Option 1 permitted concentrations for all target elements identified in the risk assessment, then all these components may be used in any proportion in the drug product. If the permitted concentrations in Table 3 are not applied, Options 2a, 2b, or 3 should be followed.

Option 2a: Common permitted concentration limits of elements across drug product components for a drug product with a specified daily dose: This option is similar to Option 1, except that the drug daily dose is not assumed to be 10 g. The common permitted concentration of each element is de-

Table 3 Permitted Concentrations of Elemental Impurities for Option 1

Element	Class	Oral Concentration ($\mu\text{g}/\text{g}$)	Parenteral Concentration ($\mu\text{g}/\text{g}$)	Inhalation Concentration ($\mu\text{g}/\text{g}$)
Cd	1	0.5	0.2	0.2
Pb	1	0.5	0.5	0.5
As	1	1.5	1.5	0.2
Hg	1	3	0.3	0.1
Co	2A	5	0.5	0.3
V	2A	10	1	0.1
Ni	2A	20	2	0.5
TI	2B	0.8	0.8	0.8
Au	2B	10	10	0.1
Pd	2B	10	1	0.1
Ir	2B	10	1	0.1
Os	2B	10	1	0.1
Rh	2B	10	1	0.1
Ru	2B	10	1	0.1
Se	2B	15	8	13
Ag	2B	15	1	0.7
Pt	2B	10	1	0.1
Li	3	55	25	2.5
Sb	3	120	9	2
Ba	3	140	70	30
Mo	3	300	150	1
Cu	3	300	30	3
Sn	3	600	60	6
Cr	3	1100	110	0.3

termined using Equation (1) and the actual maximum daily dose. This approach, for each target element, allows determination of a fixed common maximum concentration in μg per g in each component based on the actual daily dose provided. If all components in a drug product do not exceed the Option 2a permitted concentrations for all target elements identified in the risk assessment, then all these components may be used in any proportion in the drug product.

Option 2b: Permitted concentration limits of elements in individual components of a drug product with a specified daily dose: Permitted concentrations based on the distribution of elements in the components (e.g., higher concentrations in components with the presence of an element in question) may be set. For each element identified as potentially present in the components of the drug product, the maximum expected mass of the elemental impurity in the final drug product can be calculated by multiplying the mass of each component material times the permitted concentration pre-established in each material and summing over all components in the drug product, as described in Equation (2). The total mass of the elemental impurity in the drug product should comply with the PDEs unless justified according to other relevant sections of this general information. If the risk assessment has determined that a specific element is not a potential impurity in a specific component,

there is no need to establish a quantitative result for that element in that component. This approach allows that the maximum permitted concentration of an element in certain components of the drug product may be higher than the Option 1 or Option 2a limit, but this should then be compensated by lower allowable concentrations in the other components of the drug product. Equation (2) may be used to demonstrate that component-specific limits for each element in each component of a drug product assure that the PDE will be met.

$$PDE (\mu\text{g}/\text{day}) \cong \sum_{k=1}^N C_k \cdot M_k \quad (2)$$

k = an index for each of N components in the drug product

C_k = permitted concentration of the elemental impurity in component k ($\mu\text{g}/\text{g}$)

M_k = mass of component k in the maximum daily dose of the drug product (g)

Option 3: Finished Product Analysis: The concentration of each element may be measured in the final drug product. Equation (1) may be used with the maximum total daily dose of the drug product to calculate a maximum permitted concentration of the elemental impurity.

6. Speciation and Other Considerations

Speciation is defined as the distribution of elements among chemical species based on the difference of molecular structure including ionic element, molecules, or complexes, reflecting isotopic composition, electronic or oxidation state. When the toxicities of different species of the same element are known to be different, the PDE has been established using the toxicity information on the species expected to be in the drug product.

When elemental impurity measurements are used in the risk assessment, total elemental impurity levels in drug products may be used to assess compliance with the PDEs. The identification of speciation is not particularly expected, however such information could be used to justify lower or higher levels when the identified species is more or less toxic, respectively, than the species used for the calculation of the PDEs.

When total elemental impurity levels in components are used in the risk assessment, providing information on release of an elemental impurity from the component in which it is found is not expected. However, such information could be used to justify levels higher than those based on the total elemental impurity content of the drug product.

7. Analytical Procedures

The determination of elemental impurities should be conducted using appropriate procedures suitable for their intended purposes. Unless otherwise justified, the test should be specific for each elemental impurity identified for control during the risk assessment. Elemental Impurities-Procedures <2.66> or suitable alternative procedures for determining levels of elemental impurities should be used.

8. Lifecycle Management

If changes to the drug product or components have the potential to change the elemental impurity content of the drug product, the risk assessment, including established controls for elemental impurities, should be re-evaluated. Such changes could include changes in synthetic routes, excipient suppliers, raw materials, processes, equipment, container closure systems or facilities.

G3 Biotechnological/Biological Products

Add the following:

Host Cell Protein Assay

Host cell protein (HCP) is a general term for proteins derived from host cells used for the production of pharmaceutical products. This general information describes HCP assays for therapeutic proteins produced by recombinant DNA technology (recombinant therapeutic proteins).

Residual HCP in recombinant therapeutic proteins has potential to elicit immune responses against itself and may also act as adjuvants to induce anti-drug antibodies. Therefore, in order to ensure the efficacy and safety of recombinant therapeutic proteins, it is necessary to establish a purification process to reduce HCP to a level that does not affect safety. In addition, residual levels of HCP must be appropriately controlled by verifying that in-process tests can consistently eliminate HCP or by establishing purity testing of drug substance.

1. Selection of Test Methods for HCP assay

HCP assay is usually performed with a sandwich immunoassay using antibodies against HCP (anti-HCP antibodies) and detection systems including enzyme-linked immunosorbent assay (ELISA), electrochemiluminescent immunoassay (ECLIA), and time-resolved fluorescent immunoassay (TRFIA). This general information addresses the sandwich immunoassay, but does not discourage other assays.

Residual HCP from the manufacturing process of recombinant therapeutic proteins consists a large number of proteins and may have profiles that vary from one host cell to another or depending on manufacturing conditions. Based on differences in its intended use or differences in the concept of preparation of anti-HCP antibodies used for testing, HCP assay is classified into generic assay, product-specific assay, and platform assay. Generic assay is intended for wide use in pharmaceutical products manufactured using similar host cells (e.g., CHO-K1 or CHO-DG44 cells derived from CHO [Chinese hamster ovary] cells) and is a test method established using anti-HCP antibodies that are prepared with proteins from all components of the host cells (cell lysate or culture supernatant) as immunogens. Commercially available reagents or kits for an HCP assay com-

monly referred to as generic assay and need to be validated before use. Product-specific assay is intended to control HCP in a specific product and developed in consideration of characteristics of the manufacturing process of the product. Platform assay is developed for the application to recombinant therapeutic proteins (e.g., monoclonal antibodies with adequate experience) produced by a manufacturing platform.

Generic assay is intended to comprehensively obtain antibodies against a wide range of HCP by using proteins from all components of the host cells as antigens. However, it should be noted that it is difficult to obtain antibodies against all HCPs because of differences in proportions or immunogenicity of individual proteins used as antigens and that residual HCP from actual manufacturing processes may be inadequately covered because of potential different profiles of residual HCP from different manufacturing processes. In contrast, product-specific assay is expected to prepare anti-HCP antibodies that can detect residual HCP from actual manufacturing processes compared with generic assay because it uses potentially residual HCP as antigens. However, it should be noted that profiles of residual HCP may vary with modifications to manufacturing processes. Platform assay has both aspects, namely, the assay has an advantage of being able to be applied to various products prepared by a manufacturing platform; however, the assay may involve issues as generic or product-specific assay, depending on the method of preparation of antigens used for preparing anti-HCP antibodies.

In some products, it is possible that specific HCPs binding to desired products are present or that HCPs markedly increase in production amount with expression of desired products. If the residue of these HCPs is found, the need to establish other test methods for the HCPs is considered.

In light of these characteristics of the test methods for HCP assays and in consideration of properties of host cells, characteristics of manufacturing processes, knowledge about immunogenicity of HCPs, stages of development of products, etc., an appropriate test method is selected.

2. Preparation and Characterization of Reagents

2.1. HCP Antigens/HCP Reference Materials

For antigens to produce antibodies that specifically detect HCPs in products, it is necessary to prepare HCP not containing desired products. Usually, null cells are used for preparation of HCP antigen while keeping in mind that HCP appropriate to the purpose of the HCP assay are comprehensively contained. In addition, HCP are used not only as antigens but also as reference materials for HCP assay and may also be used as ligands for purification of anti-HCP antibodies by affinity chromatography.

2.1.1. Preparation of HCP Antigens/HCP Reference Materials

The method of preparation of HCP antigens/HCP reference materials varies widely depending on the type of test methods. The method of preparation of HCP used as antigens for preparation of anti-HCP antibodies or as HCP reference materials in the test methods is shown below along

with points to note.

HCP used for generic assays are prepared from culture supernatant or lysed or disrupted null cells using minimal procedures such as concentration and dialysis and keeping preservation of component proteins in mind. It should be noted that these HCPs show profiles that are different from those of residual HCP in products because of preparation under conditions different from culture processes at commercial scale.

HCP used for product-specific assays are prepared from null cells using manufacturing processes of products. Usually, the application of the purification process is minimized to obtain a wide range of HCP. However, if a suitable antibody to detect the HCP is not obtained, it may be necessary to prepare appropriate HCP antigens by exploring conditions of preparation of HCP or excluding specific HCP.

HCP used for the platform assays are prepared from null cells using a manufacturing platform that can be used in multiple products. Usually, as with the other test methods, the application of the purification process is minimized to obtain a wide range and an enough amount of HCP. In addition, a mixture of HCPs prepared under multiple conditions can be used to address differences in HCP spectra due to slight differences in manufacturing conditions.

The use of mock cells as null cells used for preparation of HCP for product-specific and platform assays has advantages such as the presence of proteins expressed as selection markers in antigens and ability to culture the cells under similar culture conditions in actual manufacturing processes. In contrast, it should be noted that even a same cell line does not show consistent properties (such as cell growth rate) among different clones and that differences such as the presence or absence of production of desired products may cause different profiles of HCP.

2.1.2. Characterization of HCP Antigens/HCP Reference Materials

Prepared HCPs are analyzed for the following items.

1) Protein Concentrations

Protein concentrations are determined by a suitable measurement method keeping in mind that host cell nucleic acids or culture medium components may be contained depending on the method of preparation of HCP. For information on detailed measurement methods and points to consider, "Protein Assay" in General Information would be helpful.

2) HCP Profiles

Usually, one-dimensional electrophoresis (SDS-PAGE) or two-dimensional electrophoresis is used to confirm that prepared HCP include HCP species that are considered to remain in manufacturing processes or drug substances. Identification of HCP species by mass spectrometry is also a helpful approach.

2.2. Anti-HCP Antibodies

2.2.1. Preparation of Anti-HCP Antibodies

Since HCPs represent a heterogeneous variety of different proteins, polyclonal antibodies are obtained as anti-HCP antibodies used for the assay to comprehensively detect HCPs. The rabbit, goat, and sheep are commonly used animal species for immunization. For immunization, it is

useful to enhance immune response with adjuvants. Due to different degrees of immunogenicity of individual proteins comprising HCPs, the timing of induction of antibodies or the amount of antibodies produced is not constant, regardless of the amount of proteins as antigens. In addition, inter-individual variability in animals used for immunization makes the profile of induced antibodies inconsistent. Several rounds of immunization are usually required and, after determining the reactivity of induced antibodies with HCPs by Western blotting using antisera in each period of immunization, whole serum is collected. Mixing of anti-HCP antibodies derived from multiple individuals is intended to obtain adequate amounts of antibodies and is also expected to contribute to the elimination of imbalance of HCP profiles.

Anti-HCP antibodies are purified from the obtained antiserum by Protein A or Protein G chromatography. In either case, aggregates may be formed from some antibodies due to use of acid conditions for antibody elution from the columns. It is useful to remove antibody aggregates by a suitable method because they may cause interference with measurement.

Anti-HCP antibodies can also be purified by affinity chromatography using HCP as ligands. This purification is expected to eliminate non-specific reactions because of concentration of antibodies specific to HCPs, however, it should be noted that anti-HCP antibodies may get less diverse due to less adsorption of low-affinity antibodies or less elution of very high-affinity antibodies.

2.2.2. Suitability of Anti-HCP Antibodies

Anti-HCP antibodies have to be able to comprehensively recognize HCPs with wide ranges of electric charges and molecular masses that potentially remain in manufacturing processes or drug substances. However, because differences in immunogenicity of each HCP species may make antibodies against some HCPs less likely to be induced, obtained anti-HCP antibodies have to be qualified, usually as measured by antigen coverage. A specific example of assessment methods is shown below. After separation of HCPs by two-dimensional electrophoresis, total protein on the gel is stained. After performing two-dimensional electrophoresis in the same manner, Western blotting using anti-HCP antibodies is performed. Spot patterns obtained from each staining are compared and the proportion of spots detected by Western blotting vs spots obtained in total protein staining is determined as antigen coverage.

2.3. Storage of Reagents

HCP reference materials and anti-HCP antibodies are stored with attention to stability. The stability of these reagents can be confirmed by continuously monitoring parameters of dose-response curves of reference materials.

3. Validation of HCP Assay

When a sandwich immunoassay is used for HCP assay, "Validation of Analytical Procedures" in General Information would be helpful for information on basic requirements for validation. However, unlike a conventional sandwich immunoassay to determine a single antigen, HCP assay is

an approach to use antibodies prepared with a mixture of various HCP species as antigens to determine the HCP species simultaneously. Therefore, changes in concentrations as a function of dilution ratios of samples (dilution linearity) may not be observed in highly purified samples even within the quantitation limits in which linearity has been obtained for HCP reference materials. This phenomenon is likely attributed to insufficient amounts of antibodies to some HCPs that are found in increased proportions in samples for measurement due to the difference of removal rates of individual HCPs in the purification process and may lead to underestimation of HCP concentrations.

Therefore, HCP assay should be validated for accuracy, precision, specificity, standard curve, quantitative range, and dilution linearity.

(1) Accuracy and Precision

Accuracy and precision are expressed as coefficients of variation of recovery rates and quantitative values of HCP reference materials, respectively, by performing spike and recovery tests of HCP reference materials in purification process pools or drug substances to be measured.

(2) Specificity

Because HCP assay involves measurement of trace amounts of HCPs remaining in samples containing large quantities of desired products, it should be confirmed that there is no interference of desired substances or ingredients in sample solutions.

(3) Standard Curve and Quantitative Range

A standard curve is generated using serially diluted HCP reference materials, a regression expression is obtained, and validity is expressed in terms of determination coefficient, etc. Quantitative values of reference materials at each concentration level are determined from the regression expression and a range of concentrations with acceptable levels of accuracy and precision is defined as quantitative range with the lowest concentration within the range being defined as the minimum limit of quantitation.

(4) Dilution Linearity

Purification process pools or drug substances to be measured are examined for the range of dilution ratios of samples in which quantitative values of samples diluted within the quantitative range of a standard curve are linear.

4. Establishment of HCP Assay

HCP assay is used for confirmation of the status of removal of HCP in manufacturing processes or as a purity test of drug substances. For information on basic concepts of procedures or data analysis in HCP assay, "Enzyme-linked Immunosorbent Assay" in General Information would be helpful.

Results from HCP assay are usually presented as contents in desired products. Contents of HCP per total protein or desired products can be determined by separately determining concentrations of the proteins in samples. For example, when total protein concentration is 2 mg/mL and an HCP concentration is 20 ng/mL, the content of HCP should be indicated as 10 ng/mg.

5. Others**5.1. Considerations for Modifications to Manufacturing Processes**

Since any modifications made to manufacturing processes for recombinant therapeutic proteins may affect profiles of residual HCP, it is necessary to confirm that appropriate measurement of HCP is performed after modifications to manufacturing processes. If HCP profiles are altered and it is considered inappropriate to apply a test method for HCP assay before modifications to manufacturing processes, a test method for HCP assay has to be established again. Changes in HCP profiles can be assessed by an analytical procedure such as two-dimensional electrophoresis or mass spectrometry.

5.2. Considerations for Modifications to Reagents for Tests

It is desirable to secure sufficient quantities of HCP antigens/HCP reference materials and anti-HCP antibodies, all important reagents, whenever possible, in consideration of the life cycle of products. When HCP antigens/HCP reference materials or anti-HCP antibodies are newly prepared, it should be confirmed that their characteristics are comparable before and after renewal by analytical procedures such as two-dimensional electrophoresis, Western blotting, and mass spectrometry. In addition, test methods should be validated again for necessary items and newly prepared reagents should be used after confirming their consistency with the reagents and test methods before renewal.

When generic assay is employed, qualified commercially available kits can also be used. However, availability of information on lot renewal of reagents, etc. is necessary to ensure consistency and quality of tests using commercially available kits, and therefore characterization of important reagents and method validation should be performed as needed.

6. Terms

Mock cell: A cell line established from the host cell line by transferring expression vectors that do not contain genes encoding desired products.

Null cell: A host cell that does not express desired products. It includes parent cells or mock cells.

Antigen coverage: The rate of detection of proteins comprising HCPs by anti-HCP antibodies. For example, an antigen coverage can be calculated from the number of spots obtained in total protein staining and the number of spots obtained in Western blotting using anti-HCP antibodies after separation of HCPs by two-dimensional electrophoresis.

Total Protein Assay

Delete the description of harmonization in the beginning and symbols (◆ ◆).

G4 Microorganisms

Delete the following items:

Media Fill Test (Process Simulation)**Microbiological Environmental Monitoring Methods of Processing Areas for Sterile Pharmaceutical Products****Parametric Release of Terminally Sterilized Pharmaceutical Products****G5 Crude Drugs****Purity Tests on Crude Drugs using Genetic Information**

Change the following as follows:

The first step in the quality assurance of natural products is the use of raw materials from the right part of the right origin. Therefore, it is clearly stated in Article 4 of the General Rules For Crude Drugs that the source of a crude drug is an approval or rejection criterion. There are various methods for differentiating the sources of crude drugs, such as morphological methods, organoleptic tests, and chemical methods, and appropriate methods for each are described in the individual monographs. Morphological methods, organoleptic tests, and chemical methods are discrimination methods for species that are based on the phenotypic characteristics of the crude drugs. On the other hand, together with recent progress in molecular biology techniques and the accumulation of genetic information on plants, differentiating methods of crude drugs based on genotypes is being established. Unlike morphological and other methods that are based on phenotypic characteristics, the genotypic methods are not affected by environmental factors. Also, the methods have several advantages, such as specialized expertise and skill for classification are not needed, and objective results are easily obtained.

The evolution of living organisms is accomplished by genetic mutation, and differences among the nucleotide sequences of genes of closely related species reflect the strain relationships between the species. Based on this theory, methods that classify species phylogenetically using the nucleotide sequence of rDNA that codes for ribosomal RNA (rRNA) on the nuclear genome have recently been adopted for the classification of microorganisms. In the same way, the sequence of this rDNA is also most often

used in the classification of higher plants based on the genotype. In particular, it is very easy to classify closely related species using the internal transcribed spacer (ITS) region of the rDNA, since nucleotide substitution is more often undertaken by comparison with the coded gene region. Furthermore, since the genes on the nuclear genome originate from the parents' genomes, there is an advantage that interspecies hybrids can be detected. Higher plants also have mitochondrial genes and chloroplastic genes. Although the genes on these genomes are also often used for classification, interspecies hybrids cannot be confirmed because the genes are normally uniparental inheritance.

The three methods presented here are, 1) the purity test of *Atractylodes Rhizome* for *Atractylodes Lancea Rhizome*, 2) the purity test of *Saposhnikovia Root and Rhizome* for *Peucedanum ledebourielloides*, which are developed based on the difference of the gene sequence of the ITS region of rDNA recently reported¹⁻⁴⁾, and the inter-laboratory validation study have been completed.

The plant sources for *Atractylodes Lancea Rhizome* stipulated in the individual monographs are *Atractylodes lancea* De Candolle and *A. chinensis* Koidzumi (*Compositae*), while those for *Atractylodes Rhizome* are *A. japonica* Koidzumi ex Kitamura and *A. macrocephala* Koidzumi (*Compositae*). The approval or rejection of the both sources is, in principle, determined by the description of the crude drug, including microscopy, together with thin-layer chromatography in identification tests. In the above scientific paper, it was shown that these 4 plant species can be clearly classified by comparing the nucleotide sequences of the ITS region mentioned above, and that the species can be easily classified without performing sequence analysis by performing PCR using a species-specific primer pair or by using a restriction enzyme which recognizes species-specific sequence.

Likewise, the plant source of *Saposhnikovia Root and Rhizome* is stipulated as *Saposhnikovia divaricata* Schischkin (*Umbelliferae*), and the approval or rejection of the source is determined by the description of the crude drug and thin-layer chromatography in identification tests. According to the report⁴⁾, crude drugs treated as *Saposhnikovia Root and Rhizome* in Shaanxi and Shanxi Provinces are frequently derived from *Peucedanum ledebourielloides*, and it was shown that the differentiation of the both is possible by using the nucleotide sequence in the ITS region of the rDNA.

In purity tests on crude drugs using genetic information, the simplicity of the test is given maximum consideration. We established methods that observe PCR amplification bands using species-specific primer pair (Mutant Allele Specific Amplification: Method 1) and methods that observe DNA fragments produced by restriction enzyme treatment of the PCR products, which are prepared using a primer pair common to each plant source (PCR—Restriction Fragment Length Polymorphism: Method 2), without nucleotide sequence analyses. In these methods based on PCR, an extremely small amount of template DNA is amplified to billions to hundreds of billions times. Therefore, when

using them as identification tests for powdered crude drugs, the target DNA fragment can be observed even if the vast majority of the crude drug for analysis is not appropriate plant species and there is only a minute amount of powder from a crude drug derived from a suitable plant. Consequently, in identification tests, either a cut or a whole crude drug must be used, as long as one is careful to avoid contamination by powder originating from other crude drugs. On the other hand, when used as a purity test, the form of the crude drug is irrelevant as long as the gene amplification is performed properly and the target gene is not polymorphic, so if DNA fragments of an inappropriate plant to be examined are confirmed in the purity test, regardless of the form of the crude drug, it becomes clear there is contamination by an inappropriate crude drug to be examined.

The methods shown here are general information and at the present stage results obtained using the methods do not affect the approval or rejection of the crude drug in each monograph. Furthermore, by performing the sequence analysis outlined in the previous paper for a crude drug sample derived from a single individual, it goes without saying that more accurate decision concerning the source species can be made.

1. DNA Amplification Equipment

DNA amplification equipment is used to amplify the DNA which is extracted from a crude drug and then purified. Since there are slight differences in the methods of temperature control, and so on depending on the equipment used, there may be differences in the intensity, etc. of the PCR amplification bands even if PCR is carried out under the stipulated conditions. Therefore, when judging results based solely on the presence or absence of PCR amplification bands as in Methods 1, the use of equipment described in the JAS analytical test handbook: genetically modified food quality, labeling analysis manual for individual products⁵⁾ is recommended. When other equipment is used, confirm that only proper amplification bands are obtained by performing PCR using DNA obtained from samples confirmed beforehand to be the source species. If proper amplification bands are not obtained, the PCR temperature conditions should be slightly adjusted. This equipment can be used for the restriction enzyme treatment in Method 2.

2. General precautions

Crude drugs are different from fresh plants in that they are dried products and a certain amount of time has passed since they were harvested. Therefore, in many cases the DNA has undergone fragmentation. Furthermore, various substances that can block or interfere with the PCR reaction may be present in the plant. For these reasons, the extraction and purification of template DNA is the process that should receive the greatest amount of attention. In the case of *Atractylodes* crude drugs, the periderm should be removed using a clean scalpel or other clean instrument before pulverizing the sample because very often there are inhibitory substances present in the periderm.

The PCR used for this test is the technique that amplify the target DNA more than hundreds of millions times, and

a trace of contamination leads an incorrect result. Therefore, careful attention is required to prevent contamination. For treatment to prevent contamination, refer to the prevention of contamination section⁶⁾ in the above manual.

3. Purity test of *Atractylodes Rhizome* for *Atractylodes Lancea Rhizome*

3.1. Method 1 (Mutant Allele Specific Amplification Method)

Generally, this method is referred to as Mutant Allele Specific Amplification (MASA) or Amplification Refractory Mutation System (ARMS), and it provides nucleotide sequence information of sample-derived template DNA, based upon the presence or absence of DNA amplification in PCR using a species specific primer pair.

3.1.1. Procedure

The following is an example procedure.

3.1.1.1. Preparation of template DNA

There are various methods with which to extract and purify DNA from the samples. It is recommended that commercially available DNA extraction kits be used when considering their advantages of not using any noxious reagents and not requiring any complicated purification procedures. In this case, attention should be paid to the final amount (concentration) of DNA obtained, and the initial amount of initial sample and the volume of liquid to elute the DNA need to be controlled. When extraction and purification are performed using silica gel membrane type kits stipulated in notifications⁷⁾ related to inspection methods of the foods produced by recombinant DNA techniques, it is appropriate to use 200 mg of sample, 1 mL of AP1 buffer solution, 2 μ L of RNase A, and 325 μ L of AP2 buffer solution. Also, the most important things are that the supernatant loaded on the first column is clear and that there is no need to load 1 mL unreasonably. Furthermore, 50 μ L is an appropriate volume used in the final elution of the DNA, and normally the initial eluate is used as the DNA sample stock solution.

3.1.1.2. Confirmation of purity of DNA in DNA sample stock solution and assay of DNA

The purity of the DNA in the stock solution can be confirmed by the $OD_{260\text{ nm}}/OD_{280\text{ nm}}$ ratio using a spectrophotometer. A ratio of 1.5 indicates that the DNA has been adequately purified. The amount of DNA is calculated using $1\ OD_{260\text{ nm}} = 50\ \mu\text{g/mL}$. The measurement mentioned above is performed using appropriately diluted DNA sample stock solution. Based on the results obtained, dilute with water to the concentration needed for the subsequent PCR reactions, dispense the solution into micro tubes as the sample DNA solution, and if necessary store frozen at not over -20°C . The dispensed DNA sample is used immediately after thawing and any remaining solution should be discarded and not refrozen. If the concentration of the DNA sample stock solution does not reach the concentration stipulated in PCR, it is used as a DNA sample solution.

3.1.1.3. PCR

When a commercially available PCR enzyme mentioned in the above notification⁸⁾ is used, it is appropriate that 25 μ L of reaction mixture consisting of 2.5 μ L of the PCR

buffer solution containing magnesium, dNTP (0.2 mmol/L), 5' and 3' primer (0.4 μ mol/L), Taq DNA polymerase (1.25 units), and 5 μ L of 10 ng/ μ L sample DNA solution (50 ng of DNA) is prepared on ice. Among them, the PCR buffer solution and dNTP are provided as adjuncts to the enzyme. When conducting purity tests on *Atractylodes Lancea Rhizome* in *Atractylodes Rhizome*, the primer sets used are C and D (C is positive with *A. lancea*, D is positive with *A. chinensis*) as described in the paper¹⁾ mentioned above, however, when primer sets A and B are used, it is possible to confirm the source species of each of the respective specimens. In order to confirm that the DNA has been extracted correctly, the reaction solution containing the positive control primer pair (Pf and Pr) as shown below should be prepared. In addition, the negative control solutions which are not containing DNA sample or either of the primer pair should be prepared and simultaneously conduct PCR.

Pf: 5'-CAT TGT CGA AGC CTG CAC AGC A-3'

Pr: 5'-CGA TGC GTG AGC CGA GAT ATC C-3'

The PCR reaction is performed under the following conditions: starting the reaction at 95°C for 10 minutes, 30 cycles of 0.5 minutes at 95°C and 0.75 minutes at 68°C (69°C only when using the primer set C), terminate reaction at 72°C for 7 minutes, and store at 4°C . The resulting reaction mixture is used for the following process as PCR amplification reaction solution.

3.1.1.4. Agarose gel electrophoresis and detection of PCR products

After completion of the PCR reaction, mix 5 μ L of the PCR amplification reaction solution with an appropriate volume of gel loading buffer solution, add the mixture to the wells of 2 w/v% agarose gel, and then perform electrophoresis using 1-fold TAE buffer solution (refer to General Information, Rapid Identification of Microorganisms Based on Molecular Biological Method). Carry out the electrophoresis together with an appropriate DNA molecular marker. Electrophoresis is terminated when the bromophenol blue dye in the gel loading buffer has advanced to a point corresponding to 1/2 to 2/3 the length of the gel.

Stain the gel after electrophoresis when not using gel stained in advance with ethidium bromide. Place the gel that has undergone electrophoresis and staining in a gel image analyzer, irradiate with ultraviolet light (312 nm), and detect its electrophoresis pattern. Compare this to the DNA molecular marker and determine the absence or presence of the target amplification band.

3.1.2. Judgment

Confirm at first that a 305 bp band is found with the reaction solution to which the positive control primer pair has been added, and confirm there are no bands in a solution with no primer sets and a solution with no sample DNA solution. Next, if a 226 bp band is confirmed when the primer set C is added or if a 200 bp band is confirmed when the primer set D is added, the sample is judged to be *Atractylodes Lancea Rhizome* (in the case of cut crude drug, contamination of *Atractylodes Lancea Rhizome* is observed)

and it is rejected. The sample is judged not to be *Atractylodes Lancea* Rhizome (in the case of cut crude drug, there is no contamination of *Atractylodes Lancea* Rhizome) and the purity test is acceptable if a 305 bp band is confirmed with the positive control primer pair, bands are not observed in reaction solution without primer and reaction solution without DNA sample solution, and a 226 bp band is not observed with the primer set C and a 200 bp band is not observed with the primer set D. If a band is not observed with the positive control primer pair, it is to be concluded that the DNA extraction failed and the procedure should be started over again from the DNA extraction step. If bands are confirmed in reaction solutions without primer sets or without DNA sample solution, it should be assumed that there was an error in the PCR procedure and therefore the procedure should be repeated again from the step 3.1.1.3. PCR.

3.2. Method 2 (PCR—Restriction Fragment Length Polymorphism)

Generally, this method is referred to as PCR—Restriction Fragment Length Polymorphism (RFLP), and it provides nucleotide sequence information of sample-derived template DNA, based upon the DNA fragment pattern produced by restriction enzyme treatment of the PCR products, which are amplified by using a primer pair common to the DNA sequence of the objective plant.

The test is performed with 25 samples randomly taken from a lot, and each sample is designated with a number from 1 to 25. Differentiation of the sources is performed by individual PCR—RFLP measurement of the samples, and decision of the acceptability of the purity is dependent on how many nonconforming samples are present in the first 20 samples, taken in numerical order, for which judgment is possible as described below.

3.2.1. Procedure

The following is an example procedure.

3.2.1.1. Preparation of template DNA

There are various methods with which to extract and purify DNA from the samples. It is recommended that commercially available DNA extraction kits be used, when considering their advantages of not using noxious reagents and not requiring complicated purification procedures. Recently, PCR reagents that inhibit the effect of PCR enzyme-inhibiting substances present in samples have become commercially available, and by using these reagents, it is possible to prepare the template DNA from the sample simply by incubating the sample with the DNA extraction reagent. Here, a recommended DNA preparing procedure using such PCR reagents is described for the convenience of experimenters.

Cut 20 mg of the sample into small pieces with a clean knife, add 400 μ L of the DNA extraction reagent, and incubate at 55°C overnight (16–18 hours). Then heat at 95°C for 5 minutes to inactivate the enzyme in the reagent. Centrifuge to precipitate the sample, and use 50 μ L of the supernatant liquid as the template DNA solution. The DNA solution prepared in this method can not be used for con-

centration measurement based on OD_{260 nm}, because it contains many foreign substances affecting OD_{260 nm} value from the sample.

The composition of the DNA extraction reagent is as follows:

2-Amino-2-hydroxymethyl-1,3-propanediol-hydrochloric acid (pH 8.0)	20 mmol/L
Ethylenediamine tetraacetate	5 mmol/L
Sodium chloride	400 mmol/L
Sodium dodecyl sulfate	0.3%
Proteinase K	200 μ g/mL

3.2.1.2. PCR

In the method using the PCR enzyme and PCR reagent as described³⁾, the reaction mixture is prepared on an ice bath in a total volume of 20 μ L of a solution containing 10.0 μ L of 2-fold concentrated PCR reagent, 5'- and 3'-primers (0.5 μ mol/L), Taq DNA polymerase (0.5 units) and 0.5 μ L of template DNA solution.

The PCR reaction is performed under the following conditions: 95°C for 10 minutes, 40 cycles of 95°C for 0.5 minute, 65°C for 0.25 minute, and 72°C for 0.25 minute and 72°C for 7 minutes. Store the solution at 4°C, and use this solution as the PCR amplified solution. A negative control (containing water instead of the template DNA solution) must be included in the procedure.

The sequence of each primer is as follows:

5'-primer: 5'-GGC ACA ACA CGT GCC AAG GAA AA-3'

3'-primer: 5'-CGA TGC GTG AGC CGA GAT ATC C-3'

3.2.1.3. Restriction enzyme treatment

The treatment is performed on individual reaction solutions using two enzymes, *Fau* I and *Msp* I. In the case of *Fau* I, to an appropriate amount of the reaction solution, composed of a reaction buffer containing 1.0 unit of enzyme, add 3.0 μ L of PCR products while cooling in an ice bath to make 15.0 μ L. In the case of *Msp* I, to an appropriate amount of the reaction solution, composed of a reaction buffer containing 20.0 units of enzyme, add 3.0 μ L of PCR products while cooling in an ice bath to make 15.0 μ L. Incubate these solutions at the temperature recommended by the manufacturer for 2 hours, and then inactivate the enzyme by heating at 72°C for 10 minutes. The negative control of the PCR reaction is also treated in the same manner.

3.2.1.4. Agarose gel electrophoresis and detection of DNA fragments

After the restriction enzyme treatment, mix the total amount of the reaction solution and an appropriate amount of the gel loading buffer solution, place it in a 4 w/v% agarose gel well, and carry out electrophoresis with 1-fold concentrated TAE buffer solution (see "Rapid Identification of Microorganisms Based on Molecular Biological Methods" under General Information). Carry out the electrophoresis together with appropriate DNA molecular marker. Stop the electrophoresis when the bromophenol blue included in the loading buffer solution has moved about 2 cm from the well. The 4 w/v% agarose gel is sticky, difficult

to prepare and hard to handle, so that it is better to use a commercially available precast gel.

After the electrophoresis, stain the gel, if it is not already stained, with ethidium bromide, and observe the gel on an illuminating device under ultraviolet light (312 nm) to confirm the electrophoretic pattern.

3.2.2. Judgment

3.2.2.1. Judgment of each sample

Confirm that no band is obtained with the negative control of the PCR, other than the primer dimer (about 40 bp) band. A sample treated with *Fau* I, showing bands of about 80 bp and 60 bp, or that treated with *Msp* I, showing bands of about 90 bp and 50 bp, is judged as *Atractylodes Lancea* Rhizome. A sample not showing any band other than a band at about 140 bp and the primer dimer band is judged as *Atractylodes* Rhizome. If a sample does not show any band other than the primer dimer band, it is considered that PCR products were not obtained, and judgment is impossible for the sample.

3.2.2.2. Judgment of the purity

Judgment of the purity is based on the result of the judgment of each sample. If there is no sample that is judged as *Atractylodes Lancea* Rhizome among 20 samples taken in order of the numbering, excluding any sample for which judgment is impossible, the lot is acceptable for purity. When there is one sample that is judged as *Atractylodes Lancea* Rhizome among the 20 samples, perform the same test with 25 newly taken samples from the lot, and if there is no sample that is judged as *Atractylodes Lancea* Rhizome, the lot is acceptable for purity. When there is a sample that is judged as *Atractylodes Lancea* Rhizome in the second test, or there is more than one sample that is judged as *Atractylodes Lancea* Rhizome in the first test, the lot is not acceptable for purity.

4. Purity test of *Saposhnikovia* Root and Rhizome for *Peucedanum ledebourielloides*

4.1. Method 1

Similarly as 3.1., this method provides nucleotide sequence information of sample-derived template DNA, based upon the presence or absence of DNA amplification band in PCR using a species specific primer pair.

4.1.1. Procedure

The following is an example procedure.

4.1.1.1. Preparation of template DNA

For *Atractylodes* crude drugs, a preparation procedure using a silica gel membrane type kit is adopted, however for the test of *Saposhnikovia* Root and Rhizome, and *Peucedanum ledebourielloides*, the simple preparation procedure shown below is adopted for the convenience of experimenters, because it was confirmed that the PCR product is stably obtained in using a DNA sample solution prepared by the simple preparation procedure shown in 3.2.1.1. as a template.

Cut 10 mg of the sample into small pieces with a clean knife, add 400 μ L of the DNA extraction reagent, and incubate at 55°C overnight (16 – 18 hours). Then heat at 95°C for 5 minutes to inactivate the enzyme in the reagent. Cen-

trifuge to precipitate the sample, and use 50 μ L of the supernatant liquid as the template DNA solution. The DNA solution prepared in this method can not be used for concentration measurement based on OD_{260nm}, because it contains many foreign substances affecting OD_{260nm} value from the sample.

The composition of the DNA extraction reagent is as follows:

2-Amino-2-hydroxymethyl-1,3-propanediol-hydrochloric acid (pH 8.0)	20 mmol/L
Ethylenediamine tetraacetate	5 mmol/L
Sodium chloride	400 mmol/L
Sodium dodecyl sulfate	0.3%
Proteinase K	200 μ g/mL

4.1.1.2. PCR

In the method using the PCR enzyme and PCR reagent as described³⁾, the reaction mixture is prepared on an ice bath in a total volume of 20 μ L of a solution containing 10.0 μ L of 2-fold concentrated PCR reagent, 5'- and 3'-primers (0.5 μ mol/L), Taq DNA polymerase (0.5 units) and 0.5 μ L of template DNA solution.

When the purity test of *Saposhnikovia* Root and Rhizome for *Peucedanum ledebourielloides* is performed, the reaction solution containing the positive control primer pair as shown below should be prepared besides the reaction solution containing a species specific primer pair in order to confirm that the DNA has been extracted correctly. In addition, the negative control solutions which are not containing DNA sample should be prepared and simultaneously conduct PCR.

The PCR reaction is performed under the following conditions: 95°C for 10 minutes, 45 cycles of 95°C for 0.5 minute, 62°C for 0.5 minute, and 72°C for 0.75 minute and 72°C for 7 minutes. Store the solution at 4°C, and use this solution as the PCR amplified solution. The sequence of each primer is as follows. The positive control 3'-primer for PCR and the species specific 3'-primer for PCR have the same sequence.

5'-primer for positive control PCR: 5'-GCG TGG GTG TCA CGC ATC G-3'

3'-primer for positive control PCR: 5'-GTA GTC CCG CCT GAC CTG-3'

5'-primer for species specific PCR: 5'-CTG AGA AGT TGT GCC CGG-3'

3'-primer for species specific PCR: 5'-GTA GTC CCG CCT GAC CTG-3'

4.1.1.3. Agarose gel electrophoresis and detection of PCR products

After completion of PCR reaction, mix 5 μ L of the PCR amplification reaction solution with an appropriate volume of gel loading buffer solution, add the mixture to the wells of 2 w/v% agarose gel, and then perform electrophoresis using 1-fold TAE buffer solution (refer to General Information, Rapid Identification of Microorganisms Based on Molecular Biological Method). Carry out the electrophoresis together with an appropriate DNA molecular marker. Electrophoresis is terminated when the bromophenol blue

dye in the gel loading buffer has moved about 2 cm from the well.

Stain the gel after electrophoresis when not using gel stained in advance with ethidium bromide. Place the gel that has undergone electrophoresis and staining in a gel image analyzer, irradiate with ultraviolet light (312 nm), and confirm its electrophoresis pattern. Compare this to the DNA molecular marker and determine the absence or presence of the target amplification band.

4.2. Judgment

Confirm at first that a 250 bp band is found with the reaction solution to which the positive control primer pair has been added, and confirm there are no bands other than the primer dimer (about 40 bp) in a solution with no sample DNA solution. Next, if a 200 bp band is confirmed when the species specific primer pair is added, the sample is judged to be contaminated with *Peucedanum ledebourielloides* and it is rejected. The sample is judged not to be contaminated with *Peucedanum ledebourielloides* and the purity test is acceptable if a 250 bp band is confirmed with the positive control primer pair, bands are not observed in reaction solution without DNA sample solution, and a 200 bp band is not observed with the species specific primer pair. If a band is not observed with the positive control primer pair, it is to be concluded that the DNA extraction failed and the procedure should be started over again from the DNA extraction step. If bands are confirmed in reaction solution without DNA sample solution, it should be assumed that there was an error in the PCR procedure and therefore the procedure should be repeated again from the step 4.1.1.2. PCR.

5. Reference

- 1) Y. Guo, *et al.*, *J. Nat. Med.* 60, 149-156 (2006).
- 2) K. Kondo, *et al.*, *J. Jpn. Bot.* 84, 356-359 (2009).
- 3) T. Maruyama, *et al.*, *Shoyakugaku Zasshi* 64, 96-101 (2010).
- 4) T. Maruyama, *et al.*, *J. Nat. Med.* in press.
- 5) JAS analytical test handbook: genetically modified food quality, labeling analysis manual for individual products, ver. 3, I Fundamental procedure 4.4.1 PCR, (September 24, 2012). Incorporated Administrative Agency Food and Agricultural Materials Inspection Center
- 6) JAS analytical test handbook: genetically modified food quality, labeling analysis manual for individual products, ver. 3, IV Contamination prevention, (September 24, 2012). Food and Agricultural Materials Inspection Center Independent Administrative Organization
- 7) Notification No. 110, Director of Food Health Department, March 2001; Partial Amendment: Notification No. 0629002, 2.2.1.2, Director of Food Safety Department, June 2006.
- 8) Notification No. 0629002, 2.1.3.1.1, Director of Food Safety Department, June 2006.

On the Scientific Names of Crude Drugs listed in the JP

Change the following as follows:

Scientific Names used in the JP and Those being used Taxonomically

Crude Drug	Scientific names used in the JP = Scientific names being used taxonomically (Combined notation, Standard form for author or authors) ----- Scientific names that are different from those written in JP but identical to them taxonomically or being regarded as identical, and typical sub-classified groups belonging to their species. The names marked with “*” are those being written together in JP.	Family
Amomum Seed シュグシヤ	<i>Amomum villosum</i> Loureiro var. <i>xanthioides</i> T. L. Wu & S. J. Chen = <i>Amomum villosum</i> Lour. var. <i>xanthioides</i> (Wall. ex Baker) T. L. Wu & S. J. Chen ----- <i>Amomum xanthioides</i> Wallich = <i>Amomum xanthioides</i> Wall. ex Baker ----- <i>Amomum villosum</i> Lour. var. <i>nanum</i> H. T. Tsai & S. W. Zhao ----- <i>Amomum villosum</i> Loureiro var. <i>villosum</i> = <i>Amomum villosum</i> Lour. var. <i>villosum</i> ----- <i>Amomum villosum</i> Lour. ----- <i>Amomum longiligulare</i> T. L. Wu	Zingiberaceae

G8 Water

Quality Control of Water for Pharmaceutical Use

Change the 4.4.2. Media Growth Promotion Test as follows:

4.4.2. Media Growth Promotion Test

In the media growth promotion test with the R2A Agar Medium, use test strains listed below or other test strains considered equivalent to these test strains.

Methylobacterium extorquens: NBRC 15911

Pseudomonas fluorescens: NBRC 15842, ATCC 17386, etc.

Prior to the test, inoculate these test strains into sterile purified water and starve them at 20 – 25°C for 3 days.

Dilute the fluid containing the test strain starved with sterile purified water to prepare microbial suspensions. When inoculating the R2A Agar Medium with the micro-organisms ($5 \times 10^1 - 2 \times 10^2$ CFU) and incubating at 20 – 25°C for 4 – 7 days, sufficient proliferation of the inoculated strains must be observed.

In the media growth promotion test with the Standard Agar Medium, use test strains listed below or other test strains considered equivalent to these test strains.

Staphylococcus aureus: ATCC 6538, NCIMB 9518, CIP 4.83 or NBRC 13276

Pseudomonas aeruginosa: ATCC 9027, NCIMB 8626, CIP 82.118 or NBRC 13275

Escherichia coli: ATCC 8739, NCIMB 8545, CIP 53.126 or NBRC 3972

Prepare microbial suspensions containing the test strains according to the procedure prescribed in the Microbiological Examination of Non-sterile Products <4.05>. When inoculating the Standard Agar Medium with a small number (not more than 100 CFU) of the micro-organisms and incubating at 30 – 35°C for 48 hours, sufficient proliferation of the inoculated strains must be observed.

G10 Others

Change as follows:

Basic Concepts for Quality Assurance of Drug Substances and Drug Products

Introduction

Quality of drug substances and products are generally assured through manufacturing and testing under appropriate Good Manufacturing Practice (GMP) conditions reflecting

knowledge obtained from designing and developmental stages and manufacturing stage on management of raw materials and other materials, control of manufacturing process, specifications, etc. As shown in the General Notice 5, JP listed drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the *Japanese Pharmacopoeia*. In addition to these, compliance with GMP, management of raw materials and other materials, and management of manufacturing process are fundamental factors required to assure the quality of JP listed products in actual production.

The present chapter summarizes general concepts concerning measures for quality assurance of drug substances and products mainly aimed at chemicals, including chemically synthesized antibiotics and semisynthetic antibiotics, synthetic peptides, oligonucleotides, and biotechnological/biological products, and shows the principle idea of quality assurance in the process listing a drug as an individual monograph in the JP. Although radiopharmaceuticals, crude drugs, herbal products, and crude products of animal or plant origin are excluded from the subjects of the concepts, these concepts are useful for the management of any type of drugs.

Basic Concept

In recent years, the mainstream concept for quality control of drugs has been implemented according to a control strategy that their quality is assured by control of manufacturing process, including management of raw material and other materials, and quality testing of final products (drug substances or drug products) that are conducted mutually complementary. The control strategy is implemented based on Quality Risk Management (QRM). The first and most important step is identifying Critical Quality Attributes (CQAs) which are the attributes or properties required to ensure the desired product quality, and it is necessary to specify physical, chemical, biological, microbiological characteristics or properties of the product which should be within the appropriate limits, ranges and distributions. The next step is to guarantee that the CQA falls within the defined range, limit, and distribution by using specification tests, in-process tests and various measures, for that the quality of the drug will eventually be realized.

The Specification is one of the elements of control strategy and not all the CQA need to be included in the specifications. CQA is (1) included in specifications and confirmed by testing final products (including periodical or skip testing, described later), (2) included in specifications and confirmed by process controls (e.g., real time release testing, described later), or (3) not included in specifications but can be ensured by controlling starting materials, raw materials and manufacturing process. As an example of (3), effective control over robust manufacturing processes can assure that certain impurities are controlled at an acceptable risk level or are efficiently removed below an acceptable level, and sometimes the purity testing for the final product may not

be required and omitted from specifications. However, in the case of a drug listed in the JP monograph, regarding the manufacturing process control related to CQA, if necessary, the control method and control value are indicated in the Manufacture in individual monograph.

What kind of control strategy should be applied to a certain CQA is individually determined by QRM according to the understanding and risk of the manufacturing process.

1. Management of manufacturing process

1.1. Considerations of manufacturing process

Adequate design of manufacturing processes and knowledge of their capacity are important to establish manufacturing processes yielding drug substances or drug products that meet specifications and fulfill CQA, and to perform consistent manufacturing control, quality control, etc. appropriately.

From this standpoint, the limits for control of manufacturing processes should be based on information obtained from the entire process spanning the period from the early development through commercial scale production. The appropriateness of the limits also need to be confirmed by evaluation, verification, review, and other examinations of manufacturing processes based on QRM.

In-process tests are tests that may be performed during the manufacture of either the drug substance or drug product, rather than specification tests for the final product. In-process tests are performed for quality verification during manufacturing processes that are likely to influence drug substance or drug product quality, or for confirmation of proper functioning of the manufacturing process. In-process tests may also be used for the evaluation of CQA.

Usually an in-process test is properly designed according to the risk on quality, however, the use of internal action limits by the manufacturer to assess the consistency of the process at less critical steps is also important. Provisional action limits should be set for the manufacturing process based on data obtained during development of the drug and during evaluation and verification of the manufacturing process, and should be further refined based on additional manufacturing experience and data accumulated after product approval for marketing.

1.2. Considerations of raw materials and other materials (starting materials, excipients, packaging materials, etc.)

The raw materials and other materials used in the production of drug substances (or drug products) should meet quality standards, appropriate for their intended use, and appropriate setting of specifications and test methods assuring CQA are required. Especially, biological raw/source materials may require careful evaluation to establish the presence or the absence of deleterious endogenous or adventitious agents. Procedures that make use of affinity chromatography (for example, employing monoclonal antibodies), should be accompanied by appropriate risk management to ensure that such process-related impurities or potential contaminants arising from their production and use do not compromise the quality and safety of the drug substance or drug product.

The quality of the excipients used in the drug product formulation (and in some cases, in the production of drug substance), as well as the primary packaging materials, should be controlled with specifications established based on the characteristics of the drug. If specifications and test procedures for a material are described by the JP, as a rule, at least the JP criteria should be satisfied. Concerning excipients and other materials not listed in the JP, appropriate specifications and test procedures should be established individually.

2. Quality tests of products (specifications)

A specification is defined as a list of tests, references to analytical procedures, and appropriate acceptance criteria which are numerical limits, ranges, or other criteria for the tests described. Specifications and test methods of the JP monograph are defined sets of quality characteristics needed for determination of whether the use of a drug substance or a drug product is appropriate for the intended purpose. "Conformance to the specifications of the JP monograph" means that the JP-listed drug substances and drug products, when tested according to the procedures described in general tests and drug monographs, will meet the all acceptance criteria except criteria of "Description", "Containers and storage (for drug products)" and "Shelf life" in the JP monographs.

However, as described in "Basic Concept" specifications of monographs and test procedures for drug substance and drug product are one part of a total control strategy for assurance of the quality and consistency of the substances/products. Other parts of control strategies include thorough characterization of the drug in developmental stage (specifications and test procedures are established based on the characterization), and management of manufacturing process and products' quality, such as evaluation, verification and review of manufacturing process, and management of raw materials, other materials and manufacturing process, that is to say, compliance with the GMP.

3. Periodic or Skip Testing

Periodic or skip testing is the performance of specified tests at release on preselected batches and/or at predetermined intervals, rather than on a batch-to-batch basis with the understanding that those batches not being tested still must meet all acceptance criteria established for that product. This concept may be applicable to, for example, residual solvents and microbiological testing for solid oral dosage forms. It is recognized that only limited data may be available at the time of submission of an application for marketing approval. Implementation of this concept should therefore generally be considered post-approval. When tested, any failure to meet acceptance criteria established for the periodic test should be handled by proper notification of the appropriate regulatory authorities. If these data demonstrate a need of testing for all lots, then batch-by-batch release testing should be reinstated.

4. Real-time release testing (RTRT) and parametric release

RTRT is a type of tests to evaluate the quality of in-

process or final products based on process data (including results of in-process testing and data on process parameters) and to assure that the quality is acceptable. RTRT is a kind of specifications and consists of a valid combination of materials attribute (intermediate products) pre-evaluated and process control. RTRT is used for judgement of products release instead of the release testing of final products when the application containing RTRT is approved by a regulatory authority.

The usage of RTRT does not mean unnecessary of setting tests of a final product directly. Even if the decision of release is made by RTRT, the tests for final products need to be set as specifications. It is because final product testing may be requested for some reasons such as failure of data acquisition due to troubles of equipments used for RTRT and evaluation of stability of final products. The final products, of course, need to meet their specifications, when tested.

Likewise, in the case that the drugs that was approved for marketing with the RTRT is listed in the JP monograph, the RTRT can be continued to use for release judgement. However specification and test procedure that assure the quality as same as the RTRT for final products should be set in the monograph. Even for drugs whose specifications are listed in the monographs, when a new application (or application for partial change) containing RTRT is approved by the regulatory authority, the products release can be judged based on the results of the RTRT instead of the tests prescribed in the monograph. In addition, it is necessary to comply with the specification in the case of conducting the compendial tests. In either case, it is unnecessary to set specification for RTRT in "Manufacture" of the monograph since the control criteria for the target CQA is already shown for the RTRT.

If RTRT results fail or trend toward failure, RTRT should not easily be substituted by final product testing. In this case, it is important to investigate the cause properly and need to take corrective action. Also, if RTRT results fail, the products cannot be released unless they were caused by analysis failure such as equipment failure. If RTRT results are trending toward failure, the products release should be made carefully based on the results of the investigation.

Parametric release can be considered a type of real time release. One example of parametric release is to determine the suitability for release of terminally sterilized drug products based on the data on sterilizing process instead of the results of sterility testing. In this case, the release of each batch is based on satisfactory results from monitoring specific parameters, e.g., temperature, pressure, and time during the terminal sterilization phase(s) of drug product manufacturing. Parametric release based on above parameters is more reliable in predicting sterility assurance than is determination of suitability for release based on sterility testing using limited number of final products. Besides, even if parametric release is applied, the final product testing need to be set because the testing is necessary in stability testing and post-marketing surveillance. If in-process

data used for parametric release are not acceptable, the products cannot be released. The parametric release differs from RTRT in the case, for example where the data of monitoring specific parameters in terminally sterilized process is failed to obtain by a certain reason such as analysis failure by equipment failure and so on. The incomplete data acquisition means no assurance on sterilization process, it is impossible to substitute parametric release by sterility testing of final products in principle.

Add the following:

Concept on Impurities in Chemically synthesized Drug Substances and Drug Products

1. Classification of impurities found in chemically synthesized pharmaceuticals and the guidance to comply with for their control

Impurities found in chemically synthesized pharmaceuticals are roughly classified into organic impurities, inorganic impurities and residual solvents. Those impurities in the new drug substances and the products are controlled by the following guidelines agreed upon at the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (hereinafter referred to as "ICH"). More specifically, "Impurities in New Drugs Substances (PAB/PCD Notification No. 877 dated September 25, 1995)" (hereinafter referred to as "ICH Q3A Guideline")¹⁾ on specifications for organic impurities in drug substances applies to applications for marketing approval after April 1, 1997, while "Impurities in New Drug Products (PAB/PCD Notification No. 539 dated June 23, 1997)" (hereinafter referred to as "ICH Q3B Guideline")²⁾ on specifications for organic impurities in drug products applies to applications for marketing approval after April 1, 1999. Meanwhile, specifications for inorganic impurities were specified by Japanese pharmacopoeial standards and known safety data. Now "Guidelines for Elemental Impurities (PFSB/ELD Notification No. 4 dated September 30, 2015)" apply to applications for marketing approval after April 1, 2017. In regard to residual solvents, "Impurities: Guidelines for Residual Solvents (PAB/ELD Notification No. 307 dated March 30, 1998)" (hereinafter referred to as "ICH Q3C Guideline") applies to applications for marketing approval after April 1, 2000. Especially in regard to DNA-reactive impurities, "Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk (PSEHB/ELD Notification No. 3 dated November 10, 2015)" applies to applications for marketing approval after January 15, 2016. Although ICH Q3A guideline does not cover optical enantiomers, a type of organic impurities, "Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (PMSB/ELD Notification No. 568 dated May 1, 2001)" (hereinafter referred to as "ICH Q6A Guideline"), which was published subse-

quently, provides that enantiomers are impurities that should be controlled and, if measurable, should be controlled in accordance with the principle of the ICH Q3A guideline.

Control of impurities in accordance with the guidelines mentioned above is expected also for pharmaceuticals other than new drug substances and new drug products. Their applications for marketing (or applications for partial changes) are subject to those guidelines when necessary. The General Notices of the JP 17th Edition states that residual solvents of all JP-listed drugs, in principle, have to be controlled in accordance with specification "Residual Solvents" in General Tests unless otherwise specified in the individual monograph. In regard to elemental impurities, it has been decided in the basic principles for the preparation of the JP 18th Edition to create a roadmap for their incorporation into the JP for listing and to address its implementation.

2. The concept of ICH Q3A and Q3B guidelines for the control of organic impurities

ICH Q3A and Q3B guidelines require setting acceptance criteria for organic impurities based on the information gained from development stages for new drugs. Concerning impurities in drug substances, ICH Q3A guideline refers to the items to be examined from chemical and safety perspectives. ICH Q3B guideline complements Q3A guideline, and have the same basic concept as Q3A. Chemical aspects to be examined include classification and identification of impurities, their reporting method, specification settings and analytical methods. Safety aspects include specific guidelines for qualifying the safety of impurities that were not present, or were present at substantially lower levels, in batches of a drug substance used in safety and clinical studies.

Qualification of the safety is the process of acquiring and evaluating data that establishes the biological safety of an individual impurity or a given impurity profile at the level(s) specified. The applicant should describe a rationale for establishing impurity acceptance criteria that includes safety considerations in attachments when applied for approval. The level of any impurities present in a new drug substance that has been adequately tested in safety and/or clinical studies would be considered qualified.

Identified impurities, unidentified impurities and total impurities are specified based on the data obtained according to the guidelines. The threshold of unspecified impurities in a drug substance is determined depending on the daily intake of the drug substance. When the maximum daily dosage is not more than 2 g, it is set at 0.10%. The establishment of individual specifications is required for impurities at a level greater than 0.10%.

In regard to drug products, the ICH Q3B guideline cover the degradation products of drug substances or reaction products between the drug substance and additive/primary packaging. Therefore, even if organic impurities other than degradation products (e.g., by-products and synthetic intermediates) in the drug substance are found as impurities in the drug product, they need not be monitored or specified since they have already been controlled as the drug sub-

stance specifications. However, degradation products elevated in the drug product need to be monitored and specified.

3. Principles for controlling organic impurities in the articles listed in the JP

Conventionally in the JP, specified impurities, unspecified impurities and total impurities are specified in accordance with ICH Q3A and Q3B guidelines for pharmaceutical products, whose impurities have been controlled by those guidelines, in the process listing in the JP. (However, this shall not apply to the long-term listed pharmaceutical products which had existed in the JP before these guidelines were applicable. However, when a new application is filed for those JP-listed pharmaceutical products, control of impurities in accordance with ICH Q3A and Q3B guidelines may be required, if necessary.) In order to specify the impurities, analysis data during development submitted from the drafting company and impurity analysis data from commercial production batches after consistent manufacturing is achieved should be assessed. Safety evaluation is not required again for the process listing in the JP since it has been performed at the time of approval.

ICH Q3A and Q3B guidelines cover impurities in the drug substances manufactured by chemical syntheses and the drug products manufactured with those drug substances. Similarly, the following types of products are not covered in the JP: biological/biotechnological products, peptides, oligonucleotides, radiopharmaceuticals, fermentation products and semi-synthetic products derived therefrom, herbal products and crude products of animal or plant origin.

When organic impurities assessed in accordance with the principles of ICH Q3A and Q3B guidelines are listed as JP tests of purity, the operational rationality of the JP is considered and its own modification is added. (i) Except in exceptional circumstances, impurity reference standards are not established. In order to identify an impurity using liquid chromatography, the relative retention time of the impurity to the drug substance is used for identification. (ii) When only unidentified impurities in highly pure pharmaceutical products (not more than 0.1%) are specified, it is generally exempted to set acceptance criteria for total impurities. (iii) When acceptance criteria set based only on actual measured values result in many impurities with slightly different acceptance criteria, consideration can be given so that the purity test consists of a small number of representative acceptance criteria, if possible. (iv) Chemical structural information and the chemical name of the impurities are not disclosed. Those measures enable impurity control without impurity reference standards, and can simplify system suitability test for highly pure pharmaceutical products.

Meanwhile, the method to identify impurities by use of relative retention time is column-dependent and analysis becomes difficult when appropriate columns are not available. Therefore, the JP 17th Edition also allows the use of the analysis method with impurity reference standards when designing purity tests for a drug substance. In addition, the

JP adopted a policy to disclose chemical names and structure formulas as the information on impurities including, in principle, optical enantiomers.

The JP-specific consideration may be given to purity tests for organic impurities in drug products in the process listing in the JP. Also in the JP, impurities derived from the products of the reaction between the drug substance and additive/primary packaging are specified as impurities in the drug product. Those impurities are formulation-dependent and may not be formed in different formulations. Since the JP is an official compendium that allows a wide variety of formulations, when it is not appropriate to specify impurities uniformly in the individual monograph, they are subject to the specifications at the time of approval, along with the statement "Being specified separately when the drug is granted approval based on the Law."

When the specifications for impurities are reviewed for a new entry of a pharmaceutical product in an individual monograph of the JP, acceptance criteria for impurities may be included in the review according to the following concepts. ICH Q6A guideline point out: Data available upon the marketing application are limited and it has to be taken into consideration that the limited data may influence the design of acceptance criteria. Regarding impurities, since impurity profiles gained during the manufacturing stages may sometimes be different from that gained from development stage, it is stated that changes in impurity profiles at the manufacturing stage should be considered as appropriate. According to this concept, for impurities which should be specified in the process listing in the JP, not only information from development stage but also information about impurity profiles if there are changes at the manufacturing stage, and information at the stage after the product manufacturing becomes stable (hereinafter referred to as the "stable production stage") should be taken into consideration.

However, it is undesirable to remove impurities that are present at substantially lower levels, or become undetectable at the stable production stage indiscriminately from the list of candidate compounds to be specified. JP-listed drugs are accepted as drugs by conformance to the specifications in the individual monograph. However, generic drugs, whose manufacturing methods are not necessarily the same as that of the drug substance used for JP monograph, may have different impurity profiles and contain such impurities. Providing information in the process listing in the JP based on the detection results during development stage may result in encompassing impurities found in drug substances and drug products distributed as JP drugs.

Therefore, before the removal of impurities that are present at substantially lower levels or become undetectable at the stable production stage from the JP specification list, the need to establish specifications should be fully examined based on ICH Q3A and Q3B guidelines with respect to safety.

For a drug substance that was approved by the method to identify its impurities with impurity reference materials, it is desirable also in the individual JP monograph, in principle,

to establish specifications and test methods appropriately so that the specified impurity becomes identifiable. In regard to impurity control during the manufacturing process, impurities can be controlled by establishing an appropriate control strategy including release testing, in-process tests and process parameters control.

References

- 1) ICH:Harmonised Tripartite Guideline, Impurities in New Drug Substances.
- 2) ICH:Harmonised Tripartite Guideline, Impurities in New Drug Products.

Add the following:

Glossary for Quality by Design (QbD), Quality Risk Management (QRM) and Pharmaceutical Quality System (PQS)

1. Introduction

The purpose of this glossary is to define terms, used for developing the new concept of quality assurance in ICH Q8-11 guidelines so-called Q quartet, and to explain the concept. The terms shown here are determined as the result of discussion for long time in ICH, and are most important to understand the concept of systematic quality assurance based on science and quality risk management, as shown by the guidelines. The usage may not necessarily accord with general usage, however it is necessary to keep in mind that the following definition is used in the regulatory application of pharmaceuticals. The terms used in ICH Q8 to Q11 are shown below in their order. For terms explained in more than one guideline, the name of duplicated guideline is described in parentheses at the end of the corresponding sentence.

2. Glossary

[ICH Q8 Guideline]

Control Strategy: A planned set of controls, derived from current product and process understanding, that ensures process performance and product quality. The controls can include parameters and attributes related to drug substance and drug product materials and components, facility and equipment operating conditions, in-process controls, finished product specifications, and the associated methods and frequency of monitoring and control (ICH Q10, Q11). A control strategy is expected irrespective of development approaches. Under the development approach using Quality by Design, testing, monitoring or controlling can be shifted earlier into the process.

Quality by Design (QbD): A systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management.

Continuous Process Verification: An alternative approach to process validation in which manufacturing process performance is continuously monitored and evaluated. Process validation protocol can use Continuous Process Verification (CPV) to the process validation protocol for the initial and ongoing commercial production (ICH Q11). Generally, for initial process validation, CPV is more appropriate when QbD approach has been applied. However, it can also be used when extensive process knowledge has been gained through commercial manufacturing experience.

Process Robustness: Ability of a process to tolerate variability of materials and changes of the process and equipment without negative impact on quality (ICH Q11).

Critical Process Parameter (CPP): A process parameter whose variability has an impact on a critical quality attribute and therefore should be monitored or controlled to ensure the process produces the desired quality.

Critical Quality Attribute (CQA): A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality (ICH Q11). For example, CQAs of solid oral dosage forms are typically those aspects affecting product purity, strength, drug release and stability as described in ICH Q8, however it is usual to include product purity and strength itself in CQAs.

Formal Experimental Design: A structured, organized method for determining the relationship between factors affecting a process and the output of that process. Also known as “Design of Experiments” (DoE). The factors to be studied in a DoE could come from the risk assessment exercise or prior knowledge.

Design Space (DS): The multidimensional combination and interaction of input variables (e.g., material attributes) and process parameters that have been demonstrated to provide assurance of quality. Working within the design space is not considered as a change. Movement out of the design space is considered to be a change and would normally initiate a regulatory post approval change process. Design space is proposed by the applicant and is subject to regulatory assessment and approval (ICH Q10, Q11). Design space can be updated over the lifecycle as additional knowledge is gained. Since Proven Acceptable Range (PAR) from only univariate experimentation may lack an understanding of interactions between process parameters and/or material attributes, it should be noted that a combination of PAR does not constitute a design space.

Quality: The degree to which a set of inherent properties of a product, system or process fulfills requirements (ICH Q6A, Q8, Q10). The suitability of either a drug substance or a drug product for its intended use. This term includes such attributes as the identity, strength, and purity (ICH Q6A, Q8, Q9, Q10).

Process Analytical Technology (PAT): A system for designing, analyzing, and controlling manufacturing through

timely measurements (i.e., during processing) of critical quality and performance attributes of raw and in-process materials and processes with the goal of ensuring final product quality.

Quality Target Product Profile (QTPP): A prospective summary of the quality characteristics of a drug product that ideally will be achieved to ensure the desired quality, taking into account safety and efficacy of the drug product. Quality Target Product Profile describes the design criteria for the product, and should therefore form the basis for development of the product (ICH Q8).

Lifecycle: All phases in the life of a product from the initial development through marketing until the product’s discontinuation (ICH Q11).

Real Time Release Testing (RTRT): The ability to evaluate and ensure the quality of in-process and/or final product based on process data, which typically include a valid combination of measured material attributes and process controls (ICH Q11). Parametric release is one type of Real Time Release Testing. It is based on process data rather than testing of material and/or a sample for a specific attribute. For details, refer to “Basic Concepts for Quality Assurance of Drug Substances and Drug Products” in General Information.

Proven Acceptable Range (PAR): A characterized range of a process parameter for which operation within this range, while keeping other parameters constant, will result in producing a material meeting relevant quality criteria.

[ICH Q9 Guideline]

Decision Maker(s): Person(s) with the competence and authority to make appropriate and timely quality risk management decisions.

Harm: Damage to health, including the damage that can occur from loss of product quality or availability.

Trend: A statistical term referring to the direction or rate of change of a variable(s).

Detectability: The ability to discover or determine the existence, presence, or fact of a hazard.

Severity: A measure of the possible consequences of a hazard.

Product Lifecycle: All phases in the life of the product from the initial development through marketing until the product’s discontinuation.

Hazard: The potential source of harm (ISO/IEC Guide 51).

Quality System: The sum of all aspects of a system that implements quality policy and ensures that quality objectives are met.

Requirements: The explicit or implicit needs or expectations of the patients or their surrogates (e.g., health care professionals, regulators and legislators). In this document (ICH Q9), “requirements” refers not only to statutory, legisla-

tive, or regulatory requirements, but also to such needs and expectations.

Stakeholder: Any individual, group or organization that can affect, be affected by, or perceive itself to be affected by a risk. Decision makers might also be stakeholders. For the purposes of this guideline, the primary stakeholders are the patient, healthcare professional, regulatory authority, and industry.

Risk: The combination of the probability of occurrence of harm and the severity of that harm (ISO/IEC Guide 51).

Risk Assessment: A systematic process of organizing information to support a risk decision to be made within a risk management process. It consists of the identification of hazards and the analysis and evaluation of risks associated with exposure to those hazards.

Risk Communication: The sharing of information about risk and risk management between the decision maker and other stakeholders.

Risk Control: Actions implementing risk management decisions (ISO Guide 73).

Risk Acceptance: The decision to accept risk (ISO Guide 73).

Risk Reduction: Actions taken to lessen the probability of occurrence of harm and the severity of that harm.

Risk Identification: The systematic use of information to identify potential sources of harm (hazards) referring to the risk question or problem description.

Risk Evaluation: The comparison of the estimated risk to given risk criteria using a quantitative or qualitative scale to determine the significance of the risk.

Risk Analysis: The estimation of the risk associated with the identified hazards.

Risk Management: The systematic application of quality management policies, procedures, and practices to the tasks of assessing, controlling, communicating and reviewing risk.

Risk Review: Review or monitoring of output/results of the risk management process considering (if appropriate) new knowledge and experience about the risk.

[ICH Q10 Guideline]

Innovation: The introduction of new technologies or methodologies.

Pharmaceutical Quality System (PQS): Management system to direct and control a pharmaceutical company with regard to quality (ICH Q10 based upon ISO 9000:2005) .

Outsourced Activities: Activities conducted by a contract acceptor under a written agreement with a contract giver.

State of Control: A condition in which the set of controls consistently provides assurance of continued process performance and product quality.

Performance Indicators: Measurable values used to quantify quality objectives to reflect the performance of an organization, process or system, also known as “performance metrics” in some regions.

Continual Improvement: Recurring activity to increase the ability to fulfil requirements (ISO 9000:2005).

Senior Management: Person(s) who direct and control a company or site at the highest levels with the authority and responsibility to mobilize resources within the company or site (ICH Q10 based in part on ISO 9000:2005).

Capability of a Process: Ability of a process to realize a product that will fulfil the requirements of that product. The concept of process capability can also be defined in statistical terms (ISO 9000:2005).

Product Realization: Achievement of a product with the quality attributes appropriate to meet the needs of patients, health care professionals, and regulatory authorities (including compliance with marketing authorization) and internal customers requirements.

Corrective Action: Action to eliminate the cause of a detected non-conformity or other undesirable situation. NOTE: Corrective action is taken to prevent recurrence whereas preventive action is taken to prevent occurrence (ISO 9000:2005).

Enabler: A tool or process which provides the means to achieve an objective.

Knowledge Management: Systematic approach to acquiring, analyzing, storing, and disseminating information related to products, manufacturing processes and components.

Quality Planning: Part of quality management focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives (ISO 9000:2005).

Quality Policy: Overall intentions and direction of an organization related to quality as formally expressed by senior management (ISO 9000:2005).

Quality Manual: Document specifying the quality management system of an organization (ISO 9000:2005).

Quality Objectives: A means to translate the quality policy and strategies into measurable activities.

Quality Risk Management (QRM): A systematic process for the assessment, control, communication and review of risks to the quality of the drug (medicinal) product across the product lifecycle (ICH Q9, Q10). For details, refer to “Basic Concept of Quality Risk Management” in General Information.

Feedback/Feedforward: The modification or control of a process or system by its results or effects. Feedback/feedforward can be applied technically in process control strategies and conceptually in quality management. Feedback is to

reflect results to a previous process (for example: a control of the supply of materials in a previous process), and feed-forward is to reflect results to a subsequent process (for example: a control of time for drying in a subsequent process).

Change Management: A systematic approach to proposing, evaluating, approving, implementing and reviewing changes.

Preventive Action: Action to eliminate the cause of a potential non-conformity or other undesirable potential situation. NOTE: Preventive action is taken to prevent occurrence whereas corrective action is taken to prevent recurrence (ISO 9000:2005).

[ICH Q11 Guideline]

Chemical Transformation Step: For Chemical Entities, a step involved in the synthesis of the chemical structure of the drug substance from precursor molecular fragments. Typically it involves C—X or C—C bond formation or breaking.

Contaminants: Any adventitiously introduced materials (e.g., chemical, biochemical, or microbial species) not intended to be part of the manufacturing process of the drug substance or drug product (ICH Q6B).

3. References

- 1) ICH: Guideline for Q8(R2), Pharmaceutical Development.
- 2) ICH: Guideline for Q9, Quality Risk Management.
- 3) ICH: Guideline for Q10, Pharmaceutical Quality Systems.
- 4) ICH: Guideline for Q11, Development and Manufacture of Drug Substance (Chemical Entities and Biotechnological/Biological Entities).
- 5) ICH: Quality Implementation Working Group, Points to Consider (R2), ICH-Endorsed Guide for ICH Q8/Q9/Q10 Implementation
- 6) ICH: Quality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers (R4)

International Harmonization Implemented in the Japanese Pharmacopoeia Seventeenth Edition

Add the following:

Sep. 2017

Harmonized items	JP 17 (Supplement II)	Remarks
Conductivity	2.51 Conductivity Measurement	
Introduction	(Introduction)	
Apparatus	1. Apparatus	
Cell constant determination	2. Cell constant determination	
Calibration of temperature	3. Calibration of temperature	
Calibration of measurement electronics	4. Calibration of measurement electronics	
Temperature compensation	5. Temperature compensation	Deletion of ISO and examples of individual monograph.
Conductivity measurement of fluids	6. Conductivity measurement of fluids	

JP's particular description: 5. Temperature compensation; Additional explanation for non-linear temperature compensation data.

Feb. 2002/Oct.2009 (Rev. 1)/May 2016 (Rev. 2)

Harmonized items	JP 17 (Supplement II)	Remarks
Ethylcellulose	Ethylcellulose	
Definition	origin, limits of content	
Identification IR	Description	Non-harmonized item
Acidity/alkalinity	Identification	
Viscosity	Purity (1) Acidity or alkalinity	
Acetaldehyde	Viscosity	
Chlorides	Purity (4) Acetaldehyde	
Loss on drying	Purity (2) Chloride	
Sulfated ash	Loss on drying	
Assay	Residue on ignition	
Labelling	Assay	Not specified for the name and concentration of antioxidant in labelling
	labelling	Non-harmonized item
	Containers and storage	

JP's particular description: Purity Heavy metals.

July 2016

Harmonized items	JP 17 (Supplement II)	Remarks
Hydroxyethylcellulose Definition Identification A (IR) Identification B pH Chlorides Nitrates Aldehydes Loss on drying Sulfated ash Assay	Hydroxyethylcellulose origin, limits of content labeling of viscosity Description Identification (1) Identification (2) Viscosity pH Purity (1) Chloride Purity (2) Nitrate Purity (4) Aldehydes Loss on drying Residue on ignition Assay Containers and storage	Non-harmonized item Non-harmonized item Non-harmonized item Non-harmonized item

JP's particular description: Purity (3) Heavy metals.

Sep. 2017 (Rev. 2)

Harmonized items	JP 17 (Supplement II)	Remarks
Anhydrous Dibasic Calcium Phosphate	Anhydrous Dibasic Calcium Phosphate	
Definition	limits of content	
Identification (1)	Description	Non-harmonized item
Identification (2)	Identification (1)	
Acid-insoluble substances	Identification (2)	
Chloride	Purity (1) Acid-insoluble substances	
Sulfate	Purity (2) Chloride	
Carbonate	Purity (3) Sulfate	
Barium	Purity (4) Carbonate	
Loss on ignition	Purity (6) Barium	
Assay	Purity (7) Arsenic	Non-harmonized item
	Loss on ignition	
	Assay	
	Containers and storage	Non-harmonized item

JP's particular description: Purity (5) Heavy metals.

Delete the following:

Saccharin

Saccharin Sodium Hydrate

Total Protein Assay

INDEX

A

- Absorptive Cream, 755
Acacia, 1791
 Powdered, 1791
Acebutolol Hydrochloride, 359
Acetylglutamide Aluminum, 359, 2671
Acemetacin, 361
 Capsules, 361
 Tablets, 362
Acetaminophen, 363
Acetazolamide, 364
Acetic Acid, 365
 Glacial, 365
Acetohexamide, 366
Acetylcholine Chloride for Injection, 367
Acetylcysteine, 368
Acetylsalicylic Acid, 449
 Tablets, 450
Achyranthes Root, 1792
Aciclovir, 369
 for Injection, 371
 for Syrup, 373
 Granules, 370
 Injection, 371
 Ointment, 372
 Ophthalmic Ointment, 372
 Syrup, 372
 Tablets, 374
Aclarubicin Hydrochloride, 375
Acrinol
 and Zinc Oxide Oil, 377
 and Zinc Oxide Oil, Compound, 377
 and Zinc Oxide Ointment, 378
 Hydrate, 376
Actinomycin D, 378
Adrenaline, 379
 Injection, 379
 Solution, 380
Adsorbed
 Diphtheria-Purified Pertussis-Tetanus Combined Vaccine, 816
 Diphtheria-Tetanus Combined Toxoid, 816
 Diphtheria Toxoid for Adult Use, 816
 Habu-venom Toxoid, 1004, 2934
 Hepatitis B Vaccine, 1018
 Purified Pertussis Vaccine, 1384
 Tetanus Toxoid, 1670
Afloqualone, 380
Agar, 1792
 Powdered, 1793
Ajmaline, 381
 Tablets, 382
Akebia Stem, 1793
Alacepril, 382
 Tablets, 383
L-Alanine, 384
Albumin Tannate, 386
Alcohol, 895
 Dehydrated, 896
 for Disinfection, 897
Aldioxa, 386
 Granules, 387
 Tablets, 387
Alendronate
 Sodium Hydrate, 388
 Sodium Injection, 389
 Sodium Tablets, 390
Alimemazine Tartrate, 391
Alisma Tuber, 1793
 Powdered, 1794, 2747
Allopurinol, 392
 Tablets, 392
Alminoprofen, 393
 Tablets, 394
Aloe, 1794
 Powdered, 1795
Alpinia Officinarum Rhizome, 1796
Alprazolam, 395
Alprenolol Hydrochloride, 396
Alprostadil, 396
 Alfadex, 400
 Injection, 398
Alum, 403
 Solution, 401
 Powder, Salicylated, 1542
Aluminum
 Acetylsalicylate, 450
 Monostearate, 402
 Potassium Sulfate Hydrate, 403
 Silicate Hydrate with Silicon Dioxide, 1796
 Silicate, Natural, 404
 Silicate, Synthetic, 405
 Sucrose Sulfate Ester, 1609
Amantadine Hydrochloride, 405
Ambenonium Chloride, 406
Amidotrizoic Acid, 407
Amikacin Sulfate, 408
 for Injection, 409
 Injection, 409
Aminoacetic Acid, 995
Aminobenzylpenicillin, 430
 Anhydrous, 429
 Sodium, 431
Aminophylline
 Hydrate, 410
 Injection, 410
Amiodarone Hydrochloride, 411
 Tablets, 412
Amitriptyline Hydrochloride, 414
 Tablets, 414
Amlexanox, 415
 Tablets, 416
Amlodipine Besilate, 417
 Orally Disintegrating Tablets, 418
 Tablets, 420
Ammonia Water, 420
Amobarbital, 421
Amomum Seed, 1797, 2973
 Powdered, 1797
Amosulalol Hydrochloride, 421
 Tablets, 422
Amoxapine, 424
Amoxicillin
 Capsules, 425
 Hydrate, 424, 2671
Amphotericin B, 426
 for Injection, 427
 Syrup, 428
 Tablets, 428, 2909
Ampicillin
 Anhydrous, 429
 Ethoxycarbonyloxyethyl Hydrochloride, 468
 Hydrate, 430, 2671
 Sodium, 431
 Sodium and Sulbactam Sodium for Injection, 433
 Sodium for Injection, 432
Ampicillinphthalidyl Hydrochloride, 1633
Ampiroxicam, 434
 Capsules, 435
Amyl Nitrite, 436
Anemarrhena Rhizome, 1797
Anesthamine, 901
Anesthetic Ether, 898
Angelica Dahurica Root, 1798
Anhydrous
 Aminobenzylpenicillin, 429
 Ampicillin, 429
 Caffeine, 543
 Citric Acid, 716
 Dibasic Calcium Phosphate, 557, 2911
 Ethanol, 896, 2693
 Lactose, 1132, 2714
 Light, Silicic Acid, 1552, 2955
 Sodium Sulfate, 1994
Antipyrine, 437
Apricot Kernel, 1798
 Water, 1799

- Aprindine Hydrochloride, 437
 Capsules, 438
 Aralia Rhizome, 1800
 Arbekacin Sulfate, 439
 Injection, 440
 Areca, 1800
 Argatroban Hydrate, 441
 L-Arginine, 442
 Hydrochloride, 443
 Hydrochloride Injection, 443
 Aromatic Castor Oil, 1826
 Arotinolol Hydrochloride, 444
 Arsenic Trioxide, 445
 Arsenical Paste, 445
 Arsenous Acid, 445
 Artemisia
 Capillaris Flower, 1800, 2747, 2973
 Leaf, 1801
 Ascorbic Acid, 445
 and Calcium Pantothenate Tablets,
 447
 Injection, 446
 Powder, 446
 Asiasarum Root, 1801
 Asparagus Root, 1802
 L-Aspartic Acid, 449
 Aspirin, 449
 Aluminum, 450
 Tablets, 450
 Aspoxicillin Hydrate, 451
 Astragalus Root, 1803
 Atenolol, 452
 Atorvastatin Calcium
 Hydrate, 453
 Tablets, 454
 Atractylodes
 Lancea Rhizome, 1803
 Lancea Rhizome, Powdered, 1804
 Rhizome, 1804
 Rhizome, Powdered, 1805
 Atropine Sulfate
 Hydrate, 456
 Injection, 456
 Auranofin, 457
 Tablets, 458
 Azathioprine, 459
 Tablets, 460
 Azelastine Hydrochloride, 461
 Granules, 462
 Azelnidipine, 463
 Tablets, 464
 Azithromycin Hydrate, 465
 Azosemide, 2672
 Tablets, 2672
 Aztreonam, 466
 for Injection, 467
- B**
- Bacampicillin Hydrochloride, 468
 Bacitracin, 469, 2674
 Baclofen, 470
 Tablets, 470
 Bakumondoto Extract, 1805, 2747
 Bamethan Sulfate, 471
 Barbitol, 472
 Barium Sulfate, 473
 Bear Bile, 1807
 Bearberry Leaf, 1807
 Beclometasone Dipropionate, 473,
 2909
 Beef Tallow, 1808
 Beeswax
 White, 1808
 Yellow, 1809
 Bekanamycin Sulfate, 474
 Belladonna
 Extract, 1810
 Root, 1809, 2973
 Total Alkaloids, 1810
 Benidipine Hydrochloride, 475
 Tablets, 476
 Benincasa Seed, 1811
 Benoxinate Hydrochloride, 1345
 Benserazide Hydrochloride, 478
 Bentonite, 478
 Benzalkonium Chloride, 479
 Solution, 480
 Solution 50, Concentrated, 480
 Benzbromarone, 481
 Benzethonium Chloride, 481
 Solution, 482
 Benzocaine, 901
 Benzoic Acid, 482
 Benzoin, 1812
 Benzyl
 Alcohol, 483
 Benzoate, 484
 Benzylpenicillin
 Benzathine Hydrate, 485
 Potassium, 486, 2674
 Potassium for Injection, 487
 Bepotastine Besilate, 488
 Tablets, 489
 Beraprost Sodium, 490
 Tablets, 492
 Berberine
 Chloride Hydrate, 493
 Tannate, 494
 Betahistine Mesilate, 495
 Tablets, 496
 Betamethasone, 497
 Dipropionate, 499, 2909
 Sodium Phosphate, 500
 Tablets, 498
 Valerate, 502
 Valerate and Gentamicin Sulfate
 Cream, 502
 Valerate and Gentamicin Sulfate
 Ointment, 504
 Betamipron, 505
 Betaxolol Hydrochloride, 506
 Bethanechol Chloride, 507
 Bezafibrate, 507
 Extended-release Tablets, 508
 Bifonazole, 509
- C**
- Biotin, 510
 Biperiden Hydrochloride, 510
 Biphasic Isophane Insulin Human (Ge-
 netical Recombination) Injectable
 Aqueous Suspension, 2706
 Bisacodyl, 511
 Suppositories, 512
 Bismuth
 Subgallate, 512
 Subnitrate, 513
 Bisoprolol Fumarate, 514
 Tablets, 515
 Bitter
 Cardamon, 1812
 Orange Peel, 1812
 Tincture, 1813, 2973
 Bleomycin
 Hydrochloride, 516
 Sulfate, 518
 Bofutsushosan Extract, 1813, 2748,
 2973
 Boiogito Extract, 1817, 2750, 2974
 Boric Acid, 520
 Bromazepam, 520
 Bromfenac Sodium
 Hydrate, 2909
 Ophthalmic Solution, 2910
 Bromhexine Hydrochloride, 521
 Bromocriptine Mesilate, 522
 Bromovalerylurea, 523
 Brotizolam, 523
 Tablets, 524
 Brown Rice, 1820
 Bucillamine, 525
 Tablets, 526
 Bucumolol Hydrochloride, 527
 Bufetolol Hydrochloride, 528
 Buformin Hydrochloride, 529
 Delayed-release Tablets, 529
 Tablets, 531
 Bumetanide, 531
 Bunazosin Hydrochloride, 532
 Bupivacaine Hydrochloride Hydrate,
 533
 Bupleurum Root, 1820
 Bupranolol Hydrochloride, 534
 Buprenorphine Hydrochloride, 535
 Burdock Fruit, 1821
 Burnt Alum, 403
 Busulfan, 536
 Butenafine Hydrochloride, 536
 Cream, 537
 Solution, 538
 Spray, 538
 Butropium Bromide, 539
 Butyl Parahydroxybenzoate, 540

- and Sodium Benzoate, 544
 Anhydrous, 543
 Hydrate, 543
 Calciferol, 882
 Calcitonin Salmon, 545
 Calcium
 Chloride Hydrate, 550
 Chloride Injection, 551
 Folate, 551
 Gluconate Hydrate, 552
 Hydroxide, 553
 Lactate Hydrate, 553
 Leucovorin, 551
 Levofolinate Hydrate, 2675
 Oxide, 554
 Pantothenate, 554
 Paraaminosalicylate Granules, 556
 Paraaminosalicylate Hydrate, 555
 Polystyrene Sulfonate, 559
 Sodium Edetate Hydrate, 561
 Stearate, 562
 Calumba, 1821, 2974
 Powdered, 1822, 2974
 Camellia Oil, 1822
 Camostat Mesilate, 562
d-Camphor, 563
dl-Camphor, 564
 Candesartan Cilexetil, 565
 and Amlodipine Besylate Tablets, 567
 and Hydrochlorothiazide Tablets, 570
 Tablets, 566
 Capsicum, 1822
 and Salicylic Acid Spirit, 1824
 Powdered, 1823
 Tincture, 1824
 Capsules, 574
Capsules
 Acemetacin, 361
 Amoxicillin, 425
 Ampiroxicam, 435
 Aprindine Hydrochloride, 438
 Cefaclor, 593
 Cefadroxil, 598
 Cefalexin, 601
 Cefdinir, 617
 Cefixime, 624
 Cinoxacin, 710
 Clindamycin Hydrochloride, 722
 Clofibrate, 729
 Clorazepate Dipotassium, 740
 Diltiazem Hydrochloride Extended-release, 807
 Doxifluridine, 835
 Droxidopa, 842
 Emedastine Fumarate Extended-release, 858
 Ethyl Icosapentate, 904
 Flopropione, 939
 Fluconazole, 941
 Hypromellose, 574
 Indometacin, 1063
 Lansoprazole Delayed-release, 1140
 Methotrexate, 1225
 Nifedipine Extended-release, 1310
 Nizatidine, 1320
 Pilsicainide Hydrochloride, 1402
 Pullulan, 574
 Ribavirin, 1512
 Rifampicin, 1519
 Roxatidine Acetate Hydrochloride Extended-release, 1531
 Sodium Iodide (¹²³I), 1579
 Sodium Iodide (¹³¹I), 1580
 Sulpiride, 1621
 Tacrolimus, 1633
 Teprenone, 1661
 Tranexamic Acid, 1709
 Tranilast, 1712
 Trientine Hydrochloride, 1727
 Ubenimex, 1742
 Captopril, 575
 Carbamazepine, 575
 Carbazochrome Sodium Sulfonate Hydrate, 576
 Carbetapentane Citrate, 1378
 Carbetapentene Citrate, 1378
 Carbidopa Hydrate, 577
 L-Carbocysteine, 578
 Tablets, 579
 Carbolic Acid, 1390
 Carbon Dioxide, 580
 Carboplatin, 580
 Injection, 582
 Carboxymethylcellulose, 583
 Calcium, 583
 Sodium, 584
 Cardamon, 1825
 Carmellose, 583
 Calcium, 583
 Sodium, 584
 Carmofur, 586
 Carnauba Wax, 1825
 Carteolol Hydrochloride, 587
 Carumonam Sodium, 587
 Carvedilol, 589
 Tablets, 590
 Cassia Seed, 1825, 2974
 Castor Oil, 1826
 Aromatic, 1826
 Catalpa Fruit, 1826
 Cefaclor, 592
 Capsules, 593
 Combination Granules, 594
 Fine Granules, 596
 Cefadroxil, 597
 Capsules, 598
 for Syrup, 599
 Cefalexin, 599
 Capsules, 601
 Combination Granules, 602
 for Syrup, 603
 Cefalotin Sodium, 604
 for Injection, 2912
 Cefatrizine Propylene Glycolate, 605
 for Syrup, 606
 Cefazolin Sodium, 607
 for Injection, 608
 Hydrate, 609
 Cefbuperazone Sodium, 610
 Cefcapene Pivoxil Hydrochloride
 Fine Granules, 613
 Hydrate, 612
 Tablets, 614
 Cefdinir, 615
 Capsules, 617
 Fine Granules, 617
 Cefditoren Pivoxil, 618
 Fine Granules, 619
 Tablets, 620
 Cefepime Dihydrochloride
 for Injection, 622
 Hydrate, 621
 Cefixime
 Capsules, 624
 Fine Granules, 2913
 Hydrate, 623, 2676
 Cefmenoxime Hydrochloride, 625
 Cefmetazole Sodium, 627
 for Injection, 628
 Cefminox Sodium Hydrate, 629
 Cefodizime Sodium, 629
 Cefoperazone Sodium, 631
 and Sulbactam Sodium for Injection, 632
 for Injection, 2677
 Cefotaxime Sodium, 634
 Cefotetan, 635
 Cefotiam
 Hexetil Hydrochloride, 637
 Hydrochloride, 639
 Hydrochloride for Injection, 640
 Cefozopran Hydrochloride, 640
 for Injection, 641
 Cefpiramide Sodium, 642
 Cefpirome Sulfate, 643
 Cefpodoxime Proxetil, 644
 for Syrup, 646
 Tablets, 647
 Cefroxadine
 for Syrup, 649
 Hydrate, 648
 Cefsulodin Sodium, 650
 Ceftazidime
 for Injection, 653
 Hydrate, 652
 Cefteram Pivoxil, 654
 Fine Granules, 655
 Tablets, 656
 Ceftibuten Hydrate, 657
 Ceftizoxime Sodium, 658, 2678
 Ceftriaxone Sodium Hydrate, 660
 Cefuroxime Axetil, 662
 Cellacéfate, 663, 2679
 Cellulose
 , 2-hydroxypropyl ether, 1033
 Acetate Phthalate, 663
 Microcrystalline, 664, 2914

- Powdered, 667
 Celmoleukin (Genetical Recombination), 668
 Cetanol, 671
 Cetirizine Hydrochloride, 671
 Tablets, 672
 Cetotiamine Hydrochloride Hydrate, 673
 Cetraxate Hydrochloride, 674
 Chenodeoxycholic Acid, 675
 Cherry Bark, 1826
 Chloral Hydrate, 676
 Chloramphenicol, 677, 2917
 and Colistin Sodium Methanesulfonate Ophthalmic Solution, 2679
 Palmitate, 677
 Sodium Succinate, 678, 2679
 Chlordiazepoxide, 679
 Powder, 680
 Tablets, 681
 Chlorhexidine
 Gluconate Solution, 682
 Hydrochloride, 683
 Chlorinated Lime, 683
 Chlorzadine Acetate, 684
 Chlorobutanol, 685
 Chlorphenesin Carbamate, 685
 Tablets, 686
 Chlorpheniramine Maleate, 687
 Injection, 688
 Powder, 689
 Tablets, 690
d-Chlorpheniramine Maleate, 691
 Chlorpromazine Hydrochloride, 692, 2918
 Injection, 692
 Tablets, 693
 Chlorpropamide, 694
 Tablets, 695
 Cholecalciferol, 696
 Cholera Vaccine, 696
 Cholesterol, 697, 2918
 Chorionic Gonadotrophin, 997
 for Injection, 999
 Chotosan Extract, 1827, 2751
 Chrysanthemum Flower, 1829, 2975
 Cibenzoline Succinate, 697
 Tablets, 698
 Ciclacillin, 699
 Ciclosporin, 700
 A, 700
 Cilastatin Sodium, 701
 Cilazapril
 Hydrate, 702
 Tablets, 703
 Cilnidipine, 704
 Tablets, 705
 Cilostazol, 707
 Tablets, 708
 Cimetidine, 709
 Cimicifuga Rhizome, 1830
 Cinchocaine Hydrochloride, 786
 Cinnamon
 Bark, 1830
 Bark, Powdered, 1831
 Oil, 1831
 Cinoxacin, 709
 Capsules, 710
 Ciprofloxacin, 711
 Hydrochloride Hydrate, 712
 Cisplatin, 714
 Cistanche Herb, 1831
 Citicoline, 715
 Citric Acid
 Anhydrous, 716
 Hydrate, 717
 Citrus Unshiu Peel, 1832
 Clarithromycin, 717, 2680
 for Syrup, 2918
 Tablets, 719
 Clebopride Malate, 720
 Clemastine Fumarate, 721
 Clematis Root, 1833
 Clindamycin
 Hydrochloride, 721
 Hydrochloride Capsules, 722
 Phosphate, 724
 Phosphate Injection, 725
 Clinofibrate, 725
 Clobetasol Propionate, 726
 Clozapramine Hydrochloride Hydrate, 727
 Clofedanol Hydrochloride, 728
 Clofibrate, 728
 Capsules, 729
 Clomifene Citrate, 730
 Tablets, 731
 Clomipramine Hydrochloride, 731
 Tablets, 2681
 Clonazepam, 732
 Fine Granules, 733
 Tablets, 733
 Clonidine Hydrochloride, 734
 Cloperastine Hydrochloride, 735, 2919
 Clopidogrel
 Sulfate, 736
 Sulfate Tablets, 738
 Clorazepate Dipotassium, 739
 Capsules, 740
 Clotiazepam, 741
 Tablets, 2682
 Clotrimazole, 742
 Clove, 1833
 Oil, 1834
 Powdered, 1833
 Cloxacillin Sodium Hydrate, 743, 2683
 Cloxazolam, 744
 Cnidium
 Monnieri Fruit, 1834
 Rhizome, 1835
 Rhizome, Powdered, 1835
 Cocaine Hydrochloride, 745
 Coconut Oil, 1835
 Codeine Phosphate
 Hydrate, 746
 Powder, 1%, 746
 Powder, 10%, 747
 Tablets, 748
 Cod Liver Oil, 745
 Codonopsis Root, 1835
 Coix Seed, 1836
 Powdered, 1836
 Colchicine, 749
 Colestimide, 750
 Granules, 751
 Tablets, 752
 Colistin
 Sodium Methanesulfonate, 752, 2683
 Sulfate, 753
 Compound
 Acrinol and Zinc Oxide Oil, 377
 Diastase and Sodium Bicarbonate Powder, 783
 Hycodenone Injection, 1347
 Iodine Glycerin, 1077
 Methyl Salicylate Spirit, 1238
 Oxycodone and Atropine Injection, 1348
 Oxycodone Injection, 1347
 Phellodendron Powder for Cataplasm, 1940
 Rhubarb and Senna Powder, 1957
 Salicylic Acid Spirit, 1541
 Scopolia Extract and Diastase Powder, 1976
 Thianthol and Salicylic Acid Solution, 1679
 Vitamin B Powder, 1765, 2971
 Concentrated
 Glycerin, 993
 Glycerol, 993
 Condurango, 1836
 Fluidextract, 1837
 Coptis Rhizome, 1837
 Powdered, 1838
 Corn
 Oil, 1839
 Starch, 1601
 Cornus Fruit, 1839, 2752
 Cortisone Acetate, 754
 Corydalis Tuber, 1840
 Powdered, 1841
 Crataegus Fruit, 1842
Creams
 Absorptive, 755
 Betamethasone Valerate and Gentamicin Sulfate, 502
 Butenafine Hydrochloride, 537
 Hydrophilic, 756
 Ibuprofen Piconol, 1044
 Ketoconazole, 1122
 Lanconazole, 2945
 Terbinafine Hydrochloride, 1663
 Cresol, 756
 Solution, 756

Solution, Saponated, 757
 Croconazole Hydrochloride, 757
 Croscarmellose Sodium, 585
 Crospovidone, 758
 Crude Glycyrrhiza Extract, 1864,
 2756, 2976
 Crystal Violet, 1237
 Curcuma Rhizome, 2753
 Cyanamide, 759
 Cyanocobalamin, 760
 Injection, 761
 Cyclopentolate Hydrochloride, 761
 Cyclophosphamide
 Hydrate, 762
 Tablets, 762
 Cycloserine, 763
 Cyperus Rhizome, 1842, 2753
 Powdered, 1843, 2753
 Cyproheptadine Hydrochloride Hy-
 drate, 764
 L-Cysteine, 765
 Hydrochloride Hydrate, 766
 L-Cystine, 766
 Cytarabine, 767

D

Daiokanzoto Extract, 1843, 2754
 Daisaikoto Extract, 1844, 2754
 Danazol, 768
 Dantrolene Sodium Hydrate, 768
 Daunorubicin Hydrochloride, 769
 Deferoxamine Mesilate, 771
 Dehydrated Alcohol, 896
 Dehydrocholate Sodium Injection,
 773
 Dehydrocholic Acid, 772, 2920
 Injection, 773
 Purified, 772, 2920
 Demethylchlortetracycline Hydrochlo-
 ride, 774, 2684
 Dental
 Antiformin, 436
 Iodine Glycerin, 1078
 Paraformaldehyde Paste, 1367
 Phenol with Camphor, 1392
 Sodium Hypochlorite Solution, 436
 Triozinc Paste, 1734
 Dermatol, 512
 Deslanoside, 775
 Injection, 776
 Dexamethasone, 776
 Dextran
 40, 777, 2684
 40 Injection, 778
 70, 779
 Sulfate Sodium Sulfur 5, 780
 Sulfate Sodium Sulfur 18, 780
 Dextrin, 781
 Dextromethorphan Hydrobromide Hy-
 drate, 782
 Diagnostic Sodium Citrate Solution,
 1572

Diastase, 782
 and Sodium Bicarbonate Powder,
 783
 and Sodium Bicarbonate Powder,
 Compound, 783
 Diazepam, 783
 Tablets, 784
 Dibasic
 Calcium Phosphate, Anhydrous,
 557, 2911
 Calcium Phosphate Hydrate, 558
 Sodium Phosphate Hydrate, 1585
 Dibekacin Sulfate, 785
 Ophthalmic Solution, 785
 Dibucaine Hydrochloride, 786
 Dichlorphenamide, 787
 Tablets, 789
 Diclofenac Sodium, 787
 Suppositories, 2920
 Diclofenamide, 787, 2684
 Tablets, 789, 2684
 Dicloxacinil Sodium Hydrate, 789
 Diethylcarbamazine Citrate, 790
 Tablets, 790
 Difenidol Hydrochloride, 791
 Diflorasone Diacetate, 792
 Diflucortolone Valerate, 793
 Digenea, 1846
 Digitoxin, 794, 2684
 Tablets, 795, 2684
 Digoxin, 796, 2685
 Injection, 797
 Tablets, 798
 Dihydrocodeine Phosphate, 800
 Powder, 1%, 800
 Powder, 10%, 801
 Dihydroergotamine Mesilate, 802
 Dihydroergotamine Mesilate, 803
 Dilazep Hydrochloride Hydrate, 805
 Diltiazem Hydrochloride, 806
 Extended-release Capsules, 807
 Dilute
 Hydrochloric Acid, 1024
 Iodine Tincture, 1076
 Diluted Opium Powder, 1924
 Dimemorfan Phosphate, 808
 Dimenhydrinate, 809
 Tablets, 809
 Dimercaprol, 810
 Injection, 811
 Dimorpholamine, 811
 Injection, 812
 Dinoprost, 812
 Dionin, 905
 Dioscorea Rhizome, 1847
 Powdered, 1847
 Diphenhydramine, 813
 and Bromovalerylurea Powder, 814
 Hydrochloride, 814
 , Phenol and Zinc Oxide Liniment,
 815
 Tannate, 815
 Diphenylhydantoin, 1396

Powder, 1396
 Sodium for Injection, 1398
 Tablets, 1397
 Diphtheria
 Antitoxin, Equine, Freeze-dried,
 816
 -Purified Pertussis-Tetanus Com-
 bined Vaccine, Absorbed, 816
 -Tetanus Combined Toxoid, 816
 -Tetanus Combined Toxoid, Ab-
 sorbed, 816
 Toxoid, 816
 Toxoid for Adult Use, Absorbed,
 816
 Dipyridamole, 817
 Disodium Edetate Hydrate, 1573
 Disopyramide, 818
 Distigmine Bromide, 818
 Tablets, 819
 Disulfiram, 820
 Dobutamine Hydrochloride, 820
 Docetaxel
 for Injection, 823
 Hydrate, 821
 Injection, 822
 Dolichos Seed, 1848
 Domperidone, 824
 Donepezil Hydrochloride, 825
 Fine Granules, 826
 Tablets, 827
 Dopamine Hydrochloride, 829
 Injection, 829
 Doripenem
 for Injection, 2924
 Hydrate, 2921
 Dorzolamide Hydrochloride, 830
 Ophthalmic Solution, 831
 Doxapram Hydrochloride Hydrate,
 832
 Doxazosin Mesilate, 823
 Tablets, 834
 Doxifluridine, 835
 Capsules, 835
 Doxorubicin Hydrochloride, 836,
 2685
 for Injection, 837
 Doxycycline Hydrochloride
 Hydrate, 838, 2686
 Tablets, 840
 Dried
 Aluminum Hydroxide Gel, 401
 Aluminum Hydroxide Gel Fine Gran-
 ules, 402
 Aluminum Potassium Sulfate, 403
 Sodium Carbonate, 1568
 Sodium Sulfite, 1592
 Thyroid, 1684
 Yeast, 1779
 Droperidol, 841
 Droxidopa, 842
 Capsules, 842
 Fine Granules, 843
 Dydrogesterone, 844

Tablets, 845

E

Ebastine, 845
Orally Disintegrating Tablets, 846
Tablets, 847

Ecabet Sodium
Granules, 849
Hydrate, 849

Ecarazine Hydrochloride, 1700

Ecothiopate Iodide, 851

Edaravone, 851
Injection, 852, 2687

Edrophonium Chloride, 853
Injection, 854

EDTA Sodium Hydrate, 1573

Elcatonin, 854

Eleutherococcus Senticosus Rhizome, 1848

Emedastine Fumarate, 857
Extended-release Capsules, 858

Emorfazone, 858
Tablets, 859

Enalapril Maleate, 860
Tablets, 861

Enflurane, 863

Enoxacin Hydrate, 863

Entacapone, 2689
Tablets, 2691

Enviomycin Sulfate, 864

Epalrestat, 865, 2692
Tablets, 866

Eperisone Hydrochloride, 867

Ephedra Herb, 1849

Ephedrine Hydrochloride, 868
Injection, 869
Powder, 870
Powder, 10%, 870
Tablets, 870

Epimedium Herb, 1850

Epinephrine, 379
Injection, 379
Solution, 380

Epirizole, 871

Epirubicin Hydrochloride, 872, 2925

Eplerenone, 874
Tablets, 875

Epoetin
Alfa (Genetical Recombination), 876
Beta (Genetical Recombination), 879

Ergocalciferol, 882

Ergometrine Maleate, 883
Injection, 883
Tablets, 884

Ergotamine Tartrate, 884

Erythromycin, 885, 2692
Delayed-release Tablets, 886
Ethylsuccinate, 887
Lactobionate, 887
Stearate, 888

Estazolam, 889

Estradiol Benzoate, 889
Injection (Aqueous Suspension), 890

Estriol, 891, 2925
Injection (Aqueous Suspension), 892
Tablets, 892

Etacrynic Acid, 893
Tablets, 893

Ethacridine Lactate, 376

Ethambutol Hydrochloride, 894

Ethanol, 895, 2693
Anhydrous, 896, 2693
for Disinfection, 897

Ethenzamide, 897

Ether, 898
Anesthetic, 898
Guaiacol Glyceryl, 1002
Polyoxyethylene Lauryl Alcohol, 1144

Ethinylestradiol, 899
Tablets, 899

Ethionamide, 900

Ethosuximide, 901

Ethoxybenzamide, 897

Ethyl
Aminobenzoate, 901
Cysteine Hydrochloride, 902
L-Cysteine Hydrochloride, 902
Icosapentate, 903
Icosapentate Capsules, 904
Parahydroxybenzoate, 906

Ethylcellulose, 2926

Ethylenediamine, 903

Ethylmorphine Hydrochloride Hydrate, 905

Etidronate Disodium, 907
Tablets, 908

Etilefrine Hydrochloride, 909
Tablets, 909

Etizolam, 910, 2927
Fine Granules, 911
Tablets, 912

Etodolac, 913

Etoposide, 914

Eucalyptus Oil, 1850, 2975

Eucommia Bark, 1851

Euodia Fruit, 1851, 2755

Exsiccated Gypsum, 1868

Extracts
Bakumondoto, 1805, 2747
Belladonna, 1810
Bofutsushosan, 1813, 2748, 2973
Boiogito, 1817, 2750, 2974
Chotosan, 1827, 2751
Crude Glycyrrhiza, 1864, 2756, 2976
Daiokanzoto, 1843, 2754
Daisaikoto, 1844, 2754
Glycyrrhiza, 1863, 2755, 2975
Goreisan, 2756
Goshajinkigan, 1865, 2758

Goshuyuto, 2976

Hachimijogan, 1868, 2759

Hangekobokuto, 1871, 2761

Hangeshashinto, 1873, 2761

Hochuekkito, 1876, 2763, 2977

Juzentaihoto, 1887, 2766, 2978

Kakkonto, 1889, 2768

Kakkontokasenkyushin'i, 1892, 2771, 2978

Kamikihito, 1895, 2772, 2978

Kamishoyosan, 1898, 2773, 2979

Keishibukuryogan, 1901, 2775

Maoto, 1912, 2776

Mukoi-Daikenchuto, 1917, 2777

Nux Vomica, 1921

Orengedokuto, 1926, 2778

Otsujito, 1929, 2778, 2980

Rikkunshito, 1957, 2780

Ryokeijutsukanto, 1961, 2781

Saibokuto, 1963, 2783

Saikokeishito, 1965, 2785

Saireito, 1968, 2787

Scopolia, 1975

Shakuyakukanzoto, 1984, 2790

Shimbuto, 1985, 2791

Shosaikoto, 1988, 2791

Shoseiryuto, 1990, 2793

Tokakujokito, 1999, 2796

Tokishakuyakusan, 2002, 2797, 2983

Yokukansan, 2010, 2798, 2983

F

Famotidine, 915
for Injection, 917
Injection, 915
Powder, 918
Tablets, 919

Faropenem Sodium
for Syrup, 920
Hydrate, 919
Tablets, 921

Felbinac, 923
Cataplasm, 923
Tape, 924

Felodipine, 927
Tablets, 2928

Fenbufen, 924

Fennel, 1851
Oil, 1852
Powdered, 1852

Fentanyl Citrate, 925

Ferrous Sulfate Hydrate, 926

Fexofenadine Hydrochloride, 926
Tablets, 927

Filgrastim (Genetical Recombination), 929
Injection, 931

Fine Granules
Cefaclor, 596
Cefcapene Pivoxil Hydrochloride, 613

- Cefdinir, 617
 Cefditoren Pivoxil, 619
 Cefixime, 2913
 Cefteram Pivoxil, 655
 Clonazepam, 733
 Donepezil Hydrochloride, 826
 Dried Aluminum Hydroxide Gel, 402
 Droxidopa, 843
 Etizolam, 911
 Haloperidol, 1005
 Ifenprodil Tartrate, 1050
 Irsogladine Maleate, 1090
 Levofloxacin, 1155
 Nifedipine, 1311
 Nifedipine Delayed-release, 1309
 Pravastatin Sodium, 1446
 Precipitated Calcium Carbonate, 548
 Probucol, 1461
 Quetiapine Fumarate, 1493
 Risperidone, 1522
 Sarpogrelate Hydrochloride, 1544
 Tranilast, 1713
 Troxipide, 1735
 Flavin Adenine Dinucleotide Sodium, 932
 Flavoxate Hydrochloride, 934
 Flecainide Acetate, 934
 Tablets, 935
 Flomoxef Sodium, 936
 for Injection, 938
 Flopropione, 939
 Capsules, 939
 Fluconazole, 940
 Capsules, 941
 Injection, 942
 Flucytosine, 943
 Fludiazepam, 944
 Fludrocortisone Acetate, 944
Fluidextracts
 Condurango, 1837
 Platycodon, 1943, 2980
 Uva Ursi, 2008
 Flunitrazepam, 945
 Fluocinolone Acetonide, 946
 Fluocinonide, 947
 Fluorescein Sodium, 948
 Fluorometholone, 949
 Fluorouracil, 950
 Fluoxymesterone, 950, 2694
 Fluphenazine Enanthate, 951
 Flurazepam Hydrochloride, 952
 Flurbiprofen, 953
 Flutamide, 954
 Flutoprazepam, 955
 Tablets, 955
 Fluoxamine Maleate, 956
 Tablets, 958
 Foeniculated Ammonia Spirit, 1852
 Folic Acid, 959, 2694
 Injection, 959
 Tablets, 960
 Formalin, 961
 Water, 961
 Formoterol Fumarate Hydrate, 962
 Forsythia Fruit, 1852
 Fosfomycin
 Calcium
 Calcium for Syrup, 963
 Calcium Hydrate, 962, 2694
 Sodium, 964, 2694
 Sodium for Injection, 965
 Fradiomycin Sulfate, 966
 Freeze-dried
 BCG Vaccine (for Percutaneous Use), 473
 Botulism Antitoxin, Equine, 520
 Diphtheria Antitoxin, Equine, 816
 Habu Antivenom, Equine, 1004
 Inactivated Tissue Culture Rabies Vaccine, 1503
 Japanese Encephalitis Vaccine, 1111
 Live Attenuated Measles Vaccine, 1196
 Live Attenuated Mumps Vaccine, 1278
 Live Attenuated Rubella Vaccine, 1535
 Mamushi Antivenom, Equine, 1191
 Smallpox Vaccine, 1563
 Smallpox Vaccine Prepared in Cell Culture, 1563
 Tetanus Antitoxin, Equine, 1670, 2967
 Fritillaria Bulb, 1853
 Fructose, 967
 Injection, 968
 Fudosteine, 968
 Tablets, 969
 Furosemide, 970
 Injection, 971
 Tablets, 972
 Fursultiamine Hydrochloride, 973
- G**
- Gabexate Mesilate, 974
 β -Galactosidase
 (Aspergillus), 975
 (Penicillium), 975
 Gallium (⁶⁷Ga) Citrate Injection, 976
 Gambir, 1853
 Powdered, 1853
 Gardenia Fruit, 1854, 2755
 Powdered, 1854
 Gas Gangrene Antitoxin, Equine, 977
 Gastrodia Tuber, 1855, 2975
 Gatifloxacin
 Hydrate, 2930
 Ophthalmic Solution, 2931
 Gefarnate, 977
 Gelatin, 978
 Purified, 980
 Gentamicin Sulfate, 982, 2695
 Injection, 2933
 Ointment, 2933
 Ophthalmic Solution, 983
 Gentian, 1856
 and Sodium Bicarbonate Powder, 1857
 Powdered, 1856
 Geranium Herb, 1857
 Powdered, 1857
 Ginger, 1857
 Powdered, 1858
 Processed, 1951
 Ginseng, 1859
 Powdered, 1860
 Glacial Acetic Acid, 365
 Glehnia Root and Rhizome, 1861
 Glibenclamide, 984
 Gliclazide, 984
 Glimepiride, 985
 Tablets, 986
 Glucose, 988
 Hydrate, 2695
 Injection, 989, 2698
 Purified, 2696
 L-Glutamic Acid, 989
 L-Glutamine, 990
 Glutathione, 991
 Glycerin, 992
 and Potash Solution, 994
 Concentrated, 993
 Glycerol, 992
 Concentrated, 993
 Glyceryl Monostearate, 995
 Glycine, 995
 Glycyrrhiza, 1862
 Extract, 1863, 2755, 2975
 Extract, Crude, 1864, 2756, 2976
 Powdered, 1863
 Prepared, 1947
 Gonadorelin Acetate, 996
 Goreisan Extract, 2756
 Goshajinkigan Extract, 1865, 2758
 Goshuyuto Extract, 2976
 Gramicidin, 1001, 2698
Granules
 Aciclovir, 370
 Aldioxa, 387
 Azelastine Hydrochloride, 462
 Calcium Paraaminosalicylate, 556
 Cefaclor Combination, 594
 Cefalexin Combination, 602
 Colestimide, 751
 Ecabet Sodium, 849
 L-Isoleucine, L-Leucine and L-Valine, 1096
 Minocycline Hydrochloride, 2949
 Montelukast Sodium, 2724
 Pas-calcium, 556
 Polaprezinc, 2953
 Ursodeoxycholic Acid, 1749
 Guaiacol Glyceryl Ether, 1002
 Guaifenesin, 1002
 Guanabenz Acetate, 1003

Guanethidine Sulfate, 1003
Gypsum, 1868

H

Hachimijiogan Extract, 1868, 2759
Haloperidol, 1004, 2934
 Fine Granules, 1005
 Injection, 1006
 Tablets, 1006
Halothane, 1007
Haloxazolam, 1008
Hangekobokuto Extract, 1871, 2761
Hangeshashinto Extract, 1873, 2761
Hedysarum Root, 1875
Hemp Fruit, 1876
Heparin
 Calcium, 1009, 2698
 Sodium, 1013, 2699
 Sodium Injection, 1017
L-Histidine, 1018
 Hydrochloride Hydrate, 1019
Hochuekkito Extract, 1876, 2763,
 2977
Homatropine Hydrobromide, 1020
Homochlorcyclizine Hydrochloride,
 1020
Honey, 1879
Houttuynia Herb, 1880
Human
 Chorionic Gonadotrophin, 997
 Chorionic Gonadotrophin for Injec-
 tion, 999
 Menopausal Gonadotrophin, 999
 Normal Immunoglobulin, 1021
Hycoato Injection, 1348
Hydralazine Hydrochloride, 1021
 for Injection, 1022
 Powder, 1022
 Tablets, 1022
Hydrochloric Acid, 1023
 Dilute, 1024
 Lemonade, 1024
Hydrochlorothiazide, 1024
Hydrocortisone, 1025, 2934
 Acetate, 1026, 2701, 2934
 and Diphenhydramine Ointment,
 1027, 2934
 Butyrate, 1028, 2701
 Sodium Phosphate, 1028
 Sodium Succinate, 1030
 Succinate, 1031
Hydrocotarnine Hydrochloride Hy-
 drate, 1031
Hydrogenated Oil, 1032
Hydrophilic
 Cream, 756
 Petrolatum, 1387
Hydrous Lanolin, 1903
Hydroxocobalamin Acetate, 1033,
 2701
Hydroxyethylcellulose, 2934
Hydroxypropylcellulose, 1033, 2702,

2937

Hydroxypropylmethylcellulose, 1038
Hydroxyzine
 Hydrochloride, 1036
 Pamoate, 1036
Hymecromone, 1037
Hypromellose, 1038, 2704, 2938
 Acetate Succinate, 1040
 Capsules, 574
 Phthalate, 1041

I

Ibudilast, 1042
Ibuprofen, 1043
 Piconol, 1044
 Piconol Cream, 1044
 Piconol Ointment, 1045
Ichthammol, 1046
Idarubicin Hydrochloride, 1046
 for Injection, 1047
Idoxuridine, 1048
 Ophthalmic Solution, 1049
Ifenprodil Tartrate, 1050
 Fine Granules, 1050
 Tablets, 1051
Imidapril Hydrochloride, 1052
 Tablets, 1053
Imipenem
 and Cilastatin Sodium for Injection,
 1056
 Hydrate, 1054
Imipramine Hydrochloride, 1057,
 2940
 Tablets, 1057, 2940
Immature Orange, 1880
Imperata Rhizome, 1880
Indapamide, 1058
 Tablets, 1059
Indenolol Hydrochloride, 1060
Indigocarmine, 1061
 Injection, 1062
Indium (¹¹¹In) Chloride Injection,
 1062
Indometacin, 1062
 Capsules, 1063
 Suppositories, 1064
Influenza HA Vaccine, 1065
Injection
 Acetylcholine Chloride for, 367
 Aciclovir, 371
 Aciclovir for, 371
 Adrenaline, 379
 Alendronate Sodium, 389
 Alprostadil, 398
 Amikacin Sulfate, 409
 Amikacin Sulfate for, 409
 Aminophylline, 410
 Amphotericin B for, 427
 Ampicillin Sodium and Sulbactam
 Sodium for, 433
 Ampicillin Sodium for, 432
 Arbekacin Sulfate, 440
L-Arginine Hydrochloride, 443
Ascorbic Acid, 446
Atropine Sulfate, 456
Aztreonam for, 467
Benzylpenicillin Potassium for, 487
Calcium Chloride, 551
Carboplatin, 582
Cefalotin Sodium for, 2912
Cefazolin Sodium for, 608
Cefepime Dihydrochloride for, 622
Cefmetazole Sodium for, 628
Cefoperazone Sodium and Sulbac-
 tam Sodium for, 632
Cefoperazone Sodium for, 2677
Cefotiam Hydrochloride for, 640
Cefozopran Hydrochloride for, 641
Ceftazidime for, 653
Chlorpheniramine Maleate, 688
Chlorpromazine Hydrochloride,
 692
Chorionic Gonadotrophin for, 999
Clindamycin Phosphate, 725
Compound Hycodone, 1347
Compound Oxycodone, 1347
Compound Oxycodone and Atro-
 pine, 1348
Cyanocobalamin, 761
Dehydrocholate Sodium, 773
Dehydrocholic Acid, 773
Deslanoside, 776
Dextran 40, 778
Digoxin, 797
Dimercaprol, 811
Dimorpholamine, 812
Diphenylhydantoin Sodium for,
 1398
Docetaxel, 822
Docetaxel for, 823
Dopamine Hydrochloride, 829
Doripenem for, 2924
Doxorubicin Hydrochloride for,
 837
Edaravone, 852, 2687
Edrophonium Chloride, 854
Ephedrine Hydrochloride, 869
Epinephrine, 379
Ergometrine Maleate, 883
Estradiol Benzoate (Aqueous Suspen-
 sion), 890
Estriol (Aqueous Suspension), 892
Famotidine, 915
Famotidine for, 917
Filgrastim (Genetical Recombina-
 tion), 931
Flomoxef Sodium for, 938
Fluconazole, 942
Folic Acid, 959
Fosfomycin Sodium for, 965
Fructose, 968
Furosemide, 971
Gallium (⁶⁷Ga) Citrate, 976
Gentamicin Sulfate, 2933
Glucose, 989, 2698

- Haloperidol, 1006
Heparin Sodium, 1017
Human Chorionic Gonadotrophin for, 999
Hycoato, 1348
Hydralazine Hydrochloride for, 1022
Idarubicin Hydrochloride for, 1047
Imipenem and Cilastatin Sodium for, 1056
Indigocarmine, 1062
Indium (¹¹¹In) Chloride, 1062
Insulin Glargine (Genetical Recombination), 1067
Insulin Human (Genetical Recombination), 1070
Interferon Alfa (NAMALWA), 1074
Iodinated (¹³¹I) Human Serum Albumin, 1075
Iohexol, 1082, 2710
Iopamidol, 1084
Isepamicin Sulfate, 1094
Isoniazid, 1100
Isotonic Sodium Chloride, 1571
Levallorphan Tartrate, 1152
Levofloxacin, 1156
Lidocaine, 1162
Lidocaine Hydrochloride, 1162
Lincomycin Hydrochloride, 1164
Magnesium Sulfate, 1190
D-Mannite, 1195
D-Mannitol, 1195
Meglumine Iotalamate, 1206
Meglumine Sodium Amidotrizoate, 1207
Mepivacaine Hydrochloride, 1213
Meropenem for, 1219
Metenolone Enanthate, 1222
Minocycline Hydrochloride for, 1256
Mitomycin C for, 1262
Morphine and Atropine, 1273
Morphine Hydrochloride, 1271
Nartograstim for (Genetical Recombination), 1293
Neostigmine Methylsulfate, 1297
Nicardipine Hydrochloride, 1299
Nicotinic Acid, 1307
Noradrenaline, 1322
Noradrenaline Hydrochloride, 1322
Norepinephrine, 1322
Norepinephrine Hydrochloride, 1322
Operidine, 1385
Opium Alkaloids and Atropine, 1338
Opium Alkaloids and Scopolamine, 1339
Opium Alkaloids Hydrochlorides, 1337
Oxytocin, 1355
Ozagrel Sodium, 1357
Ozagrel Sodium for, 1357
Panipenem and Betamipron for, 1361
Papaverine Hydrochloride, 1364
Pazufloxacin Mesilate, 2728
Peplomycin Sulfate for, 1380
Pethidine Hydrochloride, 1385
Phenolsulfonphthalein, 1393
Phenytoin Sodium for, 1398
Piperacillin Sodium for, 1418
Prednisolone Sodium Succinate for, 1456
Procainamide Hydrochloride, 1463
Procaine Hydrochloride, 1465
Progesterone, 1470
Protamine Sulfate, 1484
Purified Sodium Hyaluronate, 1576
Pyridoxine Hydrochloride, 1490
Reserpine, 1508
Riboflavin Phosphate, 1516
Riboflavin Sodium Phosphate, 1516
Ritodrine Hydrochloride, 2954
Roxatidine Acetate Hydrochloride for, 1533
Sivelestat Sodium for, 1562
Sodium Bicarbonate, 1566
Sodium Chloride, 0.9%, 1571
Sodium Chloride, 10%, 1570
Sodium Chromate (⁵¹Cr), 1571
Sodium Citrate for Transfusion, 1572
Sodium Iodohippurate (¹³¹I), 1580
Sodium Iotalamate, 1580
Sodium Pertechnetate (^{99m}Tc), 1585
Sodium Thiosulfate, 1593
Spectinomycin Hydrochloride for, 1598
Sterile Water for, in Containers, 1775
Streptomycin Sulfate for, 1609
Sulfobromophthalein Sodium, 1619
Sulpyrine, 1623
Suxamethonium Chloride, 1628, 2737
Suxamethonium Chloride for, 1628
Tazobactam and Piperacillin for, 1645
Teceleukin for (Genetical Recombination), 1652
Testosterone Enanthate, 1668
Testosterone Propionate, 1669
Thallium (²⁰¹Tl) Chloride, 1672
Thiamine Chloride Hydrochloride, 1675
Thiamylal Sodium for, 1678
Thiopental Sodium for, 1681
Tobramycin, 1696
Tranexamic Acid, 1710
Vancomycin Hydrochloride for, 1758
Vasopressin, 1759, 2740
Verapamil Hydrochloride, 2970
Vinblastine Sulfate for, 1763
Vitamin B₁ Hydrochloride, 1675
Vitamin B₂ Phosphate Ester, 1516
Vitamin B₆, 1490
Vitamin B₁₂, 761
Vitamin C, 446
Voriconazole for, 2743
Water for, 1774
Weak Opium Alkaloids and Scopolamine, 1340
Xylitol, 1778
Insulin
Aspart (Genetical Recombination), 2708
Glargine (Genetical Recombination), 1065
Glargine (Genetical Recombination) Injection, 1067
Human (Genetical Recombination), 1068
Human (Genetical Recombination) Injection, 1070
Interferon Alfa (NAMALWA), 1071
Injection, 1074
Iodinated (¹³¹I) Human Serum Albumin Injection, 1075
Iodine, 1075
Glycerin, Compound, 1077
Glycerin, Dental, 1078
, Salicylic Acid and Phenol Spirit, 1079
Tincture, 1076
Tincture, Dilute, 1076
Iodoform, 1080
Iohexol, 1080
Injection, 1082, 2710
Iopamidol, 1083
Injection, 1084
Iotalamic Acid, 1085
Iotroxic Acid, 1086
Ipecac, 1881
Powdered, 1881
Syrup, 1882
Ipratropium Bromide Hydrate, 1086
Ipriflavone, 1087
Tablets, 1088
Iproveratril Hydrochloride, 1761
Irbesartan, 1089
and Amlodipine Besilate Tablets, 2711
Tablets, 2710
Irinotecan Hydrochloride Hydrate, 2940
Irsogladine Maleate, 1090
Fine Granules, 1090
Tablets, 1091
Isepamicin Sulfate, 1093
Injection, 1094
Isoflurane, 1094
L-Isoleucine, 1096
, L-Leucine and L-Valine Granules, 1096

Isomalt, 1098, 2942
Hydrate, 1098, 2942
Isoniazid, 1099
Injection, 1100
Tablets, 1101
Isophane Insulin Human (Genetical Recombination) Injectable Aqueous Suspension, 2705
l-Isoprenaline Hydrochloride, 1102
Isopropanol, 1102
Isopropyl Alcohol, 1102
Isopropylantipyrine, 1103
Isosorbide, 1103
Dinitrate, 1104
Dinitrate Tablets, 1105
Mononitrate 70%/Lactose 30%, 1105, 2714
Mononitrate Tablets, 1107
Isotonic
Salt Solution, 1571
Sodium Chloride Injection, 1571
Sodium Chloride Solution, 1571
Isoxsuprine Hydrochloride, 1108
Tablets, 1109
Itraconazole, 1110

J

Japanese
Angelica Root, 1883, 2977
Angelica Root, Powdered, 1883, 2978
Encephalitis Vaccine, 1111
Gentian, 1884
Gentian, Powdered, 1884
Valerian, 1884
Valerian, Powdered, 1885
Zanthoxylum Peel, 1885
Zanthoxylum Peel, Powdered, 1886
Josamycin, 1112
Propionate, 1113
Tablets, 1113
Jujube, 1886, 2765
Seed, 1886, 2765
Juzentaihoto Extract, 1887, 2766, 2978

K

Kainic Acid
and Santonin Powder, 1115
Hydrate, 1114
Kakkonto Extract, 1889, 2768
Kakkontokasenyushin'i Extract, 1892, 2771, 2978
Kallidinogenase, 1116
Kamikihito Extract, 1895, 2772, 2978
Kamishoyosan Extract, 1898, 2773, 2979
Kanamycin
Monosulfate, 1118
Sulfate, 1119
Kaolin, 1120

Keishibukuryogan Extract, 1901, 2775
Ketamine Hydrochloride, 1120
Ketoconazole, 1121
Cream, 1122
Lotion, 1123
Solution, 1123
Ketoprofen, 1124
Ketotifen Fumarate, 1125
Kitasamycin, 1126
Acetate, 1127
Tartrate, 1128
Koi, 1903

L

Labetalol Hydrochloride, 1129
Tablets, 1130
Lactic Acid, 1131
L-Lactic Acid, 1131
Lactose, 1133
Hydrate, 1133, 2715
Anhydrous, 1132, 2714
Lactulose, 1134
Lafutidine, 1135
Tablets, 1136
Lanatoside C, 1137, 2715
Tablets, 1138, 2715
Lanoconazole, 2944
Cream, 2945
Cutaneous Solution, 2946
Ointment, 2946
Lanolin
Hydrous, 1903
Purified, 1904
Lansoprazole, 1139
Delayed-release Capsules, 1140
Delayed-release Orally Disintegrating Tablets, 1141
Lard, 1905
Latamoxef Sodium, 1143
Lauromacrogol, 1144
Lemonades
Hydrochloric Acid, 1024
Lenampicillin Hydrochloride, 1144
Lenograstim (Genetical Recombination), 1146
Leonurus Herb, 1905
L-Leucine, 1149
Leucomycin, 1126
Acetate, 1127
Tartrate, 1128
Leuprorelin Acetate, 1150
Levallorphan Tartrate, 1152
Injection, 1152
Levodopa, 1153
Levofloxacin
Fine Granules, 1155
Hydrate, 1154
Injection, 1156
Ophthalmic Solution, 1156
Tablets, 1157
Levomepromazine Maleate, 1159

Levothyroxine Sodium
Hydrate, 1159
Tablets, 1160
Lidocaine, 1161
Hydrochloride Injection, 1162
Injection, 1162
Light
Anhydrous Silicic Acid, 1552, 2955
Liquid Paraffin, 1365
Lilium Bulb, 1906
Limaprost Alfadex, 1162
Lincomycin Hydrochloride
Hydrate, 1164
Injection, 1164
Lindera Root, 1906
Liniments
Diphenhydramine, Phenol and Zinc Oxide, 815
Phenol and Zinc Oxide, 1392
Liothyronine Sodium, 1165
Tablets, 1166
Liquefied Phenol, 1391
Liquid Paraffin, 1365
Lisinopril
Hydrate, 1167
Tablets, 1168
Lithium Carbonate, 1169
Lithospermum Root, 1907, 2979
Live Oral Poliomyelitis Vaccine, 1428
Lobenzarit Sodium, 1171
Longan Aril, 1907
Longgu, 1907
Powdered, 1908
Lonicera Leaf and Stem, 1908
Loquat Leaf, 1909
Lorazepam, 1171
Losartan Potassium, 1172
and Hydrochlorothiazide Tablets, 1174
Tablets, 1173
Lotions
Ketoconazole, 1123
Sulfur and Camphor, 1619
Tacalcitol, 1630
Low Substituted Hydroxypropylcellulose, 1035, 2703
Loxoprofen Sodium
Hydrate, 1177
Tablets, 1178
Lycium
Bark, 1909, 2979
Fruit, 1909
Lysine Hydrochloride, 1180
L-Lysine
Acetate, 1179
Hydrochloride, 1180
Lysozyme Hydrochloride, 1181

M

Macrogol
400, 1182
1500, 1182

- 4000, 1183
6000, 1183
20000, 1184
Ointment, 1184
- Magnesium
Aluminosilicate, 2715
Aluminometasilicate, 2716
Carbonate, 1185
Oxide, 1186
Silicate, 1187
Stearate, 1188
Sulfate Hydrate, 1189
Sulfate Injection, 1190
Sulfate Mixture, 1190
- Magnolia
Bark, 1910
Bark, Powdered, 1910
Flower, 1911
- Mallotus Bark, 1911
- Malt, 1912
- Maltose Hydrate, 1190
- Manidipine Hydrochloride, 1192
Tablets, 1193
- D-Mannite Injection, 1195
- D-Mannitol, 1194, 2718
Injection, 1195
- Maoto Extract, 1912, 2776
- Maprotiline Hydrochloride, 1196
- Meclofenoxate Hydrochloride, 1197
- Mecobalamin, 1197
Tablets, 1198
- Medazepam, 1200
- Medicinal
Carbon, 1200
Soap, 1201
- Medroxyprogesterone Acetate, 1202
- Mefenamic Acid, 1203
- Mefloquine Hydrochloride, 1203
- Mefruside, 1204
Tablets, 1205
- Meglumine, 1206
Iotalamate Injection, 1206
Sodium Amidotrizoate Injection, 1207
- Melphalan, 1208
- Menatetrenone, 1209
- Mentha
Herb, 1914
Oil, 1915
Water, 1915
- dl*-Menthol, 1210
- l*-Menthol, 1211
- Mepenzolate Bromide, 1211
- Mepirizole, 871
- Mepitiostane, 1212
- Mepivacaine Hydrochloride, 1213
Injection, 1213
- Mequitazine, 1214
Tablets, 1215
- Merbromin, 1216
Solution, 1217
- Mercaptopurine Hydrate, 1215
- Mercurochrome, 1216, 2718
Solution, 1217, 2718
- Meropenem
for Injection, 1219
Hydrate, 1217
- Mesalazine, 2718
Extended-release Tablets, 2720
- Mestranol, 1220, 2947
- Metenolone
Acetate, 1220
Enanthate, 1221
Enanthate Injection, 1222
- Metformin Hydrochloride, 1222
Tablets, 1223
- Methamphetamine Hydrochloride, 1223
- L-Methionine, 1224
- Methotrexate, 1225
Capsules, 1225
Tablets, 2722
- Methoxsalen, 1227
- Methyl
Parahydroxybenzoate, 1235
Salicylate, 1238
Salicylate Spirit, Compound, 1238
- Methylbenactyzium Bromide, 1227
- Methylcellulose, 1228, 2723, 2947
- Methyldopa
Hydrate, 1229
Tablets, 1230
- dl*-Methylephedrine Hydrochloride, 1231
Powder, 1232
Powder, 10%, 1232
- Methylethylamine Maleate, 1233
Tablets, 1233
- Methylprednisolone, 1236, 2949
Succinate, 1236
- Methylrosanilinium Chloride, 1237
- Methyltestosterone, 1239
Tablets, 1240
- Metricrane, 1241
- Metildigoxin, 1242
- Metoclopramide, 1243
Tablets, 1243
- Metoprolol Tartrate, 1244
Tablets, 1245
- Metronidazole, 1246
Tablets, 1246
- Metyrapone, 1247
- Mexiletine Hydrochloride, 1248
- Miconazole, 1249
Nitrate, 1249
- Microcrystalline Cellulose, 664, 2914
- Micronomicin Sulfate, 1250
- Midecamycin, 1251
Acetate, 1252
- Miglitol, 1253
- Migrenin, 1254
- Minocycline Hydrochloride, 1255
for Injection, 1256
Granules, 2949
Tablets, 1256
- Mitiglinide Calcium
Hydrate, 1258
Tablets, 1259
- Mitomycin C, 1261
for Injection, 1262
- Mizoribine, 1262
Tablets, 1263
- Monobasic Calcium Phosphate Hydrate, 558
- Monosodium Trichloroethyl Phosphate, 1725
Syrup, 1726
- Montelukast Sodium, 1264
Chewable Tablets, 1267
Granules, 2724
Tablets, 1269
- Morphine
and Atropine Injection, 1273
Hydrochloride Hydrate, 1270
Hydrochloride Injection, 1271
Hydrochloride Tablets, 1272
Sulfate Hydrate, 1274
- Mosapride Citrate
Hydrate, 1275
Powder, 1276
Tablets, 1277
- Moutan Bark, 1915
Powdered, 1916
- Mukoi-Daikenchuto Extract, 1917, 2777
- Mulberry Bark, 1918
- Mupirocin Calcium
Hydrate, 1279
Ointment, 1280
- N**
- Nabumetone, 1281
Tablets, 1282
- Nadolol, 1283
- Nafamostat Mesilate, 1283
- Naftopidil, 1284
Orally Disintegrating Tablets, 1285
Tablets, 1286
- Nalidixic Acid, 1287
- Naloxone Hydrochloride, 1288
- Naphazoline
and Chlorpheniramine Solution, 1290
Hydrochloride, 1289
Nitrate, 1289
- Naproxen, 1291
- Narcotine, 1326
Hydrochloride, 1327
- Nartogastim (Genetical Recombination), 1291
for Injection, 1293
- Natamycin, 1404
- Nateglinide, 1294
Tablets, 1295
- Natural Aluminum Silicate, 404
- Nelumbo Seed, 1919
- Neomycin Sulfate, 966
- Neostigmine Methylsulfate, 1297

Injection, 1297
 Nicardipine Hydrochloride, 1298
 Injection, 1299
 Nicergoline, 1300
 Powder, 1301
 Tablets, 1302
 Niceritrol, 1303
 Nicomol, 1304
 Tablets, 1304
 Nicorandil, 1305
 Nicotinamide, 1306
 Nicotinic Acid, 1307
 Injection, 1307
 Nifedipine, 1308
 Delayed-release Fine Granules, 1309
 Extended-release Capsules, 1310
 Fine Granules, 1311
 Nilvadipine, 1312
 Tablets, 1313
 Nitrazepam, 1314
 Nitrendipine, 1314
 Tablets, 1315
 Nitrogen, 1316
 Nitroglycerin Tablets, 1317
 Nitrous Oxide, 1318
 Nizatidine, 1319
 Capsules, 1320
 Noradrenaline, 1321, 2726
 Hydrochloride Injection, 1322
 Injection, 1322
 Norepinephrine, 1321
 Hydrochloride Injection, 1322
 Injection, 1322
 Norethisterone, 1322
 Norfloxacin, 1323
 Norgestrel, 1324
 and Ethinylestradiol Tablets, 1324
 Nortriptyline Hydrochloride, 1326
 Tablets, 2951
 Noscapine, 1326
 Hydrochloride Hydrate, 1327
 Notopterygium, 1919
 Nuphar Rhizome, 1919
 Nutmeg, 1920
 Nux Vomica, 1920, 2979
 Extract, 1921
 Extract Powder, 1922
 Tincture, 1922
 Nystatin, 1328

O

Ofloxacin, 1328
Ointments
 Aciclovir, 372
 Aciclovir Ophthalmic, 372
 Acrinol and Zinc Oxide, 378
 Betamethasone Valerate and Gentamicin Sulfate, 504
 Gentamicin Sulfate, 2933
 Hydrocortisone and Diphenhydramine, 1027, 2934

Ibuprofen Piconol, 1045
 Lanconazole, 2946
 Macrogol, 1184
 Mupirocin Calcium, 1280
 Polyethylene Glycol, 1184
 Simple, 1993
 Sulfur, Salicylic Acid and Thianthol, 1620
 Tacalcitol, 1631
 White, 1775
 Zinc Oxide, 1784
 Olive Oil, 1923
 Olmesartan Medoxomil, 1329
 Tablets, 1330
 Olopatadine Hydrochloride, 1332
 Tablets, 1333
 Omeprazole, 1334
 Delayed-release Tablets, 1335
 Operidine, 1385
 Injection, 1385
 Ophiopogon Root, 1923
Ophthalmic Solution
 Bromfenac Sodium, 2910
 Chloramphenicol and Colistin Sodium Methanesulfonate, 2679
 Dibekacin Sulfate, 785
 Dorzolamide Hydrochloride, 831
 Gatifloxacin, 2931
 Gentamicin Sulfate, 983
 Idoxuridine, 1049
 Levofloxacin, 1156
 Pemirolast Potassium, 1373
 Purified Sodium Hyaluronate, 1577
 Silver Nitrate, 1557
 Tranilast, 1714
 Zinc Sulfate, 1785
Ophthalmic Ointment
 Aciclovir, 372
 Opium
 Ipecac Powder, 1925
 Powder, Diluted, 1924
 Powdered, 1924
 Tincture, 1925
 Opium Alkaloids
 and Atropine Injection, 1338
 and Scopolamine Injection, 1339
 Hydrochlorides, 1336
 Hydrochlorides Injection, 1337
 Orange
 Oil, 1925
 Peel Syrup, 1926
 Peel Tincture, 1926
 Orciprenaline Sulfate, 1341
 Oregedokuto Extract, 1926, 2778
 Oriental Bezoar, 1928, 2778, 2979
 Otsujito Extract, 1929, 2779, 2980
 Oxapium Iodide, 1342
 Oxaprozin, 1343
 Oxazolam, 1343
 Oxetacaine, 1344
 Oxethazaine, 1344
 Oxprenolol Hydrochloride, 1345
 Oxybuprocaine Hydrochloride, 1345

Oxycodone Hydrochloride Hydrate, 1346
 Oxydol, 1349
 Oxygen, 1350
 Oxymetholone, 1351
 Oxytetracycline Hydrochloride, 1351, 2726
 Oxytocin, 1353
 Injection, 1355
 Oyster Shell, 1932
 Powdered, 1932
 Ozagrel Sodium, 1356
 for Injection, 1357
 Injection, 1357

P

Panax Japonicus Rhizome, 1932
 Powdered, 1933
 Pancreatin, 1358
 Pancuronium Bromide, 1358
 Panipenem, 1359
 and Betamipron for Injection, 1361
 Pantethine, 1362
 Papaverine Hydrochloride, 1363
 Injection, 1364
 Paracetamol, 363
 Paraffin, 1364
 Light Liquid, 1365
 Liquid, 1365
 Paraformaldehyde, 1366
 Paste, Dental, 1367
 Parnaparin Sodium, 1367
 Paroxetine Hydrochloride Hydrate, 1369
 Tablets, 1371
 Pas-calcium
 Granules, 556
 Hydrate, 555
Paste
 Arsenical, 445
 Paraformaldehyde, Dental, 1367
 Triozinc, Dental, 1734
 Pazufloxacin Mesilate, 2726
 Injection, 2728
 Peach Kernel, 1933
 Powdered, 1934
 Peanut Oil, 1935
 Pemirolast Potassium, 1372
 for Syrup, 1374
 Ophthalmic Solution, 1373
 Tablets, 1375
 Penbutolol Sulfate, 1376
 Penicillin G Potassium, 486
 Pentazocine, 1376
 Pentobarbital Calcium, 1377, 2728
 Tablets, 2729
 Pentoxyverine Citrate, 1378
 Peony Root, 1935
 Powdered, 1936
 Peplomycin Sulfate, 1379
 for Injection, 1380
 Perilla Herb, 1937

- Perphenazine, 1381
Maleate, 1383
Maleate Tablets, 1383
Tablets, 1382
- Pethidine Hydrochloride, 1385
Injection, 1385
- Petroleum Benzin, 1387
- Peucedanum Root, 1937
- Pharbitis Seed, 1938
- Phellodendron
, Albumin Tannate and Bismuth Sub-
nitrate Powder, 1940
Bark, 1938
Bark, Powdered, 1939
Powder for Cataplasm, Compound,
1940
- Phenazone, 437
- Phenethicillin Potassium, 1388
- Phenobarbital, 1389
Powder, 1390
Powder, 10%, 1390
- Phenol, 1390
and Zinc Oxide Liniment, 1392
for Disinfection, 1391
Liquefied, 1391
with Camphor, Dental, 1392
- Phenolated Water, 1392
for Disinfection, 1392
- Phenolsulfonphthalein, 1393
Injection, 1393
- L-Phenylalanine, 1394
- Phenylbutazone, 1395
- Phenylephrine Hydrochloride, 1395
- Phenytoin, 1396
Powder, 1396
Sodium for Injection, 1398
Tablets, 1397
- Phytomenadione, 1398
- Phytonadione, 1398
- Picrasma Wood, 1941
Powdered, 1941
- Pilocarpine Hydrochloride, 1399
Tablets, 1400
- Pilsicainide Hydrochloride
Capsules, 1402
Hydrate, 1402
- Pimaricin, 1404
- Pimozide, 1405
- Pindolol, 1406
- Pinellia Tuber, 1941
- Pioglitazone Hydrochloride, 1406
and Glimepiride Tablets, 1408,
2952
and Metformin Hydrochloride
Tablets, 1411
Tablets, 1407
- Pipemidic Acid Hydrate, 1414
- Piperacillin
Hydrate, 1414
Sodium, 1416
Sodium for Injection, 1418
- Piperazine
Adipate, 1418
- Phosphate Hydrate, 1419
Phosphate Tablets, 1419
- Pirarubicin, 1420
- Pirenexine, 1421
- Pirenzepine Hydrochloride Hydrate,
1422
- Piroxicam, 1423
- Pitavastatin Calcium
Hydrate, 1424
Tablets, 1425
- Pivmecillinam Hydrochloride, 1427
Tablets, 1428
- Plantago
Herb, 1942
Seed, 1942
- Platycodon
Fluidextract, 1943, 2980
Root, 1942, 2779, 2980
Root, Powdered, 1943, 2980
- Pogostemon Herb, 1944
- Polaprezinc, 2952
Granules, 2953
- Polyethylene Glycol
400, 1182
1500, 1182
4000, 1183
6000, 1183
20000, 1184
Ointment, 1184
- Polygala Root, 1944, 2981
Powdered, 1944, 2981
- Polygonatum Rhizome, 1945
- Polygonum Root, 1945
- Polymixin B Sulfate, 1429, 2730
- Polyoxyethylene Lauryl Alcohol Ether,
1144
- Polyoxyl 40 Stearate, 1430
- Polyporus Sclerotium, 1946
Powdered, 1946
- Polysorbate 80, 1430, 2730
- Polyvidone, 1439
- Polyvinylpyrrolidone, 1439
- Poria Sclerotium, 1946
Powdered, 1947
- Potash Soap, 1432
- Potassium
Bromide, 1432
Canrenoate, 1433
Carbonate, 1433
Chloride, 1434
Clavulanate, 1434
Guaiacolsulfonate, 1436
Hydroxide, 1436
Iodide, 1437
Permanganate, 1438
Sulfate, 1438
- Potato Starch, 1602
- Povidone, 1439, 2731
-Iodine, 1441
- Powder**
Ascorbic Acid, 446
Chlordiazepoxide, 680
Chlorpheniramine Maleate, 689
- Codeine Phosphate, 1%, 746
Codeine Phosphate, 10%, 747
- Compound Diastase and Sodium Bi-
carbonate, 783
- Compound Phellodendron, for
Cataplasm, 1940
- Compound Rhubarb and Senna,
1957
- Compound Scopolia Extract and Di-
astase, 1976
- Compound Vitamin B, 1765, 2971
- Diastase and Sodium Bicarbonate,
783
- Dihydrocodeine Phosphate, 1%,
800
- Dihydrocodeine Phosphate, 10%,
801
- Diluted Opium, 1924
- Diphenhydramine and
Bromovalerylurea, 814
- Diphenylhydantoin, 1396
- Ephedrine Hydrochloride, 870
- Ephedrine Hydrochloride, 10%,
870
- Famotidine, 918
- Gentian and Sodium Bicarbonate,
1857
- Hydralazine Hydrochloride, 1022
- Kainic Acid and Santonin, 1115
- dl*-Methylephedrine Hydrochloride,
1232
- dl*-Methylephedrine Hydrochloride,
10%, 1232
- Mosapride Citrate, 1276
- Nicergoline, 1301
- Opium Ipecac, 1925
- Phellodendron, Albumin Tannate
and Bismuth Subnitrate, 1940
- Phenobarbital, 1390
- Phenobarbital, 10%, 1390
- Phenytoin, 1396
- Reserpine, 1508
- Reserpine, 0.1%, 1508
- Riboflavin, 1514
- Scopolia Extract, 1975
- Scopolia Extract and Carbon, 1976
- Scopolia Extract and Ethyl
Aminobenzoate, 1976
- Scopolia Extract, Papaverine and
Ethyl Aminobenzoate, 1977,
2790
- Swertia and Sodium Bicarbonate,
1998, 2982
- Thiamine Chloride Hydrochloride,
1675
- Vitamin B₁ Hydrochloride, 1675
- Vitamin B₂, 1514
- Vitamin C, 446
- Zinc Oxide Starch, 1785
- Powdered
Acacia, 1791
Agar, 1793
Alisma Tuber, 1794, 2747

- Aloe, 1795
 Amomum Seed, 1797
 Atractylodes Lancea Rhizome, 1804
 Atractylodes Rhizome, 1805
 Calumba, 1822, 2974
 Capsicum, 1823
 Cellulose, 667
 Cinnamon Bark, 1831
 Clove, 1833
 Cnidium Rhizome, 1835
 Coix Seed, 1836
 Coptis Rhizome, 1838
 Corydalis Tuber, 1841
 Cyperus Rhizome, 1843, 2753
 Dioscorea Rhizome, 1847
 Fennel, 1852
 Gambir, 1853
 Gardenia Fruit, 1854
 Gentian, 1856
 Geranium Herb, 1857
 Ginger, 1858
 Ginseng, 1860
 Glycyrrhiza, 1863
 Ipecac, 1881
 Japanese Angelica Root, 1883, 2978
 Japanese Gentian, 1884
 Japanese Valerian, 1885
 Japanese Zanthoxylum Peel, 1886
 Longgu, 1908
 Magnolia Bark, 1910
 Moutan Bark, 1916
 Opium, 1924
 Oyster Shell, 1932
 Panax Japonicus Rhizome, 1933
 Peach Kernel, 1934
 Peony Root, 1936
 Phellodendron Bark, 1939
 Picrasma Wood, 1941
 Platycodon Root, 1943, 2980
 Polygala Root, 1944, 2981
 Polyporus Sclerotium, 1946
 Poria Sclerotium, 1947
 Processed Aconite Root, 1949
 Rhubarb, 1956
 Rose Fruit, 1960
 Scutellaria Root, 1979
 Senega, 1981
 Senna Leaf, 1982
 Smilax Rhizome, 1993
 Sophora Root, 1995
 Sweet Hydrangea Leaf, 1996, 2796
 Swertia Herb, 1997, 2982
 Tragacanth, 2004
 Turmeric, 2006, 2798
 Pramlanate Hydrate, 1442
 Pranoprofen, 1443
 Prasterone Sodium Sulfate Hydrate, 1444
 Pravastatin Sodium, 1444
 Fine Granules, 1446
 Solution, 1447
 Tablets, 1448
 Prazepam, 1450
 Tablets, 1450
 Prazosin Hydrochloride, 1451
 Precipitated Calcium Carbonate, 548
 Fine Granules, 548
 Tablets, 549
 Prednisolone, 1452
 Acetate, 1454
 Sodium Phosphate, 1455
 Sodium Succinate for Injection, 1456
 Succinate, 1456
 Tablets, 1453
 Prepared Glycyrrhiza, 1947
 Primidone, 1458
 Probenecid, 1458
 Tablets, 1459
 Probucol, 1460
 Fine Granules, 1461
 Tablets, 1462
 Procainamide Hydrochloride, 1462
 Injection, 1463
 Tablets, 1463
 Procaine Hydrochloride, 1464
 Injection, 1465
 Procarbazine Hydrochloride, 1466
 Procaterol Hydrochloride Hydrate, 1466
 Processed
 Aconite Root, 1948
 Aconite Root, Powdered, 1949
 Ginger, 1951
 Prochlorperazine Maleate, 1467
 Tablets, 1468
 Progesterone, 1469
 Injection, 1470
 Proglumide, 1470
 L-Proline, 1471
 Promethazine Hydrochloride, 1472
 Propafenone Hydrochloride, 1473
 Tablets, 1474
 Propantheline Bromide, 1475
 Propiverine Hydrochloride, 1476
 Tablets, 1477
 Propranolol Hydrochloride, 1478
 Tablets, 1479
 Propylene Glycol, 1480
 Propyl Parahydroxybenzoate, 1481
 Propylthiouracil, 1482
 Tablets, 1482
 Propyphenazone, 1103
 Prostaglandin
 E₁, 396
 E₁ α -Cyclodextrin Clathrate Compound, 400
 F_{2a}, 812
 Protamine Sulfate, 1483
 Injection, 1484
 Prothionamide, 1484
 Protirelin, 1485
 Tartrate Hydrate, 1486
 Prunella Spike, 1951
 Pueraria Root, 1952
 Pullulan, 1487
 Capsules, 574
 Purified
 Dehydrocholic Acid, 772, 2920
 Gelatin, 980
 Glucose, 2696
 Lanolin, 1904
 Shellac, 1551
 Sodium Hyaluronate, 1575
 Sodium Hyaluronate Injection, 1576
 Sodium Hyaluronate Ophthalmic Solution, 1577
 Water, 1773
 Water in Containers, 1774
 Pyrantel Pamoate, 1487
 Pyrazinamide, 1488
 Pyridostigmine Bromide, 1489
 Pyridoxal Phosphate Hydrate, 2731
 Pyridoxine Hydrochloride, 1489
 Injection, 1490
 Pyroxylin, 1491
 Pyrrolnitrin, 1491
- Q**
- Quercus Bark, 1952
 Quetiapine Fumarate, 1492
 Fine Granules, 1493
 Tablets, 1494
 Quick Lime, 554
 Quinapril Hydrochloride, 1496
 Tablets, 1497
 Quinidine Sulfate Hydrate, 1498
 Quinine
 Ethyl Carbonate, 1499
 Hydrochloride Hydrate, 1500
 Sulfate Hydrate, 1501
- R**
- Rabepazole Sodium, 1502
 Ranitidine Hydrochloride, 1503
 Rape Seed Oil, 1953, 2780
 Rebamipide, 1504
 Tablets, 1506
 Red Ginseng, 1953
 Rehmannia Root, 1954
 Reserpine, 1507
 Injection, 1508
 Powder, 1508
 Powder, 0.1%, 1508
 Tablets, 1509
 Retinol
 Acetate, 1510
 Palmitate, 1510
 Rhubarb, 1955
 and Senna Powder, Compound, 1957
 Powdered, 1956
 Ribavirin, 1511
 Capsules, 1512

- Riboflavin, 1513
 Butyrate, 1514
 Phosphate, 1515
 Phosphate Injection, 1516
 Powder, 1514
 Sodium Phosphate, 1515
 Sodium Phosphate Injection, 1516
- Ribostamycin Sulfate, 1517
- Rice Starch, 1603
- Rifampicin, 1518
 Capsules, 1519
- Rikkunshito Extract, 1957, 2780
- Ringer's Solution, 1520
- Risperidone, 1521
 Fine Granules, 1522
 Oral Solution, 1523
 Tablets, 1524
- Ritodrine Hydrochloride, 1525
 Injection, 2954
 Tablets, 1526
- Rokitamycin, 1528, 2733
 Tablets, 1529, 2733
- Rose Fruit, 1959
 Powdered, 1960
- Rosin, 1960
- Roxatidine Acetate Hydrochloride, 1530
 Extended-release Capsules, 1531
 Extended-release Tablets, 1532
 for Injection, 1533
- Roxithromycin, 1534
 Tablets, 2733
- Royal Jelly, 1960
- Ryokeijutsukanto Extract, 1961, 2781
- S**
- Saccharated Pepsin, 1535
- Saccharin, 1535, 2955
 Sodium, 1536
 Sodium Hydrate, 1536, 2734, 2955
- Safflower, 1962, 2981
- Saffron, 1963
- Saibokuto Extract, 1963, 2783
- Saikokeishito Extract, 1965, 2785
- Saireito Extract, 1968, 2787
- Salazosulfapyridine, 1537
- Salbutamol Sulfate, 1538
- Salicylated Alum Powder, 1542
- Salicylic Acid, 1539
 Adhesive Plaster, 1540
 Spirit, 1540
 Spirit, Compound, 1541
- Salvia Miltiorrhiza Root, 1971
- Santonin, 1542
- Saponated Cresol Solution, 757
- Saposhnikovia Root and Rhizome, 1971, 2789, 2981
- Sappan Wood, 1972
- Sarpogrelate Hydrochloride, 1543
 Fine Granules, 1544
 Tablets, 1545
- Saussurea Root, 1972
- Schisandra Fruit, 1973
- Schizonepeta Spike, 1973
- Scopolamine
 Butylbromide, 1547
 Hydrobromide Hydrate, 1548
- Scopolia
 Extract, 1974
 Extract and Carbon Powder, 1976
 Extract and Ethyl Aminobenzoate Powder, 1976
 Extract and Tannic Acid Suppositories, 1978
 Extract, Papaverine and Ethyl Aminobenzoate Powder, 1977, 2790
 Extract Powder, 1975
 Rhizome, 1973, 2982
- Scutellaria Root, 1978
 Powdered, 1979
- Senega, 1980
 Powdered, 1981
 Syrup, 1981
- Senna Leaf, 1981
 Powdered, 1982
- L-Serine, 1548
- Serrapeptase, 1549, 2734
- Sesame, 1983
 Oil, 1984
- Sevoflurane, 1550
- Shakuyakukanzoto Extract, 1984, 2790
- Shellac
 Purified, 1551
 White, 1552
- Shimbuto Extract, 1985, 2791
- Shosaikoto Extract, 1988, 2791
- Shoseiryuto Extract, 1990, 2793
- Silodosin, 1553
 Tablets, 1555
- Silver
 Nitrate, 1557
 Nitrate Ophthalmic Solution, 1557
 Protein, 1557
 Protein Solution, 1558
- Simple
 Ointment, 1993
 Syrup, 1558
- Simvastatin, 1559
 Tablets, 1560
- Sinomenium Stem and Rhizome, 1993, 2982
- Sitagliptin Phosphate
 Hydrate, 2955
 Tablets, 2957
- Sivelestat Sodium
 for Injection, 1562
 Hydrate, 1561
- Slaked Lime, 553
- Smilax Rhizome, 1993
 Powdered, 1993
- Sodium
 Acetate Hydrate, 1563
 Aurothiomalate, 1564
 Benzoate, 1565
 Bicarbonate, 1566
 Bicarbonate and Bitter Tincture Mixture, 1994
 Bicarbonate Injection, 1566
 Bisulfite, 1567
 Borate, 1567
 Bromide, 1568
 Carbonate Hydrate, 1569
 Chloride, 1569
 Chloride Injection, 0.9%, 1571
 Chloride Injection, 10%, 1570
 Chromate (⁵¹Cr) Injection, 1571
 Citrate Hydrate, 1571
 Citrate Injection for Transfusion, 1572
 Cromoglicate, 1573
 Fusidate, 1574, 2959
 Hyaluronate, Purified, 1575
 Hyaluronate Injection, Purified, 1576
 Hyaluronate Ophthalmic Solution, Purified, 1577
 Hydrogen Carbonate, 1566
 Hydrogen Sulfite, 1567
 Hydroxide, 1578
 Iodide, 1579
 Iodide (¹²³I) Capsules, 1579
 Iodide (¹³¹I) Capsules, 1580
 Iodide (¹³¹I) Solution, 1580
 Iodohippurate (¹³¹I) Injection, 1580
 Iotalamate Injection, 1580
 L-Lactate Ringer's Solution, 1582
 L-Lactate Solution, 1581
 Lauryl Sulfate, 1584, 2734
 Metabisulfite, 1587
 Perchnetate (^{99m}Tc) Injection, 1585
 Picosulfate Hydrate, 1585
 Polystyrene Sulfonate, 1586
 Pyrosulfite, 1587
 Risedronate Hydrate, 1588
 Risedronate Tablets, 1589
 Salicylate, 1590
 Starch Glycolate, 1591
 Sulfate Hydrate, 1994
 Thiosulfate Hydrate, 1592
 Thiosulfate Injection, 1593
 Valproate, 1593
 Valproate Extended-release Tablets A, 2961
 Valproate Extended-release Tablets B, 2963
 Valproate Syrup, 1594
 Valproate Tablets, 1594
- Solution**
 Adrenaline, 380
 Alum, 401
 Benzalkonium Chloride, 480
 Benzethonium Chloride, 482
 Butenafine Hydrochloride, 538
 Chlorhexidine Gluconate, 682
 Compound Thianthol and Salicylic

Solution (*continued*)

Acid, 1679
 Cresol, 756
 Dental Sodium Hypochlorite, 436
 Diagnostic Sodium Citrate, 1572
 Epinephrine, 380
 Glycerin and Potash, 994
 Isotonic Salt, 1571
 Isotonic Sodium Chloride, 1571
 Ketoconazole, 1123
 Lanocanazole Cutaneous, 2946
 Merbromin, 1217
 Mercurochrome, 1217, 2718
 Naphazoline and Chlorpheniramine, 1290
 Pravastatin Sodium, 1447
 Ringer's, 1520
 Risperidone Oral, 1523
 Saponated Cresol, 757
 Silver Protein, 1558
 Sodium Iodide (¹³¹I), 1580
 Sodium L-Lactate, 1581
 Sodium L-Lactate Ringer's, 1582
 D-Sorbitol, 1597
 Terbinafine Hydrochloride, 1664
 Tolnaftate, 1705
 Sophora Root, 1995
 Powdered, 1995
 Sorbitan Sesquioleate, 1595
 D-Sorbitol, 1596
 Solution, 1597
 Soybean Oil, 1995
 Spectinomycin Hydrochloride
 for Injection, 1598
 Hydrate, 1597
 Spiramycin Acetate, 1599, 2735
Spirit
 Capsicum and Salicylic Acid, 1824
 Compound Methyl Salicylate, 1238
 Compound Salicylic Acid, 1541
 Foeniculated Ammonia, 1852
 Iodine, Salicylic Acid and Phenol, 1079
 Salicylic Acid, 1540
 Spironolactone, 1600
 Tablets, 1600
Spray
 Butenafine Hydrochloride, 538
 Terbinafine Hydrochloride, 1665
Starch
 Corn, 1601
 Potato, 1602
 Rice, 1603
 Wheat, 1604
 Stearic Acid, 1606
 Stearyl Alcohol, 1607
Sterile
 Purified Water in Containers, 1774
 Water for Injection in Containers, 1775
 Streptomycin Sulfate, 1608
 for Injection, 1609
 Sucralfate Hydrate, 1609

Sucrose, 1611
 Sulbactam Sodium, 1612, 2735
 Sulbenicillin Sodium, 1613
 Sulfadiazine Silver, 1614
 Sulfafurazole, 1617
 Sulfamethizole, 1615
 Sulfamethoxazole, 1616
 Sulfamonomethoxine Hydrate, 1616
 Sulfasalazine, 1537
 Sulfisomezole, 1616
 Sulfisoxazole, 1617
 Sulfobromophthalein Sodium, 1618
 Injection, 1619
 Sulfur, 1619
 and Camphor Lotion, 1619
 , Salicylic Acid and Thianthol Ointment, 1620
 Sulindac, 1620
 Sulpiride, 1621
 Capsules, 1621
 Tablets, 1622
 Sulpyrine
 Hydrate, 1623
 Injection, 1623
 Sultamicillin Tosilate
 Hydrate, 1624, 2736
 Tablets, 1625
 Sultiame, 1626
Suppositories
 Bisacodyl, 512
 Diclofenac Sodium, 2920
 Indometacin, 1064
 Scopolia Extract and Tannic Acid, 1978
 Suxamethonium Chloride
 for Injection, 1628
 Hydrate, 1627
 Injection, 1628, 2737
 Sweet Hydrangea Leaf, 1996
 Powdered, 1996, 2796
 Swertia
 and Sodium Bicarbonate Powder, 1998, 2982
 Herb, 1996, 2982
 Herb, Powdered, 1997, 2982
 Synthetic Aluminum Silicate, 405
Syrup
 Aciclovir, 372
 Aciclovir for, 373
 Amphotericin B, 428
 Cefadroxil for, 599
 Cefalexin for, 603
 Cefatrizine Propylene Glycolate for, 606
 Cefpodoxime Proxetil for, 646
 Cefroxadine for, 649
 Clarithromycin for, 2918
 Faropenem Sodium for, 920
 Fosfomycin Calcium for, 963
 Ipecac, 1882
 Monosodium Trichloroethyl Phosphate, 1726
 Orange Peel, 1926

Pemirolast Potassium for, 1374
 Senega, 1981
 Simple, 1558
 Sodium Valproate, 1594
 Tranilast for, 1715
 Triclofos Sodium, 1726

T**Tablets**

Acemetacin, 362
 Acetylsalicylic Acid, 450
 Aciclovir, 374
 Ajmaline, 382
 Alacepril, 383
 Aldioxa, 387
 Alendronate Sodium, 390
 Allopurinol, 392
 Alminoprofen, 394
 Amiodarone Hydrochloride, 412
 Amitriptyline Hydrochloride, 414
 Amlexanox, 416
 Amlodipine Besilate, 420
 Amlodipine Besilate Orally Disintegrating, 418
 Amosulalol Hydrochloride, 422
 Amphotericin B, 428, 2909
 Ascorbic Acid and Calcium Panthothenate, 447
 Aspirin, 450
 Atorvastatin Calcium, 454
 Auranofin, 458
 Azathioprine, 460
 Azelnidipine, 464
 Azosemide, 2672
 Baclofen, 470
 Benidipine Hydrochloride, 476
 Bepotastine Besilate, 489
 Beraprost Sodium, 492
 Betahistine Mesilate, 496
 Betamethasone, 498
 Bezafibrate Extended-release, 508
 Bisoprolol Fumarate, 515
 Brotizolam, 524
 Bucillamine, 526
 Buformin Hydrochloride, 531
 Buformin Hydrochloride Delayed-release, 529
 Cadralazine, 542
 Candesartan Cilexetil, 566
 Candesartan Cilexetil and Amlodipine Besilate, 567
 Candesartan Cilexetil and Hydrochlorothiazide, 570
 L-Carbocysteine, 579
 Carvedilol, 590
 Cefcapene Pivoxil Hydrochloride, 614
 Cefditoren Pivoxil, 620
 Cefpodoxime Proxetil, 647
 Cefteram Pivoxil, 656
 Cetirizine Hydrochloride, 672
 Chlordiazepoxide, 681

- Chlorphenesin Carbamate, 686
 Chlorpheniramine Maleate, 690
 Chlorpromazine Hydrochloride, 693
 Chlorpropamide, 695
 Cibenzoline Succinate, 698
 Cilazapril, 703
 Cilnidipine, 705
 Cilostazol, 708
 Clarithromycin, 719
 Clomifene Citrate, 731
 Clomipramine Hydrochloride, 2681
 Clonazepam, 733
 Clopidogrel Sulfate, 738
 Clotiazepam, 2682
 Codeine Phosphate, 748
 Colestimide, 752
 Cyclophosphamide, 762
 Diazepam, 784
 Dichlorphenamide, 789
 Diclofenamide, 789, 2784
 Diethylcarbamazine Citrate, 790
 Digitoxin, 795, 2684
 Digoxin, 798
 Dimenhydrinate, 809
 Diphenylhydantoin, 1397
 Distigmine Bromide, 819
 Donepezil Hydrochloride, 827
 Doxazosin Mesilate, 834
 Doxycycline Hydrochloride, 840
 Dydrogesterone, 845
 Ebastine, 847
 Ebastine Orally Disintegrating, 846
 Emorfazone, 859
 Enalapril Maleate, 861
 Entacapone, 2691
 Epalrestat, 866
 Ephedrine Hydrochloride, 870
 Eplerenone, 875
 Ergometrine Maleate, 884
 Erythromycin Delayed-release, 886
 Estriol, 892
 Etacrynic Acid, 893
 Ethinylestradiol, 899
 Etidronate Disodium, 908
 Etilefrine Hydrochloride, 909
 Etizolam, 912
 Famotidine, 919
 Faropenem Sodium, 921
 Felodipine, 2928
 Fexofenadine Hydrochloride, 927
 Flecainide Acetate, 935
 Flutoprazepam, 955
 Fluvoxamine Maleate, 958
 Folic Acid, 960
 Fudosteine, 969
 Furosemide, 972
 Glimepiride, 986
 Haloperidol, 1006
 Hydralazine Hydrochloride, 1022
 Ifenprodil Tartrate, 1051
 Imidapril Hydrochloride, 1053
 Imipramine Hydrochloride, 1057, 2940
 Indapamide, 1059
 Ipriflavone, 1088
 Irbesartan, 2710
 Irbesartan and Amlodipine Besilate, 2711
 Irsogladine Maleate, 1091
 Isoniazid, 1101
 Isosorbide Dinitrate, 1105
 Isosorbide Mononitrate, 1107
 Isoxsuprine Hydrochloride, 1109
 Josamycin, 1113
 Labetalol Hydrochloride, 1130
 Lafutidine, 1136
 Lanatoside C, 1138, 2715
 Lansoprazole Delayed-release Orally Disintegrating, 1141
 Levofloxacin, 1157
 Levothyroxine Sodium, 1160
 Liothyronine Sodium, 1166
 Lisinopril, 1168
 Losartan Potassium, 1173
 Losartan Potassium and Hydrochlorothiazide, 1174
 Loxoprofen Sodium, 1178
 Manidipine Hydrochloride, 1193
 Mecobalamin, 1198
 Mefruside, 1205
 Mequitazine, 1215
 Mesalazine Extended-release, 2720
 Metformin Hydrochloride, 1223
 Methotrexate, 2722
 Methyldopa, 1230
 Methylergometrine Maleate, 1233
 Methyltestosterone, 1240
 Metoclopramide, 1243
 Metoprolol Tartrate, 1245
 Metronidazole, 1246
 Minocycline Hydrochloride, 1256
 Mitiglinide Calcium, 1259
 Mizoribine, 1263
 Montelukast Sodium, 1269
 Montelukast Sodium Chewable, 1267
 Morphine Hydrochloride, 1272
 Mosapride Citrate, 1277
 Nabumetone, 1282
 Naftopidil, 1286
 Naftopidil Orally Disintegrating, 1285
 Nateglinide, 1295
 Nicergoline, 1302
 Nicomol, 1304
 Nilvadipine, 1313
 Nitrendipine, 1315
 Nitroglycerin, 1317
 Norgestrel and Ethinylestradiol, 1324
 Nortriptyline Hydrochloride, 2951
 Olmesartan Medoxomil, 1330
 Olopatadine Hydrochloride, 1333
 Omeprazole Delayed-release, 1335
 Paroxetine Hydrochloride, 1371
 Pemirolast Potassium, 1375
 Pentobarbital Calcium, 2729
 Perphenazine, 1382
 Perphenazine Maleate, 1383
 Phenytoin, 1397
 Pilocarpine Hydrochloride, 1400
 Pioglitazone Hydrochloride, 1407
 Pioglitazone Hydrochloride and Glimepiride, 1408, 2952
 Pioglitazone Hydrochloride and Metformin Hydrochloride, 1411
 Piperazine Phosphate, 1419
 Pitavastatin Calcium, 1425
 Pivmecillinam Hydrochloride, 1428
 Pravastatin Sodium, 1448
 Prazepam, 1450
 Precipitated Calcium Carbonate, 549
 Prednisolone, 1453
 Probenecid, 1459
 Probucof, 1462
 Procainamide Hydrochloride, 1463
 Prochlorperazine Maleate, 1468
 Propafenone Hydrochloride, 1474
 Propiverine Hydrochloride, 1477
 Propranolol Hydrochloride, 1479
 Propylthiouracil, 1482
 Quetiapine Fumarate, 1494
 Quinapril Hydrochloride, 1497
 Rebamipide, 1506
 Reserpine, 1509
 Risperidone, 1524
 Ritodrine Hydrochloride, 1526
 Rokitamycin, 1529, 2733
 Roxatidine Acetate Hydrochloride Extended-release, 1532
 Roxithromycin, 2733
 Sarpogrelate Hydrochloride, 1545
 Silodosin, 1555
 Simvastatin, 1560
 Sitagliptin Phosphate, 2957
 Sodium Risedronate, 1589
 Sodium Valproate, 1594
 Sodium Valproate Extended-release, A, 2961
 Sodium Valproate Extended-release, B, 2963
 Spironolactone, 1600
 Sulpiride, 1622
 Sultamicillin Tosilate, 1625
 Taltirelin, 1638
 Taltirelin Orally Disintegrating, 1637
 Tamsulosin Hydrochloride Extended-release, 1642
 Telmisartan, 1657
 Telmisartan and Hydrochlorothiazide, 2964
 Temocapril Hydrochloride, 1659
 Terbinafine Hydrochloride, 1665
 Thiamazole, 1673
 Tiapride Hydrochloride, 1685
 Tiaramide Hydrochloride, 1686

Tablets (continued)

- Ticlopidine Hydrochloride, 1688
 Tipepidine Hibenazate, 1692, 2967
 Tolbutamide, 1703
 Tosufloxacin Tosilate, 1707
 Tranexamic Acid, 1711
 Trichlormethiazide, 1722
 Trihexyphenidyl Hydrochloride, 1728
 Trimetazidine Hydrochloride, 1731
 Troxipide, 1736
 Ursodeoxycholic Acid, 1750
 Valaciclovir Hydrochloride, 1753
 Valsartan, 1756
 Valsartan and Hydrochlorothiazide, 2968
 Verapamil Hydrochloride, 1761, 2741
 Voglibose, 1767
 Voriconazole, 1770
 Warfarin Potassium, 1772
 Zaltoprofen, 1780
 Zolpidem Tartrate, 1789
 Zonisamide, 2745
- Tacalcitol**
 Hydrate, 1629
 Lotion, 1630
 Ointment, 1631
- Tacrolimus**
 Capsules, 1633
 Hydrate, 1632
- Talampicillin Hydrochloride, 1633
 Talc, 1634
- Taltirelin**
 Hydrate, 1636
 Orally Disintegrating Tablets, 1637
 Tablets, 1638
- Tamoxifen Citrate, 1640
 Tamsulosin Hydrochloride, 1640
 Extended-release Tablets, 1642
- Tannic Acid, 1643
 Tartaric Acid, 1643
 Taurine, 1643
 Tazobactam, 1644
 and Piperacillin for Injection, 1645
- Teceleukin**
 for Injection (Genetical Recombination), 1652
 (Genetical Recombination), 1647
- Tegafur, 1653
 Teicoplanin, 1654, 2737, 2964
 Telmisartan, 1656
 and Hydrochlorothiazide Tablets, 2964
 Tablets, 1657
- Temocapril Hydrochloride, 1658
 Tablets, 1659
- Teprenone, 1660
 Capsules, 1661
- Terbinafine Hydrochloride, 1662
 Cream, 1663
 Solution, 1664
 Spray, 1665
- Tablets, 1665
- Terbutaline Sulfate, 1666
- Testosterone**
 Enanthate, 1667, 2967
 Enanthate Injection, 1668
 Propionate, 1668
 Propionate Injection, 1669
- Tetracaine Hydrochloride, 1670
 Tetracycline Hydrochloride, 1670, 2738
- Thallium (²⁰¹Tl) Chloride Injection, 1672
- Theophylline**, 1672
- Thiamazole**, 1672
 Tablets, 1673
- Thiamine Chloride Hydrochloride**, 1674
 Injection, 1675
 Powder, 1675
- Thiamine Nitrate, 1676
- Thiamylal Sodium**, 1677
 for Injection, 1678
- Thianthol**, 1678
 and Salicylic Acid Solution, Compound, 1679
- Thiopental Sodium**, 1680
 for Injection, 1681
- Thioridazine Hydrochloride**, 1681
- L-Threonine**, 1682
- Thrombin**, 1682, 2738
- Thymol**, 1683
- Tiapride Hydrochloride**, 1684
 Tablets, 1685
- Tiaramide Hydrochloride**, 1685
 Tablets, 1686
- Ticlopidine Hydrochloride**, 1687
 Tablets, 1688
- Timepidium Bromide Hydrate**, 1689
- Timolol Maleate**, 1690
- Tincture**
 Bitter, 1813, 2973
 Capsicum, 1824
 Iodine, 1076
 Iodine, Dilute, 1076
 Nux Vomica, 1922
 Opium, 1925
 Orange Peel, 1926
- Tinidazole**, 1691
- Tipepidine Hibenazate**, 1691
 Tablets, 1692, 2967
- Titanium Oxide**, 1693
- Tizanidine Hydrochloride**, 1694
- Toad Cake**, 1998, 2983
- Tobramycin**, 1695, 2738
 Injection, 1696
- Tocopherol**, 1697
 Acetate, 1697
 Calcium Succinate, 1698
 Nicotinate, 1699
dl- α -Tocopherol, 1697
 Acetate, 1697
 Nicotinate, 1699
- Todralazine Hydrochloride Hydrate**, 1700
- Tofisopam**, 1701
- Tokakujokito Extract**, 1999, 2796
- Tokishakuyakusan Extract**, 2002, 2797, 2983
- Tolazamide**, 1702, 2738
- Tolbutamide**, 1703
 Tablets, 1703
- Tolnaftate**, 1704
 Solution, 1705
- Tolperisone Hydrochloride**, 1705
- Tosufloxacin Tosilate Hydrate**, 1706
 Tablets, 1707
- Tragacanth**, 2004
 Powdered, 2004
- Tramadol Hydrochloride**, 2739
- Tranexamic Acid**, 1708
 Capsules, 1709
 Injection, 1710
 Tablets, 1711
- Tranilast**, 1711
 Capsules, 1712
 Fine Granules, 1713
 for Syrup, 1715
 Ophthalmic Solution, 1714
- Trapidil**, 1716
- Trehalose Hydrate**, 1717
- Trepibutone**, 1718
- Tretoquinol Hydrochloride**, 1733
- Triamcinolone**, 1718
 Acetonide, 1719, 2967
- Triamterene**, 1720
- Tribulus Fruit**, 2005
- Trichlormethiazide**, 1721
 Tablets, 1722
- Trichomycin**, 1724
- Trichosanthes Root**, 2005, 2798
- Triclofos Sodium**, 1725
 Syrup, 1726
- Trientine Hydrochloride**, 1726
 Capsules, 1727
- Trihexyphenidyl Hydrochloride**, 1727
 Tablets, 1728
- Trimebutine Maleate**, 1729
- Trimetazidine Hydrochloride**, 1730
 Tablets, 1731
- Trimethadione**, 1732
- Trimetoquinol Hydrochloride Hydrate**, 1733
- Tropicamide**, 1734
- Troxipide**, 1735
 Fine Granules, 1735
 Tablets, 1736
- L-Tryptophan**, 1737
- Tulobuterol**, 1738
 Hydrochloride, 1740
- Transdermal Tape**, 1739
- Turmeric**, 2005, 2798
 Powdered, 2006, 2798
- Turpentine Oil**, 2007
- L-Tyrosine**, 1740

U

Ubenimex, 1741
 Capsules, 1742
 Ubidecarenone, 1743
 Ulinastatin, 1744
 Uncaria Hook, 2007
 Urapidil, 1746
 Urea, 1747
 Urokinase, 1747
 Ursodeoxycholic Acid, 1748, 2968
 Granules, 1749
 Tablets, 1750
 Ursodesoxycholic Acid, 1748
 Uva Ursi Fluidextract, 2008

V

Vaccine
 BCG, Freeze-dried, (for Percutaneous Use), 473
 Cholera, 696
 Diphtheria-Purified Pertussis-Tetanus Combined, Adsorbed, 816
 Hepatitis B, Adsorbed, 1018
 Influenza HA, 1065
 Inactivated Tissue Culture Rabies, Freeze-dried, 1503
 Japanese Encephalitis, 1111
 Japanese Encephalitis, Freeze-dried, 1111
 Live Attenuated Measles, Freeze-dried, 1196
 Live Attenuated Mumps, Freeze-dried, 1278
 Live Attenuated Rubella, Freeze-dried, 1535
 Live Oral Poliomyelitis, 1428
 Purified Pertussis, Adsorbed, 1384
 Smallpox, Freeze-dried, 1563
 Smallpox, Freeze-dried, Prepared in Cell Culture, 1563
 Weil's Disease and Akiyami Combined, 1775
 Valaciclovir Hydrochloride, 1751
 Tablets, 1753
 L-Valine, 1754
 Valsartan, 1755
 and Hydrochlorothiazide Tablets, 2968

Tablets, 1756
 Vancomycin Hydrochloride, 1757
 for Injection, 1758
 Vasopressin Injection, 1759, 2740
 Verapamil Hydrochloride, 1761, 2741
 Injection, 2970
 Tablets, 1761, 2741
 Vinblastine Sulfate, 1762, 2742
 for Injection, 1763
 Vincristine Sulfate, 1764, 2742
 Vitamin A
 Acetate, 1510
 Oil, 1765
 Palmitate, 1510
 Vitamin B₁
 Hydrochloride, 1674
 Hydrochloride Injection, 1675
 Hydrochloride Powder, 1675
 Nitrate, 1676
 Vitamin B₂, 1513
 Phosphate Ester, 1515
 Phosphate Ester Injection, 1516
 Powder, 1514
 Vitamin B₆, 1489
 Injection, 1490
 Vitamin B₁₂, 760
 Injection, 761
 Vitamin C, 445
 Injection, 446
 Powder, 446
 Vitamin D₂, 882
 Vitamin D₃, 696
 Vitamin E, 1697
 Acetate, 1697
 Calcium Succinate, 1698
 Nicotinate, 1699
 Vitamin K₁, 1398
 Voglibose, 1766
 Tablets, 1767
 Voriconazole, 1769
 for Injection, 2743
 Tablets, 1770

W

Warfarin Potassium, 1771
 Tablets, 1772
 Water, 1773
 for Injection, 1774
 for Injection in Containers, Sterile, 1775

in Containers, Purified, 1774
 in Containers, Sterile Purified, 1774
 Purified, 1773
 Weak Opium Alkaloids and Scopolamine Injection, 1340
 Weil's Disease and Akiyami Combined Vaccine, 1775
 Wheat Starch, 1604
 White
 Beeswax, 1808
 Ointment, 1775
 Petrolatum, 1386
 Shellac, 1552
 Soft Sugar, 1611
 Whole Human Blood, 1775
 Wine, 1776
 Wood Creosote, 2008

X

Xylitol, 1778
 Injection, 1778

Y

Yellow
 Beeswax, 1809
 Petrolatum, 1387
 Yokukansan Extract, 2010, 2798, 2983

Z

Zaltoprofen, 1780
 Tablets, 1780
 Zedoary, 2012, 2753
 Zidovudine, 1781
 Zinc
 Chloride, 1783
 Oxide, 1783
 Oxide Oil, 1784
 Oxide Ointment, 1784
 Oxide Starch Powder, 1785
 Sulfate Hydrate, 1785
 Sulfate Ophthalmic Solution, 1785
 Zinostatin Stimalamer, 1786, 2744
 Zolpidem Tartrate, 1788
 Tablets, 1789
 Zonisamide, 2744
 Tablets, 2745

INDEX IN LATIN NAME

A

Achyranthis Radix, 1792
Aconiti Radix Processa, 1948
 Radix Processa et Pulverata, 1949
Adeps Lanae Purificatus, 1904
 Suillus, 1905
Agar, 1792
 Pulveratum, 1793
Akebiae Caulis, 1793
Alismatis Tuber, 1793
 Tuber Pulveratum, 1794
Aloe, 1794
 Pulverata, 1795
Alpiniae Fructus, 1812
 Officinari Rhizoma, 1796
Amomi Semen, 1797
 Semen Pulveratum, 1797
Anemarrhenae Rhizoma, 1797
Angelicae Acutilobae Radix, 1883
 Acutilobae Radix Pulverata, 1883
 Dahuricae Radix, 1798
Apilac, 1960
Araliae Cordatae Rhizoma, 1800
Arctii Fructus, 1821
Arecae Semen, 1800
Armeniacae Semen, 1798
Artemisiae Capillaris Flos, 1800
 Folium, 1801
Asiasari Radix, 1801
Asparagi Radix, 1802
Astragali Radix, 1803
Atractylodis Lanceae Rhizoma, 1803
 Lanceae Rhizoma Pulveratum,
 1804
 Rhizoma, 1804
 Rhizoma Pulveratum, 1805
Aurantii Fructus Immaturus, 1880
 Pericarpium, 1812

B

Belladonnae Radix, 1809
Benincasae Semen, 1811
Benzoinum, 1812
Bezoar Bovis, 1928
Bufonis Crustum, 1998
Bupleuri Radix, 1820

C

Calumbae Radix, 1821
 Radix Pulverata, 1822
Cannabis Fructus, 1876
Capsici Fructus, 1822

Fructus Pulveratus, 1823
Cardamomi Fructus, 1825
Carthami Flos, 1962
Caryophylli Flos, 1833
 Flos Pulveratus, 1833
Cassiae Semen, 1825
Catalpae Fructus, 1826
Cera Alba, 1808
 Carnauba, 1825
 Flava, 1809
Chrysanthemi Flos, 1829
Cimicifugae Rhizoma, 1830
Cinnamomi Cortex, 1830
 Cortex Pulveratus, 1831
Cistanchis Herba, 1831
Citri Unshiu Pericarpium, 1832
Clematidis Radix, 1833
Cnidii Monnieris Fructus, 1834
 Rhizoma, 1835
 Rhizoma Pulveratum, 1835
Codonopsis Radix, 1835
Coicis Semen, 1836
 Semen Pulveratum, 1836
Condurango Cortex, 1836
Coptidis Rhizoma, 1837
 Rhizoma Pulveratum, 1838
Corni Fructus, 1839
Corydalis Tuber, 1840
 Tuber Pulveratum, 1841
Crataegi Fructus, 1842
Creosotum Ligni, 2008
Crocus, 1963
Curcumae Longae Rhizoma, 2798
 Rhizoma Purveratum, 2798
Curcumae Rhizoma, 2005, 2753
 Rhizoma Purveratum, 2006
Cyperii Rhizoma, 1842
 Rhizoma Pulveratum, 1843

D

Digenea, 1846
Dioscoreae Rhizoma, 1847
 Rhizoma Pulveratum, 1847
Dolichi Semen, 1848

E

Eleutherococci senticosi Rhizoma,
1848
Ephedrae Herba, 1849
Epimedii Herba, 1850
Eriobotryae Folium, 1909
Eucommiae Cortex, 1851
Euodiae Fructus, 1851

F

Fel Ursi, 1807
Foeniculi Fructus, 1851
 Fructus Pulveratus, 1852
Forsythiae Fructus, 1852
Fossilia Ossis Mastodi, 1907
 Ossis Mastodi Pulveratum, 1908
Fritillariae Bulbus, 1853
Fructus Hordei Germinatus, 1912

G

Gambir, 1853
 Pulveratum, 1853
Gardeniae Fructus, 1854
 Fructus Pulveratus, 1854
Gastrodiae Tuber, 1855
Gentianae Radix, 1856
 Radix Pulverata, 1856
 Scabrae Radix, 1884
 Scabrae Radix Pulverata, 1884
Geranii Herba, 1857
 Herba Pulverata, 1857
Ginseng Radix, 1859
 Radix Pulverata, 1860
 Radix Rubra, 1953
Glehniae Radix cum Rhizoma, 1861
Glycyrrhizae Radix, 1862
 Radix Praeparata, 1947
 Radix Pulverata, 1863
Gummi Arabicum, 1791
 Arabicum Pulveratum, 1791
Gypsum Exsiccatum, 1868
 Fibrosum, 1868

H

Hedysari Radix, 1875
Houttuyniae Herba, 1880
Hydrangeae Dulcis Folium, 1996
 Dulcis Folium Pulveratum, 1996

I

Imperatae Rhizoma, 1880
Ipecacuanhae Radix, 1881
 Radix Pulverata, 1881

K

Kasseki, 1796
Koi, 1903

L

Leonuri Herba, 1905
Lilii Bulbus, 1906
Linderæ Radix, 1906
Lithospermi Radix, 1907
Longan Arillus, 1907
Lonicerae Folium Cum Caulis, 1908
Lycii Cortex, 1909
Fructus, 1909

M

Magnoliae Cortex, 1910
Cortex Pulveratus, 1910
Flos, 1911
Malloti Cortex, 1911
Mel, 1879
Menthae Herba, 1914
Mori Cortex, 1918
Moutan Cortex, 1915
Cortex Pulveratus, 1916
Myristicae Semen, 1920

N

Nelumbis Semen, 1919
Notopterygii Rhizoma, 1919
Nupharis Rhizoma, 1919

O

Oleum Arachidis, 1935
Aurantii, 1925
Cacao, 1821
Camelliae, 1822
Caryophylli, 1834
Cinnamomi, 1831
Cocois, 1835
Eucalypti, 1850
Foeniculi, 1852
Maydis, 1839
Menthae Japonicae, 1915
Olivæ, 1923
Rapae, 1953
Ricini, 1826
Sesami, 1984
Sojæ, 1995
Terebinthinae, 2007
Ophiopogonis Radix, 1923
Opium Pulveratum, 1924
Oryzae Fructus, 1820
Ostreæ Testa, 1932
Testa Pulverata, 1932

P

Paeoniae Radix, 1935
Radix Pulverata, 1936
Panacis Japonici Rhizoma, 1932
Japonici Rhizoma Pulveratum, 1933
Perillae Herba, 1937
Persicae Semen, 1933
Semen Pulveratum, 1934
Peucedani Radix, 1937
Pharbitidis Semen, 1938
Phellodendri Cortex, 1938
Cortex Pulveratus, 1939
Picrasmae Lignum, 1941
Lignum Pulveratum, 1941
Pinelliae Tuber, 1941
Plantaginis Herba, 1942
Semen, 1942
Platycodi Radix, 1942
Radix Pulverata, 1943
Pogostemoni Herba, 1944
Polygalae Radix, 1944
Radix Pulverata, 1944
Polygonati Rhizoma, 1945
Polygoni Multiflori Radix, 1945
Polyporus, 1946
Pulveratus, 1946
Poria, 1946
Pulveratum, 1947
Prunellae Spica, 1951
Pruni Cortex, 1826
Puerariae Radix, 1952

Q

Quercus Cortex, 1952

R

Rehmanniae Radix, 1954
Resina Pini, 1960
Rhei Rhizoma, 1955
Rhizoma Pulveratum, 1956
Rosae Fructus, 1959
Fructus Pulveratus, 1960

S

Sal Mirabilis, 1994
Mirabilis Anhydricus, 1994
Salviae Miltiorrhizae Radix, 1971
Saposhnikoviae Radix, 1971
Sappan Lignum, 1972

Saussureae Radix, 1972
Schisandrae Fructus, 1973
Schizonepetae Spica, 1973
Scopoliae Rhizoma, 1973
Scutellariae Radix, 1978
Radix Pulverata, 1979
Senegae Radix, 1980
Radix Pulverata, 1981
Sennae Folium, 1981
Folium Pulveratum, 1982
Sesami Semen, 1983
Sevum Bovinum, 1808
Sinomeni Caulis et Rhizoma, 1993
Smilacis Rhizoma, 1993
Rhizoma Pulveratum, 1993
Sophorae Radix, 1995
Radix Pulverata, 1995
Strychni Semen, 1920
Swertiae Herba, 1996
Herba Pulverata, 1997

T

Tinctura Amara, 1813
Tragacantha, 2004
Pulverata, 2004
Tribuli Fructus, 2005
Trichosanthis Radix, 2005

U

Uncariae Uncis Cum Ramulus, 2007
Uvae Ursi Folium, 1807

V

Valerianae Fauriei Radix, 1884
Fauriei Radix Pulverata, 1885

Z

Zanthoxyli Piperiti Pericarpium, 1885
Piperiti Pericarpium Pulveratum, 1886
Zedoariae Rhizoma, 2012
Zingiberis Rhizoma, 1857
Rhizoma Processum, 1951
Rhizoma Pulveratum, 1858
Ziziphi Fructus, 2765
Semen, 2765
Zizyphi Fructus, 1886
Semen, 1886

INDEX IN JAPANESE

ア

- 亜鉛華デンプン 1785
亜鉛華軟膏 1784
アカメガシワ 1911
アクチノマイシン D 378
アクリルビスン塩酸塩 375
アクリノール・亜鉛華軟膏 378
アクリノール水和物 376
アクリノール・チンク油 377
アザチオプリン 459
アザチオプリン錠 460
亜酸化窒素 1318
アシクロビル 369
アシクロビル顆粒 370
アシクロビル眼軟膏 372
アシクロビル錠 374
アシクロビルシロップ 372
アシクロビル注射液 371
アシクロビル軟膏 372
アジスロマイシン水和物 465
アジマリン 381
アジマリン錠 382
亜硝酸アミル 436
アスコルビン酸 445
アスコルビン酸・パントテン酸カルシウム錠 447
アスコルビン酸散 446
アスコルビン酸注射液 446
アズトレオナム 466
L-アスパラギン酸 449
アスピリン 449
アスピリンアルミニウム 450
アスピリン錠 450
アスポキシシリン水和物 451
アセグルタミドアルミニウム 359, 2671
アセタゾラミド 364
アセチルシステイン 368
アセトアミノフェン 363
アセトヘキサミド 366
アセプトロール塩酸塩 359
アセメタシン 361
アセメタシンカプセル 361
アセメタシン錠 362
アゼラスチン塩酸塩 461
アゼラスチン塩酸塩顆粒 462
アゼルニジピン 463
アゼルニジピン錠 464
アセンヤク 1853
アセンヤク末 1853
アゾセמיד 2672
アゾセמיד錠 2672
アテノロール 452
アトルバスタチンカルシウム錠 454
アトルバスタチンカルシウム水和物 453
アドレナリン 379
アドレナリン液 380
アドレナリン注射液 379
アトロピン硫酸塩水和物 456
アトロピン硫酸塩注射液 456
亜ヒ酸 pasta 445
アブリンジン塩酸塩 437
アブリンジン塩酸塩カプセル 438
アフロクアロン 380
アヘン・トコン散 1925
アヘンアルカロイド・アトロピン注射液 1338
アヘンアルカロイド・スコポラミン注射液 1339
アヘンアルカロイド塩酸塩 1336
アヘンアルカロイド塩酸塩注射液 1337
アヘン散 1924
アヘンチンキ 1925
アヘン末 1924
アマチャ 1996
アマチャ末 1996, 2796
アマンタジン塩酸塩 405
アミオダロン塩酸塩 411
アミオダロン塩酸塩錠 412
アミカシン硫酸塩 408
アミカシン硫酸塩注射液 409
アミドトリゾ酸 407
アミドトリゾ酸ナトリウムメグルミン注射液 1207
アミトリプチリン塩酸塩 414
アミトリプチリン塩酸塩錠 414
アミノ安息香酸エチル 901
アミノフィリン水和物 410
アミノフィリン注射液 410
アムホテリシン B 426
アムホテリシン B 錠 428, 2909
アムホテリシン B シロップ 428
アムロジピンベシル酸塩 417
アムロジピンベシル酸塩口腔内崩壊錠 418
アムロジピンベシル酸塩錠 420
アモキサピン 424
アモキシシリンカプセル 425
アモキシシリン水和物 424, 2671
アモスラロール塩酸塩 421
アモスラロール塩酸塩錠 422
アモバルピタール 421
アラセプリル 382
アラセプリル錠 383
L-アラニン 384
アラビアゴム 1791
アラビアゴム末 1791
アリマジン酒石酸塩 391
亜硫酸水素ナトリウム 1567
アルガトロバン水和物 441
L-アルギニン 442
L-アルギニン塩酸塩 443
L-アルギニン塩酸塩注射液 443
アルジオキサ 386
アルジオキサ顆粒 387
アルジオキサ錠 387
アルプラゾラム 395
アルプレノロール塩酸塩 396
アルプロスタジル 396
アルプロスタジル アルファデクス 400
アルプロスタジル注射液 398
アルベカシン硫酸塩 439
アルベカシン硫酸塩注射液 440
アルミノプロフェン 393
アルミノプロフェン錠 394
アレンドロン酸ナトリウム錠 390
アレンドロン酸ナトリウム水和物 388
アレンドロン酸ナトリウム注射液 389
アロエ 1794
アロエ末 1795
アロチノロール塩酸塩 444
アロプリノール 392
アロプリノール錠 392
安息香酸 482
安息香酸ナトリウム 1565
安息香酸ナトリウムカフェイン 544
安息香酸ベンジル 484
アンソッコウ 1812
アンチピリン 437
アンピシリン水和物 430, 2671
アンピシリンナトリウム 431
アンピロキシカム 434
アンピロキシカムカプセル 435
アンベノニウム塩化物 406
アンモニア・ウイキョウ精 1852
アンモニア水 420
アンレキサノクス 415
アンレキサノクス錠 416

イ

- イオウ 1619
イオウ・カンフルローション 1619
イオウ・サリチル酸・チアントール軟膏 1620
イオタラム酸 1085
イオタラム酸ナトリウム注射液 1580
イオタラム酸メグルミン注射液 1206
イオトロクス酸 1086
イオパミドール 1083
イオパミドール注射液 1084

イオヘキソール 1080
 イオヘキソール注射液 1082, 2710
 イクタモール 1046
 イコサペント酸エチル 903
 イコサペント酸エチルカプセル 904
 イセバマイシン硫酸塩 1093
 イセバマイシン硫酸塩注射液 1094
 イソクスブリン塩酸塩 1108
 イソクスブリン塩酸塩錠 1109
 イソソルビド 1103
 イソニアジド 1099
 イソニアジド錠 1101
 イソニアジド注射液 1100
 イソフェンインスリン ヒト(遺伝子組換え)水性懸濁注射液 2705
 イソフルラン 1094
 L-イソプレナリン塩酸塩 1102
 イソプロパノール 1102
 イソプロピルアンチピリン 1103
 イソマル水和物 1098, 2942
 L-イソロイシン 1096
 イソロイシン・ロイシン・バリン顆粒 1096
 イダルビシン塩酸塩 1046
 一硝酸イソソルビド錠 1107
 70%一硝酸イソソルビド乳糖末 1105, 2714
 イドクスウリジン 1048
 イドクスウリジン点眼液 1049
 イトラコナゾール 1110
 イフェンプロジル酒石酸塩 1050
 イフェンプロジル酒石酸塩細粒 1050
 イフェンプロジル酒石酸塩錠 1051
 イブジラスト 1042
 イブプロフェン 1043
 イブプロフェンピコノール 1044
 イブプロフェンピコノールクリーム 1044
 イブプロフェンピコノール軟膏 1045
 イプラトロピウム臭化物水和物 1086
 イブリフラボン 1087
 イブリフラボン錠 1088
 イミダプリル塩酸塩 1052
 イミダプリル塩酸塩錠 1053
 イミプラミン塩酸塩 1057, 2940
 イミプラミン塩酸塩錠 1057, 2940
 イミペネム水和物 1054
 イリノテカン塩酸塩水和物 2940
 イルソグラジンマレイン酸塩 1090
 イルソグラジンマレイン酸塩細粒 1090
 イルソグラジンマレイン酸塩錠 1091
 イルベサルタン 1089
 イルベサルタン・アムロジピンベシル酸塩錠 2711
 イルベサルタン錠 2710
 イレイセン 1833
 インジゴカルミン 1061
 インジゴカルミン注射液 1062
 インスリン アスパルト(遺伝子組換え) 2708
 インスリン グラルギン(遺伝子組換え) 1065

インスリン グラルギン(遺伝子組換え)注射液 1067
 インスリン ヒト(遺伝子組換え) 1068
 インスリン ヒト(遺伝子組換え)注射液 1070
 インダバミド 1058
 インダバミド錠 1059
 インターフェロン アルファ(NAMALWA) 1071
 インターフェロン アルファ(NAMALWA)注射液 1074
 インチンコウ 1800, 2747, 2973
 インデノール塩酸塩 1060
 インドメタシン 1062
 インドメタシンカプセル 1063
 インドメタシン坐剤 1064
 インフルエンザ HA ワクチン 1065
 インヨウカク 1850

ウ

ウイキョウ 1851
 ウイキョウ末 1852
 ウイキョウ油 1852
 ウコン 2005, 2798
 ウコン末 2006, 2798
 ウベニメクス 1741
 ウベニメクスカプセル 1742
 ウヤク 1906
 ウラピジル 1746
 ウリナスタチン 1744
 ウルソデオキシコール酸 1748, 2968
 ウルソデオキシコール酸顆粒 1749
 ウルソデオキシコール酸錠 1750
 ウロキナーゼ 1747
 ウワウルシ 1807
 ウワウルシ流エキス 2008

エ

エイジツ 1959
 エイジツ末 1960
 エカベトナトリウム顆粒 849
 エカベトナトリウム水和物 849
 液状フェノール 1391
 エコチオパートヨウ化物 851
 エスタゾラム 889
 エストラジオール安息香酸エステル 889
 エストラジオール安息香酸エステル水性懸濁注射液 890
 エストリオール 891, 2925
 エストリオール錠 892
 エストリオール水性懸濁注射液 892
 エタクリン酸 893
 エタクリン酸錠 893
 エタノール 895, 2693
 エダラボン 851
 エダラボン注射液 852, 2687
 エタンブトール塩酸塩 894
 エチオナミド 900
 エチゾラム 910, 2927

エチゾラム細粒 911
 エチゾラム錠 912
 エチドロン酸ナトリウム 907
 エチドロン酸ナトリウム錠 908
 エチニルエストラジオール 899
 エチニルエストラジオール錠 899
 L-エチルシステイン塩酸塩 902
 エチルセルロース 2926
 エチルモルヒネ塩酸塩水和物 905
 エチレフリン塩酸塩 909
 エチレフリン塩酸塩錠 909
 エチレンジアミン 903
 エデト酸カルシウムナトリウム水和物 561
 エデト酸ナトリウム水和物 1573
 エーテル 898
 エテンザミド 897
 エトスクシミド 901
 エトドラク 913
 エトボシド 914
 エドロホニウム塩化物 853
 エドロホニウム塩化物注射液 854
 エナラプリルマレイン酸塩 860
 エナラプリルマレイン酸塩錠 861
 エノキサシン水和物 863
 エバスチン 845
 エバスチン口腔内崩壊錠 846
 エバスチン錠 847
 エパルレスタット 865, 2692
 エパルレスタット錠 866
 エピリゾール 871
 エピルピシン塩酸塩 872, 2925
 エフェドリン塩酸塩 868
 エフェドリン塩酸塩散10% 870
 エフェドリン塩酸塩錠 870
 エフェドリン塩酸塩注射液 869
 エプレレノン 874
 エプレレノン錠 875
 エペリゾン塩酸塩 867
 エポエチン アルファ(遺伝子組換え) 876
 エポエチン ベータ(遺伝子組換え) 879
 エメダスチンフマル酸塩 857
 エメダスチンフマル酸塩徐放カプセル 858
 エモルファゾン 858
 エモルファゾン錠 859
 エリスロマイシン 885, 2692
 エリスロマイシンエチルコハク酸エステル 887
 エリスロマイシンステアリン酸塩 888
 エリスロマイシン腸溶錠 886
 エリスロマイシンラクトビオン酸塩 887
 エルカトニン 854
 エルゴカルシフェロール 882
 エルゴタミン酒石酸塩 884
 エルゴメトリンマレイン酸塩 883
 エルゴメトリンマレイン酸塩錠 884
 エルゴメトリンマレイン酸塩注射液 883

塩化亜鉛 1783
 塩化インジウム(¹¹¹In)注射液 1062
 塩化カリウム 1434
 塩化カルシウム水和物 550
 塩化カルシウム注射液 551
 塩化タリウム(²⁰¹Tl)注射液 1672
 塩化ナトリウム 1569
 10%塩化ナトリウム注射液 1570
 エンゴサク 1840
 エンゴサク末 1841
 塩酸 1023
 塩酸リモナーデ 1024
 エンタカボン 2689
 エンタカボン錠 2691
 エンピオマイシン硫酸塩 864
 エンフルラン 863

オ

オウギ 1803
 オウゴン 1978
 オウゴン末 1979
 黄色ワセリン 1387
 オウセイ 1945
 オウバク 1938
 オウバク・タンナルピン・ピスマス散 1940
 オウバク末 1939
 オウヒ 1826
 オウレン 1837
 黄連解毒湯エキス 1926, 2778
 オウレン末 1838
 オキサゾラム 1343
 オキサピウムヨウ化物 1342
 オキサプロジン 1343
 オキシコドン塩酸塩水和物 1346
 オキシテトラサイクリン塩酸塩 1351, 2726
 オキシトシン 1353
 オキシトシン注射液 1355
 オキシドール 1349
 オキシブプロカイン塩酸塩 1345
 オキシメトロン 1351
 オキセサゼイン 1344
 オクスプレノロール塩酸塩 1345
 オザグレルナトリウム 1356
 オザグレルナトリウム注射液 1357
 乙字湯エキス 1929, 2779, 2980
 オフロキサシン 1328
 オメブラゾール 1334
 オメブラゾール腸溶錠 1335
 オーラノフィン 457
 オーラノフィン錠 458
 オリブ油 1923
 オルシプレナリン硫酸塩 1341
 オルメサルタン メドキシミル 1329
 オルメサルタン メドキシミル錠 1330
 オレンジ油 1925
 オロパタジン塩酸塩 1332
 オロパタジン塩酸塩錠 1333
 オンジ 1944, 2981
 オンジ末 1944, 2981

カ

カイニン酸・サントニン散 1115
 カイニン酸水和物 1114
 ガイヨウ 1801
 カオリン 1120
 カカオ脂 1821
 加香ヒマシ油 1826
 カゴソウ 1951
 カシュウ 1945
 ガジュツ 2012, 2753
 加水ラノリン 1903
 ガスエソウマ抗毒素 977
 ガチフロキサシン水和物 2930
 ガチフロキサシン点眼液 2931
 カッコウ 1944
 カッコン 1952
 葛根湯エキス 1889, 2768
 葛根湯加川芎辛夷エキス 1892, 2771, 2978
 カッセキ 1796
 過テクネチウム酸ナトリウム(^{99m}Tc)注射液 1585
 果糖 967
 果糖注射液 968
 カドララジン 541
 カドララジン錠 542
 カナマイシン一硫酸塩 1118
 カナマイシン硫酸塩 1119
 カノコソウ 1884
 カノコソウ末 1885
 カフェイン水和物 543
 カプセル 574
 カプトプリル 575
 ガベキサートメシル酸塩 974
 過マンガン酸カリウム 1438
 加味帰脾湯エキス 1895, 2772, 2978
 加味逍遙散エキス 1898, 2773, 2979
 カモスタットメシル酸塩 562
 β -ガラクトシダーゼ(アスペルギルス) 975
 β -ガラクトシダーゼ(ペニシリウム) 975
 カリジノゲナーゼ 1116
 カリ石ケン 1432
 カルシトニン サケ 545
 カルテオロール塩酸塩 587
 カルナウバロウ 1825
 カルバゾクロムスルホン酸ナトリウム水和物 576
 カルバマゼピン 575
 カルビドパ水和物 577
 カルベジロール 589
 カルベジロール錠 590
 L-カルボシステイン 578
 L-カルボシステイン錠 579
 カルボプラチン 580
 カルボプラチン注射液 582
 カルメロース 583
 カルメロースカルシウム 583
 カルメロースナトリウム 584
 カルモナムナトリウム 587

カルモフル 586
 カロコン 2005, 2798
 カンキョウ 1951
 カンゾウ 1862
 乾燥亜硫酸ナトリウム 1592
 カンゾウエキス 1863, 2755, 2975
 乾燥甲状腺 1684
 乾燥酵母 1779
 乾燥細胞培養痘そうワクチン 1563
 乾燥ジフテリアウマ抗毒素 816
 乾燥弱毒生おたふくかぜワクチン 1278
 乾燥弱毒生風しんワクチン 1535
 乾燥弱毒生麻しんワクチン 1196
 乾燥水酸化アルミニウムゲル 401
 乾燥水酸化アルミニウムゲル細粒 402
 カンゾウ粗エキス 1864, 2756, 2976
 乾燥組織培養不活化狂犬病ワクチン 1503
 乾燥炭酸ナトリウム 1568
 乾燥痘そうワクチン 1563
 乾燥日本脳炎ワクチン 1111
 乾燥破傷風ウマ抗毒素 1670, 2967
 乾燥はぶウマ抗毒素 1004
 乾燥BCGワクチン 473
 乾燥ボツリヌスウマ抗毒素 520
 カンゾウ末 1863
 乾燥まむしウマ抗毒素 1191
 乾燥硫酸アルミニウムカリウム 403
 カンデサルタン シレキセチル 565
 カンデサルタン シレキセチル・アムロジピンベシル酸塩錠 567
 カンデサルタン シレキセチル・ヒドロクロロチアジド錠 570
 カンデサルタン シレキセチル錠 566
 カンテン 1792
 カンテン末 1793
 含糖ペプシン 1535
 d-カンフル 563
 dl-カンフル 564
 肝油 745
 カンレノ酸カリウム 1433

キ

希塩酸 1024
 キキョウ 1942, 2779, 2980
 キキョウ末 1943, 2980
 キキョウ流エキス 1943, 2980
 キクカ 1829, 2975
 キササゲ 1826
 キジツ 1880
 キシリトール 1778
 キシリトール注射液 1778
 キタサマイシン 1126
 キタサマイシン酢酸エステル 1127
 キタサマイシン酒石酸塩 1128
 キナプリル塩酸塩 1496
 キナプリル塩酸塩錠 1497
 キニジン硫酸塩水和物 1498
 キニーネエチル炭酸エステル 1499

キニーネ塩酸塩水和物 1500
 キニーネ硫酸塩水和物 1501
 牛脂 1808
 吸水クリーム 755
 キョウカツ 1919
 キョウニン 1798
 キョウニン水 1799
 希ヨードチンキ 1076
 金チオリンゴ酸ナトリウム 1564

ク

グアイフェネシン 1002
 グアナベンズ酢酸塩 1003
 グアネチジン硫酸塩 1003
 グアヤコールスルホン酸カリウム
 1436
 クエチアピソフマル酸塩 1492
 クエチアピソフマル酸塩細粒 1493
 クエチアピソフマル酸塩錠 1494
 クエン酸ガリウム(⁶⁷Ga)注射液 976
 クエン酸水和物 717
 クエン酸ナトリウム水和物 1571
 クコシ 1909
 クジン 1995
 クジン末 1995
 苦味重曹水 1994
 苦味チンキ 1813, 2973
 クラブラン酸カリウム 1434
 グラミシジン 1001, 2698
 クラリスロマイシン 717, 2680
 クラリスロマイシン錠 719
 グリクラジド 984
 グリシン 995
 グリセリン 992
 グリセリンカリ液 994
 クリノフィブラート 725
 グリベンクラミド 984
 グリメピリド 985
 グリメピリド錠 986
 クリンダマイシン塩酸塩 721
 クリンダマイシン塩酸塩カプセル
 722
 クリンダマイシンリン酸エステル
 724
 クリンダマイシンリン酸エステル注射
 液 725
 グルコン酸カルシウム水和物 552
 グルタチオン 991
 L-グルタミン 990
 L-グルタミン酸 989
 クレゾール 756
 クレゾール水 756
 クレゾール石ケン液 757
 クレボプリドリソ酸塩 720
 クレマスチソフマル酸塩 721
 クロカブラミン塩酸塩水和物 727
 クロキサシリンナトリウム水和物
 743, 2683
 クロキサゾラム 744
 クロコナゾール塩酸塩 757
 クロスカルメロースナトリウム 585
 クロスボドン 758

クロチアゼパム 741
 クロチアゼパム錠 2682
 クロトリマゾール 742
 クロナゼパム 732
 クロナゼパム細粒 733
 クロナゼパム錠 733
 クロニジン塩酸塩 734
 クロピドグレル硫酸塩 736
 クロピドグレル硫酸塩錠 738
 クロフィブラート 728
 クロフィブラートカプセル 729
 クロフェダノール塩酸塩 728
 クロベタゾールプロピオン酸エステル
 726
 クロペラスチン塩酸塩 735, 2919
 クロミフェンクエン酸塩 730
 クロミフェンクエン酸塩錠 731
 クロミプラミン塩酸塩 731
 クロミプラミン塩酸塩錠 2681
 クロム酸ナトリウム(⁵¹Cr)注射液
 1571
 クロモグリク酸ナトリウム 1573
 クララゼブ酸二カリウム 739
 クララゼブ酸二カリウムカプセル
 740
 クロラムフェニコール 677, 2917
 クロラムフェニコールコハク酸エステ
 ルナトリウム 678, 2679
 クロラムフェニコール・コリスチンメ
 タンスルホン酸ナトリウム点眼液
 2679
 クロラムフェニコールパルミチン酸エ
 ステル 677
 クロルジアゼボキシド 679
 クロルジアゼボキシド散 680
 クロルジアゼボキシド錠 681
 クロルフェニラミンマレイン酸塩
 687
 d-クロルフェニラミンマレイン酸塩
 691
 クロルフェニラミンマレイン酸塩散
 689
 クロルフェニラミンマレイン酸塩錠
 690
 クロルフェニラミンマレイン酸塩注射
 液 688
 クロルフェネシンカルバミン酸エステ
 ル 685
 クロルフェネシンカルバミン酸エステ
 ル錠 686
 クロルプロパミド 694
 クロルプロパミド錠 695
 クロルプロマジン塩酸塩 692, 2918
 クロルプロマジン塩酸塩錠 693
 クロルプロマジン塩酸塩注射液 692
 クロルヘキシジン塩酸塩 683
 クロルヘキシジソグレルコン酸塩液
 682
 クロルマジソソ酢酸エステル 684
 クロロブタノール 685

ケ

ケイガイ 1973
 経口生ポリオワクチン 1428
 ケイ酸アルミン酸マグネシウム 2715
 ケイ酸マグネシウム 1187
 軽質無水ケイ酸 1552, 2955
 軽質流動パラフィン 1365
 桂枝茯苓丸エキス 1901, 2775
 ケイヒ 1830
 ケイヒ末 1831
 ケイヒ油 1831
 ケタミン塩酸塩 1120
 結晶セルロース 664, 2914
 ケツメイシ 1825, 2974
 ケトコナゾール 1121
 ケトコナゾール液 1123
 ケトコナゾールクリーム 1122
 ケトコナゾールローション 1123
 ケトチフェソフマル酸塩 1125
 ケトプロフェン 1124
 ケノデオキシコール酸 675
 ゲファルナート 977
 ケンゴシ 1938
 ゲンタマイシン硫酸塩 982, 2695
 ゲンタマイシン硫酸塩注射液 2933
 ゲンタマイシン硫酸塩点眼液 983
 ゲンタマイシン硫酸塩軟膏 2933
 ゲンチアナ 1856
 ゲンチアナ・重曹散 1857
 ゲンチアナ末 1856
 ゲンノショウコ 1857
 ゲンノショウコ末 1857

コ

コウイ 1903
 コウカ 1962, 2981
 硬化油 1032
 コウジン 1953
 合成ケイ酸アルミニウム 405
 コウブシ 1842, 2753
 コウブシ末 1843, 2753
 コウベイ 1820
 コウボク 1910
 コウボク末 1910
 ゴオウ 1928, 2778, 2979
 コカイン塩酸塩 745
 ゴシツ 1792
 牛車腎気丸エキス 1865, 2758
 ゴシユ 1851, 2755
 呉茱萸湯エキス 2976
 コデインリン酸塩散1% 746
 コデインリン酸塩散10% 747
 コデインリン酸塩錠 748
 コデインリン酸塩水和物 746
 ゴナドレリン酢酸塩 996
 ゴボウシ 1821
 ゴマ 1983
 ゴマ油 1984
 ゴミシ 1973
 コムギデンブソ 1604

コメデンブ 1603
 コリスチンメタンスルホン酸ナトリウム 752, 2683
 コリスチン硫酸塩 753
 コルチゾン酢酸エステル 754
 コルヒチン 749
 五苓散エキス 2756
 コレカルシフェロール 696
 コレスチミド 750
 コレスチミド顆粒 751
 コレスチミド錠 752
 コレステロール 697, 2918
 コレラワクチン 696
 コロンボ 1821, 2974
 コロンボ末 1822, 2974
 コンズランゴ 1836
 コンズランゴ流エキス 1837

サ

サイクロセリン 763
 サイコ 1820
 柴胡桂枝湯エキス 1965, 2785
 サイシン 1801
 柴朴湯エキス 1963, 2783
 柴苓湯エキス 1968, 2787
 酢酸 365
 酢酸ナトリウム水和物 1563
 サッカリン 1535, 2955
 サッカリンナトリウム水和物 1536, 2734, 2955
 サフラン 1963
 サラシ粉 683
 サラシミツロウ 1808
 サラゾスルファピリジン 1537
 サリチル・ミョウバン散 1542
 サリチル酸 1539
 サリチル酸精 1540
 サリチル酸ナトリウム 1590
 サリチル酸絆創膏 1540
 サリチル酸メチル 1238
 ザルトプロフェン 1780
 ザルトプロフェン錠 1780
 サルブタモール硫酸塩 1538
 サルボグレラート塩酸塩 1543
 サルボグレラート塩酸塩細粒 1544
 サルボグレラート塩酸塩錠 1545
 酸化亜鉛 1783
 酸化カルシウム 554
 酸化チタン 1693
 酸化マグネシウム 1186
 サンキライ 1993
 サンキライ末 1993
 サンザシ 1842
 三酸化二ヒ素 445
 サンシシ 1854, 2755
 サンシシ末 1854
 サンシユ 1839, 2752
 サンショウ 1885
 サンショウ末 1886
 酸素 1350
 サンソウニン 1886, 2765
 サントニン 1542

サンヤク 1847
 サンヤク末 1847

シ

シアスターゼ 782
 シアスターゼ・重曹散 783
 シアゼパム 783
 シアゼパム錠 784
 シアナミド 759
 シアノコバラミン 760
 シアノコバラミン注射液 761
 ジエチルカルバマジンクエン酸塩 790
 ジエチルカルバマジンクエン酸塩錠 790
 シオウ 1954
 歯科用アンチホルミン 436
 歯科用トリオジンク pasta 1734
 歯科用パラホルム pasta 1367
 歯科用フェノール・カンフル 1392
 歯科用ヨード・グリセリン 1078
 ジギトキシ 794, 2684
 ジギトキシ錠 795, 2684
 シクラシリン 699
 ジクロキサシリンナトリウム水和物 789
 シクロスポリン 700
 ジクロフェナクナトリウム 787
 ジクロフェナクナトリウム坐剤 2920
 ジクロフェナミド 787, 2684
 ジクロフェナミド錠 789, 2684
 シクロペントラート塩酸塩 761
 シクロホスファミド錠 762
 シクロホスファミド水和物 762
 シゴカ 1848
 ジゴキシ 796, 2685
 ジゴキシ錠 798
 ジゴキシ注射液 797
 ジコッピ 1909, 2979
 シコン 1907, 2979
 次硝酸ビスマス 513
 ジスチグミン臭化物 818
 ジスチグミン臭化物錠 819
 L-シスチン 766
 L-システイン 765
 L-システイン塩酸塩水和物 766
 シスプラチン 714
 ジスルフィラム 820
 ジソピラミド 818
 シタグリプチンリン酸塩錠 2957
 シタグリプチンリン酸塩水和物 2955
 シタラビン 767
 シチコリン 715
 シツリシ 2005
 ジドプジン 1781
 ジドロゲステロン 844
 ジドロゲステロン錠 845
 シノキサシン 709
 シノキサシンカプセル 710
 ジノスタチン スチマラマー 1786, 2744
 ジノプロスト 812

ジヒドロエルゴタミンメシル酸塩 802
 ジヒドロエルゴトキシメシル酸塩 803
 ジヒドロコデインリン酸塩 800
 ジヒドロコデインリン酸塩散1% 800
 ジヒドロコデインリン酸塩散10% 801
 ジピリダモール 817
 ジフェンドール塩酸塩 791
 ジフェンヒドラミン 813
 ジフェンヒドラミン・バレリル尿素散 814
 ジフェンヒドラミン・フェノール・亜鉛華リニメント 815
 ジフェンヒドラミン塩酸塩 814
 ジブカイン塩酸塩 786
 ジフテリアトキシイド 816
 ジフテリア破傷風混合トキシイド 816
 ジフルコルトロン吉草酸エステル 793
 シプロフロキサシン 711
 シプロフロキサシン塩酸塩水和物 712
 シプロヘプタジン塩酸塩水和物 764
 ジフロラゾン酢酸エステル 792
 ジベカシン硫酸塩 785
 ジベカシン硫酸塩点眼液 785
 シベレスタットナトリウム水和物 1561
 シベンゾリンコハク酸塩 697
 シベンゾリンコハク酸塩錠 698
 シメチジン 709
 ジメモルファンリン酸塩 808
 ジメルカプロール 810
 ジメルカプロール注射液 811
 ジメンヒドリナート 809
 ジメンヒドリナート錠 809
 次没食子酸ビスマス 512
 ジモルホラミン 811
 ジモルホラミン注射液 812
 シャカンブウ 1947
 弱アヘンアルカロイド・スコポラミン注射液 1340
 シャクヤク 1935
 芍薬甘草湯エキス 1984, 2790
 シャクヤク末 1936
 ジャシヨウシ 1834
 シャゼンシ 1942
 シャゼンソウ 1942
 臭化カリウム 1432
 臭化ナトリウム 1568
 十全大補湯エキス 1887, 2766, 2978
 ジュウヤク 1880
 シュクシャ 1797, 2973
 シュクシャ末 1797
 酒石酸 1643
 ショウキョウ 1857
 ショウキョウ末 1858
 小柴胡湯エキス 1988, 2791
 硝酸イソソルビド 1104
 硝酸イソソルビド錠 1105

硝酸銀 1557
 硝酸銀点眼液 1557
 常水 1773
 ショウズク 1825
 小青竜湯エキス 1990, 2793
 焼セッコウ 1868
 消毒用エタノール 897
 消毒用フェノール 1391
 消毒用フェノール水 1392
 ショウマ 1830
 ショサマイシン 1112
 ショサマイシン錠 1113
 ショサマイシンプロピオン酸エステル
 1113
 シラザプリル錠 703
 シラザプリル水和物 702
 シラストチンナトリウム 701
 シラゼブ塩酸塩水和物 805
 ジルチアゼム塩酸塩 806
 ジルチアゼム塩酸塩徐放カプセル
 807
 シルニジピン 704
 シルニジピン錠 705
 シロスタゾール 707
 シロスタゾール錠 708
 シロップ用アシクロビル 373
 シロップ用クラリスロマイシン 2918
 シロップ用セファトリジンプロピレン
 グリコール 606
 シロップ用セファドロキシル 599
 シロップ用セファレキシン 603
 シロップ用セフポドキシム プロキセ
 チル 646
 シロップ用セフロキサジン 649
 シロップ用トラニラスト 1715
 シロップ用ファロベネムナトリウム
 920
 シロップ用ペミロラストカリウム
 1374
 シロップ用ホスホマイシンカルシウム
 963
 シロドシン 1553
 シロドシン錠 1555
 シンイ 1911
 シンギ 1875
 親水クリーム 756
 親水ワセリン 1387
 診断用クエン酸ナトリウム液 1572
 シンバスタチン 1559
 シンバスタチン錠 1560
 真武湯エキス 1985, 2791

ス

水酸化カリウム 1436
 水酸化カルシウム 553
 水酸化ナトリウム 1578
 スキサメトニウム塩化物水和物 1627
 スキサメトニウム塩化物注射液
 1628, 2737
 スクラルファート水和物 1609
 スコボラミン臭化水素酸塩水和物
 1548

ステアリルアルコール 1607
 ステアリン酸 1606
 ステアリン酸カルシウム 562
 ステアリン酸ポリオキシシロ 1430
 ステアリン酸マグネシウム 1188
 ストレプトマイシン硫酸塩 1608
 スピラマイシン酢酸エステル 1599,
 2735
 スピロノラクトン 1600
 スピロノラクトン錠 1600
 スペクチノマイシン塩酸塩水和物
 1597
 スリンダク 1620
 スルタミシリントシル酸塩錠 1625
 スルタミシリントシル酸塩水和物
 1624, 2736
 スルチアム 1626
 スルバクタムナトリウム 1612, 2735
 スルピリド 1621
 スルピリドカプセル 1621
 スルピリド錠 1622
 スルピリン水和物 1623
 スルピリン注射液 1623
 スルファジアジン銀 1614
 スルファメチゾール 1615
 スルファメトキサゾール 1616
 スルファモノメトキシ水和物 1616
 スルfoisキサゾール 1617
 スルベニシリンナトリウム 1613
 スルホプロモフタレインナトリウム
 1618
 スルホプロモフタレインナトリウム注
 射液 1619

セ

成人用沈降ジフテリアトキソイド
 816
 精製水 1773
 精製水(容器入り) 1774
 精製ゼラチン 980
 精製セラック 1551
 精製デヒドロコール酸 772, 2920
 精製白糖 1611
 精製ヒアルロン酸ナトリウム 1575
 精製ヒアルロン酸ナトリウム注射液
 1576
 精製ヒアルロン酸ナトリウム点眼液
 1577
 精製ブドウ糖 2696
 精製ラノリン 1904
 生理食塩液 1571
 石油ベンジン 1387
 セタノール 671
 セチリジン塩酸塩 671
 セチリジン塩酸塩錠 672
 セッコウ 1868
 セトチアミン塩酸塩水和物 673
 セトラキサート塩酸塩 674
 セネガ 1980
 セネガシロップ 1981
 セネガ末 1981
 セファクロル 592
 セファクロルカプセル 593
 セファクロル細粒 596
 セファクロル複合顆粒 594
 セファゾリンナトリウム 607
 セファゾリンナトリウム水和物 609
 セファトリジンプロピレングリコール
 605
 セファドロキシル 597
 セファドロキシルカプセル 598
 セファレキシン 599
 セファレキシンカプセル 601
 セファレキシン複合顆粒 602
 セファロチンナトリウム 604
 セフィキシムカプセル 624
 セフィキシム細粒 2913
 セフィキシム水和物 623, 2676
 セフェピム塩酸塩水和物 621
 セフォジジムナトリウム 629
 セフォゾラン塩酸塩 640
 セフォタキシムナトリウム 634
 セフォチアム塩酸塩 639
 セフォチアム ヘキセチル塩酸塩
 637
 セフォタタン 635
 セフォペラゾンナトリウム 631
 セフカペン ピボキシル塩酸塩細粒
 613
 セフカペン ピボキシル塩酸塩錠
 614
 セフカペン ピボキシル塩酸塩水和物
 612
 セフジトレン ピボキシル 618
 セフジトレン ピボキシル細粒 619
 セフジトレン ピボキシル錠 620
 セフジニル 615
 セフジニルカプセル 617
 セフジニル細粒 617
 セフスロジンナトリウム 650
 セフタジジム水和物 652
 セフチゾキシムナトリウム 658, 2678
 セフチブテン水和物 657
 セフテラム ピボキシル 654
 セフテラム ピボキシル細粒 655
 セフテラム ピボキシル錠 656
 セフトリアキソンナトリウム水和物
 660
 セフピラミドナトリウム 642
 セフピロム硫酸塩 643
 セフブペラゾンナトリウム 610
 セフポドキシム プロキセチル 644
 セフポドキシム プロキセチル錠
 647
 セフミノクスナトリウム水和物 629
 セフメタゾールナトリウム 627
 セフメノキシム塩酸塩 625
 セフロキサジン水和物 648
 セフロキシム アキセチル 662
 セボフルラン 1550
 セラセフェート 663, 2679
 ゼラチン 978
 セラペプターゼ 1549, 2734
 L-セリン 1548
 セルモロイキン(遺伝子組換え) 668

センキュウ 1835
 センキュウ末 1835
 ゼンコ 1937
 センコツ 1919
 センソ 1998, 2983
 センナ 1981
 センナ末 1982
 センブリ 1996, 2982
 センブリ・重曹散 1998, 2982
 センブリ末 1997, 2982

ソ

ソウジュツ 1803
 ソウジュツ末 1804
 ソウハクヒ 1918
 ゴニサミド 2744
 ゴニサミド錠 2745
 ソボク 1972
 ソヨウ 1937
 ソルビタンセスキオレイン酸エステル
 1595
 ゴルビデム酒石酸塩 1788
 ゴルビデム酒石酸塩錠 1789
 D-ソルビトール 1596
 D-ソルビトール液 1597

タ

ダイオウ 1955
 大黃甘草湯エキス 1843, 2754
 ダイオウ末 1956
 大柴胡湯エキス 1844, 2754
 ダイズ油 1995
 タイソウ 1886, 2765
 ダウノルビシン塩酸塩 769
 タウリン 1643
 タカルシトール水和物 1629
 タカルシトール軟膏 1631
 タカルシトールローション 1630
 タクシャ 1793
 タクシャ末 1794, 2747
 タクロリムスカプセル 1633
 タクロリムス水和物 1632
 タゾバクタム 1644
 タナゾール 768
 タムスロシン塩酸塩 1640
 タムスロシン塩酸塩徐放錠 1642
 タモキシフェンクエン酸塩 1640
 タランピシリン塩酸塩 1633
 タルク 1634
 タルチレリン口腔内崩壊錠 1637
 タルチレリン錠 1638
 タルチレリン水和物 1636
 炭酸カリウム 1433
 炭酸水素ナトリウム 1566
 炭酸水素ナトリウム注射液 1566
 炭酸ナトリウム水和物 1569
 炭酸マグネシウム 1185
 炭酸リチウム 1169
 単シロップ 1558
 タンジン 1971
 ダントロレンナトリウム水和物 768

単軟膏 1993
 タンニン酸 1643
 タンニン酸アルブミン 386
 タンニン酸ジフェンヒドラミン 815
 タンニン酸ベルベリン 494

チ

チアプリド塩酸塩 1684
 チアプリド塩酸塩錠 1685
 チアマゾール 1672
 チアマゾール錠 1673
 チアミラルナトリウム 1677
 チアミン塩化物塩酸塩 1674
 チアミン塩化物塩酸塩散 1675
 チアミン塩化物塩酸塩注射液 1675
 チアミン硝化物 1676
 チアラミド塩酸塩 1685
 チアラミド塩酸塩錠 1686
 チアントール 1678
 チオペンタールナトリウム 1680
 チオリダジン塩酸塩 1681
 チオ硫酸ナトリウム水和物 1592
 チオ硫酸ナトリウム注射液 1593
 チクセツニンジン 1932
 チクセツニンジン末 1933
 チクロピジン塩酸塩 1687
 チクロピジン塩酸塩錠 1688
 チザニジン塩酸塩 1694
 窒素 1316
 チニダゾール 1691
 チペピジンヒベンズ酸塩 1691
 チペピジンヒベンズ酸塩錠 1692,
 2967
 チメピジウム臭化物水和物 1689
 チモ 1797
 チモール 1683
 チモロールマレイン酸塩 1690
 注射用アシクロビル 371
 注射用アズトレオナム 467
 注射用アセチルコリン塩化物 367
 注射用アミカシン硫酸塩 409
 注射用アムホテリシンB 427
 注射用アンピシリンナトリウム 432
 注射用アンピシリンナトリウム・スル
 バクタムナトリウム 433
 注射用イダルビシン塩酸塩 1047
 注射用イミペネム・シラスタチンナト
 リウム 1056
 注射用オザグレルナトリウム 1357
 注射用シベレスタットナトリウム
 1562
 注射用水 1774
 注射用水(容器入り) 1775
 注射用スキサメトニウム塩化物 1628
 注射用ストレプトマイシン硫酸塩
 1609
 注射用スペクチノマイシン塩酸塩
 1598
 注射用セファゾリンナトリウム 608
 注射用セファロチンナトリウム 2912
 注射用セフェピム塩酸塩 622
 注射用セフォゾラン塩酸塩 641

注射用セフォチアム塩酸塩 640
 注射用セフォペラゾンナトリウム
 2677
 注射用セフォペラゾンナトリウム・ス
 ルバクタムナトリウム 632
 注射用セフトアジジム 653
 注射用セフメタゾールナトリウム
 628
 注射用タゾバクタム・ピペラシリン
 1645
 注射用チアミラルナトリウム 1678
 注射用チオペンタールナトリウム
 1681
 注射用テセロイキン(遺伝子組換え)
 1652
 注射用ドキシソルピシン塩酸塩 837
 注射用ドセタキセル 823
 注射用ドリペネム 2924
 注射用ナルトグラスチム(遺伝子組換
 え) 1293
 注射用パニペネム・ベタミプロン
 1361
 注射用バンコマイシン塩酸塩 1758
 注射用ヒト絨毛性腺刺激ホルモン
 999
 注射用ヒドララジン塩酸塩 1022
 注射用ピペラシリンナトリウム 1418
 注射用ビンブラスチン硫酸塩 1763
 注射用ファモチジン 917
 注射用フェニトインナトリウム 1398
 注射用ブレドニゾロンコハク酸エステ
 ルナトリウム 1456
 注射用フロモキシセフナトリウム 938
 注射用ペプロマイシン硫酸塩 1380
 注射用ベンジルペニシリンカリウム
 487
 注射用ホスホマイシンナトリウム
 965
 注射用ポリコナゾール 2743
 注射用マイトマイシンC 1262
 注射用ミノサイクリン塩酸塩 1256
 注射用メロペネム 1219
 注射用ロキサチジン酢酸エステル塩酸
 塩 1533
 チョウジ 1833
 チョウジ末 1833
 チョウジ油 1834
 チョウトウコウ 2007
 釣藤散エキス 1827, 2751
 チョレイ 1946
 チョレイ末 1946
 L-チロシン 1740
 チンク油 1784
 沈降ジフテリア破傷風混合トキソイド
 816
 沈降精製百日せきジフテリア破傷風混
 合ワクチン 816
 沈降精製百日せきワクチン 1384
 沈降炭酸カルシウム 548
 沈降炭酸カルシウム細粒 548
 沈降炭酸カルシウム錠 549
 沈降破傷風トキソイド 1670
 沈降はぶトキソイド 1004, 2934

沈降 B 型肝炎ワクチン 1018
チンピ 1832

ツ

ツバキ油 1822
ツロブテロール 1738
ツロブテロール塩酸塩 1740
ツロブテロール経皮吸収型テープ
1739

テ

テイクプラニン 1654, 2737, 2964
低置換度ヒドロキシプロピルセルロー
ス 1035, 2703
テオフィリン 1672
テガフル 1653
デキサメタゾン 776
デキストラン40 777, 2684
デキストラン40注射液 778
デキストラン70 779
デキストラン硫酸エステルナトリウム
イオウ5 780
デキストラン硫酸エステルナトリウム
イオウ18 780
デキストリン 781
デキストロメトルファン臭化水素酸塩
水和物 782
テストステロンエナント酸エステル
1667, 2967
テストステロンエナント酸エステル注
射液 1668
テストステロンプロピオン酸エステル
1668
テストステロンプロピオン酸エステル
注射液 1669
デスラノシド 775
デスラノシド注射液 776
テセロイキン(遺伝子組換え) 1647
テトラカイン塩酸塩 1670
テトラサイクリン塩酸塩 1670, 2738
デヒドロコール酸 772, 2920
デヒドロコール酸注射液 773
デフェロキサミンメシル酸塩 771
テプレノン 1660
テプレノンカプセル 1661
デメチルクロルテトラサイクリン塩酸
塩 774, 2684
テモカプリル塩酸塩 1658
テモカプリル塩酸塩錠 1659
テルビナフィン塩酸塩 1662
テルビナフィン塩酸塩液 1664
テルビナフィン塩酸塩クリーム 1663
テルビナフィン塩酸塩錠 1665
テルビナフィン塩酸塩スプレー 1665
テルブタリン硫酸塩 1666
テルミサルタン 1656
テルミサルタン錠 1657
テルミサルタン・ヒドロクロロチアジ
ド錠 2964
テレピン油 2007
天然ケイ酸アルミニウム 404

デンプングリコール酸ナトリウム
1591

テンマ 1855, 2975
テンモンドウ 1802

ト

桃核承気湯エキス 1999, 2796
トウガシ 1811
トウガラシ 1822
トウガラシ・サリチル酸精 1824
トウガラシチンキ 1824
トウガラシ末 1823
トウキ 1883, 2977
当帰芍薬散エキス 2002, 2797, 2983
トウキ末 1883, 2978
トウジン 1835
トウニン 1933
トウニン末 1934
トウヒ 1812
トウヒシロップ 1926
トウヒチンキ 1926
トウモロコシデンプン 1601
トウモロコシ油 1839
ドキサゾシンメシル酸塩 833
ドキサゾシンメシル酸塩錠 834
ドキサプラム塩酸塩水和物 832
ドキシサイクリン塩酸塩錠 840
ドキシサイクリン塩酸塩水和物 838,
2686
ドキシフルリジン 835
ドキシフルリジンカプセル 835
ドキシソルピシン塩酸塩 836, 2685
ドクカツ 1800
トコフェロール 1697
トコフェロールコハク酸エステルカル
シウム 1698
トコフェロール酢酸エステル 1697
トコフェロールニコチン酸エステル
1699
トコン 1881
トコンシロップ 1882
トコン末 1881
トスフロキサシントシル酸塩錠 1707
トスフロキサシントシル酸塩水和物
1706
ドセタキセル水和物 821
ドセタキセル注射液 822
トチュウ 1851
トドララジン塩酸塩水和物 1700
ドネベジル塩酸塩 825
ドネベジル塩酸塩細粒 826
ドネベジル塩酸塩錠 827
ドパミン塩酸塩 829
ドパミン塩酸塩注射液 829
トフィソパム 1701
ドブタミン塩酸塩 820
トブラマイシン 1695, 2738
トブラマイシン注射液 1696
トラガント 2004
トラガント末 2004
トラザミド 1702, 2738
トラニラスト 1711

トラニラストカプセル 1712
トラニラスト細粒 1713
トラニラスト点眼液 1714
トラネキサム酸 1708
トラネキサム酸カプセル 1709
トラネキサム酸錠 1711
トラネキサム酸注射液 1710
トラピジル 1716
トラマドール塩酸塩 2739
トリアムシノロン 1718
トリアムシノロンアセトニド 1719,
2967
トリアムテレシ 1720
トリエンチン塩酸塩 1726
トリエンチン塩酸塩カプセル 1727
トリクロホスナトリウム 1725
トリクロホスナトリウムシロップ
1726
トリクロルメチアジド 1721
トリクロルメチアジド錠 1722
トリコマイシン 1724
L-トリプトファン 1737
トリヘキシフェニジル塩酸塩 1727
トリヘキシフェニジル塩酸塩錠 1728
ドリベネム水和物 2921
トリメタジオン 1732
トリメタジジン塩酸塩 1730
トリメタジジン塩酸塩錠 1731
トリメトキノール塩酸塩水和物 1733
トリメブチンマレイン酸塩 1729
ドルプラミド塩酸塩 830
ドルプラミド塩酸塩点眼液 831
トルナフタート 1704
トルナフタート液 1705
トルブタミド 1703
トルブタミド錠 1703
トルペリゾン塩酸塩 1705
L-トレオニン 1682
トレハロース水和物 1717
トレピプトン 1718
ドロキシドパ 842
ドロキシドパカプセル 842
ドロキシドパ細粒 843
トロキシピド 1735
トロキシピド細粒 1735
トロキシピド錠 1736
トロピカミド 1734
ドロペリドール 841
トロンピン 1682, 2738
豚脂 1905
ドンペリドン 824

ナ

ナイスタチン 1328
ナタネ油 1953, 2780
ナテグリニド 1294
ナテグリニド錠 1295
ナドロール 1283
ナファゾリン・クロルフェニラミン液
1290
ナファゾリン塩酸塩 1289
ナファゾリン硝酸塩 1289

ナファモスタットメシル酸塩 1283
 ナフトピジル 1284
 ナフトピジル口腔内崩壊錠 1285
 ナフトピジル錠 1286
 ナブメトン 1281
 ナブメトン錠 1282
 ナプロキセン 1291
 ナリジクス酸 1287
 ナルトグラスチム(遺伝子組換え)
 1291
 ナロキソン塩酸塩 1288

二

ニガキ 1941
 ニガキ末 1941
 ニカルジピン塩酸塩 1298
 ニカルジピン塩酸塩注射液 1299
 ニクジュヨウ 1831
 ニクズク 1920
 ニコチン酸 1307
 ニコチン酸アミド 1306
 ニコチン酸注射液 1307
 ニコモール 1304
 ニコモール錠 1304
 ニコランジル 1305
 ニザチジン 1319
 ニザチジンカプセル 1320
 ニ酸化炭素 580
 ニセリトロール 1303
 ニセルゴリン 1300
 ニセルゴリン散 1301
 ニセルゴリン錠 1302
 ニ相性イソフェンインスリン ヒト
 (遺伝子組換え)水性懸濁注射液
 2706
 ニトラゼパム 1314
 ニトレンジピン 1314
 ニトレンジピン錠 1315
 ニトログリセリン錠 1317
 ニフェジピン 1308
 ニフェジピン細粒 1311
 ニフェジピン徐放カプセル 1310
 ニフェジピン腸溶細粒 1309
 日本脳炎ワクチン 1111
 乳酸 1131
 L-乳酸 1131
 乳酸カルシウム水和物 553
 L-乳酸ナトリウム液 1581
 L-乳酸ナトリウムリンゲル液 1582
 乳糖水和物 1133, 2715
 尿素 1747
 ニルバジピン 1312
 ニルバジピン錠 1313
 ニンジン 1859
 ニンジン末 1860
 ニンドウ 1908

ネ

ネオスチグミンメチル硫酸塩 1297
 ネオスチグミンメチル硫酸塩注射液
 1297

ノ

濃グリセリン 993
 濃ベンザルコニウム塩化物液50 480
 ノスカピン 1326
 ノスカピン塩酸塩水和物 1327
 ノルアドレナリン 1321, 2726
 ノルアドレナリン注射液 1322
 ノルエチステロン 1322
 ノルゲステレル 1324
 ノルゲステレル・エチニルエストラジ
 オール錠 1324
 ノルトリプチリン塩酸塩 1326
 ノルトリプチリン塩酸塩錠 2951
 ノルフロキサシン 1323

ハ

バイモ 1853
 バカンピシリン塩酸塩 468
 バクガ 1912
 白色セラック 1552
 白色軟膏 1775
 白色ワセリン 1386
 白糖 1611
 バクモンドウ 1923
 麦門冬湯エキス 1805, 2747
 バクロフェン 470
 バクロフェン錠 470
 バシトラシン 469, 2674
 パズフロキサシンメシル酸塩 2726
 パズフロキサシンメシル酸塩注射液
 2728
 バソプレシン注射液 1759, 2740
 八味地黄丸エキス 1868, 2759
 ハチミツ 1879
 ハッカ 1914
 ハッカ水 1915
 ハッカ油 1915
 パップ用複方オウバク散 1940
 パニペネム 1359
 パパベリン塩酸塩 1363
 パパベリン塩酸塩注射液 1364
 ハマボウフウ 1861
 バメタン硫酸塩 471
 パラアミノサリチル酸カルシウム顆粒
 556
 パラアミノサリチル酸カルシウム水和
 物 555
 パラオキシ安息香酸エチル 906
 パラオキシ安息香酸ブチル 540
 パラオキシ安息香酸プロピル 1481
 パラオキシ安息香酸メチル 1235
 パラシクロピル塩酸塩 1751
 パラシクロピル塩酸塩錠 1753
 パラフィン 1364
 パラホルムアルデヒド 1366
 L-バリン 1754
 バルサルタン 1755
 バルサルタン錠 1756
 バルサルタン・ヒドロクロロチアジド
 錠 2968

パルナパリンナトリウム 1367
 バルビタール 472
 バルプロ酸ナトリウム 1593
 バルプロ酸ナトリウム錠 1594
 バルプロ酸ナトリウム徐放錠 A 2961
 バルプロ酸ナトリウム徐放錠 B 2963
 バルプロ酸ナトリウムシロップ 1594
 バレイショデンブソ 1602
 ハロキサゾラム 1008
 パロキセチン塩酸塩錠 1371
 パロキセチン塩酸塩水和物 1369
 ハロタン 1007
 ハロペリドール 1004, 2934
 ハロペリドール細粒 1005
 ハロペリドール錠 1006
 ハロペリドール注射液 1006
 パンクレアチン 1358
 パンクロニウム臭化物 1358
 ハンゲ 1941
 半夏厚朴湯エキス 1871, 2761
 半夏瀉心湯エキス 1873, 2761
 パンコマイシン塩酸塩 1757
 パンテチン 1362
 パントテン酸カルシウム 554

ヒ

ピオグリタゾン塩酸塩 1406
 ピオグリタゾン塩酸塩・グリメピリド
 錠 1408, 2952
 ピオグリタゾン塩酸塩・メトホルミン
 塩酸塩錠 1411
 ピオグリタゾン塩酸塩錠 1407
 ビオチン 510
 ピコスルファートナトリウム水和物
 1585
 ビサコジル 511
 ビサコジル坐剤 512
 L-ヒスチジン 1018
 L-ヒスチジン塩酸塩水和物 1019
 ビソプロロールフマル酸塩 514
 ビソプロロールフマル酸塩錠 515
 ピタバスタチンカルシウム錠 1425
 ピタバスタチンカルシウム水和物
 1424
 ビタミン A 油 1765
 ヒト下垂体性性腺刺激ホルモン 999
 ヒト絨毛性性腺刺激ホルモン 997
 人全血液 1775
 人免疫グロブリン 1021
 ヒドララジン塩酸塩 1021
 ヒドララジン塩酸塩散 1022
 ヒドララジン塩酸塩錠 1022
 ヒドロキシエチルセルロース 2934
 ヒドロキシジン塩酸塩 1036
 ヒドロキシジンパモ酸塩 1036
 ヒドロキシプロピルセルロース
 1033, 2702, 2937
 ヒドロキシコバラミン酢酸塩 1033,
 2701
 ヒドロクロロチアジド 1024
 ヒドロコタルニン塩酸塩水和物 1031
 ヒドロコルチゾン 1025, 2934

ヒドロコルチゾン・ジフェンヒドラミ
ン軟膏 1027, 2934
ヒドロコルチゾンコハク酸エステル
1031
ヒドロコルチゾンコハク酸エステルナ
トリウム 1030
ヒドロコルチゾン酢酸エステル
1026, 2701, 2934
ヒドロコルチゾン酪酸エステル
1028, 2701
ヒドロコルチゾンリン酸エステルナト
リウム 1028
ビメシリナム塩酸塩 1427
ビメシリナム塩酸塩錠 1428
ヒプロメロース 1038, 2704, 2938
ヒプロメロースカプセル 574
ヒプロメロース酢酸エステルコハク酸
エステル 1040
ヒプロメロースフタル酸エステル
1041
ピペミド酸水和物 1414
ピペラシリン水和物 1414
ピペラシリンナトリウム 1416
ピペラジンアジピン酸塩 1418
ピペラジンリン酸塩錠 1419
ピペラジンリン酸塩水和物 1419
ピペリデン塩酸塩 510
ビホナゾール 509
ヒマシ油 1826
ピマリシン 1404
ヒメクロモン 1037
ピモジド 1405
ジャクゴウ 1906
ジャクシ 1798
ジャクジュツ 1804
ジャクジュツ末 1805
氷酢酸 365
ピラジナミド 1488
ピラルピシン 1420
ピランテルパモ酸塩 1487
ピリドキサルリン酸エステル水和物
2731
ピリドキシン塩酸塩 1489
ピリドキシン塩酸塩注射液 1490
ピリドスチグミン臭化物 1489
ピルシカイニド塩酸塩カプセル 1402
ピルシカイニド塩酸塩水和物 1402
ブレノキシ 1421
ピレンゼピン塩酸塩水和物 1422
ピロ亜硫酸ナトリウム 1587
ピロカルピン塩酸塩 1399
ピロカルピン塩酸塩錠 1400
ピロキシカム 1423
ピロキシリン 1491
ピロールニトリン 1491
ピワヨウ 1909
ピンクリスチン硫酸塩 1764, 2742
ピンドロール 1406
ピンプラスチン硫酸塩 1762, 2742
ピンロウジ 1800

フ

ファモチジン 915
ファモチジン散 918
ファモチジン錠 919
ファモチジン注射液 915
ファロペネムナトリウム錠 921
ファロペネムナトリウム水和物 919
フィトナジオン 1398
フィルグラスチム(遺伝子組換え)
929
フィルグラスチム(遺伝子組換え)注射
液 931
フェキソフェナジン塩酸塩 926
フェキソフェナジン塩酸塩錠 927
フェニトイン 1396
フェニトイン散 1396
フェニトイン錠 1397
L-フェニルアラニン 1394
フェニルブタゾン 1395
フェニレフリン塩酸塩 1395
フェネチシリンカリウム 1388
フェノバルビタール 1389
フェノバルビタール散10% 1390
フェノール 1390
フェノール・亜鉛華リニメント 1392
フェノール水 1392
フェノールスルホンフタレイン 1393
フェノールスルホンフタレイン注射液
1393
フェルビナク 923
フェルビナクテープ 924
フェルビナクパップ 923
フェロジピン 2927
フェロジピン錠 2928
フェンタニルクエン酸塩 925
フェンブフェン 924
複方アクリノール・チンク油 377
複方オキシコドン・アトロピン注射液
1348
複方オキシコドン注射液 1347
複方サリチル酸精 1541
複方サリチル酸メチル精 1238
複方ジアスターゼ・重曹散 783
複方ダイオウ・センナ散 1957
複方チアントール・サリチル酸液
1679
複方ビタミンB散 1765, 2971
複方ヨード・グリセリン 1077
複方ロートエキス・ジアスターゼ散
1976
ブクモロール塩酸塩 527
ブクヨウ 1946
ブクヨウ末 1947
ブシ 1948
フシジン酸ナトリウム 1574, 2959
ブシ末 1949
ブシラミン 525
ブシラミン錠 526
ブスルファン 536
ブチルスコボラミン臭化物 1547
ブテナフィン塩酸塩 536

ブテナフィン塩酸塩液 538
ブテナフィン塩酸塩クリーム 537
ブテナフィン塩酸塩スプレー 538
ブドウ酒 1776
ブドウ糖 988
ブドウ糖水和物 2695
ブドウ糖注射液 989, 2698
ブドステイン 968
ブドステイン錠 969
ブトロピウム臭化物 539
ブナゾシン塩酸塩 532
ブピバカイン塩酸塩水和物 533
ブフェロール塩酸塩 528
ブプラノロール塩酸塩 534
ブプレノルフィン塩酸塩 535
ブホルミン塩酸塩 529
ブホルミン塩酸塩錠 531
ブホルミン塩酸塩腸溶錠 529
ブメタニド 531
フラジオマイシン硫酸塩 966
プラステロン硫酸エステルナトリウム
水和物 1444
プラゼパム 1450
プラゼパム錠 1450
ブラゾシン塩酸塩 1451
プラノプロフェン 1443
プラバスタチンナトリウム 1444
プラバスタチンナトリウム液 1447
プラバスタチンナトリウム細粒 1446
プラバスタチンナトリウム錠 1448
フラビンアデニンジスクレオチドナト
リウム 932
フラボキサート塩酸塩 934
プランルカスト水和物 1442
プリミドン 1458
フルオキシメステロン 950, 2694
フルオシノニド 947
フルオシノロンアセトニド 946
フルオレセインナトリウム 948
フルオロウラシル 950
フルオロメトロン 949
フルコナゾール 940
フルコナゾールカプセル 941
フルコナゾール注射液 942
フルジアゼパム 944
フルシトシン 943
フルスルチアミン塩酸塩 973
フルタミド 954
フルトプラゼパム 955
フルトプラゼパム錠 955
フルドロコルチゾン酢酸エステル
944
フルニトラゼパム 945
フルフェナジンエナント酸エステル
951
フルボキサミンマレイン酸塩 956
フルボキサミンマレイン酸塩錠 958
フルラゼパム塩酸塩 952
ブルラン 1487
ブルランカプセル 574
フルルビプロフェン 953
ブレオマイシン塩酸塩 516
ブレオマイシン硫酸塩 518

フレカイニド酢酸塩 934
 フレカイニド酢酸塩錠 935
 プレドニゾロン 1452
 プレドニゾロンコハク酸エステル
 1456
 プレドニゾロン酢酸エステル 1454
 プレドニゾロン錠 1453
 プレドニゾロンリン酸エステルナトリ
 ウム 1455
 プロカインアミド塩酸塩 1462
 プロカインアミド塩酸塩錠 1463
 プロカインアミド塩酸塩注射液 1463
 プロカイン塩酸塩 1464
 プロカイン塩酸塩注射液 1465
 プロカテロール塩酸塩水和物 1466
 プロカルバジン塩酸塩 1466
 プログルミド 1470
 プロクロルペラジンマレイン酸塩
 1467
 プロクロルペラジンマレイン酸塩錠
 1468
 プロゲステロン 1469
 プロゲステロン注射液 1470
 フロセミド 970
 フロセミド錠 972
 フロセミド注射液 971
 プロタミン硫酸塩 1483
 プロタミン硫酸塩注射液 1484
 プロチオナミド 1484
 プロチゾラム 523
 プロチゾラム錠 524
 プロチレリン 1485
 プロチレリン酒石酸塩水和物 1486
 プロテイン銀 1557
 プロテイン銀液 1558
 プロパフェノン塩酸塩 1473
 プロパフェノン塩酸塩錠 1474
 プロパンテリン臭化物 1475
 プロピベリン塩酸塩 1476
 プロピベリン塩酸塩錠 1477
 プロピルチオウラシル 1482
 プロピルチオウラシル錠 1482
 プロピレングリコール 1480
 プロブコール 1460
 プロブコール細粒 1461
 プロブコール錠 1462
 プロブランチノール塩酸塩 1478
 プロブランチノール塩酸塩錠 1479
 フロプロピオン 939
 フロプロピオンカプセル 939
 プロベネシド 1458
 プロベネシド錠 1459
 プロマゼパム 520
 ブロムフェナクナトリウム水和物
 2909
 ブロムフェナクナトリウム点眼液
 2910
 ブロムヘキシジン塩酸塩 521
 プロメタジン塩酸塩 1472
 フロモキシフェナトリウム 936
 プロモクリプチンメシル酸塩 522
 プロモバレリル尿素 523
 L-プロリン 1471

粉末セルロース 667
 へ
 ベカナマイシン硫酸塩 474
 ベクロメタゾンプロピオン酸エステル
 473, 2909
 ベザフィブラート 507
 ベザフィブラート徐放錠 508
 ベタキソロール塩酸塩 506
 ベタネコール塩化物 507
 ベタヒスチンメシル酸塩 495
 ベタヒスチンメシル酸塩錠 496
 ベタミブロン 505
 ベタメタゾン 497
 ベタメタゾン吉草酸エステル 502
 ベタメタゾン吉草酸エステル・ゲンタ
 マイシン硫酸塩クリーム 502
 ベタメタゾン吉草酸エステル・ゲンタ
 マイシン硫酸塩軟膏 504
 ベタメタゾンジプロピオン酸エステル
 499, 2909
 ベタメタゾン錠 498
 ベタメタゾンリン酸エステルナトリウ
 ム 500
 ペチジン塩酸塩 1385
 ペチジン塩酸塩注射液 1385
 ベニジピン塩酸塩 475
 ベニジピン塩酸塩錠 476
 ヘパリンカルシウム 1009, 2698
 ヘパリンナトリウム 1013, 2699
 ヘパリンナトリウム注射液 1017
 ペプロマイシン硫酸塩 1379
 ベポタスチンベシル酸塩 488
 ベポタスチンベシル酸塩錠 489
 ペミロラストカリウム 1372
 ペミロラストカリウム錠 1375
 ペミロラストカリウム点眼液 1373
 ベラドンナエキス 1810
 ベラドンナコン 1809, 2973
 ベラドンナ総アルカロイド 1810
 ベラパミル塩酸塩 1761, 2741
 ベラパミル塩酸塩錠 1761, 2741
 ベラパミル塩酸塩注射液 2970
 ベラプロストナトリウム 490
 ベラプロストナトリウム錠 492
 ペルフェナジン 1381
 ペルフェナジン錠 1382
 ペルフェナジンマレイン酸塩 1383
 ペルフェナジンマレイン酸塩錠 1383
 ベルベリン塩化物水和物 493
 ベンザルコニウム塩化物 479
 ベンザルコニウム塩化物液 480
 ベンジルアルコール 483
 ベンジルペニシリンカリウム 486,
 2674
 ベンジルペニシリンベンザチン水和物
 485
 ヘンズ 1848
 ベンズプロマロン 481
 ベンゼトニウム塩化物 481
 ベンゼトニウム塩化物液 482
 ベンセラジド塩酸塩 478

ペンタゾシン 1376
 ペントキシベリンクエン酸塩 1378
 ペントナイト 478
 ペントバルビタールカルシウム
 1377, 2728
 ペントバルビタールカルシウム錠
 2729
 ペンプトロール硫酸塩 1376

木

ボウイ 1993, 2982
 防己黄耆湯エキス 1817, 2750, 2974
 ボウコン 1880
 ホウ酸 520
 ホウ砂 1567
 ボウショウ 1994
 抱水クロラール 676
 ボウフウ 1971, 2789, 2981
 防風通聖散エキス 1813, 2748, 2973
 ボクソク 1952
 ボグリボース 1766
 ボグリボース錠 1767
 ホスホマイシンカルシウム水和物
 962, 2694
 ホスホマイシンナトリウム 964, 2694
 ボタンピ 1915
 ボタンピ末 1916
 補中益気湯エキス 1876, 2763, 2977
 ポビドン 1439, 2731
 ポビドンヨード 1441
 ホマトロピン臭化水素酸塩 1020
 ホミカ 1920, 2979
 ホミカエキス 1921
 ホミカエキス散 1922
 ホミカチンキ 1922
 ホモクロルシクリジン塩酸塩 1020
 ポラプレジック 2952
 ポラプレジック顆粒 2953
 ポリコナゾール 1769
 ポリコナゾール錠 1770
 ポリスチレンスルホン酸カルシウム
 559
 ポリスチレンスルホン酸ナトリウム
 1586
 ポリソルベート80 1430, 2730
 ホリナートカルシウム 551
 ポリミキシンB硫酸塩 1429, 2730
 ホルマリン 961
 ホルマリン水 961
 ホルモテロールフマル酸塩水和物
 962
 ボレイ 1932
 ボレイ末 1932

マ

マイトマイシンC 1261
 マオウ 1849
 麻黄湯エキス 1912, 2776
 マーキュロクロム 1216, 2718
 マーキュロクロム液 1217, 2718
 マクリ 1846

マクロゴール400 1182
 マクロゴール1500 1182
 マクロゴール4000 1183
 マクロゴール6000 1183
 マクロゴール20000 1184
 マクロゴール軟膏 1184
 マシニン 1876
 麻酔用エーテル 898
 マニジピン塩酸塩 1192
 マニジピン塩酸塩錠 1193
 マプロチリン塩酸塩 1196
 マルトース水和物 1190
 D-マンニトール 1194, 2718
 D-マンニトール注射液 1195

ミ

ミグリトール 1253
 ミグレニン 1254
 ミクロノマイシン硫酸塩 1250
 ミコナゾール 1249
 ミコナゾール硝酸塩 1249
 ミゾリピン 1262
 ミゾリピン錠 1263
 ミチグリニドカルシウム錠 1259
 ミチグリニドカルシウム水和物 1258
 ミツロウ 1809
 ミデカマイシン 1251
 ミデカマイシン酢酸エステル 1252
 ミノサイクリン塩酸塩 1255
 ミノサイクリン塩酸塩顆粒 2949
 ミノサイクリン塩酸塩錠 1256
 ミョウバン水 401

ム

無コウイ大建中湯エキス 1917, 2777
 無水アンピシリン 429
 無水エタノール 896, 2693
 無水カフェイン 543
 無水クエン酸 716
 無水乳糖 1132, 2714
 無水ボウショウ 1994
 無水リン酸水素カルシウム 557, 2911
 ムピロシンカルシウム水和物 1279
 ムピロシンカルシウム軟膏 1280

メ

メキシレチン塩酸塩 1248
 メキタジン 1214
 メキタジン錠 1215
 メグルミン 1206
 メクロフェノキサート塩酸塩 1197
 メコバラミン 1197
 メコバラミン錠 1198
 メサラジン 2718
 メサラジン徐放錠 2720
 メストラノール 1220, 2947
 メタケイ酸アルミン酸マグネシウム 2716
 メダゼパム 1200
 メタンフェタミン塩酸塩 1223

L-メチオニン 1224
 メチ克蘭 1241
 メチラボン 1247
 dl-メチルエフェドリン塩酸塩 1231
 dl-メチルエフェドリン塩酸塩散10% 1232
 メチルエルゴメトリンマレイン酸塩 1233
 メチルエルゴメトリンマレイン酸塩錠 1233
 メチルジゴキシン 1242
 メチルセルロース 1228, 2723, 2947
 メチルテストステロン 1239
 メチルテストステロン錠 1240
 メチルドパ錠 1230
 メチルドパ水和物 1229
 メチルプレドニゾロン 1236, 2949
 メチルプレドニゾロンコハク酸エステル 1236
 メチルペナクチジウム臭化物 1227
 メチルロザニリン塩化物 1237
 滅菌精製水(容器入り) 1774
 メテノロンエナント酸エステル 1221
 メテノロンエナント酸エステル注射液 1222
 メテノロン酢酸エステル 1220
 メトキサレン 1227
 メトクロプラミド 1243
 メトクロプラミド錠 1243
 メトトレキサート 1225
 メトトレキサート錠 2722
 メトトレキサートカプセル 1225
 メトプロロール酒石酸塩 1244
 メトプロロール酒石酸塩錠 1245
 メトホルミン塩酸塩 1222
 メトホルミン塩酸塩錠 1223
 メドロキシプロゲステロン酢酸エステル 1202
 メトロニダゾール 1246
 メトロニダゾール錠 1246
 メナテトレノン 1209
 メピチオスタン 1212
 メピバカイン塩酸塩 1213
 メピバカイン塩酸塩注射液 1213
 メフェナム酸 1203
 メフルシド 1204
 メフルシド錠 1205
 メフロキン塩酸塩 1203
 メペンゾラート臭化物 1211
 メルカプトプリン水和物 1215
 メルファラン 1208
 メロペネム水和物 1217
 dl-メントール 1210
 l-メントール 1211

モ

木クレオソート 2008
 モクツウ 1793
 モサプリドクエン酸塩散 1276
 モサプリドクエン酸塩錠 1277
 モサプリドクエン酸塩水和物 1275
 モッコウ 1972

モノステアリン酸アルミニウム 402
 モノステアリン酸グリセリン 995
 モルヒネ・アトロピン注射液 1273
 モルヒネ塩酸塩錠 1272
 モルヒネ塩酸塩水和物 1270
 モルヒネ塩酸塩注射液 1271
 モルヒネ硫酸塩水和物 1274
 モンテルカストナトリウム 1264
 モンテルカストナトリウム顆粒 2724
 モンテルカストナトリウム錠 1269
 モンテルカストナトリウムチュアブル錠 1267

ヤ

ヤクチ 1812
 ヤクモソウ 1905
 薬用石ケン 1201
 薬用炭 1200
 ヤシ油 1835

ユ

ユウタン 1807
 ユーカリ油 1850, 2975
 輸血用クエン酸ナトリウム注射液 1572
 ユビデカレノン 1743

ヨ

ヨウ化カリウム 1437
 ヨウ化ナトリウム 1579
 ヨウ化ナトリウム(¹²³I)カプセル 1579
 ヨウ化ナトリウム(¹³¹I)液 1580
 ヨウ化ナトリウム(¹³¹I)カプセル 1580
 ヨウ化人血清アルブミン(¹³¹I)注射液 1075
 ヨウ化ヒブール酸ナトリウム(¹³¹I)注射液 1580
 葉酸 959, 2694
 葉酸錠 960
 葉酸注射液 959
 ヨウ素 1075
 ヨクイニン 1836
 ヨクイニン末 1836
 抑肝散エキス 2010, 2798, 2983
 ヨード・サリチル酸・フェノール精 1079
 ヨードチンキ 1076
 ヨードホルム 1080

ラ

ラウリル硫酸ナトリウム 1584, 2734
 ラウロマクロゴール 1144
 ラクツロース 1134
 ラタモキセフナトリウム 1143
 ラッカセイ油 1935
 ラナトシド C 1137, 2715
 ラナトシド C 錠 1138, 2715

ラニチジン塩酸塩 1503
 ラノコナゾール 2944
 ラノコナゾール外用液 2946
 ラノコナゾールクリーム 2945
 ラノコナゾール軟膏 2946
 ラフチジン 1135
 ラフチジン錠 1136
 ラベタロール塩酸塩 1129
 ラベタロール塩酸塩錠 1130
 ラベプラゾールナトリウム 1502
 ランソプラゾール 1139
 ランソプラゾール腸溶カプセル 1140
 ランソプラゾール腸溶性口腔内崩壊錠 1141

リ

リオチロニンナトリウム 1165
 リオチロニンナトリウム錠 1166
 リシノプリル錠 1168
 リシノプリル水和物 1167
 L-リシン塩酸塩 1180
 L-リシン酢酸塩 1179
 リスペリドン 1521
 リスペリドン細粒 1522
 リスペリドン錠 1524
 リスペリドン内服液 1523
 リセドロン酸ナトリウム錠 1589
 リセドロン酸ナトリウム水和物 1588
 リゾチーム塩酸塩 1181
 六君子湯エキス 1957, 2780
 リドカイン 1161
 リドカイン注射液 1162
 リトドリン塩酸塩 1525
 リトドリン塩酸塩錠 1526
 リトドリン塩酸塩注射液 2954
 リバビリン 1511
 リバビリンカプセル 1512
 リファンピシン 1518
 リファンピシンカプセル 1519
 リボスタマイシン硫酸塩 1517
 リボフラビン 1513
 リボフラビン散 1514
 リボフラビン酪酸エステル 1514
 リボフラビンリン酸エステルナトリウム 1515
 リボフラビンリン酸エステルナトリウム注射液 1516

リマプロスト アルファデクス 1162
 リュウガンニク 1907
 リュウコツ 1907
 リュウコツ末 1908
 硫酸亜鉛水和物 1785
 硫酸亜鉛点眼液 1785
 硫酸アルミニウムカリウム水和物 403
 硫酸カリウム 1438
 硫酸鉄水和物 926
 硫酸バリウム 473
 硫酸マグネシウム水 1190
 硫酸マグネシウム水和物 1189
 硫酸マグネシウム注射液 1190
 リュウタン 1884
 リュウタン末 1884
 流動パラフィン 1365
 リュープロレリン酢酸塩 1150
 リョウキョウ 1796
 苓桂朮甘湯エキス 1961, 2781
 リンゲル液 1520
 リンコマイシン塩酸塩水和物 1164
 リンコマイシン塩酸塩注射液 1164
 リン酸水素カルシウム水和物 558
 リン酸水素ナトリウム水和物 1585
 リン酸二水素カルシウム水和物 558

レ

レセルピン 1507
 レセルピン散0.1% 1508
 レセルピン錠 1509
 レセルピン注射液 1508
 レチノール酢酸エステル 1510
 レチノールパルミチン酸エステル 1510
 レナンピシリン塩酸塩 1144
 レノグラスチム(遺伝子組換え) 1146
 レバミピド 1504
 レバミピド錠 1506
 レバロルファン酒石酸塩 1152
 レバロルファン酒石酸塩注射液 1152
 レボチロキシンナトリウム錠 1160
 レボチロキシンナトリウム水和物 1159
 レボドパ 1153
 レボフロキサシン細粒 1155
 レボフロキサシン錠 1157

レボフロキサシン水和物 1154
 レボフロキサシン注射液 1156
 レボフロキサシン点眼液 1156
 レボホリナートカルシウム水和物 2675
 レボメプロマジンマレイン酸塩 1159
 レンギョウ 1852
 レンニク 1919

ロ

L-ロイシン 1149
 ロキサチジン酢酸エステル塩酸塩 1530
 ロキサチジン酢酸エステル塩酸塩徐放カプセル 1531
 ロキサチジン酢酸エステル塩酸塩徐放錠 1532
 ロキシシロマイシン 1534
 ロキシシロマイシン錠 2733
 ロキソプロフェンナトリウム錠 1178
 ロキソプロフェンナトリウム水和物 1177
 ロキタマイシン 1528, 2733
 ロキタマイシン錠 1529, 2733
 ロサルタンカリウム 1172
 ロサルタンカリウム・ヒドロクロロチアジド錠 1174
 ロサルタンカリウム錠 1173
 ロジン 1960
 ロートエキス 1974
 ロートエキス・アネスタミン散 1976
 ロートエキス・カーボン散 1976
 ロートエキス・タンニン坐剤 1978
 ロートエキス・パパベリン・アネスタミン散 1977, 2790
 ロートエキス散 1975
 ロートコン 1973, 2982
 ロベンザリットナトリウム 1171
 ローヤルゼリー 1960
 ロラゼパム 1171

ワ

ワイル病秋やみ混合ワクチン 1775
 ワルファリンカリウム 1771
 ワルファリンカリウム錠 1772